aldosterone has been researched along with Cardiac Failure in 991 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mineralocorticoid receptor antagonist spironolactone has been shown to improve cardiac function and reverse left ventricular hypertrophy in heart failure patients, but there are no consistent findings on the efficacy and safety in hemodialysis patients." | 9.41 | Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients. ( Chen, Z; Li, Z; Liu, R; Lu, G; Sun, Y; Sun, Z, 2023) |
| " The data for this innovative medication are mainly based on the PARADIGM-HF study, which included heart failure with reduced ejection fraction (HFrEF)-diagnosed patients and indicated a major improvement in morbidity and mortality when S/V is administrated compared to enalapril." | 9.22 | Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. ( Babes, EE; Behl, T; Bungau, SG; Horvath, T; Iovanovici, DC; Moisi, M; Rus, M; Tit, DM; Vesa, CM, 2022) |
| "The long-term effects of the angiotensin-receptor blocker candesartan, the angiotensin-converting enzyme inhibitor enalapril or their combination have been incompletely studied in a large cohort of patients with heart failure not treated with beta-blockers." | 9.14 | Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. ( Afzal, R; Floras, J; McKelvie, RS; Rouleau, JL; White, M; Yusuf, S, 2009) |
| "Using a single-blinded, randomized, placebo-controlled study design, we investigated the sympathetic, hemodynamic, neurohumoral, and ventilatory effects of theophylline in patients with congestive heart failure compared with healthy control subjects closely matched for age, sex, and body mass index." | 9.11 | Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure. ( Andreas, S; Delekat, A; Grunewald, RW; Hasenfuss, G; Lüthje, L; Reiter, H; Somers, VK, 2004) |
| "ACE Insertion (I) or Deletion (D) genotype was determined in 74 patients with chronic heart failure who were randomly assigned to receive either high-dose or low-dose enalapril over a period of 6 months." | 9.11 | Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. ( Fowler, MB; Tang, WH; Vagelos, RH; Yee, YG, 2004) |
| "To compare effects of various regimens of long-term monotherapy with quinapril (an ACE inhibitor) and valsartan (a type 1 angiotensin II receptors blocker) and combined therapy with these drugs on the activity of heurohormonal systems and 24-h heart rate variability (HRV) in patients with stable moderate chronic cardiac failure (CCF)." | 9.11 | [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o ( Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV, 2005) |
| "To investigate the effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure (CHF)." | 9.11 | [Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure]. ( Gao, LJ; Lin, XY; Xiao, LZ; Zhang, HF, 2005) |
| "We evaluated whether spironolactone would improve cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure (CHF)." | 9.10 | Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T, 2002) |
| "To determine changes in RAS activation and clinical correlates following furosemide withdrawal in elderly heart failure patients without left ventricular systolic dysfunction." | 9.10 | Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. ( Hoefnagels, WH; Jansen, RW; Sweep, FC; van Kraaij, DJ, 2003) |
| "This study evaluated the short-term and long-term effects of the angiotensin II type 1 receptor antagonist candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure (CHF)." | 9.10 | Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. ( Alegria, E; Arens, HA; Dabrowski, M; Dukát, A; Kiowski, W; Lenz, K; Marks, DS; Miric, M; Mitrovic, V; Seferovic, P; Spinar, J; Willenbrock, R, 2003) |
| "We sought to compare the neurohormonal responses and clinical effects of long-term, high-dose versus low-dose enalapril in patients with chronic heart failure (CHF)." | 9.10 | Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. ( Benedict, CR; Fowler, MB; Liss, CL; Tang, WH; Vagelos, RH; Willson, K; Yee, YG, 2002) |
| "The study aimed to assess the hemodynamic and neuroendocrine effects of candoxatril and frusemide compared with placebo in patients with mild chronic heart failure." | 9.09 | Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. ( Bostrøm, P; Christensen, CC; Parikka, H; Rykke, EO; Toivonen, L; Westheim, AS, 1999) |
| "We studied acute (day 1) and long-term (day 14) effects of endothelin (ET) receptor blockade with the mixed ET(A/B) antagonist bosentan (1 g twice daily; n = 18) or placebo (n = 12) on plasma angiotensin II and aldosterone in 30 patients with symptomatic chronic heart failure taking angiotensin-converting enzyme inhibitors, diuretics, and digoxin." | 9.09 | Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. ( Bertel, O; Clozel, M; Kiowski, W; Nicholls, MG; Rickenbacher, P; Sütsch, G; Yandle, TG, 2000) |
| "We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)." | 9.09 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001) |
| "In patients with early stages of heart failure, digoxin may prevent a progressive deterioration in heart rate variability, whereas ibopamine does not show statistically significant effects." | 9.08 | Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. ( Boomsma, F; Brouwer, J; Dunselman, PH; Haaksma, J; Lie, KI; Man in 't Veld, AJ; van Veldhuisen, DJ, 1995) |
| "Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear." | 9.08 | Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. ( Cas, LD; Metra, M; Missale, C; Spano, PF, 1995) |
| "We studied 22 patients with heart failure who were receiving constant daily doses of digoxin, diuretics, and angiotensin-converting enzyme (ACE) inhibitors." | 9.08 | Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. ( Alam, M; Gheorghiade, M; Goldstein, S; Hall, VB; Jacobsen, G; Rosman, H, 1995) |
| "Our primary objective was to compare the effects of three different doses of candoxatrilat with the effects of placebo on urinary volume in patients with moderately severe heart failure." | 9.08 | Renal response to candoxatrilat in patients with heart failure. ( Cleland, JG; Good, JM; Jackson, N; Oakley, CM; Peters, M; Wilkins, M, 1995) |
| ") active dopamine (DA) agonist ibopamine, we examined 10 patients with mild to moderate congestive heart failure (CHF), who were stable while treated with digoxin and diuretics." | 9.08 | Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. ( Girbes, AR; Lie, KI; Lieverse, AG; Meijer, S; Reitsma, WD; Smit, AJ; van Veldhuisen, DJ; Zijlstra, JG, 1995) |
| "A random sample was studied of 25 outpatients with symptoms of mild to moderate heart failure, despite treatment with diuretics, digoxin, and angiotensin converting enzyme inhibitors." | 9.08 | Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure. ( Chin Kon Sung, UG; Corbeij, HM; de Vries, RJ; Dunselman, PH; Lie, KI; van Gilst, WH; van Veldhuisen, DJ, 1996) |
| "To assess the pharmacodynamic activity and safety of rising single and multiple doses of intravenous quinaprilat compared with placebo in patients with New York Heart Association (NYHA) class III and IV congestive heart failure who were receiving digitalis or diuretic therapy or both." | 9.08 | Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. ( Bakovic-Alt, R; Bonzel, T; Mitrovic, V; Mudra, H; Posvar, EL; Schmidt, W; Strand, JC, 1996) |
| "The purpose of this study was to determine the additive value of ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors." | 9.08 | Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. ( Girbes, AR; Kruik, J; Lie, KI; Szabó, BM; van der Burgh, PH; van Veldhuisen, DJ, 1996) |
| "This study was done to determine whether the difference in duration of action of the long-acting angiotensin-converting enzyme (ACE) inhibitor spirapril compared with the short-acting ACE inhibitor captopril affects clinical efficacy in patients with congestive heart failure." | 9.08 | Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure. ( de Graeff, PA; Hillege, H; Lie, KI; van den Broek, SA; van Gilst, WH; van Veldhuisen, DJ; Wesseling, H, 1997) |
| "It has been proposed that worsening of heart failure with dihydropyridines, such as nicardipine, is related to the activation of the neuroendocrine system." | 9.08 | Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy. ( Benatar, D; Gheorghiade, M; Hall, V; Reddy, S, 1998) |
| "To describe neurohormonal activation in patients with mild or moderate heart failure and how it may be modified by treatment with ramipril." | 9.07 | Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. ( Amtorp, O; Gundersen, T; Nilsson, B; Remes, J; Sigurdsson, A; Swedberg, K, 1994) |
| "Left ventricular (LV) function and plasma levels of cardiovascular hormones were examined in patients with severe chronic congestive heart failure (CHF), randomized to placebo or enalapril, in addition to conventional therapy." | 9.07 | Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). ( Eneroth, P; Eriksson, SV; Kjekshus, J; Offstad, J; Swedberg, K, 1994) |
| "This study was conducted to determine the efficacy and safety of long-term treatment with the orally active dopamine agonist ibopamine in patients with mild to moderate chronic congestive heart failure and to compare the results with those of treatment with digoxin and placebo." | 9.07 | Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). ( Brouwer, J; Dohmen, HJ; Dunselman, PH; Lie, KI; Lok, DJ; Man in 't Veld, AJ; Pasteuning, WH; Poortermans, JC; van Veldhuisen, DJ; Withagen, AJ, 1993) |
| "The acute renal effects of xamoterol, a partial beta 1-agonist, were studied in 12 patients with congestive heart failure (NYHA II-III) in stable condition on diuretic therapy for at least 6 weeks." | 9.07 | Renal effects of xamoterol in patients with moderate heart failure. ( Bøtker, HE; Jensen, HK; Krusell, LR; Sørensen, EV, 1993) |
| "In an open trial 5 mg ramipril daily for 2 weeks was administered to 11 patients with congestive heart failure." | 9.07 | Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin II and aldosterone in patients with chronic congestive heart failure. ( Brockmeier, D; Heintz, B; Kierdorf, H; Kirsten, R; Lückel, G; Maigatter, S; Nelson, K; Rangoonwala, B; Sieberth, HG; Verho, M, 1992) |
| " Nine patients with compensated heart failure were infused with synthetic arginine vasopressin at a rate of 0." | 9.07 | Renal, haemodynamic and hormonal interactions between atrial natriuretic factor and arginine vasopressin in patients with congestive heart failure. ( Arakawa, N; Funakoshi, T; Hiramori, K; Nakamura, M; Yoshida, H, 1992) |
| "In a randomized single-blind cross-over trial, the efficacy of digoxin, angiotensin-converting enzyme (ACE) inhibition by quinapril, and their combination on exercise tolerance, heart size (echocardiography), and neurohumoral systems was investigated in 19 outpatients with congestive heart failure (CHF) New York Heart Association functional class II and sinus rhythm." | 9.06 | Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm. ( Elsner, D; Kromer, EP; Riegger, GA, 1990) |
| "To study the haemodynamic and neurohumoral effects of nisoldipine (2 X 10 mg) vs captopril (3 X 25 mg), 24 patients with heart failure (New York Heart Association class II and III) due to coronary artery disease were treated in a randomized double-blind trial over 3 months." | 9.06 | Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study. ( Aschenberg, W; Hobuss, M; Schofer, J; Tews, A, 1990) |
| "The effects on cardiac function of captopril (CPT) and digoxin (D) were compared in a study of 16 patients with chronic heart failure due to ischemic heart disease (15) and to congestive cardiomyopathy (1) (New York Heart Association class II n." | 9.06 | Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. ( Agabiti Rosei, E; Alicandri, C; Beschi, M; Boni, E; Castellano, M; Fariello, R; Muiesan, G; Zaninelli, A, 1987) |
| "The acute hemodynamic, hormonal, and pharmacokinetic aspects of treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril were assessed in two studies in 24 patients with chronic stable congestive heart failure (CHF)." | 9.06 | Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. ( Dickstein, K, 1987) |
| " In this study we evaluated the effects of dopamine and the dopaminergic agonists ibopamine and dihydroergotoxine on aldosterone secretion and plasma renin activity in 13 patients with chronic heart failure." | 9.06 | Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure. ( Dei Cas, L; Memo, M; Metra, M; Missale, C; Sigala, S; Spano, PF, 1989) |
| "We evaluated the effects of intravenous hydralazine (5 to 30 mg) and oral nifedipine (20 to 80 mg) on plasma catecholamines, renin, and aldosterone in 18 patients with severe chronic heart failure." | 9.06 | Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure. ( Elkayam, U; Freidenberger, L; Hsueh, W; Rahimtoola, SH; Roth, A; Weber, L, 1986) |
| "The acute hemodynamic effects and long-term therapeutic actions of low doses of the oral angiotensin-converting enzyme (ACE) inhibitor captopril (CPT) were evaluated in 18 patients with severe chronic congestive heart failure (CHF)." | 9.05 | Hemodynamic effects of captropril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin. ( Coxon, R; Sharpe, DN, 1982) |
| "Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days." | 9.05 | Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982) |
| "The effects of human alpha atrial natriuretic factor following bolus injection of increasing doses and during a continuous 30 minute infusion were investigated in 7 patients with severe congestive cardiac failure (NYHA III-IV)." | 9.05 | [The atrial natriuretic factor in severe congestive heart failure. Plasma level, hemodynamic, hormonal and renal effects]. ( Kochsiek, K; Kromer, EP; Riegger, AJ, 1985) |
| "Aldosterone antagonists represented by nonselective spironolactone and mineralocorticoid-selective eplerenone are approved for treatment of symptomatic heart failure with reduced systolic function." | 8.87 | Aldosterone antagonists in heart failure. ( Guglin, M; Kristof-Kuteyeva, O; Novotorova, I; Pratap, P, 2011) |
| "(2) In RALES, low-dose spironolactone in addition to standard of care, produced a 30% improvement in survival in progressive heart failure, commonly assumed to reflect deleterious effects of aldosterone, with spironolactone competing with aldosterone for cardiac mineralocorticoid receptors." | 8.86 | Aldosterone, hypertension and heart failure: insights from clinical trials. ( Funder, JW, 2010) |
| "In patients with NYHA stage III or IV heart failure, addition of spironolactone to the treatment with conversion enzyme inhibitor, diuretic and/or digitalis leads to a reduction in morbidity and mortality, as demonstrated in the RALES study." | 8.82 | [Aldosterone and its antagonists in heart failure]. ( Badoual, T; Cachin, JC; Castaigne, A; Hittinger, L; Le Corvoisier, P; Lopes, ME; Merlet, P; Su, JB; Tabet, JY, 2003) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 8.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| " In contrast, when the Randomized Aldactone Evaluation Study (RALES) mortality trial was discontinued 18 months early, it was because of the prominent salutary effect of spironolactone, added to standard multidrug therapy consisting of an angiotensin converting enzyme (ACE) inhibitor and loop diuretic (with or without digoxin), in reducing the incidence of death and hospitalization in patients with severe congestive heart failure (CHF)." | 8.80 | Spironolactone in congestive heart failure. ( Soberman, JE; Weber, KT, 2000) |
| "Enalapril is an effective angiotensin-converting enzyme (ACE) inhibitor which produces salutary, beneficial haemodynamic effects in patients with congestive heart failure." | 8.78 | Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure. ( Chatterjee, K; De Marco, T, 1990) |
| "Our study suggests that urinary angiotensinogen can be used as a new biomarker in the prognosis and follow-up of heart failure patients." | 8.31 | Relationship Between Urinary Angiotensinogen and Mortality in Patients with Heart Failure with Reduced Ejection Fraction. ( Çimen, MBY; Örsçelik, Ö; Özkan, B; Sürmeli, AO; Uyar, H; Yeşil, E, 2023) |
| "Background Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF)." | 8.02 | Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. ( Alba, PR; Bress, AP; Choi, ME; Cook, J; Dodson, JA; Fang, JC; He, T; Herrick, JS; King, JB; Levitan, EB; Mohanty, AF; Obi, EN; Patterson, OV; Russo, PA; Vardeny, O, 2021) |
| "Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis." | 7.85 | Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017) |
| "To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome." | 7.85 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. ( Ballantyne, CM; Barter, PJ; Gunzburger, E; Kallend, D; Kittelson, J; Leiter, LA; Leitersdorf, E; McMurray, JJ; Nicholls, SJ; Olsson, AG; Pitts, R; Schwartz, GG; Shah, PK; Tardif, JC, 2017) |
| " On day 11, hypertension was induced by continuous angiotensin II infusion." | 7.80 | M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. ( Burnett, JC; Cataliotti, A; Chen, HH; Ichiki, T; McKie, PM; Sangaralingham, SJ, 2014) |
| " We investigated the effects of upregulating heme-oxygenase (HO) on myocardial histo-pathological lesions, proinflammatory cytokines/chemokines, oxidative mediators and important markers of heart failure such as osteopontin and osteoprotergerin in N(ω)-nitro-l-arginine methyl ester (L-NAME)-induced hypertension." | 7.80 | Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in L-NAME-induced hypertension. ( Chibbar, R; Lane, N; Ndisang, JF, 2014) |
| "The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood." | 7.80 | Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014) |
| "To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy." | 7.78 | In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. ( Chen, L; Chen, Y; Han, Y; He, T; Jin, MW; Yang, WQ, 2012) |
| "To compare the effect of the direct renin inhibitor aliskiren on neurohumoral activity in heart failure patients treated with low-dose and high-dose ACE inhibitor." | 7.77 | Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. ( Gimpelewicz, CR; Latini, R; Maggioni, AP; McMurray, JJ; Pitt, B; Sidik, NP; Solomon, SD; Wright, M, 2011) |
| "To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure." | 7.76 | Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. ( Cavallari, LH; Dai, Y; Groo, VL; Patel, SR; Stamos, TD; Viana, MA, 2010) |
| "Ucn2 and furosemide were administered for 3 hours, both singly and combined, in 7 sheep with pacing-induced heart failure." | 7.75 | Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. ( Charles, CJ; Nicholls, MG; Rademaker, MT; Richards, AM, 2009) |
| "Similar to other neurohormones that are activated in chronic heart failure (CHF), circulating arginine vasopressin (AVP) is elevated in patients with CHF." | 7.74 | Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. ( Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Suzuki, K; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2007) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 7.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| " Since chronic inhibition of nitric oxide (NO) synthase with N(omega)-nitro-L-arginine methyl ester (L-NAME) induces systemic hypertension associated with cardiovascular inflammation and remodeling, we examined the potential role of aldosterone in this process using eplerenone, a selective aldosterone receptor antagonist." | 7.73 | The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. ( Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L, 2006) |
| "To evaluate the transcardiac extraction of aldosterone before and after spironolactone administration to patients with congestive heart failure, we measured the plasma aldosterone in the aortic root and the coronary sinus in eight congestive heart failure patients with dilated cardiomyopathy." | 7.72 | Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Ishii, C; Maeda, K; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yamamoto, T, 2003) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 7.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "By inhibiting prostaglandin synthesis, aspirin can interfere with both arterial functional and angiotensin-converting enzyme inhibitor (ACEI) properties and be deleterious in chronic heart failure (CHF)." | 7.72 | Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. ( Bergmann, JF; Caulin, C; Cohen-Solal, A; Habib, A; Jondeau, G; Kevorkian, JP; Knellwolf, AL; Lebret, M; Levy, B; Mahé, I; Meune, C; Mourad, JJ; Simoneau, G, 2003) |
| " In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation." | 7.72 | [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. ( Kolloch, R; Offers, E, 2003) |
| "The aim of this study was to assess the effects of the Na+-H+ exchange inhibitor cariporide on left ventricular (LV) morphology and function as well as inflammation in rabbits with heart failure." | 7.72 | Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. ( Busch, AE; Gerl, M; Licher, T; Ruetten, H; Rungwerth, K; Schäfer, S; Schindler, U, 2004) |
| "Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM levels increase in patients with acute myocardial infarction (MI)." | 7.72 | Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. ( Asada, Y; Cao, Y; Eto, T; Imamura, T; Kangawa, K; Kato, J; Kitamura, K; Marutsuka, K; Nakamura, R; Onitsuka, H, 2004) |
| "Furosemide shortened the time to left ventricular dysfunction (35." | 7.72 | Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004) |
| "The purpose of the study was to examine the effect of fosinopril on the magnitude of neurohumoral and proinflammatory activation in patients with severe heart failure (HF)." | 7.72 | [Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure]. ( Berezin, AE, 2004) |
| "In congestive heart failure, angiotensin-converting enzyme inhibitors (ACEIs) may prevent cardiac fibrosis via interaction with both angiotensin II and endothelin-1, which enhance myocardial collagen synthesis." | 7.72 | Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. ( Dohke, T; Eguchi, Y; Fujii, M; Horie, M; Isono, T; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Wada, A; Yamamoto, T, 2004) |
| " The purpose of this study was to assess the relationship between levels of serum uric acid, activity of the renin-angiotensin-aldosterone system and TNF-alpha in heart failure patients with respect to the extent of left ventricular dysfunction." | 7.71 | Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? ( Gonsorcík, J; Kisel'ová, J; Olejníková, M; Olexa, P; Olexová, M; Tkác, I, 2002) |
| "Canrenone attenuates LV interstitial remodeling and reduces filling pressures in rats with postinfarction heart failure." | 7.71 | Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. ( Casaburi, C; Cittadini, A; Di Gianni, A; Monti, MG; Saccà, L; Saldamarco, L; Scherillo, G; Serpico, R; Vanasia, M, 2002) |
| "Short-term administration of adrenomedullin, a recently discovered peptide with potent vasodilator, natriuretic, and aldosterone-inhibitory actions, has beneficial effects in experimental and clinical heart failure." | 7.71 | Long-term adrenomedullin administration in experimental heart failure. ( Charles, CJ; Espiner, EA; Nicholls, MG; Rademaker, MT; Richards, AM, 2002) |
| "The aim of the study was to investigate a possible relationship between plasma renin activity, angiotensin II, serum levels of angiotensin-converting enzyme, aldosterone and markers of immune activation in congestive heart failure (CHF)." | 7.70 | The activated immune system and the renin-angiotensin-aldosterone system in congestive heart failure. ( Artner-Dworzak, E; Belenkov, J; Fuchs, D; Lopatin, J; Mareev, V; Nassonov, E; Samsonov, M; Tilz, GP; Wachter, H, 1998) |
| "Omapatrilat is a member of the new drug class of vasopeptidase inhibitors that may offer benefit in the treatment of heart failure (HF) through simultaneous inhibition of angiotensin-converting enzyme and neutral endopeptidase." | 7.70 | Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. ( Espiner, EA; Frampton, CM; Nicholls, MG; Powell, JD; Rademaker, MT; Richards, AM; Troughton, RW; Yandle, TG, 2000) |
| "In acute studies ibopamine, an a selective dopamine agonist, induces moderate increases of GFR and ERPF, and a fall in plasma norepinephrine levels in patients with congestive heart failure (CHF)." | 7.69 | The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure. ( Girbes, AR; Lie, KI; Lieverse, AG; Meijer, S; Reitsma, WD; Smit, AJ; Van Veldhuisen, DJ; Zijlstra, JG, 1995) |
| "To investigate the role of adrenomedullin in the pathophysiology of heart failure, we measured plasma levels of adrenomedullin in patients with heart failure." | 7.69 | Increased plasma levels of adrenomedullin in patients with heart failure. ( Eto, T; Ishimitsu, T; Kangawa, K; Kitamura, K; Matsuo, H; Matsuoka, H; Nishikimi, T; Omae, T; Saito, Y, 1995) |
| "This study examined the effect of low dose aspirin on cardiorenal and neurohumoral function and on the acute hemodynamic response to enalaprilat in a canine model of heart failure." | 7.69 | Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. ( Burnett, JC; Evans, MA; Redfield, MM, 1995) |
| "The interaction between renal prostaglandins and atrial natriuretic factor (ANF) for the regulation of renal hemodynamic and excretory function was examined in conscious dogs with arteriovenous fistula and chronic compensated high-output heart failure (n = 6)." | 7.69 | Indomethacin attenuates the renal actions of atrial natriuretic factor in dogs with chronic heart failure. ( Freeman, RH; Habibullah, AA; Simmons, JC; Villarreal, D, 1997) |
| "The acute haemodynamic and neurohumoral effects of flosequinan, a new direct-acting vasodilator, were studied in 12 patients with severe (eight in New York Heart Association grade 3, four in grade 4) cardiac failure." | 7.68 | Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy. ( Dakak, N; Halon, DA; Kahana, L; Lewis, BS; Makhoul, N; Merdler, A; Schneeweiss, A; Yechiely, H, 1993) |
| "Short- and long-term clinical effects of the angiotensin-converting enzyme (ACE) inhibitor captopril in severe congestive heart failure (CHF) were evaluated during a 3-year open study of 124 inpatients with New York Heart Association (NYHA) functional class III or IV CHF refractory to treatment with cardiac glycosides and high doses of loop diuretics." | 7.68 | Captopril and spironolactone therapy for refractory congestive heart failure. ( Dahlström, U; Karlsson, E, 1993) |
| "The pharmacokinetics of synthetic atrial natriuretic factor (ANF) and its effects on cyclic GMP, urinary sodium excretion, and hemodynamics were compared in 18 control subjects with normal hemodynamics and 12 patients with severe heart failure." | 7.68 | Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. ( Armstrong, PW; Canepa-Anson, R; Moe, GW, 1992) |
| "The clinical efficacy of enalapril was investigated in 21 patients with severe heart failure." | 7.68 | Clinical studies of enalapril treatment for patients with severe congestive heart failure. ( Sato, T; Takeshi, M; Yamamoto, A, 1992) |
| "The effect of diuretic dose on the haemodynamic response to captopril was assessed in nine patients with chronic cardiac failure." | 7.68 | The relationship between diuretic dose, and the haemodynamic response to captopril in patients with cardiac failure. ( Davies, E; Edwards, CR; Flapan, AD; Shaw, TR; Williams, BC, 1992) |
| "The hemodynamic, clinical, and neurohumeral effects of a prolonged (6-days) intravenous enoximone-infusion therapy were evaluated in 12 patients suffering from severe cardiac failure due to dilated cardiomyopathy." | 7.68 | [Continuous enoximone infusion in patients with severe heart failure in dilated cardiomyopathy, hemodynamic, neurohumoral, chemical laboratory and clinical results]. ( Lissmann, H; Mitrovic, V; Neuzner, J; Pitschner, HF; Schlepper, M, 1991) |
| "min-1 for 60 min) on secretion of atrial natriuretic factor (ANF) in 10 healthy subjects and 10 patients with congestive heart failure (CHF) (NYHA Classes III and IV)." | 7.68 | Atrial natriuretic factor after dopamine infusion in healthy subjects and in congestive heart failure. ( Bernardi, P; Capelli, M; Fontana, F; Ruffini, M, 1991) |
| "In patients with congestive heart failure (CHF), the role of aldosterone in the abnormal sodium (Na+) retention and the determinants of plasma aldosterone (PA) including plasma atrial natriuretic factor (hANF), plasma renin activity (PRA), and plasma potassium (K+) have not been fully elucidated." | 7.68 | Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. ( Abraham, WT; Dürr, JA; Hensen, J; Schrier, RW, 1991) |
| "The possible role of angiotensin-converting enzyme inhibition in preventing or minimizing tolerance to intravenous nitroglycerin in severe congestive heart failure (CHF) was studied by quantitating the degree of tolerance in 12 patients receiving nitroglycerin (group 1) and in 9 patients (group 2) receiving nitroglycerin and concurrent treatment with captopril (60 +/- 29 mg/day)." | 7.68 | Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. ( Dakak, N; Flugelman, MY; Halon, DA; Lewis, BS; Makhoul, N; Merdler, A; Schneeweiss, A; Shehadeh, H, 1990) |
| "Plasma atrial natriuretic factor, aldosterone, renin activity, and antidiuretic hormone were studied in low output heart failure syndromes: cardiogenic shock in ten patients with acute myocardial infarction of the anterior wall (first group), hypovolemic shock after melena from peptic ulcer in ten subjects (second group), and hypotension with bradycardia syndrome in ten patients with acute myocardial infarction of the inferior wall (third group)." | 7.68 | Plasma atrial natriuretic factor in low output heart failure syndromes. ( Bernardi, P; Capelli, M; Fontana, F; Spagnolo, N, 1990) |
| "The effects of captopril in several humoral factors were studied to elucidate the role of the renin-angiotensin (RA) system in arterial and venous pressures and renal function in patients with severe chronic congestive heart failure." | 7.67 | Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure. ( Kawamura, K; Kubo, S; Nishimura, H; Nishioka, A; Takatsu, T, 1984) |
| "In an attempt to study the possible mechanism(s) by which captopril controls resistant heart failure, sequential haemodynamic studies (radioisotope technique) and humoral measurements (plasma renin activity, plasma aldosterone and plasma catecholamines) were obtained in 11 such patients." | 7.67 | Captopril in congestive heart failure resistant to other vasodilators. ( Bravo, EL; El-Tobgi, S; Fouad, FM; Hart, NJ; Lim, J; Shirey, EK; Tarazi, RC, 1984) |
| "The chronic reserve for the secretion of atrial natriuretic factor (ANF) was studied in conscious dogs with an arteriovenous (a-v) fistula, a model of high-output heart failure." | 7.67 | DOCA administration and atrial natriuretic factor in dogs with chronic heart failure. ( Brands, MW; Freeman, RH; Villarreal, D, 1989) |
| "The current studies were designed to investigate the functional significance of elevated endogenous atrial natriuretic factor (ANF) in acute congestive heart failure (CHF)." | 7.67 | Role of endogenous atrial natriuretic factor in acute congestive heart failure. ( Burnett, JC; Edwards, BS; Lee, ME; Miller, WL, 1989) |
| "The hemodynamic parameters (right atrial pressure, mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac index, heart rate, blood pressure) and neurohumoral responses (alpha-ANP, plasma renin activity, aldosterone, angiotensin II) of Captopril, oral ACE inhibitor, and Bunazosin, oral alpha 1-blocker, were investigated in 28 patients with congestive heart failure at rest and after exercise." | 7.67 | [The effect of bunazosin vs captopril on hemodynamic and neurohumoral parameters in patients with congestive heart failure]. ( Hasegawa, K; Inoue, S; Kakumae, S; Kawahara, Y; Nakamura, T; Nakao, M; Nezuo, S; Sawayama, T; Tadaoka, S, 1989) |
| " The effects of the angiotensin-converting enzyme (ACE) inhibitor lisinopril on plasma vasoactive intestinal polypeptides (VIP) and plasma noradrenaline, adrenaline and dopamine were studied in 12 patients with congestive heart failure over two consecutive 48-hr periods." | 7.67 | Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes. ( Dickstein, K; Kaada, B; Woie, L, 1987) |
| "We investigated atrial natriuretic factor (ANF) in humans, measuring plasma immunoreactive (ir) ANF (in femtomoles per milliliter), and renal, hormonal, and hemodynamic responses to ANF infusion, in normal subjects (NL) and congestive heart failure patients (CHF)." | 7.67 | Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. ( Atlas, SA; Camargo, MJ; Clark, M; Cody, RJ; Covit, AB; Kubo, SH; Laragh, JH; Pondolfino, K; Ryman, KS; Shaknovich, A, 1986) |
| "The temporal changes in the plasma concentration of immunoreactive atrial natriuretic factor (iANF) were studied in six conscious dogs with an arteriovenous (AV) fistula, a model of chronic high-output heart failure." | 7.67 | Atrial natriuretic factor secretion in dogs with experimental high-output heart failure. ( Davis, JO; Freeman, RH; Vari, RC; Verburg, KM; Villarreal, D, 1987) |
| "We studied the effects of alpha-human atrial natriuretic factor (alpha-h-ANF) on diuresis, glomerular filtration rate (GFR), natriuresis, atrial blood pressure (BP), heart rate (HR) and plasmatic levels of aldosterone, renin activity (PRA), antidiuretic hormone (ADH) in 21 patients with congestive heart failure (CHF), (NYHA, class IV) and 15 healthy volunteers." | 7.67 | [Hemodynamic and renal effects of synthetic atrial natriuretic factor (alpha-h-ANF) in patients with congestive heart failure]. ( Bernardi, P; Cappelli, M; Fontana, F; Guardigli, G, 1988) |
| "The acute hemodynamic and hormonal effects of the oral angiotensin-converting enzyme (ACE) inhibitor lisinopril (MK-521) were assessed over a period of 96 hours in 12 patients with heart failure." | 7.67 | Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. ( Aarsland, T; Abrahamsen, AM; Cummings, S; Dickstein, K; Fyhrquist, F; Gomex, HJ; Hagen, E; Kristianson, K; Woie, L, 1986) |
| "In this study, the use of enalapril and captopril is compared in the treatment of congestive heart failure." | 7.67 | Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril. ( Cohn, JN; Levine, TB; Olivari, MT, 1986) |
| "Angiotensin II (AII), aldosterone (Aldo) and arginine vasopressin (AVP) in plasma were determined during basal conditions in seventeen patients with congestive heart failure and in seventeen control subjects." | 7.67 | Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure. ( Danielsen, H; Jensen, T; Madsen, M; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1986) |
| "We studied the effects of furosemide on plasma renin and plasma aldosterone in 8 patients with mild to moderate congestive heart failure." | 7.67 | Acute changes in plasma renin activity, plasma aldosterone concentration and plasma electrolyte concentrations following furosemide administration in patients with congestive heart failure--interrelationships and diuretic response. ( Mulder, H; Schopman, W; van der Lely, AJ, 1987) |
| "Acute effects of 200 mg of orally given 4-[2-(methylamino)ethyl]-o-phenylene diisobutyrate hydrochloride (ibopamine hydrochloride) which is a new diisobutyric ester of N-methyldopamine, on hemodynamics and metabolism were evaluated in 11 patients with severe heart failure (New York Heart Association class IV)." | 7.67 | Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure. ( Kakuta, Y; Kanamaru, M; Kodera, T; Konishi, T; Morimoto, Y; Nakano, T; Takezawa, H, 1986) |
| "To define the short-term haemodynamic, hormonal and electrolyte effects of enalapril in chronic heart failure, we administered it to nine patients." | 7.66 | Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure. ( Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983) |
| "1 The angiotensin-converting-enzyme inhibitor captopril is known to produce beneficial haemodynamic effects in patients with chronic congestive heart failure." | 7.66 | Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure. ( Baraldi, P; Mattioli, G; Ricci, S; Teglio, V; Zaniol, P, 1982) |
| "Studies using a competitive inhibitor of angiotensin II (saralasin) or converting enzyme inhibitors (teprotide, captopril, enalapril) have established that the renin-angiotensin system participates in the control of vascular tone in congestive heart failure both in experimental settings and in patients." | 7.66 | The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril. ( Brunner, HR; Turini, GA; Waeber, B, 1983) |
| "Enalapril, the new converting enzyme inhibitor, was administered to eight patients with heart failure (NYHA Functional Class II to IV) during standardised and intensive haemodynamic, hormone, and electrolyte monitoring." | 7.66 | Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. ( Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983) |
| "The angiotensin-converting enzyme inhibitor, captopril, was given to 19 patients with severe heart failure." | 7.66 | Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. ( Boomsma, F; Hugenholtz, PG; Laird-Meeter, K; Man in't veld, AJ; Schalekamp, MA; Simoons, ML; Wenting, GJ; Woittiez, AJ, 1983) |
| "We studied the hemodynamic response to orally administered hydralazine (30 mg) and examined the changes in neurohumoral factors in 16 aged patients with chronic congestive heart failure." | 7.66 | Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure. ( Kuwajima, I; Matsushita, S; Murakami, M; Sakai, M; Ueda, K, 1983) |
| "1 In an open study the clinical short-term and long-term effects of low-dose captopril (mean daily dose 45 +/- 15 mg) were evaluated in 20 patients with severe congestive heart failure refractory to conventional treatment with digitalis and diuretics." | 7.66 | Short and long-term effects of treatment with low dose captopril in patients with severe congestive heart failure. ( Dahlström, U; Karlberg, BE, 1982) |
| "1 The efficacy of the converting-enzyme inhibitor captopril in the management of severe congestive heart failure was assessed in 14 patients over 360-885 days by clinical evaluation, M-mode echocardiography, systolic time intervals, plasma renin activity, and plasma aldosterone." | 7.66 | Long-term treatment of congestive heart failure with captopril. ( Drobinski, G; Eugene, M; Evans, J; Grosgogeat, Y; Komajda, M; Laurenceau, JL, 1982) |
| "The long-term effects of captopril therapy were assessed by sequential hemodynamic studies over a 6 month period in 19 patients with resistant congestive heart failure." | 7.66 | Long-term control of congestive heart failure with captopril. ( Bravo, EL; Castle, LW; Fouad, FM; Hart, NJ; Salcedo, EE; Tarazi, RC, 1982) |
| "The hemodynamic and hormonal responses to acute and chronic captopril therapy and to its temporary withdrawal were studied in seven patients with congestive heart failure." | 7.66 | Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. ( Espiner, EA; Ikram, H; Maslowski, AH; Nicholls, MG; Penman, T; Scandrett, MS, 1982) |
| "The systemic, pulmonary, and limb circulatory responses to the angiotensin-converting enzyme inhibitor, captopril, were determined in 10 patients with severe, chronic heart failure." | 7.66 | Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. ( Creager, MA; Faxon, DP; Gavras, H; Halperin, JL; Ryan, TJ; Schick, EC, 1981) |
| " To assess which of these stimuli is the more potent, we measured aldosterone, potassium, and angiotensin II responses to the oral converting enzyme inhibitor captopril in five patients with resistant congestive heart failure during digoxin and furosemide maintenance therapy." | 7.66 | Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy. ( Espiner, EA; Ikram, H; Lun, S; Maslowski, AH; Nicholls, MG; Scandrett, MS, 1981) |
| "The effect of hydroflumethiazide (HFT) on renal excretion of sodium, chloride, and potassium was studied in congestive heart failure and related to urinary excretion of thiazide and aldosterone." | 7.66 | Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone. ( Aakvaag, A; Brørs, O; Enger, E; Foss, OP; Jacobsen, S, 1981) |
| "The renin-angiotensin-aldosterone system and electrolyte levels in 11 patients with heart failure controlled on digoxin and frusemide were investigated after separate periods of Slow K, spironolactone, and amiloride therapy." | 7.65 | Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. ( Espiner, EA; Hughes, H; Nicholls, MG; Rogers, T, 1976) |
| "Spironolactone was evaluated as a diuretic in the therapy of six patients with chronic severe congestive heart failure, during which metabolic balance studies were performed." | 7.64 | EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE. ( CARRUTHERS, BM; LEDRAY, RD; MCINTOSH, HW; SERAGLIA, M; WALSH, GC, 1963) |
| " Following administration of LCZ696, the Cmax of sacubitril (neprilysin inhibitor prodrug), LBQ657 (active neprilysin inhibitor), and valsartan were reached within 0." | 6.82 | Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. ( Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I, 2016) |
| "Aldosterone has a key role in the pathophysiology of heart failure." | 6.74 | Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. ( Connell, JM; Freel, EM; Latini, R; Lewsey, JD; Maggioni, AP; McMurray, JJ; Pitt, B; Solomon, S; Tsorlalis, IK, 2009) |
| "Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months." | 6.73 | Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). ( Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M, 2007) |
| "Aliskiren appeared to suppress the RAAS as effectively as ramipril in the short term." | 6.73 | Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. ( Bobillier, A; Gardner, R; Hillier, C; MacFadyen, R; Mann, J; McDonagh, T; McMurray, J; Murdoch, D; Seed, A, 2007) |
| "Aldosterone levels were determined by solid-phase radioimmunoassay." | 6.70 | Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. ( Colombo, PC; Jorde, UP; Katz, SD; Latif, F; Le Jemtel, TH; Vittorio, T, 2002) |
| "The use of nitrates for treatment of heart failure is encumbered by tolerance, caused by whatever mechanism, which has been reported only in a few instances with sydnonimines." | 6.69 | Infusions with molsidomine and isosorbide-5-mononitrate in congestive heart failure: mechanisms underlying attenuation of effects. ( Beyerle, A; Hähnel, I; Lampen, M; Lehmann, G; Reiniger, G; Schömig, A, 1998) |
| "In chronically treated heart failure patients with full angiotensin-converting enzyme-inhibition and diuretics, there is decreased compliance of the aorta and its major branches, which is inversely correlated with the aldosterone escape phenomenon." | 6.69 | Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. ( Clement, DL; Cohn, JN; De Buyzere, ML; Duprez, DA; Morgan, D; Rietzschel, ER; Taes, Y, 1998) |
| " All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12." | 6.68 | The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995) |
| " The dosage of both drugs was individually adjusted in time according to the results of serum potassium and renal function." | 6.67 | Combined therapy of captopril and spironolactone for refractory congestive heart failure. ( Han, YL; Hu, XL; Jing, QM; Liu, JQ; Tong, M, 1994) |
| "MRAs are a recognized treatment for heart failure and hypertension." | 6.66 | Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review. ( Mohammadpour, AH; Omidkhoda, N; Sahebkar, A; Sathyapalan, T; Vakilian, F, 2020) |
| "It is concluded that in patients with congestive heart failure rhein does not inhibit renal or platelet eicosanoid metabolism, nor does it modify renal function, sodium excretion or the renal response to diuretics." | 6.66 | Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure. ( Belli, B; Fascetti, P; Gentilini, P; La Villa, G; Laffi, G; Marra, F; Meacci, E, 1989) |
| "Benazepril hydrochloride is a nonsulfhydryl, long-acting angiotensin-converting enzyme inhibitor that is orally effective." | 6.66 | A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. ( Boland, MJ; Cinquegrani, MP; Insel, J; Mirvis, DM; Rubin, SA; Shanes, J; Whalen, JJ, 1989) |
| "In captopril-treated patients, the supine aldosterone levels exceeded the normal range and were as high as in placebo-treated patients." | 6.66 | Aldosterone and prolactin responsiveness after prolonged treatment of congestive heart failure with captopril. ( Althoff, PH; Bussmann, WD; Fassbinder, W; Hadler, D; Jungmann, E; Kaltenbach, M; Schöffling, K; Störger, H, 1985) |
| "In addition, obesity is accompanied by increased signaling through the leptin receptor, which can promote activation of both the sympathetic nervous system and the renin-angiotensin system and can directly stimulate the secretion of aldosterone." | 6.58 | Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. ( Packer, M, 2018) |
| " The observation of reduced nitric oxide bioavailability in hyperaldosteronism implied the generation of oxidative stress by aldosterone." | 6.48 | Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases. ( Queisser, N; Schupp, N, 2012) |
| "Aldosterone is a mineralocorticoid hormone synthesized by the adrenal glands that has several regulatory functions to help the body maintain normal volume status and electrolyte balance." | 6.47 | Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. ( Nappi, JM; Sieg, A, 2011) |
| "Aldosterone is an important mediator in the pathogenesis of heart failure, and increased plasma aldosterone levels are associated with a poor prognosis." | 6.44 | Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues. ( Francis, GS; Kalidindi, SR; Tang, WH, 2007) |
| "Aldosterone blockade has been shown to be effective in reducing mortality in patients who have severe heart failure because of systolic left ventricular dysfunction (SLVD) and those who have heart failure and SLVD post-myocardial infarction." | 6.44 | Aldosterone blockade in patients with chronic heart failure. ( Pitt, B, 2008) |
| "The neurohormonal model of congestive heart failure (CHF) has replaced the previously accepted hemodynamic model." | 6.43 | The role of aldosterone blockers in the management of chronic heart failure. ( Coca, SG; Perazella, MA, 2005) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | 6.43 | Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006) |
| "Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors." | 6.43 | Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. ( Pringle, S; Shah, NC; Struthers, A, 2006) |
| "Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases." | 6.42 | Aldosterone receptor antagonists for hypertension: what do they offer? ( Krum, H; Liew, D, 2003) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 6.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass." | 6.42 | The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 6.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| " New interest in therapy with aldosterone antagonists was stimulated by results of a 2-year study of 1663 patients with heart failure that showed a 30% relative risk reduction of death among patients given a subhemodynamic dosage of spironolactone, a nonselective aldosterone antagonist, compared with placebo, in addition to standard therapy of diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, and digitalis." | 6.41 | Aldosterone, a new appreciation of its role in heart failure. ( Cha, AJ; Judge, KW; Malecha, SE, 2000) |
| "Aldosterone has been identified as a critically important neurohormone with direct detrimental effects on the myocardium." | 6.41 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. ( Miller, AB; Srivastava, P, 2001) |
| "Aldosterone was shown to promote cardiac fibrosis in various experimental models." | 6.41 | Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. ( Alla, F; Dousset, B; Zannad, F, 2001) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 6.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment." | 6.39 | Aldosterone and heart failure. ( Zannad, F, 1995) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a detrimental effect on parasympathetic and baroreflex function." | 6.39 | Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. ( Struthers, AD, 1996) |
| "Concern about hyperkalemia is thought to contribute to this lack of evidence-based therapy." | 5.91 | Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor. ( Johnson, M; McMahon, G; Morrison, FJ; Su, M; Turchin, A, 2023) |
| "The role of taurine in the treatment of congestive heart failure (CHF) in dogs without systemic deficiency is unexplored." | 5.91 | The effect of taurine supplementation on the renin-angiotensin-aldosterone system of dogs with congestive heart failure. ( Adin, D; Brethel, S; Girens, R; Locker, S; Meurs, K; Rivera, P, 2023) |
| " In addition, the patient's BP decreased, proteinuria was reduced, diuretics could be discontinued, and his calcium channel blocker dosage was decreased." | 5.51 | Successful Depressor Effect Concomitant with Complete Normalization of High Renin and Aldosterone Profile by Percutaneous Transluminal Renal Angioplasty in a Patient with Acute Exacerbated Heart Failure with Preserved Ejection Fraction. ( Okamura, K; Shirai, K; Takamiya, Y; Urata, H, 2019) |
| "Aldosterone activation was demonstrated in all three groups; however, dietary sodium restriction, in contrast to high sodium, resulted in early (10 days) activation of PRA and aldosterone." | 5.42 | Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure. ( Borgeson, DD; Burnett, JC; Grantham, JA; Luchner, A; Miller, WL; Redfield, MM, 2015) |
| "AVP may promote ventricular remodeling." | 5.42 | The secretion patterns and roles of cardiac and circulating arginine vasopressin during the development of heart failure. ( Chen, X; Gao, X; Li, Q; Lu, G; Tang, K, 2015) |
| "The mineralocorticoid receptor antagonist spironolactone has been shown to improve cardiac function and reverse left ventricular hypertrophy in heart failure patients, but there are no consistent findings on the efficacy and safety in hemodialysis patients." | 5.41 | Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients. ( Chen, Z; Li, Z; Liu, R; Lu, G; Sun, Y; Sun, Z, 2023) |
| "Aldosterone appears to be a main marker of adverse clinical outcome, in accordance with the literature." | 5.40 | Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. ( Arnone, G; Arnone, MT; Assennato, P; Corrado, E; Mignano, A; Novo, G; Novo, S; Pitruzzella, V; Rotolo, A, 2014) |
| "Aldosterone levels increase during AHF hospitalization and remain increased long after discharge." | 5.39 | Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. ( Fought, A; Gheorghiade, M; Girerd, N; Konstam, MA; Kwasny, MJ; Maggioni, A; Pang, PS; Subacius, H; Swedberg, K; Zannad, F, 2013) |
| "Heart failure is accompanied by electrolyte disturbance including reduced calcium and sodium in the extracellular milieu but increased calcium within cells, a phenomenon called "calcium paradox"." | 5.36 | Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism. ( Abdallah, Y; Schlüter, KD; Schreckenberg, R; Tastan, I; Wenzel, S, 2010) |
| "Congestive heart failure was induced in 3 groups (n=6 per group) of dogs by tachypacing." | 5.36 | Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. ( Boerrigter, G; Burnett, JC; Cataliotti, A; Costello-Boerrigter, LC; Harty, GJ, 2010) |
| "Reversal of cardiac fibrosis is a major determinant of the salutary effects of mineralocorticoid receptor antagonists in heart failure." | 5.35 | Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. ( Beugels, IP; Cohuet, GM; de Gooyer, ME; Emmen, JM; Hermans, JJ; Hilbers, PA; Minnaard-Huiban, M; Ottenheijm, HC; Pieterse, K; Plate, R; Roumen, L; Ruijters, E; Smits, JF; van Essen, H, 2008) |
| "CHF was characterized by left ventricular remodeling and impaired systolic and diastolic function." | 5.35 | Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. ( Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2008) |
| "The appearance of SHPT in aldosteronism, induced by fallen plasma [Ca]o, leads to PTH-mediated Ca overloading of PBMC and their increased production of H2O2." | 5.33 | Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. ( Ahokas, RA; Bhattacharya, SK; Gerling, IC; Goodwin, KD; Sun, Y; Weber, KT, 2006) |
| "Carvedilol was then commenced and up titrated over the next 6-8 weeks and all samples were again obtained." | 5.33 | Carvedilol reduces aldosterone release in systolic heart failure. ( Aggarwal, A; Campbell, DJ; Wong, J, 2006) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 5.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "Aldosterone promotes collagen synthesis and structural remodeling of target organs such as the heart." | 5.31 | Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Horie, H; Kinoshita, M; Mabuchi, N; Maeda, K; Matsumoto, T; Ohnishi, M; Sawaki, M; Sugimoto, Y; Tsutamoto, T; Tsutsui, T; Wada, A, 2000) |
| ""Aldosterone escape" was defined as being present when plasma aldosterone levels were above the normal range in our laboratory (>42 nmol/L)." | 5.31 | Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. ( Anker, SD; Bonizzato, A; Cabrini, G; Cicoira, M; Coats, AJ; Franceschini, L; Golia, G; Graziani, M; Rossi, A; Zanolla, L; Zardini, P, 2001) |
| "Aldosterone escape was defined as plasma levels of aldosterone above the normal range in our laboratory (> 0." | 5.31 | Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Caruso, B; Cicoira, M; Franceschini, L; Golia, G; Rossi, A; Zanolla, L; Zardini, P; Zeni, P, 2002) |
| " On the basis of the estimate of the dosing of digoxin these patients were divided into two groups: the first with therapeutic and the second with subtherapeutic concentrations of digoxin in serum." | 5.30 | The level of plasma neuroendocrine activity and the concentration of digoxin in the serum of patients with mild chronic heart failure. ( Chmara, E; Jablecka, A; Korzeniowska, K, 1998) |
| "Although angiotensin converting enzyme inhibitor therapy is an established approach in the treatment of chronic heart failure, the required dosage remains unclear." | 5.29 | Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. ( Baumgartner, W; Bergler-Klein, J; Globits, S; Glogar, D; Ogris, E; Pacher, R; Teufelsbauer, H; Wutte, M, 1993) |
| "hr/mL and Cmax was 143." | 5.29 | Invasive pharmacodynamics of fosinopril in patients with congestive heart failure. ( Ford, NF; Fulmor, IE; Hui, KK; Natarajan, C; Smith, RA, 1995) |
| "Chagasic patients with congestive heart failure are usually treated with digitalis and converting enzyme inhibitors." | 5.29 | Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. ( Bellabarba, G; Bishop, W; Davila, DF; Donis, JH; Hernandez, L; Khoury, AM; Lemorvan, C; Torres, A, 1996) |
| "After treatment for the heart failure plasma atrial natriuretic peptide fell considerably and there were associated increases in plasma aldosterone and plasma renin activity." | 5.28 | Atrial natriuretic peptide, aldosterone, and plasma renin activity in peripartum heart failure. ( Adesanya, CO; Anjorin, FI; MacGregor, GA; Parry, EH; Sada, IA; Sagnella, GA, 1991) |
| "Thus, in patients with dilated cardiomyopathy and mild cardiac dysfunction, plasma ANF levels are not increased by volume expansion as observed in N." | 5.28 | Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. ( De Campora, P; De Luca, N; Enea, I; Lembo, G; Mele, AF; Ricciardelli, B; Romano, M; Rubattu, S; Tritto, C; Volpe, M, 1991) |
| " Angiotensin-converting enzyme inhibitors cause an acute fall in creatinine clearance which may reduce the effects of loop diuretics and attention must be paid to diuretic dosage when initiating angiotensin-converting enzyme inhibitors for the treatment of cardiac failure." | 5.28 | Acute administration of captopril lowers the natriuretic and diuretic response to a loop diuretic in patients with chronic cardiac failure. ( Davies, E; Edwards, CR; Flapan, AD; Shaw, TR; Waugh, C; Williams, BC, 1991) |
| "1) Captopril was orally administered in a dose of 12." | 5.28 | Effect of captopril on congestive heart failure. ( Matsuo, H; Nishida, M; Obata, H; Sano, H; Yasuda, H, 1990) |
| "Aldosterone values were highly correlated with the urine potassium/sodium ratio." | 5.27 | The renin-angiotensin--aldosterone system and the clinical course of acute myocardial infarction. ( Ceremuzyński, L; Michorowski, B, 1983) |
| "Patients with marked edema due to congestive heart failure had plasma levels of atrial natriuretic factor five times higher than normal (P less than 0." | 5.27 | Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. ( Grekin, RJ; Ostafin, EA; Shenker, Y; Sider, RS, 1985) |
| "Enalapril was effective therapy for chronic CHF." | 5.27 | Clinical and hemodynamic experience with enalapril in congestive heart failure. ( Cody, RJ, 1985) |
| " Therefore, during chronic captopril therapy of CHF, a reduction of diuretic dosage may be necessary to prevent orthostatic hypotension." | 5.26 | Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. ( Cody, RJ; Franklin, KW; Laragh, JH, 1982) |
| "Thus, in CMH, congestive heart failure is attended by increased plasma renin activity without a significant increase in aldosterone production, a dissociation which does not appear to be due to adrenal unresponsiveness to angiotensin II or to potassium depletion." | 5.26 | Renin and aldosterone in the cardiomyopathic hamster in congestive heart failure. ( Galla, JH; Hayslett, JP; Kotchen, TA; Schneider, G, 1977) |
| " The data for this innovative medication are mainly based on the PARADIGM-HF study, which included heart failure with reduced ejection fraction (HFrEF)-diagnosed patients and indicated a major improvement in morbidity and mortality when S/V is administrated compared to enalapril." | 5.22 | Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. ( Babes, EE; Behl, T; Bungau, SG; Horvath, T; Iovanovici, DC; Moisi, M; Rus, M; Tit, DM; Vesa, CM, 2022) |
| "Patients with SRV treated with eplerenone showed an improvement of an altered baseline CTB profile suggesting that reduction of myocardial fibrosis might be a therapeutic target in these patients." | 5.17 | Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study. ( Casaldàliga, J; Dos, L; Estruch, M; Ferreira-González, I; García-Dorado, D; Marsal, JR; Mas, A; Ordóñez-Llanos, J; Pijuan, A; Pons-Lladó, G; Pujadas, S; Serra, R; Subirana, M, 2013) |
| "The long-term effects of the angiotensin-receptor blocker candesartan, the angiotensin-converting enzyme inhibitor enalapril or their combination have been incompletely studied in a large cohort of patients with heart failure not treated with beta-blockers." | 5.14 | Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. ( Afzal, R; Floras, J; McKelvie, RS; Rouleau, JL; White, M; Yusuf, S, 2009) |
| "In patients with heart failure, few data describe the neurohormonal response to nesiritide and furosemide either alone or in combination." | 5.14 | Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction. ( Gottwald, MD; Mills, RM; Oren, RM; Sica, D, 2010) |
| "Administration of enalapril to infants with single-ventricle physiology in the first year of life did not improve somatic growth, ventricular function, or heart failure severity." | 5.14 | Enalapril in infants with single ventricle: results of a multicenter randomized trial. ( Altmann, K; Atz, AM; Barker, PC; Border, WL; Chung, WK; Ghanayem, NS; Hsu, DT; Levine, JC; Mahony, L; Margossian, R; McCrindle, BW; Mital, S; Pearson, GD; Ravishankar, C; Sleeper, LA; Stylianou, MP; Williams, RV; Zak, V, 2010) |
| "Using a single-blinded, randomized, placebo-controlled study design, we investigated the sympathetic, hemodynamic, neurohumoral, and ventilatory effects of theophylline in patients with congestive heart failure compared with healthy control subjects closely matched for age, sex, and body mass index." | 5.11 | Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure. ( Andreas, S; Delekat, A; Grunewald, RW; Hasenfuss, G; Lüthje, L; Reiter, H; Somers, VK, 2004) |
| "ACE Insertion (I) or Deletion (D) genotype was determined in 74 patients with chronic heart failure who were randomly assigned to receive either high-dose or low-dose enalapril over a period of 6 months." | 5.11 | Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. ( Fowler, MB; Tang, WH; Vagelos, RH; Yee, YG, 2004) |
| "In RALES, low doses of the mineralocorticoid receptor (MR) antagonist spironolactone, added to standard of care for severe heart failure, improved survival by 30% and lowered hospitalization by 35%." | 5.11 | RALES, EPHESUS and redox. ( Funder, JW, 2005) |
| "To compare effects of various regimens of long-term monotherapy with quinapril (an ACE inhibitor) and valsartan (a type 1 angiotensin II receptors blocker) and combined therapy with these drugs on the activity of heurohormonal systems and 24-h heart rate variability (HRV) in patients with stable moderate chronic cardiac failure (CCF)." | 5.11 | [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o ( Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV, 2005) |
| "To investigate the effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure (CHF)." | 5.11 | [Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure]. ( Gao, LJ; Lin, XY; Xiao, LZ; Zhang, HF, 2005) |
| "We evaluated whether spironolactone would improve cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure (CHF)." | 5.10 | Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T, 2002) |
| "To determine changes in RAS activation and clinical correlates following furosemide withdrawal in elderly heart failure patients without left ventricular systolic dysfunction." | 5.10 | Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. ( Hoefnagels, WH; Jansen, RW; Sweep, FC; van Kraaij, DJ, 2003) |
| "This study evaluated the short-term and long-term effects of the angiotensin II type 1 receptor antagonist candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure (CHF)." | 5.10 | Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. ( Alegria, E; Arens, HA; Dabrowski, M; Dukát, A; Kiowski, W; Lenz, K; Marks, DS; Miric, M; Mitrovic, V; Seferovic, P; Spinar, J; Willenbrock, R, 2003) |
| "The effect of torasemide and furosemide therapy was compared in 50 patients who had chronic heart failure and symptoms [NYHA class II-III] despite long-term therapy with both low-dose furosemide and angiotensin-converting enzyme inhibitors." | 5.10 | Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. ( Akutagawa, O; Fukuda, M; Hayashi, T; Honda, K; Okamoto, M; Sasaki, T; Yamato, M, 2003) |
| "We sought to compare the neurohormonal responses and clinical effects of long-term, high-dose versus low-dose enalapril in patients with chronic heart failure (CHF)." | 5.10 | Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. ( Benedict, CR; Fowler, MB; Liss, CL; Tang, WH; Vagelos, RH; Willson, K; Yee, YG, 2002) |
| "The study aimed to assess the hemodynamic and neuroendocrine effects of candoxatril and frusemide compared with placebo in patients with mild chronic heart failure." | 5.09 | Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. ( Bostrøm, P; Christensen, CC; Parikka, H; Rykke, EO; Toivonen, L; Westheim, AS, 1999) |
| "We studied acute (day 1) and long-term (day 14) effects of endothelin (ET) receptor blockade with the mixed ET(A/B) antagonist bosentan (1 g twice daily; n = 18) or placebo (n = 12) on plasma angiotensin II and aldosterone in 30 patients with symptomatic chronic heart failure taking angiotensin-converting enzyme inhibitors, diuretics, and digoxin." | 5.09 | Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. ( Bertel, O; Clozel, M; Kiowski, W; Nicholls, MG; Rickenbacher, P; Sütsch, G; Yandle, TG, 2000) |
| "We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)." | 5.09 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001) |
| "In patients with early stages of heart failure, digoxin may prevent a progressive deterioration in heart rate variability, whereas ibopamine does not show statistically significant effects." | 5.08 | Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. ( Boomsma, F; Brouwer, J; Dunselman, PH; Haaksma, J; Lie, KI; Man in 't Veld, AJ; van Veldhuisen, DJ, 1995) |
| "Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear." | 5.08 | Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. ( Cas, LD; Metra, M; Missale, C; Spano, PF, 1995) |
| "We studied 22 patients with heart failure who were receiving constant daily doses of digoxin, diuretics, and angiotensin-converting enzyme (ACE) inhibitors." | 5.08 | Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. ( Alam, M; Gheorghiade, M; Goldstein, S; Hall, VB; Jacobsen, G; Rosman, H, 1995) |
| "Our primary objective was to compare the effects of three different doses of candoxatrilat with the effects of placebo on urinary volume in patients with moderately severe heart failure." | 5.08 | Renal response to candoxatrilat in patients with heart failure. ( Cleland, JG; Good, JM; Jackson, N; Oakley, CM; Peters, M; Wilkins, M, 1995) |
| ") active dopamine (DA) agonist ibopamine, we examined 10 patients with mild to moderate congestive heart failure (CHF), who were stable while treated with digoxin and diuretics." | 5.08 | Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. ( Girbes, AR; Lie, KI; Lieverse, AG; Meijer, S; Reitsma, WD; Smit, AJ; van Veldhuisen, DJ; Zijlstra, JG, 1995) |
| "A random sample was studied of 25 outpatients with symptoms of mild to moderate heart failure, despite treatment with diuretics, digoxin, and angiotensin converting enzyme inhibitors." | 5.08 | Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure. ( Chin Kon Sung, UG; Corbeij, HM; de Vries, RJ; Dunselman, PH; Lie, KI; van Gilst, WH; van Veldhuisen, DJ, 1996) |
| "To assess the pharmacodynamic activity and safety of rising single and multiple doses of intravenous quinaprilat compared with placebo in patients with New York Heart Association (NYHA) class III and IV congestive heart failure who were receiving digitalis or diuretic therapy or both." | 5.08 | Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. ( Bakovic-Alt, R; Bonzel, T; Mitrovic, V; Mudra, H; Posvar, EL; Schmidt, W; Strand, JC, 1996) |
| "To assess the differential effects of low dose (5 mg) and high dose (20 mg) lisinopril treatment on cardiovascular hormones, renal function, and blood pressure over 24 hours in patients with heart failure." | 5.08 | Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. ( Coutie, WJ; Davidson, NC; Struthers, AD; Webb, DJ, 1996) |
| "The purpose of this study was to determine the additive value of ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors." | 5.08 | Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. ( Girbes, AR; Kruik, J; Lie, KI; Szabó, BM; van der Burgh, PH; van Veldhuisen, DJ, 1996) |
| " The aim of the study was to investigate the haemodynamic and endocrine effects of the NEP inhibitor candoxatril in patients with congestive heart failure (CHF)." | 5.08 | Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. ( Drummer, C; Gerzer, R; Kentsch, M; Müller-Esch, G; Nötges, A; Otter, W, 1996) |
| "This study was done to determine whether the difference in duration of action of the long-acting angiotensin-converting enzyme (ACE) inhibitor spirapril compared with the short-acting ACE inhibitor captopril affects clinical efficacy in patients with congestive heart failure." | 5.08 | Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure. ( de Graeff, PA; Hillege, H; Lie, KI; van den Broek, SA; van Gilst, WH; van Veldhuisen, DJ; Wesseling, H, 1997) |
| "Serum levels endothelin-1,2 aldosterone, renin activity were performed in 52 patients with chronic congestive heart failure during captopril therapy." | 5.08 | [Does captopril decrease endothelial production of endothelin?]. ( Halawa, B; Mazurek, W, 1997) |
| "It has been proposed that worsening of heart failure with dihydropyridines, such as nicardipine, is related to the activation of the neuroendocrine system." | 5.08 | Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy. ( Benatar, D; Gheorghiade, M; Hall, V; Reddy, S, 1998) |
| "To describe neurohormonal activation in patients with mild or moderate heart failure and how it may be modified by treatment with ramipril." | 5.07 | Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. ( Amtorp, O; Gundersen, T; Nilsson, B; Remes, J; Sigurdsson, A; Swedberg, K, 1994) |
| "Left ventricular (LV) function and plasma levels of cardiovascular hormones were examined in patients with severe chronic congestive heart failure (CHF), randomized to placebo or enalapril, in addition to conventional therapy." | 5.07 | Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). ( Eneroth, P; Eriksson, SV; Kjekshus, J; Offstad, J; Swedberg, K, 1994) |
| "This study was conducted to determine the efficacy and safety of long-term treatment with the orally active dopamine agonist ibopamine in patients with mild to moderate chronic congestive heart failure and to compare the results with those of treatment with digoxin and placebo." | 5.07 | Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). ( Brouwer, J; Dohmen, HJ; Dunselman, PH; Lie, KI; Lok, DJ; Man in 't Veld, AJ; Pasteuning, WH; Poortermans, JC; van Veldhuisen, DJ; Withagen, AJ, 1993) |
| "The acute renal effects of xamoterol, a partial beta 1-agonist, were studied in 12 patients with congestive heart failure (NYHA II-III) in stable condition on diuretic therapy for at least 6 weeks." | 5.07 | Renal effects of xamoterol in patients with moderate heart failure. ( Bøtker, HE; Jensen, HK; Krusell, LR; Sørensen, EV, 1993) |
| "In an open trial 5 mg ramipril daily for 2 weeks was administered to 11 patients with congestive heart failure." | 5.07 | Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin II and aldosterone in patients with chronic congestive heart failure. ( Brockmeier, D; Heintz, B; Kierdorf, H; Kirsten, R; Lückel, G; Maigatter, S; Nelson, K; Rangoonwala, B; Sieberth, HG; Verho, M, 1992) |
| " Nine patients with compensated heart failure were infused with synthetic arginine vasopressin at a rate of 0." | 5.07 | Renal, haemodynamic and hormonal interactions between atrial natriuretic factor and arginine vasopressin in patients with congestive heart failure. ( Arakawa, N; Funakoshi, T; Hiramori, K; Nakamura, M; Yoshida, H, 1992) |
| "In a randomized single-blind cross-over trial, the efficacy of digoxin, angiotensin-converting enzyme (ACE) inhibition by quinapril, and their combination on exercise tolerance, heart size (echocardiography), and neurohumoral systems was investigated in 19 outpatients with congestive heart failure (CHF) New York Heart Association functional class II and sinus rhythm." | 5.06 | Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm. ( Elsner, D; Kromer, EP; Riegger, GA, 1990) |
| "To study the haemodynamic and neurohumoral effects of nisoldipine (2 X 10 mg) vs captopril (3 X 25 mg), 24 patients with heart failure (New York Heart Association class II and III) due to coronary artery disease were treated in a randomized double-blind trial over 3 months." | 5.06 | Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study. ( Aschenberg, W; Hobuss, M; Schofer, J; Tews, A, 1990) |
| "The effects on cardiac function of captopril (CPT) and digoxin (D) were compared in a study of 16 patients with chronic heart failure due to ischemic heart disease (15) and to congestive cardiomyopathy (1) (New York Heart Association class II n." | 5.06 | Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. ( Agabiti Rosei, E; Alicandri, C; Beschi, M; Boni, E; Castellano, M; Fariello, R; Muiesan, G; Zaninelli, A, 1987) |
| "The acute hemodynamic, hormonal, and pharmacokinetic aspects of treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril were assessed in two studies in 24 patients with chronic stable congestive heart failure (CHF)." | 5.06 | Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. ( Dickstein, K, 1987) |
| " In this study we evaluated the effects of dopamine and the dopaminergic agonists ibopamine and dihydroergotoxine on aldosterone secretion and plasma renin activity in 13 patients with chronic heart failure." | 5.06 | Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure. ( Dei Cas, L; Memo, M; Metra, M; Missale, C; Sigala, S; Spano, PF, 1989) |
| "We evaluated the effects of intravenous hydralazine (5 to 30 mg) and oral nifedipine (20 to 80 mg) on plasma catecholamines, renin, and aldosterone in 18 patients with severe chronic heart failure." | 5.06 | Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure. ( Elkayam, U; Freidenberger, L; Hsueh, W; Rahimtoola, SH; Roth, A; Weber, L, 1986) |
| "The acute effects of the angiotensin converting-enzyme inhibitor captopril on regional blood flow, renal hemodynamics and sodium excretion were studied in 12 patients with severe congestive heart failure." | 5.05 | Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. ( Bernard, DB; Creager, MA; Faxon, DP; Gavras, H; Halperin, JL; Melidossian, CD; Ryan, TJ, 1981) |
| "The acute hemodynamic effects and long-term therapeutic actions of low doses of the oral angiotensin-converting enzyme (ACE) inhibitor captopril (CPT) were evaluated in 18 patients with severe chronic congestive heart failure (CHF)." | 5.05 | Hemodynamic effects of captropril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin. ( Coxon, R; Sharpe, DN, 1982) |
| "Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days." | 5.05 | Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982) |
| "The effects of human alpha atrial natriuretic factor following bolus injection of increasing doses and during a continuous 30 minute infusion were investigated in 7 patients with severe congestive cardiac failure (NYHA III-IV)." | 5.05 | [The atrial natriuretic factor in severe congestive heart failure. Plasma level, hemodynamic, hormonal and renal effects]. ( Kochsiek, K; Kromer, EP; Riegger, AJ, 1985) |
| " Studies using gene-modified mice deficient in Nox2 activity indicate that Nox2 activation contributes to angiotensin II-induced cardiomyocyte hypertrophy, atrial fibrillation, and the development of interstitial fibrosis but may also positively modulate physiological excitation-contraction coupling." | 4.89 | NADPH oxidases in heart failure: poachers or gamekeepers? ( Ghigo, A; Hirsch, E; Perino, A; Shah, AM; Zhang, M, 2013) |
| "Aldosterone antagonists represented by nonselective spironolactone and mineralocorticoid-selective eplerenone are approved for treatment of symptomatic heart failure with reduced systolic function." | 4.87 | Aldosterone antagonists in heart failure. ( Guglin, M; Kristof-Kuteyeva, O; Novotorova, I; Pratap, P, 2011) |
| "(2) In RALES, low-dose spironolactone in addition to standard of care, produced a 30% improvement in survival in progressive heart failure, commonly assumed to reflect deleterious effects of aldosterone, with spironolactone competing with aldosterone for cardiac mineralocorticoid receptors." | 4.86 | Aldosterone, hypertension and heart failure: insights from clinical trials. ( Funder, JW, 2010) |
| "In patients with NYHA stage III or IV heart failure, addition of spironolactone to the treatment with conversion enzyme inhibitor, diuretic and/or digitalis leads to a reduction in morbidity and mortality, as demonstrated in the RALES study." | 4.82 | [Aldosterone and its antagonists in heart failure]. ( Badoual, T; Cachin, JC; Castaigne, A; Hittinger, L; Le Corvoisier, P; Lopes, ME; Merlet, P; Su, JB; Tabet, JY, 2003) |
| " The selective aldosterone blocker, eplerenone (Inspra), is under development for human therapeutic use for treatment of hypertension and heart failure post-myocardial infarction (MI)." | 4.82 | Aldosterone target organ protection by eplerenone. ( McMahon, EG; Rocha, R; Rudolph, AE, 2004) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 4.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| " The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure." | 4.81 | Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. ( Funder, JW; Young, MJ, 2002) |
| " The therapeutic efficacy of spironolactone (Pharmacia Corp) in severe chronic heart failure is established." | 4.81 | The role of aldosterone receptor blockade in the management of cardiovascular disease. ( Krum, H; Liew, D, 2002) |
| "Until recently, spironolactone was considered only as an antagonist at the aldosterone receptors of the epithelial cells of the kidney and was used clinically in the treatment of hyperaldosteronism and, occasionally, as a K(+)-sparing diuretic." | 4.81 | The spironolactone renaissance. ( Brown, L; Doggrell, SA, 2001) |
| " In contrast, when the Randomized Aldactone Evaluation Study (RALES) mortality trial was discontinued 18 months early, it was because of the prominent salutary effect of spironolactone, added to standard multidrug therapy consisting of an angiotensin converting enzyme (ACE) inhibitor and loop diuretic (with or without digoxin), in reducing the incidence of death and hospitalization in patients with severe congestive heart failure (CHF)." | 4.80 | Spironolactone in congestive heart failure. ( Soberman, JE; Weber, KT, 2000) |
| " Due to the potential importance of these mechanisms, the finding that there is a significant correlation between aldosterone production and mortality in patients with heart failure, as well as evidence that an aldosterone antagonist, spironolactone, when administered to patients with heart failure treated with conventional therapy including an ACE inhibitor results in increased diuresis and symptomatic improvement, an international prospective multicenter study has been organized, the Randomized Aldactone Evaluation Study (RALES Pilot Study), to evaluate the safety of blocking the effects of aldosterone in patients with heart failure treated with an ACE inhibitor." | 4.79 | "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. ( Pitt, B, 1995) |
| "Enalapril is an effective angiotensin-converting enzyme (ACE) inhibitor which produces salutary, beneficial haemodynamic effects in patients with congestive heart failure." | 4.78 | Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure. ( Chatterjee, K; De Marco, T, 1990) |
| "Our study suggests that urinary angiotensinogen can be used as a new biomarker in the prognosis and follow-up of heart failure patients." | 4.31 | Relationship Between Urinary Angiotensinogen and Mortality in Patients with Heart Failure with Reduced Ejection Fraction. ( Çimen, MBY; Örsçelik, Ö; Özkan, B; Sürmeli, AO; Uyar, H; Yeşil, E, 2023) |
| "Background Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF)." | 4.02 | Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. ( Alba, PR; Bress, AP; Choi, ME; Cook, J; Dodson, JA; Fang, JC; He, T; Herrick, JS; King, JB; Levitan, EB; Mohanty, AF; Obi, EN; Patterson, OV; Russo, PA; Vardeny, O, 2021) |
| "Simultaneous blockade of angiotensin receptors and enhancement of natriuretic peptides (NP) by the first-in-class angiotensin receptor neprilysin (NEP) inhibitor sacubitril/valsartan constitutes an effective approach to treating heart failure." | 3.91 | Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. ( Danhof, M; Giraudel, J; Mochel, JP; Peyrou, M; Rigel, DF; Teng, CH, 2019) |
| "Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis." | 3.85 | Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017) |
| "To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome." | 3.85 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. ( Ballantyne, CM; Barter, PJ; Gunzburger, E; Kallend, D; Kittelson, J; Leiter, LA; Leitersdorf, E; McMurray, JJ; Nicholls, SJ; Olsson, AG; Pitts, R; Schwartz, GG; Shah, PK; Tardif, JC, 2017) |
| " On day 11, hypertension was induced by continuous angiotensin II infusion." | 3.80 | M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. ( Burnett, JC; Cataliotti, A; Chen, HH; Ichiki, T; McKie, PM; Sangaralingham, SJ, 2014) |
| " We investigated the effects of upregulating heme-oxygenase (HO) on myocardial histo-pathological lesions, proinflammatory cytokines/chemokines, oxidative mediators and important markers of heart failure such as osteopontin and osteoprotergerin in N(ω)-nitro-l-arginine methyl ester (L-NAME)-induced hypertension." | 3.80 | Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in L-NAME-induced hypertension. ( Chibbar, R; Lane, N; Ndisang, JF, 2014) |
| "The physiological mechanisms involved in isoproterenol (ISO)-induced chronic heart failure (CHF) are not fully understood." | 3.80 | Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. ( Chen, LL; Hong, HS; Li, YH; Lin, XH; Zhu, XQ, 2014) |
| "To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy." | 3.78 | In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. ( Chen, L; Chen, Y; Han, Y; He, T; Jin, MW; Yang, WQ, 2012) |
| " We analysed the effects of early chronic VPI (50 mg/kg/day Omapatrilat) on cardiac remodelling and neurohumoral function during the progression of rapid ventricular pacing-induced heart failure in rabbits (early left ventricular dysfunction [ELVD]: 10 days at 330 bpm, CHF: further 10 days at 360 bpm)." | 3.78 | Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. ( Birner, C; Bratfisch, M; Dietl, A; Götz, T; Luchner, A; Riegger, GA; Schweda, F; Ulucan, C, 2012) |
| "To compare the effect of the direct renin inhibitor aliskiren on neurohumoral activity in heart failure patients treated with low-dose and high-dose ACE inhibitor." | 3.77 | Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. ( Gimpelewicz, CR; Latini, R; Maggioni, AP; McMurray, JJ; Pitt, B; Sidik, NP; Solomon, SD; Wright, M, 2011) |
| "To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure." | 3.76 | Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. ( Cavallari, LH; Dai, Y; Groo, VL; Patel, SR; Stamos, TD; Viana, MA, 2010) |
| "Ucn2 and furosemide were administered for 3 hours, both singly and combined, in 7 sheep with pacing-induced heart failure." | 3.75 | Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. ( Charles, CJ; Nicholls, MG; Rademaker, MT; Richards, AM, 2009) |
| "Similar to other neurohormones that are activated in chronic heart failure (CHF), circulating arginine vasopressin (AVP) is elevated in patients with CHF." | 3.74 | Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. ( Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Suzuki, K; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2007) |
| " In a substudy, 20 patients with decompensated cardiomyopathy-related heart failure received 72 hours of nesiritide with prospective assessment of aldosterone, norepinephrine, plasma renin, and endothelin-1 levels before and after therapy." | 3.74 | Safety and efficacy of nesiritide in pediatric heart failure. ( Chang, AC; Clunie, SK; Denfield, SW; Dreyer, WJ; Grenier, MA; Jefferies, JL; McMahon, CJ; Moffett, BS; Price, JF; Smith, EO; Thomas, A; Towbin, JA; Wann, TS, 2007) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 3.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| "Aldosterone plays an important role in the pathophysiology of congestive heart failure (CHF), and spironolactone improves cardiovascular function and survival rates in patients with CHF." | 3.73 | Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. ( Abassi, Z; Gamliel-Lazarovich, A; Hamoud, S; Hayek, T; Kaplan, M; Karry, R; Keidar, S; Pavlotzky, E, 2005) |
| " Since chronic inhibition of nitric oxide (NO) synthase with N(omega)-nitro-L-arginine methyl ester (L-NAME) induces systemic hypertension associated with cardiovascular inflammation and remodeling, we examined the potential role of aldosterone in this process using eplerenone, a selective aldosterone receptor antagonist." | 3.73 | The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. ( Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L, 2006) |
| "To evaluate the transcardiac extraction of aldosterone before and after spironolactone administration to patients with congestive heart failure, we measured the plasma aldosterone in the aortic root and the coronary sinus in eight congestive heart failure patients with dilated cardiomyopathy." | 3.72 | Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Ishii, C; Maeda, K; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yamamoto, T, 2003) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 3.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "By inhibiting prostaglandin synthesis, aspirin can interfere with both arterial functional and angiotensin-converting enzyme inhibitor (ACEI) properties and be deleterious in chronic heart failure (CHF)." | 3.72 | Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. ( Bergmann, JF; Caulin, C; Cohen-Solal, A; Habib, A; Jondeau, G; Kevorkian, JP; Knellwolf, AL; Lebret, M; Levy, B; Mahé, I; Meune, C; Mourad, JJ; Simoneau, G, 2003) |
| " In patients with severe left ventricular dysfunction spironolactone could reduce death and hospitalisation." | 3.72 | [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. ( Kolloch, R; Offers, E, 2003) |
| "The aim of this study was to assess the effects of the Na+-H+ exchange inhibitor cariporide on left ventricular (LV) morphology and function as well as inflammation in rabbits with heart failure." | 3.72 | Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. ( Busch, AE; Gerl, M; Licher, T; Ruetten, H; Rungwerth, K; Schäfer, S; Schindler, U, 2004) |
| "Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM levels increase in patients with acute myocardial infarction (MI)." | 3.72 | Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. ( Asada, Y; Cao, Y; Eto, T; Imamura, T; Kangawa, K; Kato, J; Kitamura, K; Marutsuka, K; Nakamura, R; Onitsuka, H, 2004) |
| "Several clinical trials have demonstrated that angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II type 1 receptor blocker (ARB) are equally effective in the treatment of chronic heart failure." | 3.72 | Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol. ( Hasebe, N; Izawa, K; Jin, YT; Kido, S; Kikuchi, K; Natori, S; Ohta, T; Sato, M; Tsuji, S, 2004) |
| "Furosemide shortened the time to left ventricular dysfunction (35." | 3.72 | Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004) |
| "The purpose of the study was to examine the effect of fosinopril on the magnitude of neurohumoral and proinflammatory activation in patients with severe heart failure (HF)." | 3.72 | [Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure]. ( Berezin, AE, 2004) |
| "In congestive heart failure, angiotensin-converting enzyme inhibitors (ACEIs) may prevent cardiac fibrosis via interaction with both angiotensin II and endothelin-1, which enhance myocardial collagen synthesis." | 3.72 | Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. ( Dohke, T; Eguchi, Y; Fujii, M; Horie, M; Isono, T; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Wada, A; Yamamoto, T, 2004) |
| " The purpose of this study was to assess the relationship between levels of serum uric acid, activity of the renin-angiotensin-aldosterone system and TNF-alpha in heart failure patients with respect to the extent of left ventricular dysfunction." | 3.71 | Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? ( Gonsorcík, J; Kisel'ová, J; Olejníková, M; Olexa, P; Olexová, M; Tkác, I, 2002) |
| "Canrenone attenuates LV interstitial remodeling and reduces filling pressures in rats with postinfarction heart failure." | 3.71 | Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. ( Casaburi, C; Cittadini, A; Di Gianni, A; Monti, MG; Saccà, L; Saldamarco, L; Scherillo, G; Serpico, R; Vanasia, M, 2002) |
| "Short-term administration of adrenomedullin, a recently discovered peptide with potent vasodilator, natriuretic, and aldosterone-inhibitory actions, has beneficial effects in experimental and clinical heart failure." | 3.71 | Long-term adrenomedullin administration in experimental heart failure. ( Charles, CJ; Espiner, EA; Nicholls, MG; Rademaker, MT; Richards, AM, 2002) |
| "The aim of the study was to investigate a possible relationship between plasma renin activity, angiotensin II, serum levels of angiotensin-converting enzyme, aldosterone and markers of immune activation in congestive heart failure (CHF)." | 3.70 | The activated immune system and the renin-angiotensin-aldosterone system in congestive heart failure. ( Artner-Dworzak, E; Belenkov, J; Fuchs, D; Lopatin, J; Mareev, V; Nassonov, E; Samsonov, M; Tilz, GP; Wachter, H, 1998) |
| "We assessed the relations among polymorphism of the angiotensin-converting enzyme gene, angiotensinogen M235T (AGT) gene, and angiotensin type I receptor A1166C gene with left ventricular systolic function, left and right ventricular diastolic function, serum angiotensin-converting enzyme, plasma aldosterone and atrial natriuretic peptide levels at presentation, and clinical outcome at 1 year (survival, hospital admissions) in a cohort of Chinese patients with typical systolic heart failure (n = 82)." | 3.70 | Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. ( Arumanayagam, M; Sanderson, JE; Shum, IO; Wei, S; Woo, KS; Young, RP; Yu, CM, 1999) |
| "To follow chronic heart failure patients on ACE inhibitors for 18 months to assess whether or not angiotensin II and aldosterone reactivation are progressive with time, whether reactivation of both occurs simultaneously, and whether different ACE inhibitors have different neurohormonal profiles." | 3.70 | Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. ( Lee, AF; MacFadyen, RJ; Struthers, AD, 1999) |
| "Omapatrilat is a member of the new drug class of vasopeptidase inhibitors that may offer benefit in the treatment of heart failure (HF) through simultaneous inhibition of angiotensin-converting enzyme and neutral endopeptidase." | 3.70 | Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. ( Espiner, EA; Frampton, CM; Nicholls, MG; Powell, JD; Rademaker, MT; Richards, AM; Troughton, RW; Yandle, TG, 2000) |
| "In acute studies ibopamine, an a selective dopamine agonist, induces moderate increases of GFR and ERPF, and a fall in plasma norepinephrine levels in patients with congestive heart failure (CHF)." | 3.69 | The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure. ( Girbes, AR; Lie, KI; Lieverse, AG; Meijer, S; Reitsma, WD; Smit, AJ; Van Veldhuisen, DJ; Zijlstra, JG, 1995) |
| "To investigate the role of adrenomedullin in the pathophysiology of heart failure, we measured plasma levels of adrenomedullin in patients with heart failure." | 3.69 | Increased plasma levels of adrenomedullin in patients with heart failure. ( Eto, T; Ishimitsu, T; Kangawa, K; Kitamura, K; Matsuo, H; Matsuoka, H; Nishikimi, T; Omae, T; Saito, Y, 1995) |
| "This study examined the effect of low dose aspirin on cardiorenal and neurohumoral function and on the acute hemodynamic response to enalaprilat in a canine model of heart failure." | 3.69 | Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. ( Burnett, JC; Evans, MA; Redfield, MM, 1995) |
| "To evaluate the effects of endogenous angiotensin II (ANG II) on the development of congestive heart failure (CHF), we examined cardiorenal and hormonal factors after chronic administration of the ANG II type 1 receptor antagonist TCV-116 in dogs with CHF induced by rapid right ventricular pacing." | 3.69 | Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP. ( Fukai, D; Kinoshita, M; Maeda, Y; Tsutamoto, T; Wada, A, 1997) |
| "The interaction between renal prostaglandins and atrial natriuretic factor (ANF) for the regulation of renal hemodynamic and excretory function was examined in conscious dogs with arteriovenous fistula and chronic compensated high-output heart failure (n = 6)." | 3.69 | Indomethacin attenuates the renal actions of atrial natriuretic factor in dogs with chronic heart failure. ( Freeman, RH; Habibullah, AA; Simmons, JC; Villarreal, D, 1997) |
| "Plasma levels of atrial natriuretic peptide (ANP), angiotensin II, aldosterone, and catecholamines were followed for 1 month and then for 4 to 6 months in 55 patients with acute myocardial infarction." | 3.68 | Short- and long-term neurohormonal activation following acute myocardial infarction. ( Held, P; Sigurdsson, A; Swedberg, K, 1993) |
| "The acute haemodynamic and neurohumoral effects of flosequinan, a new direct-acting vasodilator, were studied in 12 patients with severe (eight in New York Heart Association grade 3, four in grade 4) cardiac failure." | 3.68 | Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy. ( Dakak, N; Halon, DA; Kahana, L; Lewis, BS; Makhoul, N; Merdler, A; Schneeweiss, A; Yechiely, H, 1993) |
| "Short- and long-term clinical effects of the angiotensin-converting enzyme (ACE) inhibitor captopril in severe congestive heart failure (CHF) were evaluated during a 3-year open study of 124 inpatients with New York Heart Association (NYHA) functional class III or IV CHF refractory to treatment with cardiac glycosides and high doses of loop diuretics." | 3.68 | Captopril and spironolactone therapy for refractory congestive heart failure. ( Dahlström, U; Karlsson, E, 1993) |
| "The acute hemodynamic and hormonal effects of incremental doses of a specific ovine renin inhibitor (RI: EMD 52 297) and captopril were compared in an ovine model of heart failure." | 3.68 | Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure. ( Charles, CJ; Espiner, EA; Fitzpatrick, MA; Ikram, H; Nussberger, J; Rademaker, MT; Yandle, TG, 1992) |
| "The pharmacokinetics of synthetic atrial natriuretic factor (ANF) and its effects on cyclic GMP, urinary sodium excretion, and hemodynamics were compared in 18 control subjects with normal hemodynamics and 12 patients with severe heart failure." | 3.68 | Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. ( Armstrong, PW; Canepa-Anson, R; Moe, GW, 1992) |
| "Urinary excretion of albumin and beta 2-microglobulin were measured in 13 patients with congestive heart failure, NYHA class II-IV, before and after captopril treatment for 4 weeks, and in 13 healthy control subjects." | 3.68 | Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition. ( Bagger, JP; Eiskjaer, H; Mogensen, CE; Pedersen, EB; Schmitz, A, 1992) |
| "We have previously demonstrated that baroreceptor discharge sensitivity is depressed in dogs with experimental heart failure and that this depressed sensitivity can be reversed by the Na+,K(+)-ATPase inhibitor ouabain." | 3.68 | Aldosterone reduces baroreceptor discharge in the dog. ( McClain, JM; Wang, W; Zucker, IH, 1992) |
| "The clinical efficacy of enalapril was investigated in 21 patients with severe heart failure." | 3.68 | Clinical studies of enalapril treatment for patients with severe congestive heart failure. ( Sato, T; Takeshi, M; Yamamoto, A, 1992) |
| "The effect of diuretic dose on the haemodynamic response to captopril was assessed in nine patients with chronic cardiac failure." | 3.68 | The relationship between diuretic dose, and the haemodynamic response to captopril in patients with cardiac failure. ( Davies, E; Edwards, CR; Flapan, AD; Shaw, TR; Williams, BC, 1992) |
| "The hemodynamic, clinical, and neurohumeral effects of a prolonged (6-days) intravenous enoximone-infusion therapy were evaluated in 12 patients suffering from severe cardiac failure due to dilated cardiomyopathy." | 3.68 | [Continuous enoximone infusion in patients with severe heart failure in dilated cardiomyopathy, hemodynamic, neurohumoral, chemical laboratory and clinical results]. ( Lissmann, H; Mitrovic, V; Neuzner, J; Pitschner, HF; Schlepper, M, 1991) |
| "min-1 for 60 min) on secretion of atrial natriuretic factor (ANF) in 10 healthy subjects and 10 patients with congestive heart failure (CHF) (NYHA Classes III and IV)." | 3.68 | Atrial natriuretic factor after dopamine infusion in healthy subjects and in congestive heart failure. ( Bernardi, P; Capelli, M; Fontana, F; Ruffini, M, 1991) |
| "In patients with congestive heart failure (CHF), the role of aldosterone in the abnormal sodium (Na+) retention and the determinants of plasma aldosterone (PA) including plasma atrial natriuretic factor (hANF), plasma renin activity (PRA), and plasma potassium (K+) have not been fully elucidated." | 3.68 | Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. ( Abraham, WT; Dürr, JA; Hensen, J; Schrier, RW, 1991) |
| "The possible role of angiotensin-converting enzyme inhibition in preventing or minimizing tolerance to intravenous nitroglycerin in severe congestive heart failure (CHF) was studied by quantitating the degree of tolerance in 12 patients receiving nitroglycerin (group 1) and in 9 patients (group 2) receiving nitroglycerin and concurrent treatment with captopril (60 +/- 29 mg/day)." | 3.68 | Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. ( Dakak, N; Flugelman, MY; Halon, DA; Lewis, BS; Makhoul, N; Merdler, A; Schneeweiss, A; Shehadeh, H, 1990) |
| "Plasma atrial natriuretic factor, aldosterone, renin activity, and antidiuretic hormone were studied in low output heart failure syndromes: cardiogenic shock in ten patients with acute myocardial infarction of the anterior wall (first group), hypovolemic shock after melena from peptic ulcer in ten subjects (second group), and hypotension with bradycardia syndrome in ten patients with acute myocardial infarction of the inferior wall (third group)." | 3.68 | Plasma atrial natriuretic factor in low output heart failure syndromes. ( Bernardi, P; Capelli, M; Fontana, F; Spagnolo, N, 1990) |
| "The effect of a single oral dose (50 mg) of captopril was studied in 12 hypertensive patients divided into 2 groups: 6 had a normal hemodynamic profile; the other 6 had NYHA class III or IV heart failure." | 3.68 | [Captopril and hypertensive cardiopathy : therapeutic effects and hormonal changes]. ( D'Aprile, N; Faglia, S; Galli, M; Kristodhullu, S; Martorelli, T; Mondillo, S; Palazzuoli, V, 1990) |
| "The effects of captopril in several humoral factors were studied to elucidate the role of the renin-angiotensin (RA) system in arterial and venous pressures and renal function in patients with severe chronic congestive heart failure." | 3.67 | Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure. ( Kawamura, K; Kubo, S; Nishimura, H; Nishioka, A; Takatsu, T, 1984) |
| "In an attempt to study the possible mechanism(s) by which captopril controls resistant heart failure, sequential haemodynamic studies (radioisotope technique) and humoral measurements (plasma renin activity, plasma aldosterone and plasma catecholamines) were obtained in 11 such patients." | 3.67 | Captopril in congestive heart failure resistant to other vasodilators. ( Bravo, EL; El-Tobgi, S; Fouad, FM; Hart, NJ; Lim, J; Shirey, EK; Tarazi, RC, 1984) |
| "The chronic reserve for the secretion of atrial natriuretic factor (ANF) was studied in conscious dogs with an arteriovenous (a-v) fistula, a model of high-output heart failure." | 3.67 | DOCA administration and atrial natriuretic factor in dogs with chronic heart failure. ( Brands, MW; Freeman, RH; Villarreal, D, 1989) |
| "The current studies were designed to investigate the functional significance of elevated endogenous atrial natriuretic factor (ANF) in acute congestive heart failure (CHF)." | 3.67 | Role of endogenous atrial natriuretic factor in acute congestive heart failure. ( Burnett, JC; Edwards, BS; Lee, ME; Miller, WL, 1989) |
| "The hemodynamic parameters (right atrial pressure, mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac index, heart rate, blood pressure) and neurohumoral responses (alpha-ANP, plasma renin activity, aldosterone, angiotensin II) of Captopril, oral ACE inhibitor, and Bunazosin, oral alpha 1-blocker, were investigated in 28 patients with congestive heart failure at rest and after exercise." | 3.67 | [The effect of bunazosin vs captopril on hemodynamic and neurohumoral parameters in patients with congestive heart failure]. ( Hasegawa, K; Inoue, S; Kakumae, S; Kawahara, Y; Nakamura, T; Nakao, M; Nezuo, S; Sawayama, T; Tadaoka, S, 1989) |
| " The effects of the angiotensin-converting enzyme (ACE) inhibitor lisinopril on plasma vasoactive intestinal polypeptides (VIP) and plasma noradrenaline, adrenaline and dopamine were studied in 12 patients with congestive heart failure over two consecutive 48-hr periods." | 3.67 | Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes. ( Dickstein, K; Kaada, B; Woie, L, 1987) |
| "Plasma concentrations of antidiuretic hormone (ADH) were measured in 8 patients with congestive heart failure (CHF) of NYHA functional class III-IV, before and during treatment with captopril, 6." | 3.67 | Antidiuretic hormone and atrial natriuretic peptide in congestive heart failure. ( Fyhrquist, F; Tikkanen, I, 1986) |
| "We investigated atrial natriuretic factor (ANF) in humans, measuring plasma immunoreactive (ir) ANF (in femtomoles per milliliter), and renal, hormonal, and hemodynamic responses to ANF infusion, in normal subjects (NL) and congestive heart failure patients (CHF)." | 3.67 | Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. ( Atlas, SA; Camargo, MJ; Clark, M; Cody, RJ; Covit, AB; Kubo, SH; Laragh, JH; Pondolfino, K; Ryman, KS; Shaknovich, A, 1986) |
| "The temporal changes in the plasma concentration of immunoreactive atrial natriuretic factor (iANF) were studied in six conscious dogs with an arteriovenous (AV) fistula, a model of chronic high-output heart failure." | 3.67 | Atrial natriuretic factor secretion in dogs with experimental high-output heart failure. ( Davis, JO; Freeman, RH; Vari, RC; Verburg, KM; Villarreal, D, 1987) |
| "The present study evaluates the inter-relationship between the alteration in atrial natriuretic factor (ANF) and the renal handling of Na in rats with chronic aortocaval (a-v) fistula, an experimental model of congestive heart failure." | 3.67 | Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. ( Burnett, JC; Haramati, A; Hoffman, A; Winaver, J, 1988) |
| "Plasma concentrations of atrial natriuretic factor (ANF), catecholamines (adrenaline, noradrenaline, dopamine) and aldosterone, and plasma renin activity (PRA) were measured in a group of 20 patients with moderate to medium heart failure (NYHA class II 7 patients, class III 13 patients), 24 hours after treatment was discontinued." | 3.67 | [Atrial natriuretic factor, catecholamines and the renin-angiotensin system in cardiac insufficiency. Relation to hemodynamic parameters]. ( Carayon, A; Drobinski, G; Grosgogeat, Y; Komajda, M; Landault, C; Legrand, JC; Legrand, S; Maistre, G; Nguyen, JP, 1988) |
| "We studied the effects of alpha-human atrial natriuretic factor (alpha-h-ANF) on diuresis, glomerular filtration rate (GFR), natriuresis, atrial blood pressure (BP), heart rate (HR) and plasmatic levels of aldosterone, renin activity (PRA), antidiuretic hormone (ADH) in 21 patients with congestive heart failure (CHF), (NYHA, class IV) and 15 healthy volunteers." | 3.67 | [Hemodynamic and renal effects of synthetic atrial natriuretic factor (alpha-h-ANF) in patients with congestive heart failure]. ( Bernardi, P; Cappelli, M; Fontana, F; Guardigli, G, 1988) |
| "The acute hemodynamic and hormonal effects of the oral angiotensin-converting enzyme (ACE) inhibitor lisinopril (MK-521) were assessed over a period of 96 hours in 12 patients with heart failure." | 3.67 | Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. ( Aarsland, T; Abrahamsen, AM; Cummings, S; Dickstein, K; Fyhrquist, F; Gomex, HJ; Hagen, E; Kristianson, K; Woie, L, 1986) |
| "In this study, the use of enalapril and captopril is compared in the treatment of congestive heart failure." | 3.67 | Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril. ( Cohn, JN; Levine, TB; Olivari, MT, 1986) |
| "Angiotensin II (AII), aldosterone (Aldo) and arginine vasopressin (AVP) in plasma were determined during basal conditions in seventeen patients with congestive heart failure and in seventeen control subjects." | 3.67 | Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure. ( Danielsen, H; Jensen, T; Madsen, M; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1986) |
| "We studied the effects of furosemide on plasma renin and plasma aldosterone in 8 patients with mild to moderate congestive heart failure." | 3.67 | Acute changes in plasma renin activity, plasma aldosterone concentration and plasma electrolyte concentrations following furosemide administration in patients with congestive heart failure--interrelationships and diuretic response. ( Mulder, H; Schopman, W; van der Lely, AJ, 1987) |
| "Acute effects of 200 mg of orally given 4-[2-(methylamino)ethyl]-o-phenylene diisobutyrate hydrochloride (ibopamine hydrochloride) which is a new diisobutyric ester of N-methyldopamine, on hemodynamics and metabolism were evaluated in 11 patients with severe heart failure (New York Heart Association class IV)." | 3.67 | Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure. ( Kakuta, Y; Kanamaru, M; Kodera, T; Konishi, T; Morimoto, Y; Nakano, T; Takezawa, H, 1986) |
| "We examined renal function and Na+ balance in a patient with congestive heart failure who was treated with demeclocycline (DMC) on three separate occasions under strict metabolic balance conditions." | 3.67 | Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies. ( Braden, GL; Cox, M; Geheb, MA; Shook, A; Singer, I, 1985) |
| "In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol." | 3.67 | Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine. ( Barreca, T; Cantoni, V; Cicchetti, V; Franceschini, R; Gianrossi, R; Marchetti, G; Rolandi, E, 1986) |
| "To define the short-term haemodynamic, hormonal and electrolyte effects of enalapril in chronic heart failure, we administered it to nine patients." | 3.66 | Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure. ( Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983) |
| "The effects of long-term therapy with captopril (CPT) were studied in 11 patients with severe chronic congestive heart failure (CHF)." | 3.66 | Variable clinical response to long-term angiotensin inhibition in severe heart failure: demonstration of additive benefits of alpha-receptor blockade. ( Frishman, W; Kugler, J; LeJemtel, TH; Maskin, CS; Sonnenblick, EH, 1982) |
| "Eight patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were given captopril (seven patients) or teprotide (one patient)." | 3.66 | Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. ( Colucci, WS; Curfman, G; Dzau, VJ; Hollenberg, NK; Meggs, L; Williams, GH, 1980) |
| "1 The angiotensin-converting-enzyme inhibitor captopril is known to produce beneficial haemodynamic effects in patients with chronic congestive heart failure." | 3.66 | Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure. ( Baraldi, P; Mattioli, G; Ricci, S; Teglio, V; Zaniol, P, 1982) |
| "Studies using a competitive inhibitor of angiotensin II (saralasin) or converting enzyme inhibitors (teprotide, captopril, enalapril) have established that the renin-angiotensin system participates in the control of vascular tone in congestive heart failure both in experimental settings and in patients." | 3.66 | The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril. ( Brunner, HR; Turini, GA; Waeber, B, 1983) |
| "Enalapril, the new converting enzyme inhibitor, was administered to eight patients with heart failure (NYHA Functional Class II to IV) during standardised and intensive haemodynamic, hormone, and electrolyte monitoring." | 3.66 | Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. ( Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983) |
| "The angiotensin-converting enzyme inhibitor, captopril, was given to 19 patients with severe heart failure." | 3.66 | Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. ( Boomsma, F; Hugenholtz, PG; Laird-Meeter, K; Man in't veld, AJ; Schalekamp, MA; Simoons, ML; Wenting, GJ; Woittiez, AJ, 1983) |
| "We studied the hemodynamic response to orally administered hydralazine (30 mg) and examined the changes in neurohumoral factors in 16 aged patients with chronic congestive heart failure." | 3.66 | Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure. ( Kuwajima, I; Matsushita, S; Murakami, M; Sakai, M; Ueda, K, 1983) |
| "1 In an open study the clinical short-term and long-term effects of low-dose captopril (mean daily dose 45 +/- 15 mg) were evaluated in 20 patients with severe congestive heart failure refractory to conventional treatment with digitalis and diuretics." | 3.66 | Short and long-term effects of treatment with low dose captopril in patients with severe congestive heart failure. ( Dahlström, U; Karlberg, BE, 1982) |
| "1 The efficacy of the converting-enzyme inhibitor captopril in the management of severe congestive heart failure was assessed in 14 patients over 360-885 days by clinical evaluation, M-mode echocardiography, systolic time intervals, plasma renin activity, and plasma aldosterone." | 3.66 | Long-term treatment of congestive heart failure with captopril. ( Drobinski, G; Eugene, M; Evans, J; Grosgogeat, Y; Komajda, M; Laurenceau, JL, 1982) |
| "The long-term effects of captopril therapy were assessed by sequential hemodynamic studies over a 6 month period in 19 patients with resistant congestive heart failure." | 3.66 | Long-term control of congestive heart failure with captopril. ( Bravo, EL; Castle, LW; Fouad, FM; Hart, NJ; Salcedo, EE; Tarazi, RC, 1982) |
| "The hemodynamic and hormonal responses to acute and chronic captopril therapy and to its temporary withdrawal were studied in seven patients with congestive heart failure." | 3.66 | Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. ( Espiner, EA; Ikram, H; Maslowski, AH; Nicholls, MG; Penman, T; Scandrett, MS, 1982) |
| " Since important interrelationships between haemodynamic and hormone indices are possible in cardiac failure, measurements of cardiac output, mean pulmonary artery pressure, plasma renin activity, angiotensin II and aldosterone were carried out before and during acute and chronic frusemide therapy in patients with oedematous heart failure who had been given digoxin." | 3.66 | Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. ( Chan, W; Espiner, EA; Ikram, H; Nicholls, MG, 1980) |
| "The systemic, pulmonary, and limb circulatory responses to the angiotensin-converting enzyme inhibitor, captopril, were determined in 10 patients with severe, chronic heart failure." | 3.66 | Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. ( Creager, MA; Faxon, DP; Gavras, H; Halperin, JL; Ryan, TJ; Schick, EC, 1981) |
| " To assess which of these stimuli is the more potent, we measured aldosterone, potassium, and angiotensin II responses to the oral converting enzyme inhibitor captopril in five patients with resistant congestive heart failure during digoxin and furosemide maintenance therapy." | 3.66 | Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy. ( Espiner, EA; Ikram, H; Lun, S; Maslowski, AH; Nicholls, MG; Scandrett, MS, 1981) |
| "The effect of hydroflumethiazide (HFT) on renal excretion of sodium, chloride, and potassium was studied in congestive heart failure and related to urinary excretion of thiazide and aldosterone." | 3.66 | Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone. ( Aakvaag, A; Brørs, O; Enger, E; Foss, OP; Jacobsen, S, 1981) |
| "The renin-angiotensin-aldosterone system and electrolyte levels in 11 patients with heart failure controlled on digoxin and frusemide were investigated after separate periods of Slow K, spironolactone, and amiloride therapy." | 3.65 | Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. ( Espiner, EA; Hughes, H; Nicholls, MG; Rogers, T, 1976) |
| "Spironolactone was evaluated as a diuretic in the therapy of six patients with chronic severe congestive heart failure, during which metabolic balance studies were performed." | 3.64 | EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE. ( CARRUTHERS, BM; LEDRAY, RD; MCINTOSH, HW; SERAGLIA, M; WALSH, GC, 1963) |
| "Aldosterone level was significantly greater in HF patients relative to controls." | 3.30 | Serum aldosterone in right ventricular failure versus left ventricular failure before and after mineralocorticoid receptor antagonists: case-control clinical trial. ( El-Hefny, NEAM; El-Mahdy, RI; Haridi, SHM; Mohamed, AS; Mohammed, HSE, 2023) |
| " Therefore, we aimed to assess whether new potassium binders are effective and safe to promote medical optimization in patients with HF." | 3.01 | Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. ( Carvalho, PEP; Gewehr, DM; Lacerda, H; Nunes, MCP; Simões E Silva, AC; Tofanelli, MR; Veiga, TMA, 2023) |
| " Adverse events occurred in 4 of 18 participants receiving AZD9977 (22." | 2.94 | Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study. ( Albayaty, M; Backlund, A; Ericsson, H; Forte, P; Greasley, PJ; Hartleib-Geschwindner, J; Heijer, M; Kjaer, M; Kragh, ÅM; Unwin, R; Wernevik, L; Whittaker, A, 2020) |
| "Early detection of adverse effects of novel therapies and understanding of their mechanisms could improve the safety and efficiency of drug development." | 2.87 | Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. ( DeLisle, RK; Ganz, P; Hyde, C; Malarstig, A; Murthy, AC; Ostroff, R; Segal, MR; Weiss, SJ; Williams, SA, 2018) |
| "In patients with primary aldosteronism, adrenalectomy or treatment with mineralocorticoid receptor antagonists significantly mitigate adverse aldosterone effects, reducing the risk of cardiovascular events, mortality, and incident atrial fibrillation." | 2.82 | Aldosterone as a Mediator of Cardiovascular Damage. ( Buffolo, F; Monticone, S; Mulatero, P; Tetti, M, 2022) |
| " Following administration of LCZ696, the Cmax of sacubitril (neprilysin inhibitor prodrug), LBQ657 (active neprilysin inhibitor), and valsartan were reached within 0." | 2.82 | Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. ( Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I, 2016) |
| "Aldosterone has a key role in the pathophysiology of heart failure." | 2.74 | Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. ( Connell, JM; Freel, EM; Latini, R; Lewsey, JD; Maggioni, AP; McMurray, JJ; Pitt, B; Solomon, S; Tsorlalis, IK, 2009) |
| "Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months." | 2.73 | Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). ( Boccanelli, A; Cacciatore, G; Clemenza, F; De Maria, R; de Simone, G; Di Lenarda, A; Gavazzi, A; Gonzini, L; Latini, R; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M, 2007) |
| "Aliskiren appeared to suppress the RAAS as effectively as ramipril in the short term." | 2.73 | Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. ( Bobillier, A; Gardner, R; Hillier, C; MacFadyen, R; Mann, J; McDonagh, T; McMurray, J; Murdoch, D; Seed, A, 2007) |
| "Heart failure is associated with many comorbidities and among them, cancer has stood out as a contributor of death in these patients." | 2.72 | RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. ( Cambrón-Mora, D; Garcia-Garduño, TC; Padilla-Gutierrez, JR; Valle, Y, 2021) |
| "Aldosterone levels were determined by solid-phase radioimmunoassay." | 2.70 | Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. ( Colombo, PC; Jorde, UP; Katz, SD; Latif, F; Le Jemtel, TH; Vittorio, T, 2002) |
| "The use of nitrates for treatment of heart failure is encumbered by tolerance, caused by whatever mechanism, which has been reported only in a few instances with sydnonimines." | 2.69 | Infusions with molsidomine and isosorbide-5-mononitrate in congestive heart failure: mechanisms underlying attenuation of effects. ( Beyerle, A; Hähnel, I; Lampen, M; Lehmann, G; Reiniger, G; Schömig, A, 1998) |
| "In chronically treated heart failure patients with full angiotensin-converting enzyme-inhibition and diuretics, there is decreased compliance of the aorta and its major branches, which is inversely correlated with the aldosterone escape phenomenon." | 2.69 | Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. ( Clement, DL; Cohn, JN; De Buyzere, ML; Duprez, DA; Morgan, D; Rietzschel, ER; Taes, Y, 1998) |
| " All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12." | 2.68 | The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995) |
| " The dosage of both drugs was individually adjusted in time according to the results of serum potassium and renal function." | 2.67 | Combined therapy of captopril and spironolactone for refractory congestive heart failure. ( Han, YL; Hu, XL; Jing, QM; Liu, JQ; Tong, M, 1994) |
| "MRAs are a recognized treatment for heart failure and hypertension." | 2.66 | Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review. ( Mohammadpour, AH; Omidkhoda, N; Sahebkar, A; Sathyapalan, T; Vakilian, F, 2020) |
| "It is concluded that in patients with congestive heart failure rhein does not inhibit renal or platelet eicosanoid metabolism, nor does it modify renal function, sodium excretion or the renal response to diuretics." | 2.66 | Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure. ( Belli, B; Fascetti, P; Gentilini, P; La Villa, G; Laffi, G; Marra, F; Meacci, E, 1989) |
| "Benazepril hydrochloride is a nonsulfhydryl, long-acting angiotensin-converting enzyme inhibitor that is orally effective." | 2.66 | A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. ( Boland, MJ; Cinquegrani, MP; Insel, J; Mirvis, DM; Rubin, SA; Shanes, J; Whalen, JJ, 1989) |
| "In captopril-treated patients, the supine aldosterone levels exceeded the normal range and were as high as in placebo-treated patients." | 2.66 | Aldosterone and prolactin responsiveness after prolonged treatment of congestive heart failure with captopril. ( Althoff, PH; Bussmann, WD; Fassbinder, W; Hadler, D; Jungmann, E; Kaltenbach, M; Schöffling, K; Störger, H, 1985) |
| "Aldosterone (Aldo) has been intensively studied for years since its isolation by Simpson and Tait in the 1950s." | 2.61 | Aldosterone and Myocardial Pathology. ( Cannavo, A; Elia, A; Koch, WJ; Liccardo, D; Rengo, G, 2019) |
| "In addition, obesity is accompanied by increased signaling through the leptin receptor, which can promote activation of both the sympathetic nervous system and the renin-angiotensin system and can directly stimulate the secretion of aldosterone." | 2.58 | Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. ( Packer, M, 2018) |
| "There is a strong association between abdominal obesity and circulating levels of aldosterone, and markers of abdominal obesity identify patients most likely to benefit from mineralocorticoid receptor antagonism." | 2.58 | Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists. ( Packer, M, 2018) |
| "Aldosterone has been implicated in atrial remodelling representing a potential target for upstream therapies." | 2.53 | Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. ( Korantzopoulos, P; Letsas, KP; Li, G; Liu, T; Shao, Q; Zhang, Z, 2016) |
| "19." | 2.53 | Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. ( Bomback, AS, 2016) |
| "They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues." | 2.53 | Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. ( Yang, J; Young, MJ, 2016) |
| "Primary aldosteronism, caused by autonomous secretion of aldosterone by the adrenals, is estimated to account for at least 5% of hypertension cases." | 2.52 | Pharmacological treatment of aldosterone excess. ( Deinum, J; Lenders, JW; Riksen, NP, 2015) |
| "Heart failure is a complex syndrome that affects almost all organs and systems of the body." | 2.50 | [Organ damage and cardiorenal syndrome in acute heart failure]. ( Casado Cerrada, J; Pérez Calvo, JI, 2014) |
| " The dose-response relationship for natriuresis with spironolactone has not been explored completely as to its combination therapy responses." | 2.50 | Aldosterone and volume management in hypertensive heart disease. ( Sica, DA, 2014) |
| "Aldosterone is a downstream effector of angiotensin II in the renin-angiotensin-aldosterone system and binds to the mineralocorticoid receptor." | 2.49 | Aldosterone receptor antagonists: current perspectives and therapies. ( Ahmed, MI; Calhoun, DA; Clark, D; Guichard, JL, 2013) |
| "In the setting of primary aldosteronism, renal and faecal calcium loss triggers increased PTH secretion which in turn aggravates aldosterone secretion and CV damage." | 2.48 | Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. ( Drechsler, C; Fahrleitner-Pammer, A; Horina, JH; Kienreich, K; März, W; Ofner, M; Pieber, TR; Pieske, B; Pilz, S; Ritz, E; Tomaschitz, A, 2012) |
| " The observation of reduced nitric oxide bioavailability in hyperaldosteronism implied the generation of oxidative stress by aldosterone." | 2.48 | Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases. ( Queisser, N; Schupp, N, 2012) |
| "Fibrosis is a fundamental component of the adverse structural remodeling of myocardium present in the failing heart." | 2.47 | Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. ( Ahokas, RA; Bhattacharya, SK; Gandhi, MS; Gerling, IC; Kamalov, G; Shahbaz, AU; Sun, Y; Weber, KT, 2011) |
| "Aldosterone is a mineralocorticoid hormone synthesized by the adrenal glands that has several regulatory functions to help the body maintain normal volume status and electrolyte balance." | 2.47 | Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. ( Nappi, JM; Sieg, A, 2011) |
| "Heart failure is a frequent and life-threatening syndrome which is not only the result of myocardial injury or hemodynamic overload as commonly perceived, but appears to be the result of an interplay among genetic, neurohormonal, inflammatory, and biochemical factors, collectively referred to as biomarkers." | 2.47 | Biomarkers: optimizing treatment guidance in heart failure. ( Böhm, M; Bramlage, P; Ketelslegers, JM; Schirmer, SH; Turgonyi, E; Voors, AA; Zannad, F, 2011) |
| "Aldosterone is an adrenal hormone that regulates sodium, fluid, and potassium balance." | 2.45 | Aldosterone and cardiovascular disease. ( Calhoun, DA; Gaddam, KK; Husain, S; Pimenta, E, 2009) |
| " Moreover, ACE gene polymorphisms contribute to the modulation and adequacy of the neurohormonal response to long-term ACE inhibition, at least in patients with CHF (up to 45% of CHF patients have elevated Ang II levels despite the long-term use of an ACEI) or diabetes." | 2.44 | Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? ( Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2007) |
| "Aldosterone is an important mediator in the pathogenesis of heart failure, and increased plasma aldosterone levels are associated with a poor prognosis." | 2.44 | Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues. ( Francis, GS; Kalidindi, SR; Tang, WH, 2007) |
| "Primary aldosteronism has been shown to represent 8-13% (rather than <1%) of unselected hypertensive patients, and patients with primary aldosteronism to have higher indices of cardiovascular damage than controls of the same age, sex, and BP status." | 2.44 | The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. ( Funder, JW, 2007) |
| "The clinical syndrome congestive heart failure (CHF) has its origins rooted in a salt-avid state mediated largely by effector hormones of the renin-angiotensin-aldosterone system (RAAS)." | 2.44 | The importance of lost minerals in heart failure. ( Bhattacharya, SK; Goodwin, KD; Hatcher, EA; Neal, MT; Newman, KP; Roberts, M, 2007) |
| "Heart failure is a very serious cardiovascular disease that affects more than five million people in North America." | 2.44 | Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. ( El-Kadi, AO; Zordoky, BN, 2008) |
| "Aldosterone blockade has been shown to be effective in reducing mortality in patients who have severe heart failure because of systolic left ventricular dysfunction (SLVD) and those who have heart failure and SLVD post-myocardial infarction." | 2.44 | Aldosterone blockade in patients with chronic heart failure. ( Pitt, B, 2008) |
| "Aldosterone plays an important role in the pathophysiology of sodium/potassium and water homeostasis of the body." | 2.43 | Cardiovascular effects of aldosterone. ( Murin, J, 2005) |
| "The use of ARAs for the treatment of myocardial failure and selected cases of hypertension, in combination with the current therapy, has been strongly supported by trials such as the Randomized Aldactone Evaluation Study (RALES) and the Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS)." | 2.43 | Aldosterone receptor antagonists: biology and novel therapeutic applications. ( Magni, P; Motta, M, 2005) |
| "The neurohormonal model of congestive heart failure (CHF) has replaced the previously accepted hemodynamic model." | 2.43 | The role of aldosterone blockers in the management of chronic heart failure. ( Coca, SG; Perazella, MA, 2005) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | 2.43 | Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006) |
| "Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors." | 2.43 | Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. ( Pringle, S; Shah, NC; Struthers, A, 2006) |
| " Fibrosis of the right ventricle, the atria, and the pulmonary artery supports the concept that these effects are BP independent, corroborated by the finding that spironolactone in a dosage not sufficient to lower BP prevents myocardial fibrosis." | 2.42 | Aldosterone-induced cardiac damage: focus on blood pressure independent effects. ( Schmidt, BM; Schmieder, RE, 2003) |
| "Heart failure is a major health problem of epidemic proportions." | 2.42 | Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. ( Ahokas, RA; Gerling, IC; Guntaka, RV; Kiani, MF; Postlethwaite, AE; Sun, Y; Warrington, KJ; Weber, KT, 2003) |
| "Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases." | 2.42 | Aldosterone receptor antagonists for hypertension: what do they offer? ( Krum, H; Liew, D, 2003) |
| "Hypertension is an important determinant of heart failure." | 2.42 | A neuroendocrine-immune interface. The immunostimulatory state of aldosteronism. ( Weber, KT, 2003) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 2.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Beneficial effects of anti-aldosterone treatment in heart failure may thus be secondary in part to blockade of cardiac aldosterone action." | 2.42 | Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects. ( Ambroisine, ML; Bendall, JK; Delcayre, C; Fuchs, S; Garnier, A; Heymes, C; Milliez, P; Nehme, J; Robidel, E; Swynghedauw, B, 2004) |
| "Aldosterone also promotes myocardial fibrosis and cardiac remodelling by enhancing collagen synthesis, resulting in increased myocardial stiffness and increased left ventricular mass." | 2.42 | The clinical implications of aldosterone escape in congestive heart failure. ( Struthers, AD, 2004) |
| "Aldosterone promotes sodium and water retention, sympathoadrenergic activation, endothelial dysfunction, and cardiovascular fibrosis and hypertrophy." | 2.42 | Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. ( Bauersachs, J; Fraccarollo, D; Galuppo, P, 2004) |
| "Aldosterone has several deleterious properties." | 2.41 | Aldosterone: cardiovascular assault. ( Struthers, AD, 2002) |
| "Aldosterone production plays an important role in the remodeling of the heart." | 2.41 | Molecular mechanisms of myocardial remodeling. The role of aldosterone. ( Delcayre, C; Swynghedauw, B, 2002) |
| "This interstitial fibrosis is an important determinant of pathologic hypertrophy in chronic heart failure." | 2.41 | Aldosterone and myocardial fibrosis in heart failure. ( Brilla, CG, 2000) |
| " New interest in therapy with aldosterone antagonists was stimulated by results of a 2-year study of 1663 patients with heart failure that showed a 30% relative risk reduction of death among patients given a subhemodynamic dosage of spironolactone, a nonselective aldosterone antagonist, compared with placebo, in addition to standard therapy of diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, and digitalis." | 2.41 | Aldosterone, a new appreciation of its role in heart failure. ( Cha, AJ; Judge, KW; Malecha, SE, 2000) |
| "Most patients with chronic congestive heart failure can be managed efficiently outside the hospital setting by the proper use of nonpharmacologic therapies." | 2.41 | Neurohormonal factors in heart failure. ( Mendzef, SD, 2000) |
| "Aldosterone has been identified as a critically important neurohormone with direct detrimental effects on the myocardium." | 2.41 | Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. ( Miller, AB; Srivastava, P, 2001) |
| "Aldosterone was shown to promote cardiac fibrosis in various experimental models." | 2.41 | Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. ( Alla, F; Dousset, B; Zannad, F, 2001) |
| "Heart failure is a physiopathological condition, with an increasing incidence and prevalence, involving the action of a series of mechanisms known as 'compensators', which are phylogenetically ready to normalize minute volume and blood pressure." | 2.39 | [Neurohormonal factors in heart failure. I]. ( Cosín Aguilar, J; Cruz Fernández, JM; de Teresa Galván, E; Ferreira Montero, IJ; López-Sendón, J; Soler Soler, J; Tamargo Menéndez, J, 1996) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 2.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Symptomatic heart failure is accompanied by diastolic ventricular dysfunction due largely to an extensive reactive and reparative fibrosis." | 2.39 | Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. ( Campbell, SE; Sun, Y; Weber, KT, 1995) |
| "In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment." | 2.39 | Aldosterone and heart failure. ( Zannad, F, 1995) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a detrimental effect on parasympathetic and baroreflex function." | 2.39 | Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. ( Struthers, AD, 1996) |
| "Enalapril maleate is a prodrug which when administered orally is hydrolysed to release the active converting enzyme inhibitor enalaprilat." | 2.37 | An overview of the clinical pharmacology of enalapril. ( Davies, RO; Gomez, HJ; Irvin, JD; Walker, JF, 1984) |
| "When used in congestive heart failure, ACE inhibitors exert a balanced vasodilator effect on arterial and venous beds and do not induce tachycardia or fluid retention." | 2.37 | Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy. ( Abrams, WB; Davies, RO; Ferguson, RK, 1984) |
| "In patients with congestive heart failure treated with digitalis, these natriuretic agents are particularly useful because of their potassium-sparing properties." | 2.37 | Clinical applications of antimineralocorticoids. ( Brunner, HR; Nüssberger, J; Waeber, B, 1988) |
| "Concern about hyperkalemia is thought to contribute to this lack of evidence-based therapy." | 1.91 | Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor. ( Johnson, M; McMahon, G; Morrison, FJ; Su, M; Turchin, A, 2023) |
| "The role of taurine in the treatment of congestive heart failure (CHF) in dogs without systemic deficiency is unexplored." | 1.91 | The effect of taurine supplementation on the renin-angiotensin-aldosterone system of dogs with congestive heart failure. ( Adin, D; Brethel, S; Girens, R; Locker, S; Meurs, K; Rivera, P, 2023) |
| "Patients with bilateral primary aldosteronism (PA) generally are treated with antihypertensive drugs, but optimal treatment for patients with complications due to refractory hypertension has not been established." | 1.91 | Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication. ( Akaihata, H; Hata, J; Honda-Takinami, R; Hoshi, S; Kataoka, M; Kojima, Y; Matsuoka, K; Ogawa, S; Onagi, A; Sato, Y; Tanji, R, 2023) |
| "Evidence of primary aldosteronism physiology was prevalent (11." | 1.72 | Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study. ( Ballantyne, CM; Boerwinkle, E; Brown, JM; Claggett, BL; Coresh, J; Grams, ME; Shah, AM; Solomon, SD; Vaidya, A; Wang, Z; Wijkman, MO; Yu, B, 2022) |
| " In addition, the patient's BP decreased, proteinuria was reduced, diuretics could be discontinued, and his calcium channel blocker dosage was decreased." | 1.51 | Successful Depressor Effect Concomitant with Complete Normalization of High Renin and Aldosterone Profile by Percutaneous Transluminal Renal Angioplasty in a Patient with Acute Exacerbated Heart Failure with Preserved Ejection Fraction. ( Okamura, K; Shirai, K; Takamiya, Y; Urata, H, 2019) |
| "HFpEF mice developed hypertension, left ventricular hypertrophy, and diastolic dysfunction and had higher myocardial natriuretic peptide expression." | 1.43 | Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. ( Aprahamian, T; Fuster, JJ; Hulsmans, M; Li, S; Nahrendorf, M; Sam, F; Scherer, PE; Valero-Muñoz, M; Wilson, RM, 2016) |
| "Aldosterone activation was demonstrated in all three groups; however, dietary sodium restriction, in contrast to high sodium, resulted in early (10 days) activation of PRA and aldosterone." | 1.42 | Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure. ( Borgeson, DD; Burnett, JC; Grantham, JA; Luchner, A; Miller, WL; Redfield, MM, 2015) |
| "AVP may promote ventricular remodeling." | 1.42 | The secretion patterns and roles of cardiac and circulating arginine vasopressin during the development of heart failure. ( Chen, X; Gao, X; Li, Q; Lu, G; Tang, K, 2015) |
| "Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years." | 1.42 | Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up. ( Bailey, KR; Buglioni, A; Burnett, JC; Cannone, V; Heublein, DM; Rodeheffer, RJ; Sangaralingham, SJ; Sarzani, R; Scott, CG, 2015) |
| "Aldosterone appears to be a main marker of adverse clinical outcome, in accordance with the literature." | 1.40 | Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. ( Arnone, G; Arnone, MT; Assennato, P; Corrado, E; Mignano, A; Novo, G; Novo, S; Pitruzzella, V; Rotolo, A, 2014) |
| "Aldosterone levels increase during AHF hospitalization and remain increased long after discharge." | 1.39 | Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. ( Fought, A; Gheorghiade, M; Girerd, N; Konstam, MA; Kwasny, MJ; Maggioni, A; Pang, PS; Subacius, H; Swedberg, K; Zannad, F, 2013) |
| "We postulate that hyperreninemic-hyperaldosteronism followed by fluid retention caused a sudden severe increase in ventricular afterload and subsequent congestive heart failure in this patient." | 1.37 | Congestive heart failure as an initial manifestation of reninoma. ( Cho, MJ; Lee, HD; Park, JA; Sung, EY, 2011) |
| "Heart failure is accompanied by electrolyte disturbance including reduced calcium and sodium in the extracellular milieu but increased calcium within cells, a phenomenon called "calcium paradox"." | 1.36 | Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism. ( Abdallah, Y; Schlüter, KD; Schreckenberg, R; Tastan, I; Wenzel, S, 2010) |
| "Congestive heart failure was induced in 3 groups (n=6 per group) of dogs by tachypacing." | 1.36 | Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. ( Boerrigter, G; Burnett, JC; Cataliotti, A; Costello-Boerrigter, LC; Harty, GJ, 2010) |
| "Inhibiting ventricular remodeling early may be an effective way to postpone heart failure for patients with cardiovascular illness." | 1.36 | Effect of sodium houttuyfonate on inhibiting ventricular remodeling induced by abdominal aortic banding in rats. ( Chen, CX; Gao, JP; Gu, WL; Li, X; Wu, Q, 2010) |
| "The influence of chronic administration of eplerenone on the intracrine as well as on the extracellular action of angiotensin II (Ang II) on L-type inward calcium current was investigated in the failing heart of cardiomyopathic hamsters (TO-2)." | 1.35 | Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. ( De Mello, WC; Gerena, Y, 2008) |
| "In untreated Graves' disease serum BNP level was significantly elevated in patients with HF or AF." | 1.35 | Serum concentrations of BNP and ANP in patients with thyrotoxicosis. ( Isozaki, O; Kato, K; Murakami, H; Takano, K; Tsushima, T, 2009) |
| "Reversal of cardiac fibrosis is a major determinant of the salutary effects of mineralocorticoid receptor antagonists in heart failure." | 1.35 | Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. ( Beugels, IP; Cohuet, GM; de Gooyer, ME; Emmen, JM; Hermans, JJ; Hilbers, PA; Minnaard-Huiban, M; Ottenheijm, HC; Pieterse, K; Plate, R; Roumen, L; Ruijters, E; Smits, JF; van Essen, H, 2008) |
| "CHF was characterized by left ventricular remodeling and impaired systolic and diastolic function." | 1.35 | Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. ( Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2008) |
| "The appearance of SHPT in aldosteronism, induced by fallen plasma [Ca]o, leads to PTH-mediated Ca overloading of PBMC and their increased production of H2O2." | 1.33 | Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. ( Ahokas, RA; Bhattacharya, SK; Gerling, IC; Goodwin, KD; Sun, Y; Weber, KT, 2006) |
| "Carvedilol was then commenced and up titrated over the next 6-8 weeks and all samples were again obtained." | 1.33 | Carvedilol reduces aldosterone release in systolic heart failure. ( Aggarwal, A; Campbell, DJ; Wong, J, 2006) |
| "To date, its therapeutic actions in congestive heart failure (CHF) remain undefined." | 1.32 | Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. ( Boerrigter, G; Burnett, JC; Cataliotti, A; Costello-Boerrigter, LC; Harty, GJ; Lapp, H; Stasch, JP; Tsuruda, T, 2003) |
| "Patients with liver cirrhosis and chronic heart failure (CHF) have a reduced capacity to excrete water." | 1.32 | Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. ( Bech, JN; Bentzen, H; Nyvad, O; Pedersen, EB; Pedersen, RS, 2003) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 1.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "The study was made in 45 patients with congestive heart failure treated in the Department of Cardiology." | 1.32 | [Cytokines and remodeling of the heart in patients with congestive heart failure]. ( Jołda-Mydłowska, B; Salomon, P, 2003) |
| "Aldosterone promotes collagen synthesis and structural remodeling of target organs such as the heart." | 1.31 | Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Horie, H; Kinoshita, M; Mabuchi, N; Maeda, K; Matsumoto, T; Ohnishi, M; Sawaki, M; Sugimoto, Y; Tsutamoto, T; Tsutsui, T; Wada, A, 2000) |
| ""Aldosterone escape" was defined as being present when plasma aldosterone levels were above the normal range in our laboratory (>42 nmol/L)." | 1.31 | Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. ( Anker, SD; Bonizzato, A; Cabrini, G; Cicoira, M; Coats, AJ; Franceschini, L; Golia, G; Graziani, M; Rossi, A; Zanolla, L; Zardini, P, 2001) |
| "The syndrome of congestive heart failure (CHF) entails complex autonomic and hormonal responses." | 1.31 | Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure. ( Aronson, D; Burger, AJ, 2001) |
| "Aldosterone escape was defined as plasma levels of aldosterone above the normal range in our laboratory (> 0." | 1.31 | Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Caruso, B; Cicoira, M; Franceschini, L; Golia, G; Rossi, A; Zanolla, L; Zardini, P; Zeni, P, 2002) |
| " On the basis of the estimate of the dosing of digoxin these patients were divided into two groups: the first with therapeutic and the second with subtherapeutic concentrations of digoxin in serum." | 1.30 | The level of plasma neuroendocrine activity and the concentration of digoxin in the serum of patients with mild chronic heart failure. ( Chmara, E; Jablecka, A; Korzeniowska, K, 1998) |
| "Chronic heart failure was induced in seven pigs by rapid left atrial pacing for three weeks." | 1.30 | An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure. ( Aakvaag, A; Djøseland, O; Hall, C; Hystad, M; Karlberg, BE; Kjekshus, J; Klinge, R, 1998) |
| "Compared with control animals, rats with congestive heart failure displayed a slight increase in the number of peripheral granules, adjacent to the sarcolemma, but not centrally located in the Golgi areas." | 1.29 | Morphometric analysis of atrial natriuretic peptide-containing granules in atriocytes of rats with experimental congestive heart failure. ( Avramovitch, N; Haramati, A; Hoffman, A; Lewinson, D; Winaver, J, 1995) |
| "It has been proposed that in congestive heart failure reduction of cardiac output and any associated decrease in blood pressure cause underfilling of the arterial compartment, which promotes and perpetuates neurohumoral activation and the retention of fluid." | 1.29 | Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. ( Agostoni, P; Giraldi, F; Guazzi, M; Guazzi, MD; Lauri, G; Marenzi, G; Matturri, M; Perego, B; Salvioni, A, 1994) |
| "Although angiotensin converting enzyme inhibitor therapy is an established approach in the treatment of chronic heart failure, the required dosage remains unclear." | 1.29 | Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. ( Baumgartner, W; Bergler-Klein, J; Globits, S; Glogar, D; Ogris, E; Pacher, R; Teufelsbauer, H; Wutte, M, 1993) |
| "hr/mL and Cmax was 143." | 1.29 | Invasive pharmacodynamics of fosinopril in patients with congestive heart failure. ( Ford, NF; Fulmor, IE; Hui, KK; Natarajan, C; Smith, RA, 1995) |
| "Furosemide was added after the 3-week examination, and at 6 months, dogs had received furosemide for at least 4 months." | 1.29 | Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. ( Häggström, J; Hansson, K; Karlberg, BE; Kvart, C; Madej, A; Olsson, K, 1996) |
| "Chagasic patients with congestive heart failure are usually treated with digitalis and converting enzyme inhibitors." | 1.29 | Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. ( Bellabarba, G; Bishop, W; Davila, DF; Donis, JH; Hernandez, L; Khoury, AM; Lemorvan, C; Torres, A, 1996) |
| "After treatment for the heart failure plasma atrial natriuretic peptide fell considerably and there were associated increases in plasma aldosterone and plasma renin activity." | 1.28 | Atrial natriuretic peptide, aldosterone, and plasma renin activity in peripartum heart failure. ( Adesanya, CO; Anjorin, FI; MacGregor, GA; Parry, EH; Sada, IA; Sagnella, GA, 1991) |
| "Thus, in patients with dilated cardiomyopathy and mild cardiac dysfunction, plasma ANF levels are not increased by volume expansion as observed in N." | 1.28 | Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. ( De Campora, P; De Luca, N; Enea, I; Lembo, G; Mele, AF; Ricciardelli, B; Romano, M; Rubattu, S; Tritto, C; Volpe, M, 1991) |
| " Angiotensin-converting enzyme inhibitors cause an acute fall in creatinine clearance which may reduce the effects of loop diuretics and attention must be paid to diuretic dosage when initiating angiotensin-converting enzyme inhibitors for the treatment of cardiac failure." | 1.28 | Acute administration of captopril lowers the natriuretic and diuretic response to a loop diuretic in patients with chronic cardiac failure. ( Davies, E; Edwards, CR; Flapan, AD; Shaw, TR; Waugh, C; Williams, BC, 1991) |
| "1) Captopril was orally administered in a dose of 12." | 1.28 | Effect of captopril on congestive heart failure. ( Matsuo, H; Nishida, M; Obata, H; Sano, H; Yasuda, H, 1990) |
| "Emphasis is on the arrhythmia component and the complex interrelationships of critical electrolytes and pathophysiologic factors that can lead to sudden cardiac death." | 1.28 | Short- and long-term mechanisms of sudden cardiac death in congestive heart failure. ( Helfant, RH, 1990) |
| "Aldosterone values were highly correlated with the urine potassium/sodium ratio." | 1.27 | The renin-angiotensin--aldosterone system and the clinical course of acute myocardial infarction. ( Ceremuzyński, L; Michorowski, B, 1983) |
| "The hyponatremia is usually of the dilutional type." | 1.27 | Hyponatremia in congestive heart failure treated with diuretics. ( Orinius, E, 1984) |
| "The most common causes of virilization are considered unlikely on the basis of clinical and laboratory data." | 1.27 | Aldosteronism in pregnancy: association with virilization of female offspring. ( Elterman, JJ; Hagen, GA, 1983) |
| "Patients with marked edema due to congestive heart failure had plasma levels of atrial natriuretic factor five times higher than normal (P less than 0." | 1.27 | Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. ( Grekin, RJ; Ostafin, EA; Shenker, Y; Sider, RS, 1985) |
| "Further volume expansion in liver cirrhosis by saline infusion led to the further increase in ANP (13." | 1.27 | Radioimmunoassay of atrial natriuretic peptide in human plasma: application to studies of volume and blood pressure homeostasis. ( Horký, K; Lachmanová, J; Srámková, J; Tesar, V; Widimský, J, 1988) |
| "Enalapril was effective therapy for chronic CHF." | 1.27 | Clinical and hemodynamic experience with enalapril in congestive heart failure. ( Cody, RJ, 1985) |
| "Treatment with enalaprilat was accompanied by significant reductions in heart preload and afterload and in plasma hormone concentrations." | 1.27 | Plasma concentrations of angiotensin II and aldosterone during acute left ventricular failure in the dog. Effect of converting enzyme inhibition. ( Hall, C; Karlberg, BE, 1986) |
| "Because hyponatremia is frequently associated with preceding diuretic treatment and unrestricted fluid intake--conditions which have not been addressed sufficiently in published literature--we studied the pathophysiology and the clinical setting of such hyponatremia in a large group of internal medicine patients." | 1.27 | Role of diuretics, hormonal derangements, and clinical setting of hyponatremia in medical patients. ( Gross, P; Hackenthal, E; Hausmann, C; Ketteler, M; Rascher, W; Reinhard, C; Ritz, E; Schömig, A, 1988) |
| "The study has shown that in congestive cardiomyopathy shifts in the renin-angiotensin-aldosterone system are of the same nature as in patients with congestive heart failure of another etiology." | 1.27 | [Plasma renin activity and aldosterone concentration of patients with congestive cardiomyopathy]. ( Botnar', VI; Popovich, MI; Zatushevskiĭ, IF, 1986) |
| "6 fluid overloaded patients with congestive heart failure, NYHA classification IV, resistant to drug therapy, were treated by pump driven venovenous hemofiltration." | 1.27 | [Hemofiltration and the neurohumoral system in patients with severe heart failure]. ( Glogar, DH; Kaindl, F; Silberbauer, K; Stummvoll, HK; Templ, H; Wittels, P, 1985) |
| "To elucidate the effect of bed rest used as an adjunct to increased diuretic treatment, twelve patients with chronic congestive heart failure (CHF) had a 50% increase in loop diuretic dosage and were allocated to either continuous bed rest or bed rest during nights only." | 1.27 | Bed rest and increased diuretic treatment in chronic congestive heart failure. ( Abildgaard, U; Aldershvile, J; Christensen, NJ; Falk, J; Giese, J; Hammer, M; Henriksen, JH; Ring-Larsen, H, 1985) |
| "Chronic congestive heart failure patients being treated with the loop-blocking diuretic, furosemide, were found to have significantly reduced lymphocyte magnesium (p less than 0." | 1.26 | The effect of diuretics on lymphocyte magnesium and potassium. ( Counihan, TB; Ryan, MF; Ryan, MP, 1981) |
| "Hyperaldosteronism is an important factor contributing to fluid and sodium retention in infants with heart failure." | 1.26 | The occurrence of hyperaldosteronism in infants with congestive heart failure. ( Baylen, BG; Johnson, G; Kaplan, S; Srivastava, L; Tsang, R, 1980) |
| " Therefore, during chronic captopril therapy of CHF, a reduction of diuretic dosage may be necessary to prevent orthostatic hypotension." | 1.26 | Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. ( Cody, RJ; Franklin, KW; Laragh, JH, 1982) |
| "Thus, in CMH, congestive heart failure is attended by increased plasma renin activity without a significant increase in aldosterone production, a dissociation which does not appear to be due to adrenal unresponsiveness to angiotensin II or to potassium depletion." | 1.26 | Renin and aldosterone in the cardiomyopathic hamster in congestive heart failure. ( Galla, JH; Hayslett, JP; Kotchen, TA; Schneider, G, 1977) |
| " In normal subjects, Sar1-Ile-AII showed pressor (agonistic) activity, which was related to both dosage and sodium intake." | 1.26 | Changes of blood pressure, plasma renin activity and plasma aldosterone concentration following the infusion of Sar1-Ile8-angiotensin II in hypertensive, fluid and electrolyte disorders. ( Doi, K; Hata, T; Ichihara, K; Kumahara, Y; Ogihara, T; Yamamoto, T, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 349 (35.22) | 18.7374 |
| 1990's | 150 (15.14) | 18.2507 |
| 2000's | 261 (26.34) | 29.6817 |
| 2010's | 163 (16.45) | 24.3611 |
| 2020's | 68 (6.86) | 2.80 |
| Authors | Studies |
|---|---|
| Mamazhakypov, A | 1 |
| Hein, L | 1 |
| Lother, A | 1 |
| Lytvyn, Y | 1 |
| Burns, KD | 1 |
| Testani, JM | 1 |
| Lytvyn, A | 1 |
| Ambinathan, JPN | 1 |
| Osuntokun, O | 1 |
| Godoy, LC | 1 |
| Cherney, DZI | 1 |
| Parker, JD | 1 |
| Mohanty, AF | 1 |
| Levitan, EB | 1 |
| King, JB | 1 |
| Dodson, JA | 1 |
| Vardeny, O | 1 |
| Cook, J | 1 |
| Herrick, JS | 1 |
| He, T | 2 |
| Patterson, OV | 1 |
| Alba, PR | 1 |
| Russo, PA | 1 |
| Obi, EN | 1 |
| Choi, ME | 1 |
| Fang, JC | 2 |
| Bress, AP | 1 |
| Bauersachs, J | 6 |
| López-Andrés, N | 2 |
| Biegus, J | 1 |
| Nawrocka-Millward, S | 1 |
| Zymliński, R | 1 |
| Fudim, M | 1 |
| Testani, J | 1 |
| Marciniak, D | 1 |
| Rosiek-Biegus, M | 1 |
| Ponikowska, B | 1 |
| Guzik, M | 1 |
| Garus, M | 1 |
| Ponikowski, P | 3 |
| Krim, SR | 1 |
| Borges, JI | 2 |
| Ferraino, KE | 1 |
| Cora, N | 1 |
| Nagliya, D | 1 |
| Suster, MS | 1 |
| Carbone, AM | 1 |
| Lymperopoulos, A | 5 |
| Sharma, A | 1 |
| Elharram, M | 1 |
| Afilalo, J | 1 |
| Flannery, A | 1 |
| Afilalo, M | 1 |
| Tselios, C | 1 |
| Ni, J | 1 |
| Ezekowitz, JA | 2 |
| Cheng, MP | 1 |
| Ambrosy, AP | 1 |
| Zannad, F | 13 |
| Brophy, JM | 1 |
| Giannetti, N | 1 |
| Bessissow, A | 1 |
| Kronfli, N | 1 |
| Marelli, A | 1 |
| Aziz, H | 1 |
| Alqahtani, M | 1 |
| Aflaki, M | 1 |
| Craig, M | 1 |
| Lopes, RD | 1 |
| Ferreira, JP | 2 |
| Parksook, WW | 1 |
| Williams, GH | 5 |
| Asleh, R | 1 |
| Briasoulis, A | 1 |
| Borlaug, BA | 2 |
| Brown, JM | 1 |
| Wijkman, MO | 1 |
| Claggett, BL | 1 |
| Shah, AM | 2 |
| Ballantyne, CM | 2 |
| Coresh, J | 1 |
| Grams, ME | 1 |
| Wang, Z | 2 |
| Yu, B | 1 |
| Boerwinkle, E | 1 |
| Vaidya, A | 1 |
| Solomon, SD | 2 |
| Abdelhamid, M | 1 |
| Rosano, G | 1 |
| Metra, M | 5 |
| Adamopoulos, S | 1 |
| Böhm, M | 2 |
| Chioncel, O | 1 |
| Filippatos, G | 4 |
| Jankowska, EA | 1 |
| Lopatin, Y | 1 |
| Lund, L | 1 |
| Milicic, D | 1 |
| Moura, B | 1 |
| Ben Gal, T | 1 |
| Ristic, A | 1 |
| Rakisheva, A | 1 |
| Savarese, G | 3 |
| Mullens, W | 3 |
| Piepoli, M | 1 |
| Bayes-Genis, A | 1 |
| Thum, T | 2 |
| Anker, SD | 5 |
| Seferovic, P | 2 |
| Coats, AJS | 2 |
| Al-Kuraishy, HM | 1 |
| Al-Gareeb, AI | 1 |
| Alexiou, A | 1 |
| Batiha, GE | 1 |
| Buffolo, F | 1 |
| Tetti, M | 1 |
| Mulatero, P | 1 |
| Monticone, S | 1 |
| Ramos, R | 1 |
| Moliner, P | 1 |
| Comin-Colet, J | 1 |
| Ageev, FT | 1 |
| Escobar, C | 1 |
| Luis-Bonilla, J | 1 |
| Crespo-Leiro, MG | 2 |
| Esteban-Fernández, A | 1 |
| Farré, N | 1 |
| Garcia, A | 1 |
| Nuñez, J | 1 |
| Soborun, N | 1 |
| Müller, M | 1 |
| Abdurashidova, T | 1 |
| Tzimas, G | 1 |
| Schukraft, S | 1 |
| Lu, H | 1 |
| Hugli, O | 1 |
| Vollenweider, P | 1 |
| Garnier, A | 2 |
| Monney, P | 1 |
| Hullin, R | 1 |
| Iovanovici, DC | 1 |
| Bungau, SG | 1 |
| Vesa, CM | 1 |
| Moisi, M | 1 |
| Babes, EE | 1 |
| Tit, DM | 1 |
| Horvath, T | 1 |
| Behl, T | 1 |
| Rus, M | 1 |
| Salama, ABM | 1 |
| Abouleisa, RRE | 1 |
| Ou, Q | 1 |
| Tang, XL | 1 |
| Alhariry, N | 1 |
| Hassan, S | 1 |
| Gebreil, A | 1 |
| Dastagir, M | 1 |
| Abdulwali, F | 1 |
| Bolli, R | 1 |
| Mohamed, TMA | 1 |
| Hegyi, B | 3 |
| Mira Hernandez, J | 3 |
| Ko, CY | 3 |
| Hong, J | 3 |
| Shen, EY | 3 |
| Spencer, ER | 3 |
| Smoliarchuk, D | 3 |
| Navedo, MF | 3 |
| Bers, DM | 3 |
| Bossuyt, J | 3 |
| Tardif, JC | 3 |
| Rouleau, J | 1 |
| Chertow, GM | 1 |
| Al-Shurbaji, A | 1 |
| Lisovskaja, V | 1 |
| Gustavson, S | 1 |
| Zhao, Y | 1 |
| Bouabdallaoui, N | 1 |
| Desai, AS | 1 |
| Chernyavskiy, A | 1 |
| Evsina, M | 1 |
| Merkely, B | 1 |
| McMurray, JJV | 1 |
| Pfeffer, MA | 2 |
| Johnson, M | 1 |
| Morrison, FJ | 1 |
| McMahon, G | 1 |
| Su, M | 1 |
| Turchin, A | 1 |
| Kanda, E | 1 |
| Rastogi, A | 1 |
| Murohara, T | 2 |
| Lesén, E | 1 |
| Agiro, A | 1 |
| Arnold, M | 1 |
| Chen, G | 1 |
| Yajima, T | 1 |
| Järbrink, K | 1 |
| Pollack, CV | 1 |
| Berkowicz, P | 1 |
| Totoń-Żurańska, J | 1 |
| Kwiatkowski, G | 1 |
| Jasztal, A | 1 |
| Csípő, T | 1 |
| Kus, K | 1 |
| Tyrankiewicz, U | 1 |
| Orzyłowska, A | 1 |
| Wołkow, P | 1 |
| Tóth, A | 1 |
| Chlopicki, S | 1 |
| Sun, Z | 1 |
| Chen, Z | 1 |
| Liu, R | 1 |
| Lu, G | 3 |
| Li, Z | 2 |
| Sun, Y | 6 |
| Schneider, BK | 1 |
| Ward, J | 1 |
| Sotillo, S | 1 |
| Garelli-Paar, C | 1 |
| Guillot, E | 1 |
| Prikazsky, M | 1 |
| Mochel, JP | 2 |
| Lee, SH | 1 |
| Rhee, TM | 1 |
| Shin, D | 1 |
| Hong, D | 1 |
| Choi, KH | 1 |
| Kim, HK | 1 |
| Park, TK | 1 |
| Yang, JH | 1 |
| Song, YB | 1 |
| Hahn, JY | 1 |
| Choi, SH | 1 |
| Chae, SC | 1 |
| Cho, MC | 1 |
| Kim, CJ | 1 |
| Kim, JH | 1 |
| Kim, HS | 2 |
| Gwon, HC | 1 |
| Jeong, MH | 1 |
| Lee, JM | 1 |
| Ward, T | 1 |
| Lewis, RD | 1 |
| Brown, T | 1 |
| Baxter, G | 1 |
| de Arellano, AR | 1 |
| Sudani, HA | 1 |
| Shah, S | 1 |
| Lo, KB | 1 |
| Essa, H | 1 |
| Wattoo, A | 1 |
| Angelim, L | 1 |
| Brousas, S | 1 |
| Whybrow-Huppatz, I | 1 |
| Vellanki, S | 1 |
| Sankaranarayanan, R | 1 |
| Rangaswami, J | 1 |
| Carvalho, PEP | 1 |
| Veiga, TMA | 1 |
| Lacerda, H | 1 |
| Tofanelli, MR | 1 |
| Gewehr, DM | 1 |
| Nunes, MCP | 1 |
| Simões E Silva, AC | 1 |
| Örsçelik, Ö | 1 |
| Yeşil, E | 1 |
| Uyar, H | 1 |
| Sürmeli, AO | 1 |
| Özkan, B | 1 |
| Çimen, MBY | 1 |
| Brethel, S | 1 |
| Locker, S | 1 |
| Girens, R | 1 |
| Rivera, P | 1 |
| Meurs, K | 1 |
| Adin, D | 1 |
| Monzo, L | 1 |
| Huttin, O | 1 |
| Lamiral, Z | 1 |
| Bozec, E | 1 |
| Beaumont, M | 1 |
| Micard, E | 1 |
| Baudry, G | 1 |
| Marie, PY | 1 |
| Eschalier, R | 1 |
| Rossignol, P | 3 |
| Girerd, N | 2 |
| Dattani, R | 1 |
| Ul-Haq, Z | 1 |
| Shah, M | 1 |
| Goldet, G | 1 |
| Darzi, LA | 1 |
| Ashrafian, H | 1 |
| Kamalati, T | 1 |
| Frankel, AH | 1 |
| Tam, FWK | 1 |
| Beer, BN | 1 |
| Schrage, B | 1 |
| Chinnadurai, R | 1 |
| Rengarajan, S | 1 |
| Budden, JJ | 1 |
| Quinn, CM | 1 |
| Kalra, PA | 1 |
| El-Hefny, NEAM | 1 |
| Mohammed, HSE | 1 |
| El-Mahdy, RI | 1 |
| Haridi, SHM | 1 |
| Mohamed, AS | 1 |
| Hoshi, S | 1 |
| Onagi, A | 1 |
| Tanji, R | 1 |
| Honda-Takinami, R | 1 |
| Matsuoka, K | 1 |
| Hata, J | 1 |
| Sato, Y | 2 |
| Akaihata, H | 1 |
| Kataoka, M | 2 |
| Ogawa, S | 1 |
| Kojima, Y | 1 |
| Scott, NJA | 2 |
| Rademaker, MT | 12 |
| Charles, CJ | 10 |
| Espiner, EA | 15 |
| Richards, AM | 16 |
| Whittaker, A | 1 |
| Kragh, ÅM | 1 |
| Hartleib-Geschwindner, J | 1 |
| Albayaty, M | 1 |
| Backlund, A | 1 |
| Greasley, PJ | 1 |
| Heijer, M | 1 |
| Kjaer, M | 1 |
| Forte, P | 1 |
| Unwin, R | 1 |
| Wernevik, L | 1 |
| Ericsson, H | 1 |
| Takamiya, Y | 1 |
| Okamura, K | 1 |
| Shirai, K | 1 |
| Urata, H | 1 |
| Seccia, TM | 1 |
| Caroccia, B | 1 |
| Maiolino, G | 1 |
| Cesari, M | 2 |
| Rossi, GP | 4 |
| Huang, WC | 1 |
| Chen, YY | 1 |
| Lin, YH | 1 |
| Chen, L | 3 |
| Lin, PC | 1 |
| Lin, YF | 1 |
| Liu, YC | 1 |
| Wu, CH | 1 |
| Chueh, JS | 1 |
| Chu, TS | 1 |
| Wu, KD | 1 |
| Huang, CY | 1 |
| Wu, VC | 1 |
| Kassem, H | 1 |
| Chatila, K | 1 |
| Wetmore, JB | 1 |
| Yan, H | 1 |
| Horne, L | 1 |
| Peng, Y | 1 |
| Gilbertson, DT | 1 |
| Leenen, FHH | 1 |
| Wang, HW | 1 |
| Hamlyn, JM | 1 |
| Yamashita, K | 1 |
| Ito, K | 1 |
| Endo, J | 1 |
| Matsuhashi, T | 1 |
| Katsumata, Y | 1 |
| Yamamoto, T | 13 |
| Shirakawa, K | 1 |
| Isobe, S | 2 |
| Yoshida, N | 1 |
| Goto, S | 1 |
| Moriyama, H | 2 |
| Kitakata, H | 1 |
| Mitani, F | 1 |
| Fukuda, K | 1 |
| Goda, N | 1 |
| Ichihara, A | 1 |
| Sano, M | 1 |
| Koh, CY | 1 |
| Kini, RM | 1 |
| Lainscak, M | 1 |
| Laroche, C | 3 |
| Piepoli, MF | 2 |
| Rosano, GMC | 1 |
| Seferovic, PM | 1 |
| Ruschitzka, F | 1 |
| Mebazaa, A | 1 |
| McDonagh, T | 2 |
| Sahuquillo, A | 1 |
| Penco, M | 1 |
| Maggioni, AP | 6 |
| Lund, LH | 3 |
| Garg, A | 1 |
| Foinquinos, A | 1 |
| Jung, M | 1 |
| Janssen-Peters, H | 1 |
| Biss, S | 1 |
| Gupta, SK | 1 |
| Omidkhoda, N | 1 |
| Vakilian, F | 1 |
| Mohammadpour, AH | 1 |
| Sathyapalan, T | 1 |
| Sahebkar, A | 1 |
| Azizi, M | 1 |
| Howlett, JG | 1 |
| Culebras, E | 1 |
| Hernández, F | 1 |
| Ouwerkerk, W | 1 |
| Teng, TK | 1 |
| Tromp, J | 1 |
| Tay, WT | 1 |
| Cleland, JG | 4 |
| van Veldhuisen, DJ | 16 |
| Dickstein, K | 6 |
| Ng, LL | 1 |
| Lang, CC | 2 |
| Hung, CL | 1 |
| Sawhney, JPS | 1 |
| Naik, A | 1 |
| Shimizu, W | 2 |
| Hagiwara, N | 1 |
| Wander, GS | 1 |
| Anand, I | 2 |
| Voors, AA | 4 |
| Lam, CSP | 1 |
| Schmidt, IM | 1 |
| Verma, A | 1 |
| Waikar, SS | 1 |
| Grosman-Rimon, L | 2 |
| Kachel, E | 1 |
| McDonald, MA | 2 |
| Lalonde, SD | 1 |
| Yip, P | 2 |
| Ribeiro, RVP | 1 |
| Adamson, MB | 1 |
| Cherney, DZ | 2 |
| Rao, V | 2 |
| Ho, JE | 1 |
| Benson, L | 1 |
| Sundström, J | 1 |
| Sbolli, M | 1 |
| O'Connor, CM | 2 |
| Kohno, T | 1 |
| Kohsaka, S | 1 |
| Tomasoni, D | 1 |
| Petrie, MC | 1 |
| Adamo, M | 1 |
| Volterrani, M | 2 |
| Perrone, V | 2 |
| Sangiorgi, D | 1 |
| Giacomini, E | 1 |
| Iellamo, F | 1 |
| Degli Esposti, L | 2 |
| Boorsma, EM | 1 |
| Ter Maaten, JM | 1 |
| Damman, K | 1 |
| Santos, K | 1 |
| Guitart-Mampel, M | 1 |
| Urquiza, P | 1 |
| Solesio, ME | 1 |
| Ke, B | 1 |
| Tan, X | 1 |
| Ren, L | 1 |
| Fan, Y | 1 |
| Zhang, Y | 1 |
| Li, F | 1 |
| Sun, Q | 1 |
| Liu, T | 2 |
| Jia, L | 1 |
| Wang, Y | 1 |
| Du, J | 1 |
| Garcia-Garduño, TC | 1 |
| Padilla-Gutierrez, JR | 1 |
| Cambrón-Mora, D | 1 |
| Valle, Y | 1 |
| Valero-Muñoz, M | 2 |
| Oh, A | 1 |
| Faudoa, E | 1 |
| Bretón-Romero, R | 1 |
| El Adili, F | 1 |
| Bujor, A | 1 |
| Sam, F | 6 |
| Vaduganathan, M | 1 |
| Fonarow, GC | 1 |
| Greene, SJ | 1 |
| Devore, AD | 2 |
| Albert, NM | 2 |
| Duffy, CI | 1 |
| Hill, CL | 1 |
| Patterson, JH | 1 |
| Spertus, JA | 2 |
| Thomas, LE | 1 |
| Williams, FB | 1 |
| Hernandez, AF | 5 |
| Butler, J | 2 |
| Fukushima, A | 1 |
| Kinugawa, S | 1 |
| Pan, A | 1 |
| Kosmala, W | 2 |
| Marwick, TH | 2 |
| Peverill, RE | 1 |
| Gelman, JS | 1 |
| Ames, MK | 2 |
| Atkins, CE | 2 |
| Eriksson, A | 1 |
| Hess, AM | 1 |
| Yang, Y | 1 |
| Liu, S | 1 |
| Zhang, RY | 1 |
| Luo, H | 1 |
| He, WF | 1 |
| Lei, R | 1 |
| Liu, MR | 1 |
| Hu, HX | 1 |
| Chen, M | 1 |
| Bilchenko, О | 1 |
| Kravtsova, V | 1 |
| Samburh, Y | 1 |
| Hodlevska, O | 1 |
| Gavrilyuk, V | 1 |
| Williams, SA | 1 |
| Murthy, AC | 1 |
| DeLisle, RK | 1 |
| Hyde, C | 1 |
| Malarstig, A | 1 |
| Ostroff, R | 1 |
| Weiss, SJ | 1 |
| Segal, MR | 1 |
| Ganz, P | 1 |
| Sparks, ER | 1 |
| Beavers, JC | 1 |
| Pitt, B | 17 |
| Packer, M | 4 |
| Kitzman, DW | 2 |
| Cooper, LB | 1 |
| Freedman, D | 1 |
| Han, L | 1 |
| Chai, S | 1 |
| Xing, G | 1 |
| Wang, H | 1 |
| Yuan, B | 1 |
| Su, S | 1 |
| Cannone, V | 2 |
| Buglioni, A | 2 |
| Sangaralingham, SJ | 3 |
| Scott, C | 1 |
| Bailey, KR | 2 |
| Rodeheffer, R | 1 |
| Redfield, MM | 9 |
| Sarzani, R | 2 |
| Burnett, JC | 18 |
| Garcia-Fernandez, N | 1 |
| Lavilla, J | 1 |
| Martín, PL | 1 |
| Romero-González, G | 1 |
| González, A | 2 |
| López, B | 2 |
| Ravassa, S | 1 |
| Díez, J | 3 |
| Teng, CH | 1 |
| Peyrou, M | 1 |
| Giraudel, J | 1 |
| Danhof, M | 1 |
| Rigel, DF | 1 |
| Nordqvist, A | 1 |
| Granberg, KL | 1 |
| Young, MJ | 3 |
| Adler, GK | 1 |
| Cannavo, A | 3 |
| Elia, A | 1 |
| Liccardo, D | 3 |
| Rengo, G | 5 |
| Koch, WJ | 5 |
| Yata, M | 1 |
| Kooistra, HS | 1 |
| Beijerink, NJ | 1 |
| Papademetriou, V | 1 |
| Toumpourleka, M | 1 |
| Imprialos, KP | 1 |
| Alataki, S | 1 |
| Manafis, A | 1 |
| Stavropoulos, K | 1 |
| Könemann, S | 2 |
| Sartori, LV | 1 |
| Gross, S | 1 |
| Hadlich, S | 1 |
| Kühn, JP | 1 |
| Samal, R | 2 |
| Bahls, M | 1 |
| Felix, SB | 2 |
| Wenzel, K | 2 |
| Vergaro, G | 4 |
| Passino, C | 5 |
| Emdin, M | 6 |
| Wang, Q | 2 |
| Cui, W | 1 |
| Zhang, HL | 1 |
| Hu, HJ | 1 |
| Zhang, YN | 1 |
| Liu, DM | 1 |
| Liu, J | 1 |
| Jiang, Y | 1 |
| Qin, Y | 1 |
| Li, Y | 2 |
| Xia, Q | 1 |
| Masutani, S | 1 |
| Saiki, H | 1 |
| Kurishima, C | 1 |
| Ishido, H | 1 |
| Tamura, M | 1 |
| Senzaki, H | 1 |
| Pang, PS | 1 |
| Swedberg, K | 5 |
| Fought, A | 1 |
| Kwasny, MJ | 1 |
| Subacius, H | 1 |
| Konstam, MA | 2 |
| Maggioni, A | 1 |
| Gheorghiade, M | 5 |
| Nakagawa, M | 1 |
| Guichard, JL | 1 |
| Clark, D | 1 |
| Calhoun, DA | 2 |
| Ahmed, MI | 1 |
| Mignano, A | 1 |
| Pitruzzella, V | 1 |
| Arnone, G | 1 |
| Arnone, MT | 1 |
| Rotolo, A | 1 |
| Assennato, P | 1 |
| Novo, G | 1 |
| Corrado, E | 1 |
| Novo, S | 1 |
| Bress, A | 1 |
| Han, J | 1 |
| Patel, SR | 2 |
| Desai, AA | 1 |
| Mansour, I | 1 |
| Groo, V | 1 |
| Progar, K | 1 |
| Shah, E | 1 |
| Stamos, TD | 2 |
| Wing, C | 1 |
| Garcia, JG | 1 |
| Kittles, R | 1 |
| Cavallari, LH | 2 |
| Konstantinou, DM | 1 |
| Chatzizisis, YS | 1 |
| Giannoglou, GD | 1 |
| Dos, L | 1 |
| Pujadas, S | 1 |
| Estruch, M | 1 |
| Mas, A | 1 |
| Ferreira-González, I | 1 |
| Pijuan, A | 1 |
| Serra, R | 1 |
| Ordóñez-Llanos, J | 1 |
| Subirana, M | 1 |
| Pons-Lladó, G | 1 |
| Marsal, JR | 1 |
| García-Dorado, D | 1 |
| Casaldàliga, J | 1 |
| Bathgate-Siryk, A | 1 |
| Dabul, S | 1 |
| Pandya, K | 1 |
| Walklett, K | 1 |
| De Lucia, C | 1 |
| Gao, E | 1 |
| Leosco, D | 2 |
| Bech, JN | 2 |
| Starklint, J | 1 |
| Bentzen, H | 2 |
| Nyvad, O | 2 |
| Pedersen, EB | 4 |
| Sayer, G | 1 |
| Bhat, G | 1 |
| McKie, PM | 1 |
| Cataliotti, A | 7 |
| Ichiki, T | 2 |
| Chen, HH | 5 |
| Łabuzek, K | 1 |
| Liber, S | 1 |
| Bułdak, Ł | 1 |
| Krupej-Kędzierska, J | 1 |
| Machnik, G | 1 |
| Bobrzyk, M | 1 |
| Okopień, B | 1 |
| Boxer, RS | 1 |
| Hoit, BD | 1 |
| Schmotzer, BJ | 1 |
| Stefano, GT | 1 |
| Gomes, A | 1 |
| Negrea, L | 1 |
| Kasama, S | 2 |
| Toyama, T | 2 |
| Iwasaki, T | 2 |
| Sumino, H | 1 |
| Kumakura, H | 2 |
| Minami, K | 1 |
| Ichikawa, S | 4 |
| Matsumoto, N | 1 |
| Nakata, T | 2 |
| Kurabayashi, M | 2 |
| Ndisang, JF | 1 |
| Chibbar, R | 1 |
| Lane, N | 1 |
| Hu, J | 1 |
| Cheng, W | 1 |
| Yang, Z | 1 |
| Wang, F | 1 |
| Lv, P | 1 |
| Niu, C | 1 |
| Hou, Y | 1 |
| Yan, Y | 1 |
| Ge, J | 1 |
| Casado Cerrada, J | 1 |
| Pérez Calvo, JI | 1 |
| Hassan, M | 1 |
| Qureshi, W | 1 |
| Sroujieh, LS | 1 |
| Albashaireh, D | 1 |
| BouMalham, S | 1 |
| Liroff, M | 1 |
| Amjad, W | 1 |
| Khalid, F | 1 |
| Hadid, H | 1 |
| Alirhayim, Z | 1 |
| Zhu, XQ | 1 |
| Hong, HS | 1 |
| Lin, XH | 1 |
| Chen, LL | 1 |
| Li, YH | 1 |
| Sica, DA | 2 |
| Dai, Z | 2 |
| Yu, S | 2 |
| Zhao, Q | 2 |
| Meng, Y | 1 |
| He, H | 1 |
| Tang, Y | 2 |
| Wang, X | 5 |
| Xiao, J | 2 |
| Huang, C | 2 |
| Kreusser, MM | 1 |
| Lehmann, LH | 1 |
| Riffel, JH | 1 |
| Haass, M | 1 |
| Maser-Gluth, C | 1 |
| Backs, J | 1 |
| Katus, HA | 1 |
| Buss, SJ | 1 |
| Tanaka, K | 2 |
| Wilson, RM | 3 |
| Essick, EE | 1 |
| Duffen, JL | 1 |
| Scherer, PE | 2 |
| Ouchi, N | 1 |
| D'Elia, E | 2 |
| Krum, H | 7 |
| Imazu, M | 1 |
| Takahama, H | 2 |
| Asanuma, H | 1 |
| Funada, A | 2 |
| Sugano, Y | 2 |
| Ohara, T | 2 |
| Hasegawa, T | 2 |
| Asakura, M | 1 |
| Kanzaki, H | 2 |
| Anzai, T | 3 |
| Kitakaze, M | 3 |
| Fatini, C | 1 |
| Mirizzi, G | 1 |
| Poletti, R | 4 |
| Borrelli, C | 1 |
| Prontera, C | 2 |
| Latini, R | 6 |
| Clerico, A | 3 |
| Calvier, L | 1 |
| Martinez-Martinez, E | 1 |
| Miana, M | 1 |
| Cachofeiro, V | 1 |
| Rousseau, E | 1 |
| Sádaba, JR | 1 |
| Mentz, RJ | 1 |
| Stevens, SR | 1 |
| Lala, A | 1 |
| Vader, JM | 1 |
| AbouEzzeddine, OF | 1 |
| Khazanie, P | 1 |
| Stevenson, LW | 1 |
| Goldsmith, SR | 1 |
| Bart, BA | 1 |
| Anstrom, KJ | 1 |
| Braunwald, E | 2 |
| Felker, GM | 1 |
| Verbrugge, FH | 2 |
| Tang, WH | 5 |
| Gravez, B | 1 |
| Tarjus, A | 1 |
| Pelloux, V | 1 |
| Ouvrard-Pascaud, A | 1 |
| Delcayre, C | 5 |
| Samuel, J | 1 |
| Clément, K | 1 |
| Farman, N | 1 |
| Jaisser, F | 3 |
| Messaoudi, S | 2 |
| Güder, G | 2 |
| Hammer, F | 1 |
| Deutschbein, T | 1 |
| Brenner, S | 1 |
| Berliner, D | 1 |
| Deubner, N | 1 |
| Bidlingmaier, M | 1 |
| Ertl, G | 4 |
| Allolio, B | 2 |
| Angermann, CE | 2 |
| Fassnacht, M | 2 |
| Störk, S | 2 |
| Ueda, T | 1 |
| Kawakami, R | 1 |
| Nishida, T | 1 |
| Onoue, K | 1 |
| Soeda, T | 1 |
| Okayama, S | 1 |
| Takeda, Y | 2 |
| Watanabe, M | 1 |
| Kawata, H | 1 |
| Uemura, S | 1 |
| Saito, Y | 5 |
| Miller, WL | 2 |
| Borgeson, DD | 2 |
| Grantham, JA | 1 |
| Luchner, A | 3 |
| Chen, X | 2 |
| Tang, K | 1 |
| Li, Q | 1 |
| Gao, X | 2 |
| Ameling, S | 1 |
| Grube, K | 1 |
| Hammer, E | 1 |
| Könemann, R | 1 |
| Völker, U | 1 |
| Nakada, Y | 1 |
| Amaki, M | 1 |
| Yoshida, A | 1 |
| Yasuda, S | 1 |
| Ogawa, H | 3 |
| Huang, H | 1 |
| Deinum, J | 1 |
| Riksen, NP | 1 |
| Lenders, JW | 1 |
| Mitter, SS | 1 |
| Shah, SJ | 1 |
| Eyuboglu, M | 1 |
| Montes-Cobos, E | 1 |
| Li, X | 2 |
| Fischer, HJ | 1 |
| Sasse, A | 1 |
| Kügler, S | 1 |
| Didié, M | 1 |
| Toischer, K | 1 |
| Dressel, R | 1 |
| Reichardt, HM | 1 |
| Heublein, DM | 2 |
| Scott, CG | 2 |
| Rodeheffer, RJ | 1 |
| Korantzopoulos, P | 1 |
| Shao, Q | 1 |
| Zhang, Z | 1 |
| Letsas, KP | 1 |
| Li, G | 1 |
| Li, S | 2 |
| Hulsmans, M | 1 |
| Aprahamian, T | 1 |
| Fuster, JJ | 1 |
| Nahrendorf, M | 1 |
| Bomback, AS | 1 |
| Eguchi, A | 1 |
| Elliott, KJ | 1 |
| Traynham, CJ | 1 |
| Ibetti, J | 1 |
| Eguchi, S | 1 |
| Ferrara, N | 1 |
| Yang, J | 1 |
| Kobalava, Z | 1 |
| Kotovskaya, Y | 1 |
| Averkov, O | 1 |
| Pavlikova, E | 1 |
| Moiseev, V | 1 |
| Albrecht, D | 1 |
| Chandra, P | 1 |
| Ayalasomayajula, S | 1 |
| Prescott, MF | 1 |
| Pal, P | 1 |
| Langenickel, TH | 1 |
| Jordaan, P | 1 |
| Rajman, I | 1 |
| Rodan, AR | 1 |
| Araujo, CM | 1 |
| Hermidorff, MM | 2 |
| Amancio, Gde C | 1 |
| Lemos, Dda S | 1 |
| Silva, ME | 1 |
| de Assis, LV | 2 |
| Isoldi, MC | 2 |
| Tamura, K | 1 |
| Kobayashi, R | 1 |
| Haku, S | 1 |
| Azushima, K | 1 |
| Wakui, H | 1 |
| Sakaguchi, T | 2 |
| Hirata, A | 2 |
| Kashiwase, K | 1 |
| Higuchi, Y | 1 |
| Ohtani, T | 3 |
| Sakata, Y | 2 |
| Koretsune, Y | 2 |
| Yasumura, Y | 2 |
| Xanthakis, V | 1 |
| Enserro, DM | 1 |
| Larson, MG | 2 |
| Wollert, KC | 1 |
| Januzzi, JL | 1 |
| Levy, D | 2 |
| Aragam, J | 1 |
| Benjamin, EJ | 2 |
| Cheng, S | 1 |
| Wang, TJ | 2 |
| Mitchell, GF | 1 |
| Vasan, RS | 2 |
| Nitta, D | 1 |
| Hisatake, S | 1 |
| Kiuchi, S | 1 |
| Kabuki, T | 1 |
| Oka, T | 1 |
| Dobashi, S | 1 |
| Ikeda, T | 1 |
| Boonen, L | 1 |
| Nijst, P | 1 |
| Noyens, P | 1 |
| De Vusser, P | 1 |
| Verhaert, D | 1 |
| Van Lierde, J | 1 |
| Vrolix, M | 1 |
| Dupont, M | 1 |
| Meijers, WC | 1 |
| van der Velde, AR | 1 |
| Muller Kobold, AC | 1 |
| Dijck-Brouwer, J | 1 |
| Wu, AH | 1 |
| Jaffe, A | 1 |
| de Boer, RA | 1 |
| Chadwick, JA | 1 |
| Swager, SA | 1 |
| Lowe, J | 1 |
| Welc, SS | 1 |
| Tidball, JG | 1 |
| Gomez-Sanchez, CE | 1 |
| Gomez-Sanchez, EP | 1 |
| Rafael-Fortney, JA | 1 |
| Furuzono, S | 1 |
| Meguro, M | 1 |
| Miyauchi, S | 1 |
| Inoue, S | 2 |
| Homma, T | 1 |
| Yamada, K | 1 |
| Tagawa, YI | 1 |
| Nara, F | 1 |
| Nagayama, T | 1 |
| Luo, J | 1 |
| Luo, C | 1 |
| Peng, L | 1 |
| Zuo, Z | 1 |
| Pitts, R | 1 |
| Gunzburger, E | 1 |
| Barter, PJ | 1 |
| Kallend, D | 1 |
| Leiter, LA | 1 |
| Leitersdorf, E | 1 |
| Nicholls, SJ | 1 |
| Shah, PK | 1 |
| Olsson, AG | 1 |
| McMurray, JJ | 4 |
| Kittelson, J | 1 |
| Schwartz, GG | 1 |
| Senni, M | 1 |
| Miyata, M | 1 |
| Kinugawa, K | 1 |
| Inoue, T | 1 |
| Tei, C | 1 |
| Lewis, GA | 1 |
| Miller, CA | 1 |
| De Mello, WC | 1 |
| Gerena, Y | 1 |
| Geft, D | 1 |
| Schwartzenberg, S | 1 |
| George, J | 1 |
| Kato, K | 1 |
| Murakami, H | 1 |
| Isozaki, O | 1 |
| Tsushima, T | 1 |
| Takano, K | 1 |
| Kurita, T | 1 |
| Onishi, K | 1 |
| Dohi, K | 1 |
| Takamura, T | 1 |
| Fujimoto, N | 1 |
| Tanigawa, T | 1 |
| Imanaka-Yoshida, K | 1 |
| Wada, H | 1 |
| Nobori, T | 1 |
| Ito, M | 1 |
| Paterna, S | 3 |
| Parrinello, G | 1 |
| Cannizzaro, S | 1 |
| Fasullo, S | 2 |
| Torres, D | 1 |
| Sarullo, FM | 2 |
| Di Pasquale, P | 2 |
| Zincarelli, C | 2 |
| Donniacuo, M | 1 |
| Soltys, S | 1 |
| Rabinowitz, JE | 1 |
| Gaddam, KK | 1 |
| Pimenta, E | 1 |
| Husain, S | 1 |
| Funder, JW | 10 |
| Klotz, S | 1 |
| Burkhoff, D | 1 |
| Garrelds, IM | 1 |
| Boomsma, F | 7 |
| Danser, AH | 1 |
| White, M | 1 |
| Rouleau, JL | 2 |
| Afzal, R | 2 |
| Floras, J | 1 |
| Yusuf, S | 1 |
| McKelvie, RS | 2 |
| Gómez, AM | 1 |
| Rueda, A | 1 |
| Sainte-Marie, Y | 1 |
| Pereira, L | 1 |
| Zissimopoulos, S | 1 |
| Zhu, X | 1 |
| Schaub, R | 1 |
| Perrier, E | 1 |
| Perrier, R | 1 |
| Latouche, C | 1 |
| Richard, S | 1 |
| Picot, MC | 1 |
| Lai, FA | 1 |
| Valdivia, HH | 1 |
| Benitah, JP | 1 |
| Harada, K | 1 |
| Izawa, H | 1 |
| Nishizawa, T | 1 |
| Hirashiki, A | 1 |
| Murase, Y | 1 |
| Kobayashi, M | 1 |
| Cheng, XW | 1 |
| Noda, A | 1 |
| Nagata, K | 1 |
| Yokota, M | 1 |
| Siddiqi, L | 1 |
| Joles, JA | 1 |
| Grassi, G | 1 |
| Blankestijn, PJ | 1 |
| Reeder, DN | 1 |
| Anderson, SD | 1 |
| De Silva, DS | 1 |
| Sato, K | 1 |
| Izumiya, Y | 1 |
| Shafiq, MM | 1 |
| Miller, AB | 3 |
| Freel, EM | 1 |
| Tsorlalis, IK | 1 |
| Lewsey, JD | 1 |
| Solomon, S | 1 |
| Connell, JM | 2 |
| Wenzel, S | 1 |
| Tastan, I | 1 |
| Abdallah, Y | 1 |
| Schreckenberg, R | 1 |
| Schlüter, KD | 1 |
| Mori, T | 1 |
| Kurumazuka, D | 1 |
| Matsumoto, C | 1 |
| Shirakawa, H | 1 |
| Kimura, S | 1 |
| Kitada, K | 1 |
| Kobayashi, K | 1 |
| Matsuda, H | 1 |
| Hayashi, T | 2 |
| Kitaura, Y | 1 |
| Matsumura, Y | 1 |
| Yamaji, M | 2 |
| Tsutamoto, T | 17 |
| Tanaka, T | 4 |
| Kawahara, C | 2 |
| Nishiyama, K | 2 |
| Fujii, M | 11 |
| Horie, M | 7 |
| Nicholls, MG | 21 |
| Groo, VL | 1 |
| Viana, MA | 1 |
| Dai, Y | 1 |
| Brubaker, PH | 1 |
| Moore, JB | 1 |
| Stewart, KP | 1 |
| Wesley, DJ | 1 |
| Nakayama, M | 4 |
| Nakano, H | 1 |
| Costello-Boerrigter, LC | 3 |
| Boerrigter, G | 4 |
| Harty, GJ | 2 |
| Poggio, R | 1 |
| Grancelli, HO | 1 |
| Miriuka, SG | 1 |
| Gandhi, MS | 1 |
| Kamalov, G | 2 |
| Shahbaz, AU | 1 |
| Bhattacharya, SK | 5 |
| Ahokas, RA | 4 |
| Gerling, IC | 4 |
| Weber, KT | 18 |
| Sata, Y | 1 |
| Sica, D | 1 |
| Oren, RM | 1 |
| Gottwald, MD | 1 |
| Mills, RM | 1 |
| Hsu, DT | 1 |
| Zak, V | 1 |
| Mahony, L | 1 |
| Sleeper, LA | 1 |
| Atz, AM | 1 |
| Levine, JC | 1 |
| Barker, PC | 1 |
| Ravishankar, C | 1 |
| McCrindle, BW | 1 |
| Williams, RV | 1 |
| Altmann, K | 1 |
| Ghanayem, NS | 1 |
| Margossian, R | 1 |
| Chung, WK | 1 |
| Border, WL | 1 |
| Pearson, GD | 1 |
| Stylianou, MP | 1 |
| Mital, S | 1 |
| Mohammed, SF | 1 |
| Korinek, J | 1 |
| Lam, CS | 1 |
| Larsen, K | 1 |
| Simari, RD | 1 |
| Valencik, ML | 1 |
| Gao, JP | 1 |
| Chen, CX | 1 |
| Wu, Q | 1 |
| Gu, WL | 1 |
| Martinez, FA | 1 |
| Velagaleti, RS | 1 |
| Gona, P | 1 |
| Selhub, J | 1 |
| Jacques, PF | 1 |
| Meigs, JB | 1 |
| Tofler, GH | 1 |
| Volpe, M | 3 |
| Francia, P | 1 |
| Tocci, G | 1 |
| Rubattu, S | 2 |
| Cangianiello, S | 1 |
| Elena Rao, MA | 1 |
| Trimarco, B | 2 |
| Condorelli, M | 3 |
| Guglin, M | 1 |
| Kristof-Kuteyeva, O | 1 |
| Novotorova, I | 1 |
| Pratap, P | 1 |
| Hakki, T | 1 |
| Hübel, K | 1 |
| Waldmann, H | 1 |
| Bernhardt, R | 1 |
| Kim, J | 1 |
| Tomaschitz, A | 4 |
| Pilz, S | 4 |
| März, W | 4 |
| Ellmers, LJ | 1 |
| Lewis, LK | 1 |
| Iervasi, A | 1 |
| Zyw, L | 1 |
| Gabutti, A | 2 |
| Mammini, C | 2 |
| Giannoni, A | 1 |
| Fontana, M | 1 |
| Boccanelli, A | 2 |
| Agostoni, P | 4 |
| Ivanes, F | 1 |
| Susen, S | 1 |
| Mouquet, F | 1 |
| Pigny, P | 1 |
| Cuilleret, F | 1 |
| Sautière, K | 1 |
| Collet, JP | 1 |
| Beygui, F | 1 |
| Hennache, B | 1 |
| Ennezat, PV | 1 |
| Juthier, F | 1 |
| Richard, F | 1 |
| Dallongeville, J | 1 |
| Hillaert, MA | 1 |
| Doevendans, PA | 1 |
| Jude, B | 1 |
| Bertrand, M | 1 |
| Montalescot, G | 1 |
| Van Belle, E | 1 |
| Nappi, JM | 1 |
| Sieg, A | 1 |
| Maeder, MT | 1 |
| Khammy, O | 1 |
| dos Remedios, C | 1 |
| Kaye, DM | 1 |
| McMurray, J | 2 |
| Sidik, NP | 1 |
| Wright, M | 1 |
| Gimpelewicz, CR | 1 |
| Ketelslegers, JM | 1 |
| Schirmer, SH | 1 |
| Turgonyi, E | 1 |
| Bramlage, P | 1 |
| Azibani, F | 2 |
| Mill, JG | 1 |
| Stefanon, I | 1 |
| dos Santos, L | 1 |
| Baldo, MP | 1 |
| Przybyła, A | 1 |
| Czarnecka, D | 1 |
| Kusiak, A | 1 |
| Wiliński, J | 1 |
| Sondej, T | 1 |
| Jastrzebski, M | 1 |
| Kawecka-Jaszcz, K | 1 |
| Leopold, JA | 1 |
| Ritz, E | 4 |
| Grammer, T | 1 |
| Amrein, K | 2 |
| Merger, S | 1 |
| Meinitzer, A | 2 |
| Winkelmann, BR | 1 |
| Boehm, BO | 1 |
| Funder, J | 1 |
| Chabot, A | 1 |
| Jiang, BH | 1 |
| Shi, Y | 1 |
| Dupuis, J | 1 |
| Fujiwara, H | 1 |
| Takatsu, Y | 1 |
| Chen, Y | 1 |
| Han, Y | 1 |
| Yang, WQ | 1 |
| Jin, MW | 1 |
| Cho, MJ | 1 |
| Sung, EY | 1 |
| Park, JA | 1 |
| Lee, HD | 1 |
| Pieske, B | 2 |
| Fahrleitner-Pammer, A | 2 |
| Kienreich, K | 2 |
| Horina, JH | 1 |
| Drechsler, C | 2 |
| Ofner, M | 1 |
| Pieber, TR | 1 |
| Shah, KB | 1 |
| Tang, DG | 1 |
| Kasirajan, V | 1 |
| Gunnerson, KJ | 1 |
| Hess, ML | 1 |
| Collins, SP | 1 |
| Givertz, MM | 1 |
| Teerlink, JR | 1 |
| Walsh, MN | 1 |
| Westlake Canary, CA | 1 |
| Carson, PE | 1 |
| Colvin-Adams, M | 1 |
| Hershberger, RE | 1 |
| Katz, SD | 2 |
| Rogers, JG | 1 |
| Stevenson, WG | 1 |
| Sweitzer, NK | 1 |
| Stough, WG | 1 |
| Starling, RC | 1 |
| Galuppo, P | 3 |
| Noda, K | 1 |
| Kobara, M | 1 |
| Hamada, J | 1 |
| Yoshifuji, Y | 1 |
| Shiraishi, T | 1 |
| Wang, J | 2 |
| Toba, H | 1 |
| Kober, L | 1 |
| Nowack, C | 1 |
| Kolkhof, P | 1 |
| Kim, SY | 1 |
| Queisser, N | 1 |
| Schupp, N | 1 |
| Fazal, L | 1 |
| Chatziantoniou, C | 1 |
| Samuel, JL | 1 |
| Zhang, M | 1 |
| Perino, A | 1 |
| Ghigo, A | 1 |
| Hirsch, E | 1 |
| Birner, C | 1 |
| Ulucan, C | 1 |
| Bratfisch, M | 1 |
| Götz, T | 1 |
| Dietl, A | 1 |
| Schweda, F | 1 |
| Riegger, GA | 4 |
| He, BJ | 1 |
| Anderson, ME | 1 |
| Bishu, K | 1 |
| Deswal, A | 1 |
| LeWinter, MM | 1 |
| Lewis, GD | 1 |
| Semigran, MJ | 1 |
| McNulty, S | 1 |
| Ruzicka, M | 1 |
| Floras, JS | 1 |
| McReynolds, AJ | 1 |
| Coletta, E | 1 |
| Haddad, H | 1 |
| Davies, R | 1 |
| Leenen, FH | 1 |
| Mezősi, E | 1 |
| Bajnok, L | 1 |
| Tóth, K | 1 |
| Dobnig, H | 1 |
| Verheyen, N | 1 |
| Kraigher-Krainer, E | 1 |
| Colantonio, C | 1 |
| Wagner, D | 1 |
| Andrew, P | 1 |
| Soberman, J | 1 |
| Chafin, CC | 1 |
| Wada, A | 13 |
| Ohnishi, M | 10 |
| Matsumoto, T | 6 |
| Kinoshita, M | 9 |
| Jorde, UP | 2 |
| Vittorio, T | 1 |
| Colombo, PC | 1 |
| Latif, F | 1 |
| Le Jemtel, TH | 1 |
| Olexa, P | 1 |
| Olexová, M | 1 |
| Gonsorcík, J | 1 |
| Tkác, I | 1 |
| Kisel'ová, J | 1 |
| Olejníková, M | 1 |
| Takayama, Y | 1 |
| Suzuki, T | 2 |
| Roche, BM | 1 |
| Schwartz, D | 1 |
| Lehnhard, RA | 1 |
| McKeever, KH | 1 |
| Nakayama, T | 1 |
| Kirby, TE | 1 |
| Robitaille, PM | 1 |
| Hamlin, RL | 1 |
| Sanderson, JE | 3 |
| Cittadini, A | 1 |
| Casaburi, C | 1 |
| Monti, MG | 1 |
| Di Gianni, A | 1 |
| Serpico, R | 1 |
| Scherillo, G | 1 |
| Saldamarco, L | 1 |
| Vanasia, M | 2 |
| Saccà, L | 1 |
| Struthers, AD | 16 |
| Simko, F | 1 |
| Bada, V | 1 |
| Simková, M | 1 |
| Simko, J | 1 |
| Kovács, L | 1 |
| Hulín, I | 1 |
| Liew, D | 3 |
| Varagic, J | 1 |
| Frohlich, ED | 1 |
| Wong, F | 1 |
| Blei, AT | 1 |
| Blendis, LM | 1 |
| Thuluvath, PJ | 1 |
| Swynghedauw, B | 2 |
| Schmidt, BM | 1 |
| Schmieder, RE | 1 |
| Francis, J | 1 |
| Weiss, RM | 2 |
| Johnson, AK | 1 |
| Felder, RB | 2 |
| Shinohara, H | 2 |
| Fukuda, N | 1 |
| Soeki, T | 1 |
| Sakabe, K | 1 |
| Onose, Y | 1 |
| Tamura, Y | 1 |
| van Kraaij, DJ | 1 |
| Jansen, RW | 1 |
| Sweep, FC | 1 |
| Hoefnagels, WH | 1 |
| Tsuruda, T | 2 |
| Lapp, H | 1 |
| Stasch, JP | 1 |
| Carelock, J | 1 |
| Clark, AP | 1 |
| Pedersen, RS | 1 |
| Grzybowski, J | 1 |
| Bilińska, ZT | 1 |
| Janas, J | 1 |
| Michalak, E | 1 |
| Skwarek, M | 1 |
| Ruzyłło, W | 1 |
| Lopes, ME | 1 |
| Le Corvoisier, P | 1 |
| Tabet, JY | 1 |
| Su, JB | 1 |
| Badoual, T | 1 |
| Cachin, JC | 1 |
| Merlet, P | 1 |
| Castaigne, A | 1 |
| Hittinger, L | 1 |
| Mitrovic, V | 5 |
| Willenbrock, R | 2 |
| Miric, M | 1 |
| Spinar, J | 1 |
| Dabrowski, M | 1 |
| Kiowski, W | 2 |
| Marks, DS | 1 |
| Alegria, E | 1 |
| Dukát, A | 1 |
| Lenz, K | 1 |
| Arens, HA | 1 |
| Jessup, M | 1 |
| Nordstrom, LJ | 1 |
| Maeda, K | 5 |
| Hayashi, M | 5 |
| Tsutsui, T | 5 |
| Takayama, T | 3 |
| Ishii, C | 2 |
| Rajagopalan, S | 1 |
| Rayner, BL | 1 |
| Owen, EP | 1 |
| King, JA | 1 |
| Soule, SG | 1 |
| Vreede, H | 1 |
| Opie, LH | 1 |
| Marais, D | 1 |
| Davidson, JS | 1 |
| Yamato, M | 1 |
| Sasaki, T | 1 |
| Honda, K | 1 |
| Fukuda, M | 1 |
| Akutagawa, O | 1 |
| Okamoto, M | 2 |
| Kambara, A | 1 |
| Holycross, BJ | 2 |
| Wung, P | 1 |
| Schanbacher, B | 1 |
| Ghosh, S | 1 |
| McCune, SA | 2 |
| Bauer, JA | 1 |
| Kwiatkowski, P | 1 |
| Qin, W | 1 |
| Rudolph, AE | 3 |
| Bond, BR | 1 |
| Rocha, R | 3 |
| Blomme, EA | 1 |
| Goellner, JJ | 1 |
| McMahon, EG | 4 |
| Meune, C | 1 |
| Mahé, I | 1 |
| Mourad, JJ | 1 |
| Cohen-Solal, A | 1 |
| Levy, B | 1 |
| Kevorkian, JP | 1 |
| Jondeau, G | 1 |
| Habib, A | 1 |
| Lebret, M | 1 |
| Knellwolf, AL | 1 |
| Simoneau, G | 1 |
| Caulin, C | 1 |
| Bergmann, JF | 1 |
| Kiani, MF | 1 |
| Guntaka, RV | 1 |
| Postlethwaite, AE | 2 |
| Warrington, KJ | 2 |
| Strametz-Juranek, J | 1 |
| Pacher, R | 3 |
| Kos, T | 1 |
| Woloszczuk, W | 1 |
| Grimm, M | 1 |
| Zuckermann, A | 1 |
| Stanek, B | 1 |
| Jołda-Mydłowska, B | 1 |
| Salomon, P | 1 |
| Fung, JW | 1 |
| Yu, CM | 2 |
| Yip, G | 1 |
| Chan, S | 1 |
| Yandle, TG | 6 |
| Domanski, M | 1 |
| Norman, J | 1 |
| Haigney, M | 1 |
| Hanlon, S | 1 |
| Peyster, E | 1 |
| Sato, A | 1 |
| Saruta, T | 1 |
| LUETSCHER, JA | 6 |
| NEHER, R | 1 |
| WETTSTEIN, A | 1 |
| MACH, RS | 4 |
| MANNING, EL | 4 |
| MULLER, AF | 8 |
| RIONDEL, AM | 4 |
| DAVIS, JO | 18 |
| PECHET, MM | 1 |
| BALL, WC | 1 |
| GOODKIND, MJ | 1 |
| GOLDBERGER, E | 2 |
| WOLFF, HP | 9 |
| KOCZOREK, KR | 2 |
| BUCHBORN, E | 2 |
| DRISCOL, TE | 1 |
| MAULTSBY, MM | 1 |
| FARRELL, GL | 1 |
| BERNE, RM | 1 |
| FARINELLI, A | 1 |
| RUBERTI, A | 1 |
| YATES, FE | 2 |
| URQUHART, J | 3 |
| HERBST, AL | 1 |
| DI PERRI, T | 3 |
| GUIDERI, R | 3 |
| KODEJSZKO, E | 2 |
| KOLINSKA, M | 2 |
| KUCZEWSKA, K | 2 |
| TATON, J | 2 |
| KUCHEL, O | 2 |
| RAIMONDI, A | 1 |
| BRUNO, V | 1 |
| LENZI, F | 2 |
| CANIGGIA, A | 1 |
| RAVENNI, G | 3 |
| BIANCHI, V | 1 |
| MONCIATTI, C | 1 |
| RUBEGNI, M | 2 |
| BRACONI, M | 1 |
| Catuzzo, B | 1 |
| Ciancamerla, F | 1 |
| Bobbio, M | 1 |
| Longo, M | 1 |
| Trevi, GP | 1 |
| GERARD, A | 1 |
| Hill, SR | 1 |
| Hood, WG | 1 |
| Farmer, TA | 1 |
| Burnum, JF | 1 |
| NORTH, JD | 1 |
| HOWIE, RN | 1 |
| SIMS, FH | 1 |
| OGDEN, DA | 1 |
| SCHERR, L | 1 |
| SPRITZ, N | 1 |
| RUBIN, AL | 1 |
| PERRINI, M | 1 |
| PILIEGO, N | 2 |
| RICCIARDI, G | 1 |
| PINTO, I | 1 |
| RUTISHAUSER, W | 1 |
| RHOMBERG, F | 1 |
| SACK, P | 1 |
| THOMAS, JP | 1 |
| BARTTER, FC | 2 |
| VIALA, JJ | 1 |
| FATH, A | 1 |
| JUSTIN-BESANCON, L | 2 |
| NENNA, A | 2 |
| ETIENNE, JP | 2 |
| CREMER, G | 2 |
| DAS GUPTA, D | 1 |
| GIROUD, CJ | 1 |
| CARPENTER, CC | 1 |
| WALLACE, CR | 1 |
| HAMILTON, WF | 1 |
| GHIRINGHELLI, L | 1 |
| COMOLI, G | 1 |
| STRATA, A | 1 |
| PREIS, H | 1 |
| SURIANI, L | 2 |
| GARAGNANI, A | 1 |
| BRILLANTE, C | 2 |
| ARTUSO, P | 1 |
| TAKABATAKE, Y | 1 |
| STUART-HARRIS, CH | 1 |
| COX, JR | 2 |
| LEONARD, PJ | 2 |
| SINGER, B | 1 |
| WAREMBOURG, H | 1 |
| LINQUETTE, M | 1 |
| FOSSATI, P | 1 |
| ANDRIEU, J | 1 |
| PEYRIDIEUX, R | 1 |
| ISORNI, P | 1 |
| ANICHINI, M | 1 |
| GARGANO, N | 1 |
| BARTORELLI, C | 1 |
| CHIERICI, F | 1 |
| MANZINI, E | 1 |
| CRABBE, J | 1 |
| DE MARTINIS, C | 2 |
| FONZO, D | 1 |
| PUPITA, F | 1 |
| MENSA, R | 1 |
| CAMARGO, CA | 4 |
| COHN, AP | 1 |
| DOWDY, AJ | 5 |
| CALLAGHAN, AM | 1 |
| FRANCAVIGLIA, A | 1 |
| GAGLIO, M | 1 |
| MAZZONE, O | 1 |
| MODICA, G | 1 |
| RAGUSA, G | 1 |
| SMILARI, L | 3 |
| TAMBURINO, G | 1 |
| BLASI, A | 1 |
| ZINNARI, A | 1 |
| FOELDI, M | 1 |
| FRANKEN, FH | 1 |
| KUKES, VG | 2 |
| GERASIMOVA, EN | 1 |
| CARRUTHERS, BM | 1 |
| LEDRAY, RD | 1 |
| SERAGLIA, M | 1 |
| MCINTOSH, HW | 1 |
| WALSH, GC | 1 |
| SCHROEDER, R | 1 |
| GOMEZ, RE | 1 |
| PRIETO, ME | 1 |
| DOMINGUEZ, JP | 1 |
| GENERINI, G | 1 |
| MANZO, S | 1 |
| FORCONI, S | 1 |
| ALTSCHULE, MD | 1 |
| SANDERS, LL | 1 |
| MELBY, JC | 1 |
| TEODORESCU, P | 1 |
| HIGGINS, JT | 2 |
| DAVIES-JONES, AB | 1 |
| ROSSINI, P | 1 |
| DELZOTTI, G | 1 |
| CURCIO, R | 1 |
| CASSIA, B | 1 |
| YOSHITOSHI, Y | 2 |
| MASUYAMA, Y | 1 |
| UEDA, Y | 1 |
| KONDO, A | 1 |
| ARMASCRUZ, R | 1 |
| GOMEZ, R | 1 |
| MARDONES, J | 1 |
| PLAZADELOSREYES, M | 1 |
| POLIMENI, R | 1 |
| MARCHESE, G | 1 |
| NAGAI, I | 1 |
| ARGUEELLES, AE | 1 |
| CHEKHERDEMIAN, M | 1 |
| MUNIAGURRIA, JL | 1 |
| RICCA, A | 1 |
| RUBIN, EC | 1 |
| HARTROFT, PM | 1 |
| BLACK, DA | 1 |
| GLAZ, E | 1 |
| SUGAR, K | 1 |
| JACONO, A | 1 |
| BUONINCONTI, R | 1 |
| VITALE, P | 1 |
| BOJS, GE | 1 |
| CONN, HL | 2 |
| TAIT, JF | 1 |
| LITTLE, B | 1 |
| TAIT, SA | 1 |
| FLOOD, C | 1 |
| BOUGAS, J | 1 |
| WEXLER, BC | 3 |
| KITTINGER, GW | 1 |
| HANCOCK, EW | 4 |
| NOKES, GW | 3 |
| LABOS, I | 1 |
| LOMMER, D | 4 |
| TORBICA, M | 1 |
| OLICHNEY, MJ | 1 |
| BROWN, TC | 1 |
| BINNION, PF | 1 |
| MALAMOS, B | 1 |
| MOIRAS, K | 1 |
| LEVIS, G | 1 |
| ROMANI, JD | 1 |
| HORKY, K | 2 |
| DONOCIK, A | 1 |
| LARAGH, JH | 10 |
| LEPPLA, W | 1 |
| TIEFENSEE, H | 1 |
| LOIZEAU, E | 1 |
| VEYRAT, R | 4 |
| MUDGE, WA | 1 |
| OLESEN, K | 2 |
| SANDOE, E | 2 |
| PAGET, M | 1 |
| LANGERON, L | 1 |
| CROCCEL, L | 1 |
| ROUTIER, G | 1 |
| CROCCEL, E | 1 |
| PROTIN, M | 1 |
| Pasini, E | 1 |
| Cargnioni, A | 1 |
| Pastore, F | 1 |
| Razzetti, R | 1 |
| Bongrani, S | 1 |
| Gitti, GL | 1 |
| Ferrari, R | 4 |
| Wodi, LA | 1 |
| Munir, A | 2 |
| Jahangir, E | 1 |
| Magni, P | 2 |
| Motta, M | 2 |
| Piano, MR | 1 |
| Prasun, M | 1 |
| Kolloch, R | 1 |
| Offers, E | 1 |
| Miyamori, I | 1 |
| Ohbayashi, Y | 1 |
| Kanamori, T | 1 |
| Yokohama, H | 1 |
| Sichiri, G | 1 |
| Hukai, D | 1 |
| Okabayashi, T | 1 |
| Ozawa, T | 1 |
| Ohno, K | 3 |
| Masson, S | 3 |
| Salio, M | 2 |
| Hester, A | 1 |
| Judd, D | 1 |
| Barlera, S | 1 |
| Tognoni, G | 1 |
| Cohn, JN | 3 |
| Christ, M | 1 |
| Grimm, W | 1 |
| Maisch, B | 2 |
| Duprez, DA | 3 |
| Dawson, A | 1 |
| Davies, JI | 2 |
| Miyatake, K | 1 |
| Okamoto, H | 1 |
| Miyauchi, T | 1 |
| Kawana, M | 1 |
| Matsubara, H | 2 |
| Takaoka, H | 1 |
| Himeno, H | 1 |
| Yokoyama, H | 1 |
| Yokoya, K | 1 |
| Shintani, U | 1 |
| Hashimoto, K | 1 |
| Nakamura, Y | 1 |
| Imai, K | 1 |
| Maruyama, S | 1 |
| Masaoka, Y | 1 |
| Sekiya, M | 1 |
| Shiraki, T | 1 |
| Ozono, K | 1 |
| Matsuoka, T | 1 |
| Miyao, Y | 1 |
| Nomura, F | 1 |
| Folkeringa, RJ | 1 |
| Pinto, YM | 2 |
| Crijns, HJ | 3 |
| Ghali, JK | 1 |
| Lösel, R | 1 |
| Schultz, A | 1 |
| Wehling, M | 1 |
| Bhargava, A | 1 |
| Pearce, D | 1 |
| Heymes, C | 1 |
| Fuchs, S | 1 |
| Bendall, JK | 1 |
| Nehme, J | 1 |
| Ambroisine, ML | 1 |
| Robidel, E | 1 |
| Milliez, P | 1 |
| Huang, Y | 1 |
| Hunyor, SN | 1 |
| Jiang, L | 1 |
| Kawaguchi, O | 1 |
| Shirota, K | 1 |
| Ikeda, Y | 1 |
| Yuasa, T | 1 |
| Gallagher, G | 1 |
| Zeng, B | 1 |
| Zheng, X | 1 |
| Khan, NU | 1 |
| Movahed, A | 1 |
| Rungwerth, K | 1 |
| Schindler, U | 1 |
| Gerl, M | 1 |
| Schäfer, S | 1 |
| Licher, T | 1 |
| Busch, AE | 1 |
| Ruetten, H | 1 |
| Abassi, Z | 2 |
| Karram, T | 1 |
| Ellaham, S | 1 |
| Winaver, J | 3 |
| Hoffman, A | 3 |
| Epstein, M | 2 |
| Nakamura, R | 1 |
| Kato, J | 2 |
| Kitamura, K | 3 |
| Onitsuka, H | 1 |
| Imamura, T | 2 |
| Cao, Y | 1 |
| Marutsuka, K | 1 |
| Asada, Y | 1 |
| Kangawa, K | 3 |
| Eto, T | 3 |
| O'Meara, E | 1 |
| Ohta, T | 1 |
| Hasebe, N | 1 |
| Tsuji, S | 1 |
| Izawa, K | 1 |
| Jin, YT | 1 |
| Kido, S | 1 |
| Natori, S | 1 |
| Sato, M | 2 |
| Kikuchi, K | 1 |
| Alvelos, M | 1 |
| Ferreira, A | 2 |
| Bettencourt, P | 2 |
| Serrão, P | 1 |
| Pestana, M | 2 |
| Cerqueira-Gomes, M | 2 |
| Soares-Da-Silva, P | 2 |
| Tan, LB | 1 |
| Schlosshan, D | 1 |
| Barker, D | 1 |
| Fraccarollo, D | 2 |
| McCurley, JM | 1 |
| Hanlon, SU | 1 |
| Wei, SK | 1 |
| Wedam, EF | 1 |
| Michalski, M | 1 |
| Haigney, MC | 1 |
| Cascorbi, I | 1 |
| Paul, M | 1 |
| Kroemer, HK | 1 |
| Nakamura, S | 2 |
| Yoshimura, M | 7 |
| Ito, T | 6 |
| Mizuno, Y | 3 |
| Harada, E | 3 |
| Sakamoto, T | 2 |
| Nakao, K | 2 |
| Yasue, H | 3 |
| TRUNINGER-RATHE, I | 1 |
| SPUHLER, O | 1 |
| Andreas, S | 1 |
| Reiter, H | 1 |
| Lüthje, L | 1 |
| Delekat, A | 1 |
| Grunewald, RW | 1 |
| Hasenfuss, G | 1 |
| Somers, VK | 1 |
| Vagelos, RH | 2 |
| Yee, YG | 2 |
| Fowler, MB | 2 |
| Berezin, AE | 1 |
| Sakai, H | 3 |
| Ishikawa, C | 2 |
| Dohke, T | 2 |
| Bos, R | 1 |
| Mougenot, N | 1 |
| Findji, L | 1 |
| Médiani, O | 1 |
| Vanhoutte, PM | 1 |
| Lechat, P | 1 |
| Gunaruwan, P | 1 |
| Schmitt, M | 1 |
| Sharman, J | 1 |
| Lee, L | 1 |
| Struthers, A | 3 |
| Frenneaux, M | 1 |
| Schiffrin, EL | 2 |
| Touyz, RM | 1 |
| Yano, M | 1 |
| Nishikimi, T | 2 |
| Hagaman, JR | 1 |
| Takahashi, N | 1 |
| Matsuoka, H | 2 |
| Smithies, O | 1 |
| Maeda, N | 1 |
| Isono, T | 1 |
| Eguchi, Y | 1 |
| Martin, FL | 1 |
| Stevens, TL | 1 |
| Schirger, JA | 1 |
| Murin, J | 1 |
| Witham, MD | 1 |
| Radauceanu, A | 1 |
| Davies, E | 3 |
| Hu, X | 1 |
| Lala, DS | 1 |
| Gosling, O | 1 |
| Martin, M | 1 |
| Clarke, E | 1 |
| Smith, A | 1 |
| Coombes, E | 1 |
| Dawes, M | 1 |
| Bramanti, F | 1 |
| Keidar, S | 1 |
| Gamliel-Lazarovich, A | 1 |
| Kaplan, M | 1 |
| Pavlotzky, E | 1 |
| Hamoud, S | 1 |
| Hayek, T | 1 |
| Karry, R | 1 |
| De Feo, S | 1 |
| Franceschini, L | 3 |
| Brighetti, G | 1 |
| Cicoira, M | 3 |
| Zanolla, L | 3 |
| Rossi, A | 3 |
| Golia, G | 3 |
| Zardini, P | 3 |
| Skvortsov, AA | 1 |
| Nasonova, SN | 1 |
| Sychev, AV | 1 |
| Arbolishvili, GN | 1 |
| Baklanova, NA | 1 |
| Mareev, VIu | 1 |
| Belenkov, IuN | 1 |
| Jennings, DL | 1 |
| Kalus, JS | 1 |
| O'Dell, KM | 1 |
| van de Wal, RM | 1 |
| Asselbergs, FW | 1 |
| Plokker, HW | 1 |
| Smilde, TD | 1 |
| Lok, D | 1 |
| van Gilst, WH | 4 |
| Coca, SG | 1 |
| Perazella, MA | 1 |
| Kotlyar, E | 2 |
| Vita, JA | 1 |
| Winter, MR | 1 |
| Awtry, EH | 1 |
| Siwik, DA | 1 |
| Keaney, JF | 1 |
| Sawyer, DB | 1 |
| Cupples, LA | 1 |
| Colucci, WS | 3 |
| Kalantarinia, K | 1 |
| Okusa, MD | 1 |
| Lin, XY | 1 |
| Xiao, LZ | 1 |
| Gao, LJ | 1 |
| Zhang, HF | 1 |
| Severino, S | 1 |
| Nassi, G | 1 |
| Donderski, R | 1 |
| Grajewska, M | 1 |
| Manitius, J | 1 |
| Tsukamoto, O | 1 |
| Minamino, T | 1 |
| Sanada, S | 1 |
| Okada, K | 1 |
| Fujita, M | 1 |
| Shintani, Y | 1 |
| Yulin, L | 1 |
| Asano, Y | 1 |
| Takashima, S | 1 |
| Yamasaki, S | 1 |
| Tomoike, H | 1 |
| Hori, M | 2 |
| Schrier, RW | 5 |
| Odedra, K | 1 |
| Ferro, A | 1 |
| Collins, RP | 1 |
| Palmer, BR | 1 |
| Pilbrow, AP | 1 |
| Frampton, CM | 3 |
| Troughton, RW | 2 |
| Skelton, L | 1 |
| Cameron, VA | 1 |
| Tatsumi, T | 1 |
| Goodwin, KD | 2 |
| Aggarwal, A | 1 |
| Wong, J | 1 |
| Campbell, DJ | 1 |
| Horita, Y | 1 |
| Taura, K | 1 |
| Taguchi, T | 1 |
| Furusu, A | 1 |
| Kohno, S | 1 |
| Ohta, M | 1 |
| Yamamoto, K | 1 |
| Mano, T | 1 |
| Nishio, M | 1 |
| Yoshida, J | 1 |
| Miwa, T | 1 |
| Masuyama, T | 1 |
| Nonaka, Y | 1 |
| Shah, NC | 1 |
| Pringle, S | 1 |
| Chikin, PA | 1 |
| Kiktev, VG | 1 |
| Storozhilova, AN | 1 |
| Sergakova, LM | 1 |
| Masenko, VP | 3 |
| Golitsyn, SP | 1 |
| Suri, D | 1 |
| Alonso, M | 1 |
| Weiss, RE | 1 |
| Frantz, S | 1 |
| Weismann, D | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Kakafika, AI | 1 |
| Tziomalos, K | 1 |
| Karagiannis, A | 1 |
| López, N | 1 |
| Varo, N | 1 |
| Fortuño, MA | 1 |
| Jolobe, OM | 1 |
| Kalidindi, SR | 1 |
| Francis, GS | 2 |
| Biolo, A | 1 |
| Chao, T | 1 |
| Duhaney, TA | 1 |
| Allensworth-Davies, D | 1 |
| Loscalzo, J | 1 |
| Carmona-Bayonas, A | 1 |
| Soler, IO | 1 |
| Gómez, FI | 1 |
| Billalabeitia, EG | 1 |
| Saura, HP | 1 |
| Tafalla, MS | 1 |
| Díaz, MP | 1 |
| Gaspare, P | 1 |
| Cacciatore, G | 1 |
| Mureddu, GF | 1 |
| de Simone, G | 1 |
| Clemenza, F | 1 |
| De Maria, R | 1 |
| Di Lenarda, A | 1 |
| Gavazzi, A | 1 |
| Porcu, M | 1 |
| Gonzini, L | 1 |
| Veeraveedu, PT | 2 |
| Watanabe, K | 2 |
| Ma, M | 2 |
| Palaniyandi, SS | 2 |
| Yamaguchi, K | 2 |
| Suzuki, K | 1 |
| Kodama, M | 2 |
| Aizawa, Y | 2 |
| Jefferies, JL | 1 |
| Price, JF | 1 |
| Denfield, SW | 1 |
| Chang, AC | 1 |
| Dreyer, WJ | 1 |
| McMahon, CJ | 1 |
| Grenier, MA | 1 |
| Clunie, SK | 1 |
| Thomas, A | 1 |
| Moffett, BS | 1 |
| Wann, TS | 1 |
| Smith, EO | 1 |
| Towbin, JA | 1 |
| Minnaard-Huiban, M | 1 |
| Emmen, JM | 1 |
| Roumen, L | 1 |
| Beugels, IP | 1 |
| Cohuet, GM | 1 |
| van Essen, H | 1 |
| Ruijters, E | 1 |
| Pieterse, K | 1 |
| Hilbers, PA | 1 |
| Ottenheijm, HC | 1 |
| Plate, R | 1 |
| de Gooyer, ME | 1 |
| Smits, JF | 1 |
| Hermans, JJ | 1 |
| Seed, A | 1 |
| Gardner, R | 1 |
| Hillier, C | 1 |
| Murdoch, D | 1 |
| MacFadyen, R | 1 |
| Bobillier, A | 1 |
| Mann, J | 1 |
| Newman, KP | 2 |
| Neal, MT | 1 |
| Roberts, M | 1 |
| Hatcher, EA | 1 |
| Davis, RC | 1 |
| Soberman, JE | 2 |
| Ramanathan, KB | 1 |
| Vittorio, TJ | 1 |
| Ahuja, K | 1 |
| Kasper, M | 1 |
| Turalic, H | 1 |
| Tseng, CH | 1 |
| Go, C | 1 |
| Yu, Y | 1 |
| Wei, SG | 1 |
| Zhang, ZH | 1 |
| Gomez-Sanchez, E | 1 |
| Yan, AT | 1 |
| Yan, RT | 1 |
| Spinale, FG | 2 |
| Gunasinghe, HR | 1 |
| Stroud, RE | 1 |
| Liu, PP | 1 |
| Zordoky, BN | 1 |
| El-Kadi, AO | 1 |
| Schraut, S | 1 |
| Kneitz, S | 1 |
| van Rooijen, N | 1 |
| Selektor, Y | 1 |
| Seller, RH | 1 |
| Brest, AN | 2 |
| Witte, MH | 1 |
| Levine, N | 1 |
| Dumont, AE | 1 |
| Kjekshus, J | 3 |
| Aarsland, T | 2 |
| Woie, L | 3 |
| Kremer, D | 1 |
| Abrahamsen, AM | 2 |
| Davies, RO | 2 |
| Gomez, HJ | 1 |
| Irvin, JD | 1 |
| Walker, JF | 1 |
| Fitzpatrick, D | 2 |
| Ikram, H | 7 |
| Kugler, J | 1 |
| Maskin, CS | 1 |
| Frishman, W | 1 |
| Sonnenblick, EH | 1 |
| LeJemtel, TH | 1 |
| Dipalma, JR | 1 |
| Kubo, S | 4 |
| Nishioka, A | 3 |
| Nishimura, H | 2 |
| Kawamura, K | 2 |
| Takatsu, T | 4 |
| Dzau, VJ | 2 |
| Curfman, G | 1 |
| Meggs, L | 1 |
| Hollenberg, NK | 2 |
| Barger, AC | 3 |
| Creager, MA | 3 |
| Halperin, JL | 2 |
| Bernard, DB | 1 |
| Faxon, DP | 2 |
| Melidossian, CD | 1 |
| Gavras, H | 2 |
| Ryan, TJ | 2 |
| McGrath, BP | 1 |
| Denham, IM | 1 |
| Johnston, CI | 2 |
| Antonaccio, MJ | 1 |
| Sharpe, DN | 2 |
| Coxon, R | 2 |
| Ricci, S | 1 |
| Zaniol, P | 1 |
| Teglio, V | 1 |
| Baraldi, P | 1 |
| Mattioli, G | 1 |
| Turini, GA | 1 |
| Waeber, B | 2 |
| Brunner, HR | 2 |
| Abrams, WB | 1 |
| Ferguson, RK | 1 |
| Johansson, BW | 1 |
| Wenting, GJ | 1 |
| Man in't veld, AJ | 1 |
| Woittiez, AJ | 1 |
| Laird-Meeter, K | 1 |
| Simoons, ML | 1 |
| Hugenholtz, PG | 1 |
| Schalekamp, MA | 1 |
| Brown, JJ | 2 |
| Fraser, R | 1 |
| Lever, AF | 2 |
| Robertson, JI | 3 |
| Michorowski, B | 2 |
| Ceremuzyński, L | 2 |
| Covit, AB | 3 |
| Schaer, GL | 2 |
| Sealey, JE | 3 |
| Cody, RJ | 7 |
| Ueda, K | 1 |
| Sakai, M | 1 |
| Matsushita, S | 1 |
| Kuwajima, I | 1 |
| Murakami, M | 1 |
| Fouad, FM | 3 |
| El-Tobgi, S | 1 |
| Tarazi, RC | 4 |
| Bravo, EL | 3 |
| Hart, NJ | 2 |
| Shirey, EK | 1 |
| Lim, J | 1 |
| Orinius, E | 1 |
| Dargie, HJ | 1 |
| Ball, SG | 1 |
| Hodsman, GP | 1 |
| Budaj, A | 1 |
| Hirota, Y | 1 |
| Walsh, WF | 1 |
| Lee, CL | 1 |
| Dahlström, U | 3 |
| Karlberg, BE | 6 |
| Komajda, M | 2 |
| Eugene, M | 1 |
| Evans, J | 1 |
| Drobinski, G | 2 |
| Laurenceau, JL | 1 |
| Grosgogeat, Y | 2 |
| Nagasaka, M | 1 |
| Harris, P | 3 |
| Castle, LW | 1 |
| Salcedo, EE | 1 |
| Maslowski, AH | 2 |
| Scandrett, MS | 2 |
| Penman, T | 1 |
| Franklin, KW | 2 |
| Kluger, J | 1 |
| Elterman, JJ | 1 |
| Hagen, GA | 1 |
| Ryan, MP | 2 |
| Ryan, MF | 2 |
| Counihan, TB | 2 |
| Polis, O | 1 |
| Franken, P | 1 |
| Colassin, R | 1 |
| Henuzet, C | 1 |
| Baylen, BG | 1 |
| Johnson, G | 1 |
| Tsang, R | 1 |
| Srivastava, L | 1 |
| Kaplan, S | 1 |
| Sonotani, N | 1 |
| Chan, W | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Schick, EC | 1 |
| Lun, S | 1 |
| Sakamaki, T | 2 |
| Matsuo, H | 4 |
| Skorecki, KL | 1 |
| Brenner, BM | 1 |
| Yui, Y | 1 |
| Nakajima, H | 1 |
| Kawai, C | 1 |
| Murakami, T | 1 |
| Brørs, O | 1 |
| Enger, E | 1 |
| Jacobsen, S | 1 |
| Aakvaag, A | 2 |
| Foss, OP | 1 |
| Korolenko, SS | 1 |
| Lieverse, AG | 2 |
| Girbes, AR | 4 |
| Smit, AJ | 2 |
| Zijlstra, JG | 2 |
| Meijer, S | 2 |
| Lie, KI | 7 |
| Reitsma, WD | 2 |
| de Vries, RJ | 2 |
| Queré, M | 1 |
| Lok, DJ | 2 |
| Sijbring, P | 1 |
| Bucx, JJ | 1 |
| Dunselman, PH | 4 |
| Villarreal, D | 7 |
| Freeman, RH | 9 |
| Brouwer, J | 2 |
| Man in 't Veld, AJ | 2 |
| Haaksma, J | 1 |
| Ishimitsu, T | 1 |
| Omae, T | 1 |
| Missale, C | 2 |
| Spano, PF | 2 |
| Cas, LD | 1 |
| Hall, VB | 1 |
| Jacobsen, G | 1 |
| Alam, M | 1 |
| Rosman, H | 1 |
| Goldstein, S | 1 |
| Good, JM | 1 |
| Peters, M | 1 |
| Wilkins, M | 1 |
| Jackson, N | 1 |
| Oakley, CM | 2 |
| Evans, MA | 1 |
| Avramovitch, N | 1 |
| Haramati, A | 2 |
| Lewinson, D | 1 |
| Reed, S | 1 |
| Greene, P | 1 |
| Ryan, T | 1 |
| Cerimele, B | 1 |
| Schwertschlag, U | 1 |
| Weinberger, M | 1 |
| Voelker, J | 1 |
| Han, YL | 1 |
| Tong, M | 1 |
| Jing, QM | 1 |
| Hu, XL | 1 |
| Liu, JQ | 1 |
| Sigurdsson, A | 3 |
| Amtorp, O | 1 |
| Gundersen, T | 1 |
| Nilsson, B | 1 |
| Remes, J | 2 |
| Eriksson, SV | 1 |
| Eneroth, P | 1 |
| Offstad, J | 1 |
| Guazzi, MD | 3 |
| Perego, B | 1 |
| Lauri, G | 5 |
| Salvioni, A | 4 |
| Giraldi, F | 4 |
| Matturri, M | 2 |
| Guazzi, M | 6 |
| Marenzi, G | 5 |
| Elsner, D | 3 |
| Muders, F | 1 |
| Müntze, A | 2 |
| Kromer, EP | 4 |
| Forssmann, WG | 1 |
| Dohmen, HJ | 1 |
| Poortermans, JC | 1 |
| Withagen, AJ | 1 |
| Pasteuning, WH | 1 |
| Moser, DK | 1 |
| Lage, SG | 1 |
| Kopel, L | 1 |
| Monachini, MC | 1 |
| Medeiros, CJ | 1 |
| Pileggi, F | 1 |
| Polak, JF | 1 |
| Ullman, B | 1 |
| Park, JW | 1 |
| Heinzler, R | 1 |
| Wirtz, JH | 1 |
| Fieten-Rumswinkel, M | 1 |
| Braun, P | 1 |
| May, E | 1 |
| Hetzer, R | 1 |
| Heinrich, KW | 1 |
| Derchi, G | 1 |
| Bellone, P | 1 |
| Tommasini, G | 1 |
| Biorci, ML | 1 |
| Randazzo, M | 1 |
| Primarolo, P | 1 |
| Vecchio, C | 1 |
| Riley, DJ | 1 |
| Weir, M | 1 |
| Bakris, GL | 1 |
| Motwani, JG | 1 |
| Fenwick, MK | 1 |
| Morton, JJ | 2 |
| Held, P | 1 |
| Dakak, N | 2 |
| Makhoul, N | 2 |
| Merdler, A | 2 |
| Yechiely, H | 1 |
| Kahana, L | 1 |
| Halon, DA | 2 |
| Schneeweiss, A | 2 |
| Lewis, BS | 2 |
| Grazi, S | 1 |
| Perego, G | 1 |
| Karlsson, E | 2 |
| Globits, S | 2 |
| Bergler-Klein, J | 2 |
| Teufelsbauer, H | 2 |
| Wutte, M | 2 |
| Baumgartner, W | 1 |
| Ogris, E | 2 |
| Glogar, D | 1 |
| Bøtker, HE | 1 |
| Jensen, HK | 1 |
| Krusell, LR | 1 |
| Sørensen, EV | 1 |
| Schuller, M | 1 |
| Krauter, A | 1 |
| Rödler, S | 1 |
| Hartter, E | 2 |
| Ford, NF | 1 |
| Natarajan, C | 1 |
| Fulmor, IE | 1 |
| Smith, RA | 1 |
| Hui, KK | 1 |
| Fujiwara, M | 1 |
| Asakuma, S | 1 |
| Nakamura, T | 2 |
| Nakamura, K | 2 |
| Koch, J | 1 |
| Pedersen, HD | 1 |
| Jensen, AL | 1 |
| Flagstad, A | 1 |
| Poulsen, K | 1 |
| Perego, GB | 2 |
| Agostoni, PG | 2 |
| Gu, A | 1 |
| Wilshire-Clement, M | 1 |
| Sackner-Bernstein, J | 1 |
| Goldsmith, R | 1 |
| Medina, N | 1 |
| Yushak, M | 1 |
| Miller, M | 1 |
| Dutka, DP | 1 |
| Olivotto, I | 1 |
| Ward, S | 1 |
| Nihoyannopoulos, P | 1 |
| al-Subaili, M | 1 |
| Impallomeni, M | 1 |
| de Groote, P | 1 |
| Millaire, A | 1 |
| Racadot, A | 1 |
| Decoulx, E | 1 |
| Ducloux, G | 1 |
| Clarkson, PB | 1 |
| Wheeldon, NM | 1 |
| MacFadyen, RJ | 4 |
| Pringle, SD | 2 |
| MacDonald, TM | 1 |
| Cosín Aguilar, J | 1 |
| Cruz Fernández, JM | 1 |
| de Teresa Galván, E | 1 |
| Ferreira Montero, IJ | 1 |
| López-Sendón, J | 2 |
| Soler Soler, J | 1 |
| Tamargo Menéndez, J | 1 |
| Chin Kon Sung, UG | 1 |
| Corbeij, HM | 1 |
| Mudra, H | 2 |
| Bonzel, T | 2 |
| Schmidt, W | 2 |
| Strand, JC | 1 |
| Bakovic-Alt, R | 1 |
| Posvar, EL | 1 |
| Pitt, D | 1 |
| Campbell, SE | 1 |
| Brilla, CG | 3 |
| Rupp, H | 1 |
| Funck, R | 1 |
| Davidson, NC | 1 |
| Coutie, WJ | 1 |
| Webb, DJ | 1 |
| Reuge, L | 1 |
| Metzger, J | 1 |
| Burri, M | 1 |
| Kehtari, R | 1 |
| Anand, IS | 2 |
| Ceconi, C | 2 |
| De Giuli, F | 1 |
| Poole-Wilson, PA | 3 |
| Kato, M | 1 |
| Kinugawa, T | 1 |
| Omodani, H | 1 |
| Osaki, S | 1 |
| Ahmmed, GU | 1 |
| Ogino, K | 1 |
| Hisatome, I | 1 |
| Miyakoda, H | 1 |
| Thames, MD | 1 |
| Szabó, BM | 1 |
| van der Burgh, PH | 1 |
| Kruik, J | 1 |
| Häggström, J | 2 |
| Hansson, K | 2 |
| Kvart, C | 2 |
| Madej, A | 1 |
| Olsson, K | 2 |
| Khoury, AM | 1 |
| Davila, DF | 1 |
| Bellabarba, G | 1 |
| Donis, JH | 1 |
| Torres, A | 1 |
| Lemorvan, C | 1 |
| Hernandez, L | 1 |
| Bishop, W | 1 |
| Vuolteenaho, O | 1 |
| Kentsch, M | 1 |
| Otter, W | 1 |
| Drummer, C | 1 |
| Nötges, A | 1 |
| Gerzer, R | 1 |
| Müller-Esch, G | 1 |
| Schlepper, M | 2 |
| Jacquet, L | 1 |
| Sekiguchi, H | 1 |
| Shimada, K | 1 |
| Lerch, R | 1 |
| Montessuit, C | 1 |
| Maeda, Y | 2 |
| Fukai, D | 3 |
| Summers, BM | 1 |
| Dunn, RB | 1 |
| Habibullah, AA | 1 |
| Simmons, JC | 1 |
| Pohar, B | 1 |
| Horvat, M | 1 |
| van den Broek, SA | 1 |
| de Graeff, PA | 1 |
| Hillege, H | 1 |
| Wesseling, H | 1 |
| de Gasparo, M | 1 |
| Whitebread, S | 1 |
| Hebbar, L | 1 |
| Clair, MJ | 1 |
| Melton, DM | 1 |
| Krombach, RS | 1 |
| Mukherjee, R | 1 |
| Iannini, JP | 1 |
| O, SJ | 1 |
| Kosoglou, T | 1 |
| Protter, AA | 1 |
| Hisanaga, T | 1 |
| Mabuchi, N | 4 |
| Mazurek, W | 1 |
| Halawa, B | 1 |
| Lehmann, G | 1 |
| Hähnel, I | 1 |
| Reiniger, G | 1 |
| Lampen, M | 1 |
| Beyerle, A | 1 |
| Schömig, A | 2 |
| Samsonov, M | 1 |
| Lopatin, J | 1 |
| Tilz, GP | 1 |
| Artner-Dworzak, E | 1 |
| Nassonov, E | 1 |
| Mareev, V | 1 |
| Belenkov, J | 1 |
| Wachter, H | 1 |
| Fuchs, D | 1 |
| Abraham, WT | 2 |
| Lowes, BD | 1 |
| Ferguson, DA | 1 |
| Odom, J | 1 |
| Kim, JK | 1 |
| Robertson, AD | 1 |
| Bristow, MR | 1 |
| Potocka-Plazak, K | 1 |
| Kolasa, R | 1 |
| Poplawski, T | 1 |
| Kulczycka, J | 1 |
| Plazak, W | 1 |
| Bevilacqua, M | 1 |
| Vago, T | 1 |
| Sessa, F | 1 |
| Torri, M | 1 |
| Anesini, A | 1 |
| Pasotti, E | 1 |
| Agnello, D | 1 |
| Santoro, L | 1 |
| Catania, A | 1 |
| Ghezzi, P | 1 |
| Moccetti, T | 1 |
| Tuinenburg, AE | 1 |
| Van Den Berg, MP | 2 |
| De Kam, PJ | 3 |
| Kano, H | 1 |
| Orita, S | 1 |
| Hirose, M | 1 |
| Kawano, M | 1 |
| Okamura, M | 1 |
| Tani, T | 1 |
| Minami, M | 1 |
| Yokokawa, A | 1 |
| Haraguchi, M | 1 |
| Yasunari, K | 1 |
| Yoshikawa, J | 1 |
| De Buyzere, ML | 2 |
| Rietzschel, ER | 2 |
| Taes, Y | 1 |
| Clement, DL | 3 |
| Morgan, D | 1 |
| van der Ent, M | 1 |
| Remme, WJ | 1 |
| de Leeuw, PW | 1 |
| Bartels, GL | 1 |
| Missouris, CG | 1 |
| Grouzmann, E | 1 |
| Buckley, MG | 1 |
| Barron, J | 1 |
| MacGregor, GA | 2 |
| Singer, DR | 1 |
| Jablecka, A | 1 |
| Chmara, E | 1 |
| Korzeniowska, K | 1 |
| Klinge, R | 1 |
| Hystad, M | 1 |
| Djøseland, O | 1 |
| Hall, C | 2 |
| Young, RP | 1 |
| Shum, IO | 1 |
| Wei, S | 1 |
| Arumanayagam, M | 1 |
| Woo, KS | 1 |
| Benatar, D | 1 |
| Hall, V | 1 |
| Reddy, S | 1 |
| Lee, AF | 2 |
| Braith, RW | 1 |
| Welsch, MA | 1 |
| Feigenbaum, MS | 1 |
| Kluess, HA | 1 |
| Pepine, CJ | 1 |
| Westheim, AS | 1 |
| Bostrøm, P | 1 |
| Christensen, CC | 1 |
| Parikka, H | 1 |
| Rykke, EO | 1 |
| Toivonen, L | 1 |
| Fukuma, Y | 1 |
| Munakata, K | 1 |
| Fukuma, N | 1 |
| Kishida, H | 1 |
| Hayakawa, H | 2 |
| Takano, T | 2 |
| Bussotti, M | 1 |
| Arutiunov, GP | 1 |
| Rylova, AK | 1 |
| Lim, PO | 1 |
| Teisman, AC | 1 |
| Tjeerdsma, G | 2 |
| de Zeeuw, D | 2 |
| Sütsch, G | 1 |
| Bertel, O | 1 |
| Rickenbacher, P | 1 |
| Clozel, M | 1 |
| Rietzschel, E | 1 |
| Mantero, F | 1 |
| Lucarelli, G | 1 |
| Soto Alvarez, J | 1 |
| Hillege, HL | 1 |
| Charlesworth, A | 1 |
| Hampton, JR | 1 |
| Hirano, S | 1 |
| Matsuo, T | 1 |
| Ishiyama, Y | 1 |
| Koiwaya, Y | 1 |
| Duprez, D | 1 |
| De Buyzere, M | 1 |
| Hameedi, A | 1 |
| Chadow, HL | 1 |
| Sawaki, M | 2 |
| Horie, H | 2 |
| Sugimoto, Y | 1 |
| Cha, AJ | 1 |
| Malecha, SE | 1 |
| Judge, KW | 1 |
| Powell, JD | 1 |
| Mendzef, SD | 1 |
| Pasquale, PD | 1 |
| Stefano, GD | 1 |
| Diercks, GF | 1 |
| Overdiek, JW | 1 |
| Matsui, T | 2 |
| Doggrell, SA | 1 |
| Brown, L | 1 |
| Buchhorn, R | 1 |
| Ross, RD | 1 |
| Bartmus, D | 1 |
| Wessel, A | 1 |
| Hulpke-Wette, M | 1 |
| Bürsch, J | 1 |
| Cabrini, G | 1 |
| Bonizzato, A | 1 |
| Graziani, M | 1 |
| Coats, AJ | 1 |
| Srivastava, P | 1 |
| Assanelli, E | 1 |
| Grazi, M | 2 |
| Famoso, G | 1 |
| Burger, AJ | 2 |
| Aronson, D | 2 |
| Williams, G | 1 |
| Remme, W | 1 |
| Martinez, F | 1 |
| Neaton, J | 1 |
| Roniker, B | 1 |
| Hurley, S | 1 |
| Burns, D | 1 |
| Bittman, R | 1 |
| Kleiman, J | 1 |
| Radzevich, AE | 1 |
| Ditiatkov, AE | 1 |
| Tikhonov, VA | 1 |
| Kikuchi, M | 1 |
| Nakamura, M | 2 |
| Takino, T | 1 |
| Hiramori, K | 2 |
| Nagaya, N | 1 |
| Uematsu, M | 1 |
| Kojima, M | 1 |
| Date, Y | 1 |
| Nakazato, M | 1 |
| Okumura, H | 1 |
| Hosoda, H | 1 |
| Yamagishi, M | 1 |
| Oya, H | 1 |
| Koh, H | 1 |
| Yutani, C | 1 |
| Dousset, B | 1 |
| Alla, F | 1 |
| Kjaer, A | 2 |
| Hesse, B | 2 |
| Groenning, BA | 1 |
| Nilsson, JC | 1 |
| Sondergaard, L | 1 |
| Larsson, HB | 1 |
| Hildebrandt, PR | 1 |
| Benedict, CR | 1 |
| Willson, K | 1 |
| Liss, CL | 1 |
| Massie, BM | 1 |
| Cavallin, M | 1 |
| Nussdorfer, GG | 1 |
| Pessina, AC | 1 |
| Mittleman, MA | 1 |
| Jougasaki, M | 1 |
| Costello, LC | 1 |
| Lee, SC | 1 |
| Malatino, LS | 1 |
| Zeni, P | 1 |
| Caruso, B | 1 |
| Sathyamurthy, I | 1 |
| Jayanthi, K | 1 |
| Pimenta, J | 1 |
| Friões, F | 1 |
| Philipp, S | 1 |
| Dietz, R | 1 |
| Palmieri, EA | 1 |
| Biondi, B | 1 |
| Fazio, S | 1 |
| Heitmann, M | 1 |
| Davidsen, U | 1 |
| Stokholm, KH | 1 |
| Rasmussen, K | 1 |
| Burchardt, H | 1 |
| Petersen, EB | 1 |
| Fujii, H | 1 |
| Yamamoto, N | 1 |
| Shimasaki, Y | 1 |
| Jan de Kam, P | 1 |
| González-Juanatey, JR | 1 |
| Mazón Ramos, P | 1 |
| Marks, P | 1 |
| Anderson, J | 1 |
| Vincent, R | 1 |
| Huston, G | 1 |
| Ceimo, JK | 1 |
| Watkins, L | 1 |
| Burton, JA | 1 |
| Haber, E | 1 |
| Cant, JR | 1 |
| Smith, FW | 1 |
| Donald, RA | 2 |
| Malaia, LT | 1 |
| Rachinskiĭ, ID | 1 |
| Shushliapin, OI | 2 |
| Williams, GM | 4 |
| DeForrest, JM | 2 |
| Seymour, AA | 2 |
| Rowe, BP | 2 |
| Cannon, PJ | 1 |
| Detweiler, DK | 2 |
| Knight, DH | 1 |
| Oelkers, W | 1 |
| Dunne, A | 1 |
| Knight, RK | 1 |
| Miall, PA | 1 |
| Hawkins, LA | 2 |
| Dacombe, J | 2 |
| Edwards, CR | 3 |
| Hamer, J | 2 |
| Tonooka, S | 1 |
| Sugai, Y | 1 |
| Murata, K | 1 |
| Brezis, M | 1 |
| Litvin, Y | 1 |
| Barratt, LJ | 1 |
| Chonko, AM | 1 |
| Bay, WH | 1 |
| Stein, JH | 2 |
| Ferris, TF | 1 |
| Heim, J | 1 |
| Dewailly, P | 1 |
| Jaillard, J | 1 |
| Reineck, HJ | 1 |
| Levy, M | 1 |
| Watkins, BE | 1 |
| Stephens, GA | 1 |
| Morris, BJ | 1 |
| Zatzman, ML | 1 |
| Galla, JH | 1 |
| Schneider, G | 1 |
| Kotchen, TA | 1 |
| Hayslett, JP | 1 |
| Hughes, H | 2 |
| Rogers, T | 1 |
| Korochkin, IM | 3 |
| Matveeva, IV | 3 |
| Doi, K | 1 |
| Ogihara, T | 2 |
| Ichihara, K | 1 |
| Hata, T | 1 |
| Kumahara, Y | 1 |
| Porter, GA | 2 |
| Bennett, WM | 2 |
| Wilson, JW | 1 |
| Bobkova, VI | 1 |
| Kartitskií, VS | 1 |
| Lapkes, TG | 1 |
| Mazurova, SV | 1 |
| Nielsen, I | 1 |
| Bollerup, AC | 1 |
| Olesen, KH | 1 |
| Uhrenholdt, A | 1 |
| del Greco, F | 2 |
| Knight, R | 1 |
| Miall, P | 1 |
| Cugini, P | 1 |
| Gasbarrone, L | 1 |
| Lucia, P | 1 |
| Cianetti, A | 1 |
| Canova, R | 1 |
| Di Palma, L | 1 |
| Sepe, FA | 1 |
| Pozzilli, P | 1 |
| Scibilia, G | 1 |
| Cioli, AR | 1 |
| Heintz, B | 1 |
| Verho, M | 1 |
| Brockmeier, D | 1 |
| Kirsten, R | 1 |
| Nelson, K | 1 |
| Rangoonwala, B | 1 |
| Maigatter, S | 1 |
| Lückel, G | 1 |
| Kierdorf, H | 1 |
| Sieberth, HG | 1 |
| Yoshida, H | 2 |
| Funakoshi, T | 1 |
| Arakawa, N | 1 |
| Schianni, M | 1 |
| Fitzpatrick, MA | 1 |
| Nussberger, J | 2 |
| Moe, GW | 1 |
| Canepa-Anson, R | 2 |
| Armstrong, PW | 1 |
| Nicholls, DP | 1 |
| Riley, M | 1 |
| Elborn, JS | 1 |
| Stanford, CF | 1 |
| Shaw, C | 1 |
| McKillop, JM | 1 |
| Buchanan, KD | 1 |
| Eiskjaer, H | 1 |
| Bagger, JP | 1 |
| Mogensen, CE | 1 |
| Schmitz, A | 1 |
| Zirm, B | 1 |
| Zirm, A | 1 |
| Kargl, R | 1 |
| Khaĭdarova, GKh | 1 |
| Wang, W | 1 |
| McClain, JM | 1 |
| Zucker, IH | 1 |
| Sato, T | 1 |
| Takeshi, M | 1 |
| Yamamoto, A | 1 |
| Flapan, AD | 2 |
| Williams, BC | 2 |
| Shaw, TR | 2 |
| Hensen, J | 2 |
| Levenson, B | 1 |
| Schröder, K | 1 |
| Jereczek, M | 1 |
| Spielberg, C | 1 |
| Schwenn, K | 1 |
| Gross, P | 2 |
| König, PS | 1 |
| Lhotta, K | 1 |
| Kronenberg, F | 1 |
| Joannidis, M | 1 |
| Herold, M | 1 |
| Neuzner, J | 1 |
| Pitschner, HF | 1 |
| Lissmann, H | 1 |
| Riegger, AJ | 4 |
| Adesanya, CO | 1 |
| Anjorin, FI | 1 |
| Sada, IA | 1 |
| Parry, EH | 1 |
| Sagnella, GA | 1 |
| Tikkanen, I | 3 |
| Fyhrquist, F | 4 |
| Pyörälä, K | 1 |
| Gutierrez-Marcos, FM | 1 |
| Fernandez-Cruz, A | 1 |
| Gutkowska, J | 1 |
| Herrero, C | 1 |
| Blesa, A | 1 |
| Estrada, V | 1 |
| Loscos, C | 1 |
| López-Novoa, JM | 1 |
| Gorbacheva, ON | 1 |
| Zharova, EA | 1 |
| Nasonov, EL | 1 |
| Samoriadova, OS | 1 |
| Karpov, IuA | 1 |
| Fontana, F | 4 |
| Bernardi, P | 5 |
| Ruffini, M | 2 |
| Capelli, M | 3 |
| Liu, YZ | 1 |
| Guo, SP | 1 |
| Tritto, C | 2 |
| De Luca, N | 1 |
| Mele, AF | 2 |
| Lembo, G | 2 |
| Romano, M | 1 |
| De Campora, P | 1 |
| Enea, I | 1 |
| Ricciardelli, B | 2 |
| DeLuca, N | 1 |
| Marchegiano, R | 1 |
| Gibbs, JS | 1 |
| Keegan, J | 1 |
| Wright, C | 1 |
| Fox, KM | 1 |
| Dürr, JA | 1 |
| Waugh, C | 1 |
| Monder, C | 1 |
| Schofer, J | 1 |
| Hobuss, M | 1 |
| Aschenberg, W | 1 |
| Tews, A | 1 |
| Caponnetto, S | 1 |
| Terrachini, V | 1 |
| Canale, C | 1 |
| Bruzzone, F | 1 |
| Masperone, MA | 1 |
| Pastorino, L | 1 |
| Licciardello, L | 1 |
| Marchetti, GV | 1 |
| Qin, S | 1 |
| Ma, C | 1 |
| Nishida, M | 1 |
| Sano, H | 1 |
| Obata, H | 1 |
| Yasuda, H | 1 |
| Flugelman, MY | 1 |
| Shehadeh, H | 1 |
| Spagnolo, N | 1 |
| Palazzuoli, V | 1 |
| Mondillo, S | 1 |
| Galli, M | 1 |
| Kristodhullu, S | 1 |
| Faglia, S | 1 |
| D'Aprile, N | 1 |
| Martorelli, T | 1 |
| Chatterjee, K | 1 |
| De Marco, T | 1 |
| Usov, VIu | 1 |
| Lishmanov, IuB | 1 |
| Chernov, VI | 1 |
| Rezapov, BR | 1 |
| Akhmedov, ShD | 1 |
| Travkov, IuA | 1 |
| Helfant, RH | 1 |
| Gavrisiuk, VK | 1 |
| Bezdvernyĭ, IuI | 1 |
| Morozova, NA | 1 |
| Didenko, SO | 1 |
| Alicandri, C | 1 |
| Fariello, R | 1 |
| Boni, E | 1 |
| Zaninelli, A | 1 |
| Castellano, M | 1 |
| Beschi, M | 1 |
| Agabiti Rosei, E | 1 |
| Muiesan, G | 1 |
| Sigala, S | 1 |
| Memo, M | 1 |
| Dei Cas, L | 1 |
| La Villa, G | 1 |
| Marra, F | 1 |
| Laffi, G | 1 |
| Belli, B | 1 |
| Meacci, E | 1 |
| Fascetti, P | 1 |
| Gentilini, P | 1 |
| Mizelle, HL | 1 |
| Hall, JE | 1 |
| Montani, JP | 1 |
| Brands, MW | 1 |
| Carlone, S | 1 |
| Palange, P | 1 |
| Mannix, ET | 1 |
| Salatto, MP | 1 |
| Serra, P | 1 |
| Weinberger, MH | 1 |
| Aronoff, GR | 1 |
| Cockerill, EM | 1 |
| Manfredi, F | 1 |
| Farber, MO | 1 |
| Lee, ME | 1 |
| Edwards, BS | 1 |
| Insel, J | 1 |
| Mirvis, DM | 1 |
| Boland, MJ | 1 |
| Cinquegrani, MP | 1 |
| Shanes, J | 1 |
| Rubin, SA | 1 |
| Whalen, JJ | 1 |
| Wambach, G | 1 |
| Schittenhelm, U | 1 |
| Bönner, G | 1 |
| Kaufmann, W | 4 |
| Krämer, B | 1 |
| Hoffmeister, HM | 1 |
| Müller-Schauenburg, W | 1 |
| Risler, T | 1 |
| Seipel, L | 1 |
| Broqvist, M | 1 |
| Marklund, T | 1 |
| Kawahara, Y | 1 |
| Hasegawa, K | 1 |
| Sawayama, T | 1 |
| Kakumae, S | 1 |
| Tadaoka, S | 1 |
| Nakao, M | 1 |
| Nezuo, S | 1 |
| Borek, M | 1 |
| Charlap, S | 1 |
| Frishman, WH | 1 |
| Scammell, AM | 1 |
| Diver, MJ | 1 |
| Seino, Y | 1 |
| Shimai, S | 1 |
| Veall, N | 1 |
| Kalra, GS | 1 |
| Sutton, G | 2 |
| Lipkin, D | 1 |
| Orynchak, MA | 1 |
| Zaruba, AIu | 1 |
| Kutsenko, AI | 1 |
| Kukharchuk, VV | 1 |
| Kaada, B | 1 |
| Elkayam, U | 1 |
| Roth, A | 1 |
| Hsueh, W | 1 |
| Weber, L | 1 |
| Freidenberger, L | 1 |
| Rahimtoola, SH | 1 |
| Kirlin, PC | 2 |
| Dansby, C | 2 |
| Laird, C | 1 |
| Willis, PW | 2 |
| Wilson, BC | 1 |
| Rector, TS | 1 |
| Kochsiek, K | 1 |
| Shenker, Y | 1 |
| Sider, RS | 1 |
| Ostafin, EA | 1 |
| Grekin, RJ | 1 |
| Crozier, IG | 1 |
| Cuneo, RC | 1 |
| McCormick, D | 1 |
| Atlas, SA | 1 |
| Kubo, SH | 1 |
| Ryman, KS | 1 |
| Shaknovich, A | 1 |
| Pondolfino, K | 1 |
| Clark, M | 1 |
| Camargo, MJ | 1 |
| Verburg, KM | 1 |
| Vari, RC | 1 |
| Vierhapper, H | 1 |
| Waldhäusl, W | 1 |
| Marumo, F | 1 |
| Katoh, Y | 1 |
| Kurosawa, T | 2 |
| Takeda, S | 1 |
| Kurokawa, S | 1 |
| Sakamoto, H | 1 |
| Kikawada, R | 1 |
| Ando, K | 1 |
| Ishigami, T | 1 |
| Forslund, T | 1 |
| Frøysaker, T | 1 |
| Myhre, E | 1 |
| Riddervold, F | 1 |
| Simonsen, S | 1 |
| Kortas, C | 1 |
| Bichet, D | 1 |
| de Champlain, J | 3 |
| Carayon, A | 1 |
| Nguyen, JP | 1 |
| Maistre, G | 1 |
| Legrand, S | 1 |
| Landault, C | 1 |
| Legrand, JC | 1 |
| Srámková, J | 1 |
| Tesar, V | 1 |
| Lachmanová, J | 1 |
| Widimský, J | 1 |
| Hara, H | 1 |
| Nakamaru, M | 1 |
| Rakugi, H | 1 |
| Tateyama, H | 1 |
| Guardigli, G | 1 |
| Cappelli, M | 1 |
| Cummings, S | 1 |
| Gomex, HJ | 1 |
| Hagen, E | 1 |
| Kristianson, K | 1 |
| Wester, PO | 1 |
| Dyckner, T | 1 |
| Levine, TB | 1 |
| Olivari, MT | 1 |
| Ketteler, M | 1 |
| Hausmann, C | 1 |
| Reinhard, C | 1 |
| Hackenthal, E | 1 |
| Rascher, W | 1 |
| Danielsen, H | 1 |
| Jensen, T | 1 |
| Madsen, M | 1 |
| Sørensen, SS | 1 |
| Thomsen, OO | 1 |
| Ring-Larsen, H | 2 |
| Henriksen, JH | 2 |
| Wilken, C | 1 |
| Clausen, J | 1 |
| Pals, H | 1 |
| Christensen, NJ | 2 |
| Nakano, T | 2 |
| Isaka, N | 1 |
| Konishi, T | 2 |
| Tekezawa, H | 1 |
| Morimoto, Y | 2 |
| Kakuta, Y | 2 |
| Kodera, T | 2 |
| Kanamaru, M | 2 |
| Laird, CK | 1 |
| Melloni, R | 2 |
| Scarazatti, E | 2 |
| Gandini, C | 2 |
| Melloni, GF | 3 |
| Feldschuh, J | 1 |
| Bayliss, J | 1 |
| Norell, M | 1 |
| Poole-Wilson, P | 1 |
| Popovich, MI | 1 |
| Zatushevskiĭ, IF | 1 |
| Botnar', VI | 1 |
| Mulder, H | 1 |
| Schopman, W | 2 |
| van der Lely, AJ | 1 |
| Takezawa, H | 1 |
| Jungmann, E | 1 |
| Störger, H | 1 |
| Althoff, PH | 1 |
| Hadler, D | 1 |
| Fassbinder, W | 1 |
| Bussmann, WD | 1 |
| Kaltenbach, M | 1 |
| Schöffling, K | 1 |
| Wittels, P | 1 |
| Silberbauer, K | 1 |
| Glogar, DH | 1 |
| Stummvoll, HK | 1 |
| Templ, H | 1 |
| Kaindl, F | 1 |
| Abildgaard, U | 1 |
| Aldershvile, J | 1 |
| Falk, J | 1 |
| Giese, J | 1 |
| Hammer, M | 1 |
| Braden, GL | 1 |
| Geheb, MA | 1 |
| Shook, A | 1 |
| Singer, I | 1 |
| Cox, M | 1 |
| Rolandi, E | 1 |
| Marchetti, G | 1 |
| Franceschini, R | 1 |
| Cicchetti, V | 1 |
| Gianrossi, R | 1 |
| Cantoni, V | 1 |
| Barreca, T | 1 |
| Dorhout Mees, EJ | 1 |
| Koomans, HA | 1 |
| Malaia, IT | 1 |
| Lazareva, SA | 1 |
| Majoor, CL | 1 |
| Kahn, A | 1 |
| Felt, V | 1 |
| Stárka, L | 1 |
| Santambrogio, S | 1 |
| Natangelo, R | 1 |
| Lucchelli, PD | 1 |
| Blaise, BH | 1 |
| Düsterdieck, G | 3 |
| Jahnecke, J | 3 |
| Kobayashi, T | 1 |
| Krück, F | 1 |
| Schieffer, H | 1 |
| Jenny, M | 1 |
| Sotgiu, G | 1 |
| Lenzi, S | 2 |
| Howards, SS | 1 |
| Wright, FS | 1 |
| Genest, J | 3 |
| Granger, P | 2 |
| Boucher, R | 3 |
| Koiw, E | 1 |
| Eliseev, OM | 1 |
| Vandongen, R | 1 |
| Gordon, RD | 1 |
| Peltola, P | 2 |
| Lahovaara, S | 1 |
| Paasonen, MK | 1 |
| Kashii, C | 1 |
| Cantin, M | 1 |
| Leone, A | 1 |
| Bajusz, E | 1 |
| Guyton, AC | 1 |
| Coleman, TG | 1 |
| Granger, HJ | 1 |
| Blaine, EH | 1 |
| Harris, PD | 1 |
| Descovich, GC | 1 |
| Hidaka, H | 1 |
| Kato, T | 1 |
| Yoshitoski, Y | 1 |
| Kusukawa, R | 1 |
| Yamazaki, N | 1 |
| Carey, RM | 1 |
| Wooster, LD | 1 |
| Hook, EW | 1 |
| Guedon, J | 1 |
| Luscko, M | 1 |
| Lissac, J | 1 |
| Klahr, S | 1 |
| Slatopolsky, E | 1 |
| Speranskaia, NV | 1 |
| Kuz'mina, AE | 2 |
| Priscu, R | 1 |
| Maiorescu, M | 1 |
| Sichitiu, S | 1 |
| Judd, JT | 2 |
| Lutmer, RJ | 1 |
| Saroff, J | 2 |
| Bagby, GC | 1 |
| Antonovic, JN | 1 |
| Dioguardi, N | 1 |
| Lamont, NM | 1 |
| Manku, MS | 1 |
| Mugambi, M | 1 |
| von Lilienfeld-Toal, H | 1 |
| Buckesfeld, RP | 1 |
| Bolte, HD | 1 |
| Lankisch, PG | 1 |
| Larbig, D | 1 |
| Hayase, S | 1 |
| Miyahara, M | 1 |
| Saimyoji, H | 1 |
| Seriu, Y | 1 |
| Takayasu, M | 1 |
| Weil, MH | 1 |
| Shubin, H | 1 |
| Vinogradov, AV | 5 |
| Sycheva, IM | 6 |
| Liebowitz, HR | 1 |
| Kiseleva, ZM | 2 |
| Gill, JR | 1 |
| Kono, T | 1 |
| Holzgreve, H | 1 |
| Eigler, J | 1 |
| Shimizu, N | 1 |
| Bonvalet, JP | 1 |
| Baglin, A | 1 |
| Radó, JP | 1 |
| Marosi, J | 1 |
| Takó, J | 1 |
| Dévényi, I | 1 |
| Krumlovsky, F | 1 |
| Hilmer, W | 1 |
| Lim, P | 1 |
| Jacob, E | 1 |
| Vizir, AD | 1 |
| Lutmer, RF | 1 |
| Korolova, SA | 1 |
| Kinouchi, T | 1 |
| Oshima, M | 1 |
| Hara, A | 1 |
| Steiner, B | 2 |
| Dürr, F | 2 |
| Meurer, KA | 2 |
| Behn, C | 1 |
| Sanyal, SK | 1 |
| Halloran, KH | 1 |
| Gardner, TH | 1 |
| Talner, NS | 2 |
| Berman, EI | 1 |
| Lipparini, R | 1 |
| Di Feliciantonio, R | 1 |
| Guaragna, RF | 1 |
| Figus, E | 1 |
| Bacci, G | 1 |
| Crane, MG | 1 |
| Harris, JJ | 1 |
| Schneider, EG | 1 |
| Baumber, JS | 1 |
| Johnson, JA | 1 |
| Men'shikov, VV | 1 |
| Bass, ZhZh | 1 |
| Shekhter, IM | 1 |
| Anastas'ina, GV | 1 |
| Belleau, L | 1 |
| Mion, H | 1 |
| Simard, S | 1 |
| Bertranou, E | 1 |
| Nowaczynski, W | 1 |
| Manta, I | 1 |
| Hodîrnău, A | 1 |
| Proinov, I | 1 |
| Băltescu, V | 1 |
| Schneider, E | 1 |
| Kritsman, MG | 1 |
| Udel'nov, ME | 1 |
| Serebrovskaia, IuA | 1 |
| Saurgnani, E | 1 |
| Camerini, L | 1 |
| Fassini, G | 1 |
| Marangoni, R | 1 |
| Brunner, FP | 1 |
| Bull, MB | 1 |
| Vecsei, P | 2 |
| Sidorenko, BA | 1 |
| Arshakuni, RO | 1 |
| Vagnucci, AH | 1 |
| Awamura, M | 1 |
| Shvets, LV | 1 |
| McGiff, J | 1 |
| Luchi, RJ | 1 |
| Cheville, RA | 1 |
| Moyer, JH | 1 |
| Licitra, G | 2 |
| Zappia, A | 2 |
| Hickie, JB | 1 |
| Lazarus, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial[NCT04508985] | 46 participants (Actual) | Interventional | 2020-10-01 | Completed | |||
| Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study (SomaSignal Study)[NCT04836117] | 200 participants (Anticipated) | Interventional | 2021-08-12 | Recruiting | |||
| Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjec[NCT00134264] | Phase 3 | 15,067 participants (Actual) | Interventional | 2004-07-31 | Terminated | ||
| Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579] | Phase 4 | 8,000 participants (Anticipated) | Interventional | 2023-04-16 | Enrolling by invitation | ||
| A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients[NCT04515095] | 30 participants (Actual) | Interventional | 2020-08-16 | Completed | |||
| Aldosterone Antagonists in Systemic Right Ventricle: a Randomized Clinical Trial.[NCT00703352] | Phase 4 | 26 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial[NCT03049540] | Phase 3 | 100 participants (Actual) | Interventional | 2017-10-25 | Completed | ||
| Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA[NCT01681823] | Phase 2 | 60 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| CARdiorenal REScue Study in Acute Decompensated Heart Failure: CARRESS[NCT00608491] | Phase 3 | 188 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)[NCT00577135] | Phase 3 | 308 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Pathophysiologic and Outcomes Impact of the Relation of Intravascular Volume Expansion to Neuroendocrine-Renal Function Profiles in Chronic Heart Failure - Pathway to More Individualized Therapy[NCT04156854] | 15 participants (Actual) | Interventional | 2020-01-30 | Completed | |||
| An Open Label, Non-randomised Study to Explore Safety/Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure[NCT00913653] | Phase 2 | 30 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Diuretic Efficiency in Patients With Stable Heart Failure: Ion Excretion Capacity of the Kidneys (DIPSTICK) Study[NCT02288819] | 50 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to Slow recruitment and a lack of funding to complete further follow-up) | |||
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome[NCT00658515] | Phase 3 | 15,871 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Normal Sodium Diet Preserves Serum Sodium Levels During Treatment of Acute Decompensated Heart Failure[NCT03722069] | 44 participants (Actual) | Interventional | 2014-07-20 | Completed | |||
| The Evaluation of Renal Denervation on Several Biological Variables in Patients With Uncontrolled Hypertension. An Observational Feasibility Study.[NCT01427049] | 54 participants (Actual) | Observational | 2011-08-31 | Completed | |||
| Exercise Conditioning in Elderly Patients With Heart Failure[NCT01113840] | 201 participants (Actual) | Interventional | 1993-07-31 | Completed | |||
| Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)[NCT00113087] | Phase 3 | 230 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Randomized, Double-blind, Multi-center Study to Assess Safety and Tolerability of Different Oral Doses of BAY94-8862 in Subjects With Stable Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Mild (Part A) or Moderate (Part B) Chronic [NCT01345656] | Phase 2 | 457 participants (Actual) | Interventional | 2011-05-09 | Completed | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Prospective Cross-sectional Study on Prevalence of Primary Aldosteronism in Resistant Hypertension and Association With Cardiometabolic Complications[NCT04213963] | 100 participants (Anticipated) | Observational | 2011-09-01 | Recruiting | |||
| [NCT00000516] | Phase 3 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF)[NCT01474200] | 224 participants (Actual) | Interventional | 2012-01-31 | Terminated (stopped due to Closed due to patient recruitment challenges. No interim analyses were completed; study closure was not related to any concerns about safety or futility.) | |||
| Lung Injury (Pulmonary Edema) in COVID-19: Treatment With Furosemide and Negative Fluid Balance (NEGBAL): a Case-Control Study[NCT05304702] | 120 participants (Actual) | Observational | 2021-11-28 | Completed | |||
| Comparative Effect of Water-based and Land-based Exercise Training on Exercise Capacity and Other Selected Cardiovascular Parameters in Patients With Coronary Artery Disease[NCT02831829] | 90 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure[NCT02429388] | Phase 4 | 0 participants (Actual) | Interventional | 2014-05-31 | Withdrawn (stopped due to Principal Investigator left institution prior to subjects being enrolled) | ||
| Hair Cortisol and Testosterone Levels and Their Correlation With Heart Failure Status in Patients With Chronic Congestive Heart Failure[NCT01139697] | 46 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure[NCT00403910] | Phase 3 | 500 participants | Interventional | 2002-09-30 | Completed | ||
| Withdrawal of Beta- Blockers and ACE Inhibitors After Left Ventricular Systolic Function Recovery in Patient With Dilated Cardiomyopathy: A Randomized Control Trial.[NCT02770443] | 22 participants (Actual) | Interventional | 2016-02-19 | Terminated (stopped due to Study closed to recruitment early as endpoints were reached on several participants) | |||
| A Single-center, Pharmacokinetic Evaluation of Nesiritide in the Pediatric Population With Heart Failure[NCT00166010] | 0 participants (Actual) | Interventional | 2004-10-31 | Withdrawn (stopped due to Observational study that DSMB placed on hold (withdrew 4 subjects). Protocol revised and received IND to become interventional PK study (no subjects enrolled).) | |||
| Effectiveness of Combined Aerobic and Strength Training in Acute and Chronic Adaptations in Patients With Heart Failure[NCT03320655] | 28 participants (Actual) | Interventional | 2017-10-09 | Completed | |||
| Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure[NCT02133105] | Phase 3 | 33 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| E_Stethoscope : Portable Digital Auscultation Based on Wireless Sensor Node to Diagnose Diastolic Dysfunction in Hypertensive Heart Disease[NCT02809040] | 60 participants (Anticipated) | Observational | 2015-02-28 | Active, not recruiting | |||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| Innovative Strategies for Implementing New CHF Guideline Recommendations[NCT00012974] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| Exercise Intolerance in Elderly Diastolic Heart Failure[NCT00123955] | Phase 3 | 80 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars[NCT05259137] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Core laboratory when available. If not available, local laboratory results were used. (NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | mL/min (Mean) |
|---|---|
| Stepped Pharmacologic Care | 8.86 |
| Ultrafiltration | 5.63 |
Core laboratory when available. If not available, local laboratory results were used. (NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.28 |
| Ultrafiltration | -0.12 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -109.13 |
| Ultrafiltration | -3.07 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -6.91 |
| Ultrafiltration | 40.35 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -74.26 |
| Ultrafiltration | 68.13 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | mEq/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 3.29 |
| Ultrafiltration | -1.01 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | mEq/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 3.07 |
| Ultrafiltration | -0.70 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | ug/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 7.63 |
| Ultrafiltration | 9.07 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | ug/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 2.24 |
| Ultrafiltration | 4.57 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | ug/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 10.21 |
| Ultrafiltration | 10.54 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | mg/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 0.14 |
| Ultrafiltration | 0.22 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | mg/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.18 |
| Ultrafiltration | -0.03 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | mg/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 0.12 |
| Ultrafiltration | 0.09 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.76 |
| Ultrafiltration | -1.13 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.82 |
| Ultrafiltration | -1.32 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.69 |
| Ultrafiltration | -1.24 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | g/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 0.38 |
| Ultrafiltration | -0.01 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | g/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 0.35 |
| Ultrafiltration | -0.02 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | mg/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | -1.71 |
| Ultrafiltration | 1.89 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | mg/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | -13.62 |
| Ultrafiltration | 1.99 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | mg/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | -6.39 |
| Ultrafiltration | 2.18 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 47.38 |
| Ultrafiltration | -38.95 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -17.48 |
| Ultrafiltration | -73.58 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 37.28 |
| Ultrafiltration | -37.16 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -490.56 |
| Ultrafiltration | -937.69 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -1071.88 |
| Ultrafiltration | -740.82 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | pg/mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -978.61 |
| Ultrafiltration | -814.45 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | mEq/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.23 |
| Ultrafiltration | 0.26 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | mEq/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.14 |
| Ultrafiltration | 0.27 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | ug/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 0.22 |
| Ultrafiltration | -0.64 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | ug/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 0.75 |
| Ultrafiltration | 0.58 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | ug/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.07 |
| Ultrafiltration | -0.93 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | mEq/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | 0.00 |
| Ultrafiltration | -2.3 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | mEq/L (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.49 |
| Ultrafiltration | -2.02 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 5.68 |
| Ultrafiltration | 12.54 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 7.23 |
| Ultrafiltration | 13.81 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.31 |
| Ultrafiltration | -0.54 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 1.10 |
| Ultrafiltration | -0.15 |
"Scale range: -100 , +100~-100=worse, +100=better" (NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | units on a scale (Mean) |
|---|---|
| Stepped Pharmacologic Care | 22.8 |
| Ultrafiltration | 19.4 |
Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40) (NCT00608491)
Timeframe: Baseline to Day 30
| Intervention | mg (Mean) |
|---|---|
| Stepped Pharmacologic Care | 9.8 |
| Ultrafiltration | 27.3 |
Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40) (NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | mg (Mean) |
|---|---|
| Stepped Pharmacologic Care | -12.4 |
| Ultrafiltration | 8.8 |
Furosemide-Equivalent Dose is the dose bumetanide or torsemide converted to furosemide equivalent (Torsemide dose x 2,Bumetanide dose x 40) (NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | mg (Mean) |
|---|---|
| Stepped Pharmacologic Care | 2.2 |
| Ultrafiltration | -20.6 |
"Scale range: -100 , +100~-100=worse, +100=better Participants asked to mark their global well being on a 10 cm vertical line, with the top labeled best you have ever felt and the bottom labeled worst you have ever felt." (NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | units on a scale (Mean) |
|---|---|
| Stepped Pharmacologic Care | 25.8 |
| Ultrafiltration | 16.9 |
"Scale range: -100 , +100~-100=worse, +100=better Participants asked to mark their global well being on a 10 cm vertical line, with the top labeled best you have ever felt and the bottom labeled worst you have ever felt." (NCT00608491)
Timeframe: Change from Baseline to Day 4
| Intervention | units on a scale (Mean) |
|---|---|
| Stepped Pharmacologic Care | 22.8 |
| Ultrafiltration | 13.7 |
(NCT00608491)
Timeframe: Change from Baseline to Day 4
| Intervention | mL/min (Mean) |
|---|---|
| Stepped Pharmacologic Care | 1.67 |
| Ultrafiltration | 0.93 |
(NCT00608491)
Timeframe: Change from Baseline to Day 7
| Intervention | mL/min (Mean) |
|---|---|
| Stepped Pharmacologic Care | 2.06 |
| Ultrafiltration | 1.82 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | ng/mL/hr (Mean) |
|---|---|
| Stepped Pharmacologic Care | 5.78 |
| Ultrafiltration | 12.67 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | ng/mL/hr (Mean) |
|---|---|
| Stepped Pharmacologic Care | -2.18 |
| Ultrafiltration | 0.54 |
(NCT00608491)
Timeframe: Baseline to Day 7/Discharge
| Intervention | ng/mL/hr (Mean) |
|---|---|
| Stepped Pharmacologic Care | 2.58 |
| Ultrafiltration | 11.40 |
(NCT00608491)
Timeframe: Change from Baseline to Day 4
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.04 |
| Ultrafiltration | 0.23 |
(NCT00608491)
Timeframe: Change from Baseline to Day 7
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.00 |
| Ultrafiltration | 0.11 |
(NCT00608491)
Timeframe: Baseline to Day 4
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 1.06 |
| Ultrafiltration | -0.23 |
(NCT00608491)
Timeframe: Change from Baseline to Day 3
| Intervention | lbs (Mean) |
|---|---|
| Stepped Pharmacologic Care | -10.8 |
| Ultrafiltration | -11.7 |
(NCT00608491)
Timeframe: Change from Baseline to Day 4
| Intervention | lbs (Mean) |
|---|---|
| Stepped Pharmacologic Care | -12.1 |
| Ultrafiltration | -12.6 |
(NCT00608491)
Timeframe: Change from Baseline to Day 6
| Intervention | lbs (Mean) |
|---|---|
| Stepped Pharmacologic Care | -16.5 |
| Ultrafiltration | -15.7 |
(NCT00608491)
Timeframe: Change from Baseline to Day 1
| Intervention | lbs (Mean) |
|---|---|
| Stepped Pharmacologic Care | -3.4 |
| Ultrafiltration | -4.4 |
(NCT00608491)
Timeframe: Change from Baseline to Day 2
| Intervention | lbs (Mean) |
|---|---|
| Stepped Pharmacologic Care | -7.4 |
| Ultrafiltration | -8.8 |
(NCT00608491)
Timeframe: Change from Baseline to Day 5
| Intervention | lbs (Mean) |
|---|---|
| Stepped Pharmacologic Care | -15.6 |
| Ultrafiltration | -14.3 |
(NCT00608491)
Timeframe: Baseline to Day 30
| Intervention | mg/dL (Mean) |
|---|---|
| Stepped Pharmacologic Care | -0.25 |
| Ultrafiltration | -0.12 |
(NCT00608491)
Timeframe: Randomization through Day 1
| Intervention | mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 1714.1 |
| Ultrafiltration | 2193.6 |
(NCT00608491)
Timeframe: Randomization through Day 2
| Intervention | mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 3814.2 |
| Ultrafiltration | 4705.8 |
(NCT00608491)
Timeframe: Randomization through Day 3
| Intervention | mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 5706.8 |
| Ultrafiltration | 6257.1 |
(NCT00608491)
Timeframe: Randomization through Day 4
| Intervention | mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 7081.5 |
| Ultrafiltration | 7443.0 |
(NCT00608491)
Timeframe: Randomization through Day 5
| Intervention | mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 8358.8 |
| Ultrafiltration | 8308.4 |
(NCT00608491)
Timeframe: Randomization through Day 6
| Intervention | mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 9700.7 |
| Ultrafiltration | 9822.1 |
(NCT00608491)
Timeframe: Randomization through Day 7
| Intervention | mL (Mean) |
|---|---|
| Stepped Pharmacologic Care | 11659.6 |
| Ultrafiltration | 10595.1 |
"Scale range: -100 , +100~-100=worse, +100=better" (NCT00608491)
Timeframe: Change from Baseline to Day 4
| Intervention | units on a scale (Mean) |
|---|---|
| Stepped Pharmacologic Care | 20.5 |
| Ultrafiltration | 16.5 |
(NCT00608491)
Timeframe: Baseline to Day 30
| Intervention | mL/min (Mean) |
|---|---|
| Stepped Pharmacologic Care | 7.95 |
| Ultrafiltration | 6.07 |
(NCT00608491)
Timeframe: Baseline to Day 30
| Intervention | lbs (Mean) |
|---|---|
| Stepped Pharmacologic Care | -15.9 |
| Ultrafiltration | -13.4 |
(NCT00608491)
Timeframe: Baseline to Day 60
| Intervention | lbs (Mean) |
|---|---|
| Stepped Pharmacologic Care | -17.2 |
| Ultrafiltration | -15.4 |
Change in NTproBNP (NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1316.2 |
| Continuous Infusion | -1773.2 |
| Low Intensification | -1193.8 |
| High Intensification | -1881.6 |
(NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.11 |
| Continuous Infusion | 0.17 |
| Low Intensification | 0.12 |
| High Intensification | 0.17 |
(NCT00577135)
Timeframe: baseline and day 60
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.20 |
| Continuous Infusion | 0.16 |
| Low Intensification | 0.18 |
| High Intensification | 0.18 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/L (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.21 |
| Continuous Infusion | 0.16 |
| Low Intensification | 0.16 |
| High Intensification | 0.21 |
(NCT00577135)
Timeframe: baseline and Day 60
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1449.3 |
| Continuous Infusion | -1035.1 |
| Low Intensification | -1445.6 |
| High Intensification | -1038.5 |
(NCT00577135)
Timeframe: baseline and Day 7
| Intervention | pg/mL (Mean) |
|---|---|
| Q 12 Hour Bolus | -1133.3 |
| Continuous Infusion | -1552.0 |
| Low Intensification | -1037.2 |
| High Intensification | -1629.7 |
(NCT00577135)
Timeframe: baseline and 24 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.00 |
| Continuous Infusion | 0.01 |
| Low Intensification | -0.01 |
| High Intensification | 0.02 |
(NCT00577135)
Timeframe: baseline and 48 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.02 |
| Continuous Infusion | 0.05 |
| Low Intensification | 0.01 |
| High Intensification | 0.06 |
(NCT00577135)
Timeframe: baseline and 96 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.06 |
| Continuous Infusion | 0.05 |
| Low Intensification | 0.05 |
| High Intensification | 0.07 |
(NCT00577135)
Timeframe: baseline and day 60
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.09 |
| Continuous Infusion | 0.07 |
| Low Intensification | 0.09 |
| High Intensification | 0.07 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.10 |
| Continuous Infusion | 0.04 |
| Low Intensification | 0.07 |
| High Intensification | 0.08 |
(NCT00577135)
Timeframe: Measured at baseline and 72 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.05 |
| Continuous Infusion | 0.07 |
| Low Intensification | 0.04 |
| High Intensification | 0.08 |
(NCT00577135)
Timeframe: baseline and 72 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.30 |
| Continuous Infusion | 0.44 |
| Low Intensification | 0.11 |
| High Intensification | 0.61 |
(NCT00577135)
Timeframe: baseline and Day 60
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | -0.09 |
| Continuous Infusion | -0.71 |
| Low Intensification | -0.13 |
| High Intensification | -0.67 |
(NCT00577135)
Timeframe: baseline and day 7
| Intervention | mg/dL (Mean) |
|---|---|
| Q 12 Hour Bolus | 0.40 |
| Continuous Infusion | 0.09 |
| Low Intensification | 0.07 |
| High Intensification | 0.42 |
(NCT00577135)
Timeframe: baseline and 96 hours
| Intervention | lbs (Mean) |
|---|---|
| Q 12 Hour Bolus | -8.0 |
| Continuous Infusion | -9.1 |
| Low Intensification | -7.4 |
| High Intensification | -9.6 |
Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better (NCT00577135)
Timeframe: 48 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 2876.6 |
| Continuous Infusion | 3033.1 |
| Low Intensification | 2924.9 |
| High Intensification | 2981.3 |
Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better (NCT00577135)
Timeframe: 72 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 4455.6 |
| Continuous Infusion | 4699.1 |
| Low Intensification | 4477.9 |
| High Intensification | 4668.3 |
Global Visual Analog Scale Scale Range 0-2400; higher score is better (NCT00577135)
Timeframe: Measured at 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 1370.8 |
| Continuous Infusion | 1453.8 |
| Low Intensification | 1426.0 |
| High Intensification | 1398.2 |
(NCT00577135)
Timeframe: Through 24 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 1595.7 |
| Continuous Infusion | 1796.4 |
| Low Intensification | 1209.7 |
| High Intensification | 2149.6 |
(NCT00577135)
Timeframe: Through 48 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 2996.7 |
| Continuous Infusion | 3120.6 |
| Low Intensification | 2334.8 |
| High Intensification | 3747.4 |
(NCT00577135)
Timeframe: Through 72 hours
| Intervention | mL (Mean) |
|---|---|
| Q 12 Hour Bolus | 4236.7 |
| Continuous Infusion | 4249.2 |
| Low Intensification | 3575.2 |
| High Intensification | 4898.9 |
Global Visual Analog Scale Scale Range 0-2400; higher score is better (NCT00577135)
Timeframe: Measured at 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 1280.8 |
| Continuous Infusion | 1303.0 |
| Low Intensification | 1288.6 |
| High Intensification | 1294.8 |
Global Visual Analog Scale Scale Range 0-4800; higher score is better (NCT00577135)
Timeframe: 48 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 2722.6 |
| Continuous Infusion | 2792.6 |
| Low Intensification | 2706.5 |
| High Intensification | 2805.2 |
Global Visual Analog Scale Scale Range 0-7200; higher score is better (NCT00577135)
Timeframe: Measured at 72 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Q 12 Hour Bolus | 4236 |
| Continuous Infusion | 4372.7 |
| Low Intensification | 4170.8 |
| High Intensification | 4429.6 |
(NCT00577135)
Timeframe: Within 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 17.4 |
| Continuous Infusion | 19.2 |
| Low Intensification | 13.6 |
| High Intensification | 22.7 |
(NCT00577135)
Timeframe: Measured at 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 14.4 |
| Continuous Infusion | 15.3 |
| Low Intensification | 11.2 |
| High Intensification | 18.2 |
Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization (NCT00577135)
Timeframe: Within 72 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Q 12 Hour Bolus | 38.1 |
| Continuous Infusion | 38.8 |
| Low Intensification | 36.7 |
| High Intensification | 40.0 |
(NCT02288819)
Timeframe: 30 days after baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Loop Diuretic Downtitration | 1 |
"NYHA class is a semi-quantitative measurement of functional capacity on a scale from 1 to 4:~No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).~Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).~Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.~Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.~For the purpose of this outcome parameter, the patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator." (NCT02288819)
Timeframe: 30 days after baseline
| Intervention | units on a scale from 1 to 4 (Mean) |
|---|---|
| Loop Diuretic Downtitration | 1.41 |
Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics. (NCT02288819)
Timeframe: 30 days after baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Loop Diuretic Downtitration | 1 |
Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline. (NCT02288819)
Timeframe: 30 days after baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Loop Diuretic Downtitration | 1 |
After baseline evaluation, loop diuretics are temporarily downtitrated or stopped for 7 consecutive days. The patient is instructed to measure his/her weight in the morning of these days, immediately after waking up, on the same balance. In case of weight increase >1,5 kg, the original dose of diuretics is restored. To check this, patients are contacted by phone after 3 and 7 days. If the patient has not gained >1,5 kg of weight after 7 days, loop diuretics are considered to be successfully downtitrated. (NCT02288819)
Timeframe: 7 days after baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Loop Diuretic Downtitration | 37 |
The patient is contacted by phone 30 days after baseline and asked for self-reported presence of lower leg edema. (NCT02288819)
Timeframe: 30 days after baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Loop Diuretic Downtitration | 1 |
The patient is contacted by phone 30 days after baseline and asked for self-reported orthopnea. (NCT02288819)
Timeframe: 30 days after baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Loop Diuretic Downtitration | 5 |
Weight change [kg] 30 days after baseline compared to weight 7 days after baseline (after achieving the final dose of loop diuretics). (NCT02288819)
Timeframe: 30 days after baseline
| Intervention | kg (Mean) |
|---|---|
| Loop Diuretic Downtitration | -0.261 |
Weight change [kg] 7 days after baseline compared to baseline weight. (NCT02288819)
Timeframe: 7 days after baseline
| Intervention | kg (Mean) |
|---|---|
| Loop Diuretic Downtitration | 0.502 |
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
(NCT00658515)
Timeframe: At 53 Months
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Dalcetrapib (RO4607381) | 44.96 |
| Placebo | 15.60 |
(NCT00658515)
Timeframe: Throughout Study, up to 53 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dalcetrapib (RO4607381) | 226 |
| Placebo | 229 |
Number of cardiovascular events per patient per year (NCT00658515)
Timeframe: From date of randomization to first event up to 48 months
| Intervention | Event per Patient Years of Followup (Number) |
|---|---|
| Dalcetrapib (RO4607381) | 0.034050 |
| Placebo | 0.032759 |
B-Type Natriuretic Peptide (BNP) level. (NCT00113087)
Timeframe: Measured just prior to the Glenn surgery
| Intervention | pg/ml (Median) |
|---|---|
| Enalapril | 79 |
| Placebo | 84 |
B-type natriuretic peptide (BNP) level. (NCT00113087)
Timeframe: at the time of the 14 month visit
| Intervention | pg/ml (Median) |
|---|---|
| Enalapril | 25 |
| Placebo | 39 |
Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction (%) is defined as percentage of stroke volume of a ventricle (i.e. the difference between end diastolic and end systolic volumes)relative to end diastolic volume. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | percent (of end diastolic volume) (Mean) |
|---|---|
| Enalapril | 59.3 |
| Placebo | 57.9 |
Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction % is defined as the percentage of the stroke volume (i.e. difference between end-diastolic and end-systolic volumes) in a ventricle relative to end-diastolic volume. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | percent (of end diastolic volume) (Mean) |
|---|---|
| Enalapril | 57.9 |
| Placebo | 56.6 |
Two-dimensional echocardiography endpoint -total End diastolic volume z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | 2.3 |
| Placebo | 2.1 |
Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | ml (Mean) |
|---|---|
| Enalapril | 29.2 |
| Placebo | 30.7 |
Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | ml (Mean) |
|---|---|
| Enalapril | 24.1 |
| Placebo | 23.2 |
Two-dimensional echocardiography endpoint -total end-diastolic volume z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | 1.1 |
| Placebo | 1.3 |
Head circumference-for-age z-score at 14 months of age.In primary analysis outcome is defined as predicted mean of Head circumference z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age
| Intervention | standard deviation (Least Squares Mean) |
|---|---|
| Enalapril | -0.55 |
| Placebo | 0.09 |
Height-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of height z-score at age 14 months based on longitudinal modeling (adjusted bor baseline value) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age
| Intervention | standard deviation (Least Squares Mean) |
|---|---|
| Enalapril | -1.00 |
| Placebo | -0.86 |
MacArthur-Bates Communicative Development inventory( Words and Gestures)-Phrases Understood z-score. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -0.48 |
| Placebo | -0.92 |
MacArthur-Bates Communicative Development inventory( Words and Gestures)-Total Gestures z-score. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -0.86 |
| Placebo | -1.31 |
MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Produced z-score. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Median) |
|---|---|
| Enalapril | -0.60 |
| Placebo | -0.63 |
MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Understood z-score. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -0.46 |
| Placebo | -0.82 |
Functional status II (Revised) Total Score. Scale ranges up to 100.00, the higher the better. The score presents an instrument for assessing health status for children surviving long term with chronic physcial disorders. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | units on a scale (Median) |
|---|---|
| Enalapril | 96.4 |
| Placebo | 96.4 |
"Neurodevelopmental status (PDI):~the Bayley Scales of Infant Development: Psychomotor Development index z-score ." (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -1.29 |
| Placebo | -1.32 |
Neurodevelopmental status(MDI):Bayley Scales of infant development, Mental Developmental Index z-score . (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -0.26 |
| Placebo | -0.33 |
Number of participants with moderate to severe AV valve regurgitation. (NCT00113087)
Timeframe: at age 14 months
| Intervention | participants (Number) |
|---|---|
| Enalapril | 11 |
| Placebo | 22 |
Number of participants with Moderate to severe AV valve regurgitation. (NCT00113087)
Timeframe: just before the pre-Glenn surgery
| Intervention | participants (Number) |
|---|---|
| Enalapril | 20 |
| Placebo | 32 |
Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise. (NCT00113087)
Timeframe: Just prior to the pre-Glenn surgery
| Intervention | Participants (Number) |
|---|---|
| Enalapril | 53 |
| Placebo | 56 |
Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise. (NCT00113087)
Timeframe: Measured at 14 months of age
| Intervention | participants (Number) |
|---|---|
| Enalapril | 72 |
| Placebo | 77 |
Ventricular filling pressure measured by catherization (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | mmHg (Mean) |
|---|---|
| Enalapril | 10.9 |
| Placebo | 11.1 |
Two-dimensional echocardiography endpoint - Total Ventricular mass (g) per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | g (Mean) |
|---|---|
| Enalapril | 25.5 |
| Placebo | 28.1 |
Two-Dimensional Echocardiography endpoint-Total Ventricular mass (g) per Core Laboratory assessment. Range from 15.60 to 70.40 (NCT00113087)
Timeframe: At 14 months of age
| Intervention | g (Mean) |
|---|---|
| Enalapril | 31.4 |
| Placebo | 34.4 |
Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment. (NCT00113087)
Timeframe: Measured at 14 months of age
| Intervention | g/ml (Mean) |
|---|---|
| Enalapril | 1.14 |
| Placebo | 1.20 |
Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment. (NCT00113087)
Timeframe: Measured just before the Glenn surgery
| Intervention | g/ml (Mean) |
|---|---|
| Enalapril | 1.15 |
| Placebo | 1.31 |
Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | 2.5 |
| Placebo | 3.1 |
Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | 4.0 |
| Placebo | 4.9 |
Weight-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of weight z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age
| Intervention | standard deviation (Least Squares Mean) |
|---|---|
| Enalapril | -0.62 |
| Placebo | -0.42 |
Defined as jugular venous distention of < or equal to 8 cm, with no orthopnea, and with trace peripheral edema or no edema at hospital discharge (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | Participants (Number) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 40 |
| IV Loop Diuretics (LD) | 46 |
AQ-Fluid removed by AQ plus urine voided minus fluid intake versus urine voided minus fluid intake with the IV diuretics. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | mL (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 12921 |
| IV Loop Diuretics (LD) | 8907 |
Time from hospital admission to time patient is free of congestion in the hospital. Freedom from congestion is defined as jugular venous distention of < or equal to 8 cm, with no orthopnea and with trace peripheral edema or no edema. Measurement taken every 24 hours after treatment initiation. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | Days (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 5.28 |
| IV Loop Diuretics (LD) | 3.86 |
AQ-Fluid removed by AQ plus urine voided versus urine voided when treated with IV diuretics (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | mL (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 18700 |
| IV Loop Diuretics (LD) | 14043 |
Weight at hospital discharge minus weight at hospital admission. Negative mean values indicate weight loss. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | lbs (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | -17.12 |
| IV Loop Diuretics (LD) | -16.21 |
Weight at 72 hours after treatment initiation minus weight at treatment initiation. Negative mean values indicate weight loss. (NCT01474200)
Timeframe: 72 hours after treatment initiation
| Intervention | lbs (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | -10.69 |
| IV Loop Diuretics (LD) | -10.30 |
Number of days patient is in hospital for HF treatment. (NCT01474200)
Timeframe: Index hospitalization admission to index hospitalization discharge
| Intervention | Days (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 8.49 |
| IV Loop Diuretics (LD) | 7.19 |
Death due to any cause within index hospitalization and 90 days following hospital discharge. (NCT01474200)
Timeframe: Time from randomization to 90 days post-hospital discharge
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 15.45 |
| IV Loop Diuretics (LD) | 12.61 |
"Time to first HF event within 90 days after discharge from index HF hospitalization. HF events are defined as~HF rehospitalization or~unscheduled outpatient or emergency room treatment with IV loop diuretics or~unscheduled outpatient Aquapheresis treatment" (NCT01474200)
Timeframe: 90 days after discharge from index HF hospitalization.
| Intervention | Days (Median) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 62 |
| IV Loop Diuretics (LD) | 34 |
Any cause that required hospitalization for treatment within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Rehospitalizations/100 Pt-Days at Risk (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 0.899 | 1.109 |
| IV Loop Diuretics (LD) | 1.278 | 1.237 |
KCCQ Questionnaire analysis based on patient's self-assessment of how they feel at various intervals compared to how they felt prior to index treatment. Scores were transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01474200)
Timeframe: Within 90 days after hospital discharge
| Intervention | Scores on a Scale (Mean) | ||
|---|---|---|---|
| Baseline | 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 28.26 | 54.78 | 57.21 |
| IV Loop Diuretics (LD) | 31.83 | 53.08 | 60.56 |
CV symptoms that required hospitalization for treatment within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Rehospitalizations (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 17 | 46 |
| IV Loop Diuretics (LD) | 33 | 66 |
The total number of days spent in the hospital due to CV related events at 30 days and 90 days from hospital discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Days (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 88 | 377 |
| IV Loop Diuretics (LD) | 207 | 554 |
Days rehospitalized for HF symptoms requiring hospital, emergency room or clinic treatment involving the use of IV diuretics and /or positive inotropic or vasodilator drugs. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Days (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 68 | 338 |
| IV Loop Diuretics (LD) | 172 | 460 |
Number of visits for HF symptoms requiring ED or clinic treatment involving the use of IV diuretics and /or positive inotropic or vasodilator drugs (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Visits (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 4 | 7 |
| IV Loop Diuretics (LD) | 5 | 8 |
Number of different times patient was admitted to hospital for HF symptoms within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Rehospitalizations (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 11 | 36 |
| IV Loop Diuretics (LD) | 24 | 52 |
Number of days patients were alive and out of the hospital at 30 and 90 days after discharge. (NCT01474200)
Timeframe: Within 30 and 90 days after hospital discharge
| Intervention | Days (Mean) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 27.29 | 62 |
| IV Loop Diuretics (LD) | 26.46 | 61.38 |
Change in BNP levels over time at 72 hours, discharge, and 90 days after discharge. (NCT01474200)
Timeframe: Baseline and at 72 hours from baseline, hospital discharge and at 90 days after hospital discharge
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | 72 hours from baseline | Discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 814.0 | -169.8 | -250.2 | -159.9 |
| IV Loop Diuretics (LD) | 904.1 | -120.5 | -219.1 | -201.3 |
Questionnaire assessed patients quality of life prior to index treatment versus timeframes following hospital discharge. Scores were transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01474200)
Timeframe: Within 90 days after hospital discharge
| Intervention | Scores on a Scale (Mean) | ||
|---|---|---|---|
| Baseline | 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 25.39 | 52.06 | 59.72 |
| IV Loop Diuretics (LD) | 28.64 | 49.36 | 58.50 |
Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Discharge | 30 days after discharge | 60 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 8.38 | 1.72 | 1.85 | 2.50 |
| IV Loop Diuretics (LD) | 7.62 | 6.56 | 3.16 | -3.78 |
Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Discharge | 30 days after discharge | 60 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 3.77 | 0.28 | 0.07 | 5.66 |
| IV Loop Diuretics (LD) | 3.03 | 1.65 | 1.97 | 1.72 |
Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization
| Intervention | mL/min/1.73m2 (Mean) | |||
|---|---|---|---|---|
| Discharge | 30 days after discharge | 60 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | -2.31 | -0.56 | -2.49 | 5.70 |
| IV Loop Diuretics (LD) | -2.68 | -3.33 | 2.15 | 7.41 |
Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Discharge | 30 days after discharge | 60 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 0.12 | 0.37 | 1.34 | -0.30 |
| IV Loop Diuretics (LD) | 0.12 | 0.17 | -0.01 | -0.24 |
"Left ventricle measurements by MRI:~Mass/end diastolic volume ratio: g/ml" (NCT00123955)
Timeframe: Baseline, 9 month
| Intervention | g/ml (Mean) | |
|---|---|---|
| baseline | 9 month | |
| Placebo | 1.7 | 1.6 |
| Spironolactone | 1.8 | 1.7 |
Peak exercise VO2 (NCT00123955)
Timeframe: Baseline, 4 and 9 months
| Intervention | ml/kg/min (Mean) | ||
|---|---|---|---|
| Baseline | 4 months | 9 months | |
| Placebo | 13.3 | 13.5 | 13.9 |
| Spironolactone | 13.5 | 13.6 | 13.8 |
"Echocardiography Doppler measurement of left ventricular diastolic function:~Early mitral annulus velocity (lateral) (Ea; cm/s)" (NCT00123955)
Timeframe: Baseline, 4 month and 9 month
| Intervention | cm/s (Mean) | ||
|---|---|---|---|
| baseline | 4 month | 9 month | |
| Placebo | 6.8 | 6.8 | 6.6 |
| Spironolactone | 7.0 | 7.0 | 7.4 |
"The Minnesota Living with Heart Failure Questionnaire (MLHF) is a self-administered disease-specific questionnaire for patients with Heart Failure, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25). The other eight items (of the total of 21) are only considered for the calculation of the total score.~Scale of 0-105:The higher the score the worse the heart failure related Quality of Life." (NCT00123955)
Timeframe: Baseline, 4 and 9 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 4 months | Final- 9 months | |
| Placebo | 28 | 29 | 25 |
| Spironolactone | 32 | 29 | 29 |
231 reviews available for aldosterone and Cardiac Failure
| Article | Year |
|---|---|
Mineralocorticoid receptors in pulmonary hypertension and right heart failure: From molecular biology to therapeutic targeting.
Topics: Aldosterone; Animals; Endothelial Cells; Heart Failure; Humans; Hypertension, Pulmonary; Mice; Miner | 2022 |
Mineralocorticoid receptor in cardiovascular diseases-Clinical trials and mechanistic insights.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Heart Failure; Myocardium; Receptors, Mineralocortico | 2022 |
Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair.
Topics: Aldosterone; Epinephrine; Heart Failure; Humans; Norepinephrine; Receptors, Adrenergic; Receptors, G | 2022 |
Aldosterone and cardiovascular diseases.
Topics: Aldosterone; Atherosclerosis; Atrial Fibrillation; Cardiovascular Diseases; Heart Failure; Humans; H | 2023 |
Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angioten | 2022 |
Aldosterone as a Mediator of Cardiovascular Damage.
Topics: Aldosterone; Atrial Fibrillation; Cardiovascular System; Heart Failure; Humans; Hyperaldosteronism; | 2022 |
Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Dru | 2022 |
Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients.
Topics: Aldosterone; Heart Failure; Humans; Hypertrophy, Left Ventricular; Multicenter Studies as Topic; Pro | 2023 |
"Renalism" with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2023 |
Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.
Topics: Aldosterone; Angiotensins; Heart Failure; Humans; Hyperkalemia; Hypokalemia; Mineralocorticoid Recep | 2023 |
Arterial Hypertension, Aldosterone, and Atrial Fibrillation.
Topics: Aldosterone; Atrial Fibrillation; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Randomize | 2019 |
Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how?
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Potassium; Renal Insuffi | 2020 |
Sodium pumps, ouabain and aldosterone in the brain: A neuromodulatory pathway underlying salt-sensitive hypertension and heart failure.
Topics: Aldosterone; Animals; Brain; Heart Failure; Humans; Hypertension; Ouabain; Sodium Chloride, Dietary; | 2020 |
Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review.
Topics: Aldosterone; Heart Failure; Humans; Hypertension, Pulmonary; Mineralocorticoid Receptor Antagonists; | 2020 |
Aldosterone receptor antagonists.
Topics: Aldosterone; Blood Pressure; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagon | 2021 |
Impact of Aldosterone on the Failing Myocardium: Insights from Mitochondria and Adrenergic Receptors Signaling and Function.
Topics: Aldosterone; Animals; Heart Failure; Humans; Mitochondria, Heart; Myocardial Infarction; Myocardium; | 2021 |
RAAS: A Convergent Player in Ischemic Heart Failure and Cancer.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Myocar | 2021 |
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compou | 2018 |
Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
Topics: Adipose Tissue; Adiposity; Aldosterone; Heart Failure; Heart Ventricles; Humans; Leptin; Neprilysin; | 2018 |
Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists.
Topics: Aldosterone; Clinical Trials as Topic; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists | 2018 |
Aldosterone and Myocardial Pathology.
Topics: Aldosterone; Gene Expression Regulation; Heart Failure; Humans; Myocardium; Receptors, Mineralocorti | 2019 |
The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Stroke Volume | 2018 |
The renin-angiotensin-aldosterone system and its suppression.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2019 |
Aldosterone receptor antagonists: current perspectives and therapies.
Topics: Aldosterone; Animals; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Rec | 2013 |
Heart failure with preserved ejection fraction: future directions in medical treatment.
Topics: Aldosterone; Animals; Calcium; Heart Failure; Humans; Stroke Volume; Treatment Outcome | 2013 |
The renin-angiotensin-aldosterone system and heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2014 |
[Organ damage and cardiorenal syndrome in acute heart failure].
Topics: Aldosterone; Cardiac Output; Cardio-Renal Syndrome; Comorbidity; Endothelium, Vascular; Heart Failur | 2014 |
Aldosterone and volume management in hypertensive heart disease.
Topics: Aldosterone; Area Under Curve; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineraloc | 2014 |
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?
Topics: Aldosterone; Angiotensins; Biomarkers; Heart Failure; Humans; Renin; Reproducibility of Results | 2015 |
Pharmacological treatment of aldosterone excess.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Dihydropyridines; Drug Interactions; Epithelial Sodium Channe | 2015 |
Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Tr | 2015 |
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
Topics: Aldosterone; Atrial Fibrillation; Cardiac Surgical Procedures; Eplerenone; Heart Failure; Humans; Mi | 2016 |
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure, | 2016 |
Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid | 2016 |
Potassium: friend or foe?
Topics: Aldosterone; Cation Exchange Resins; Cell Membrane; Child; Heart Failure; Homeostasis; Humans; Hyper | 2017 |
Genomic and rapid effects of aldosterone: what we know and do not know thus far.
Topics: Aldosterone; Animals; Cardiovascular System; Gene Expression Regulation; Genomics; Heart Failure; Hu | 2017 |
Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.
Topics: Adrenomedullin; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; beta-N-Acetyl-Galactosaminid | 2017 |
Circulating endothelial progenitor cells in cardiovascular disorders.
Topics: Acute Coronary Syndrome; Aldosterone; Animals; Apoptosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Aldosterone and cardiovascular disease.
Topics: Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular | 2009 |
Reconsidering the roles of the mineralocorticoid receptor.
Topics: Aldosterone; Blood Pressure; Heart Failure; Humans; Hydrocortisone; Hypertension; Mineralocorticoid | 2009 |
Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system?
Topics: Aldosterone; Angiotensins; Blood Pressure; Heart Failure; Humans; Kidney; Metabolic Syndrome; Renin; | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; | 2009 |
Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
Topics: Aldosterone; Diuretics; Evidence-Based Medicine; Heart Failure; Humans; Hyperkalemia; Mineralocortic | 2010 |
Cellular and molecular pathways to myocardial necrosis and replacement fibrosis.
Topics: Aldosterone; Animals; Disease Models, Animal; Fibrosis; Heart Failure; Humans; Hypercalciuria; Hyper | 2011 |
The future of pharmacological therapy for heart failure.
Topics: Aldosterone; Angiotensins; Drug Therapy; Heart Failure; Humans; Renin | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotesto | 2010 |
Aldosterone antagonists in heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor An | 2011 |
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
Topics: Aldosterone; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Mineralocorticoid Recept | 2011 |
Biomarkers: optimizing treatment guidance in heart failure.
Topics: Aldosterone; Biomarkers; Extracellular Matrix; Heart Failure; Humans; Natriuretic Peptides; Patient | 2011 |
Aldosterone, mineralocorticoid receptor, and heart failure.
Topics: Aldosterone; Animals; Heart Failure; Humans; Hydrocortisone; Mice; Mineralocorticoid Receptor Antago | 2012 |
Remodeling in the ischemic heart: the stepwise progression for heart failure.
Topics: Adrenergic Neurons; Aldosterone; Angiotensins; Apoptosis; Arrhythmias, Cardiac; Heart; Heart Failure | 2011 |
The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure.
Topics: Aged; Aging; Aldosterone; Comorbidity; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists | 2012 |
Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorti | 2011 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Ran | 2011 |
Biochemical markers in heart failure.
Topics: Aldosterone; Angiotensins; Biomarkers; Cytokines; Heart Failure; Humans; Natriuretic Peptide, Brain; | 2012 |
Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Chronic Disease; Heart Failure; Hemodynamics; Humans; | 2012 |
The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure.
Topics: Adrenal Glands; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Endotheli | 2012 |
Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
Topics: Aldosterone; Genetic Techniques; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Ant | 2012 |
Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Disease Models, Animal; Heart Failure; Humans; Hypera | 2012 |
NADPH oxidases in heart failure: poachers or gamekeepers?
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Arrhythmias, Cardiac; Enzyme Activation; Fibroblast | 2013 |
Aldosterone and cardiovascular disease: the heart of the matter.
Topics: Aldosterone; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiovascular Diseases; C | 2013 |
[The heart as an endocrine organ].
Topics: Adipocytes; Adipokines; Aldosterone; Biomarkers; Cardiomegaly; Coronary Artery Disease; Cytokines; H | 2012 |
Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; Heart Failure; Humans; Hyperaldosteronism | 2002 |
Aldosterone antagonists in congestive heart failure.
Topics: Aldosterone; Animals; Clinical Trials as Topic; Heart Failure; Humans; Mineralocorticoid Receptor An | 2002 |
Aldosterone: cardiovascular assault.
Topics: Aldosterone; Autonomic Nervous System Diseases; Cardiomegaly; Endothelium, Vascular; Fibrinolysis; F | 2002 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibr | 2002 |
[The significance of aldosterone in chronic heart failure: the RALES study].
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2002 |
The role of aldosterone receptor blockade in the management of cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hypertension; Mine | 2002 |
Local cardiac renin-angiotensin system: hypertension and cardiac failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically | 2002 |
Molecular mechanisms of myocardial remodeling. The role of aldosterone.
Topics: Aldosterone; Animals; Cardiomyopathies; Female; Fibrosis; Heart Failure; Humans; Mice; Mice, Transge | 2002 |
Aldosterone-induced cardiac damage: focus on blood pressure independent effects.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomyopathies; Heart Failure; Hyperaldosteronism; Hypertens | 2003 |
Heart failure: pathophysiologic mechanisms.
Topics: Activities of Daily Living; Aldosterone; Apoptosis; Catecholamines; Cytokines; Diastole; Heart Failu | 2001 |
[Aldosterone and its antagonists in heart failure].
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; | 2003 |
Improving clinical outcomes with drug treatment in heart failure: what have trials taught?
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia | 2003 |
Aldosterone as a target in congestive heart failure.
Topics: Aldosterone; Cardiovascular Agents; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Minera | 2003 |
Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics.
Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Diuresis; Diureti | 2003 |
Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets.
Topics: Aldosterone; Animals; Biomarkers; Coronary Circulation; Fibrosis; Heart Failure; Humans; Hyperaldost | 2003 |
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Clinical Trials as Topic; Diu | 2003 |
Aldosterone receptor antagonists for hypertension: what do they offer?
Topics: Aldosterone; Clinical Trials as Topic; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; M | 2003 |
SODIUM RETENTION AND OEDEMA.
Topics: Aldosterone; Edema; Heart Failure; Humans; Hypernatremia; Metabolism; Physiology; Sodium; Sodium, Di | 1963 |
CHRONIC CARDIAC DECOMPENSATION.
Topics: Aldosterone; Blood Chemical Analysis; Blood Proteins; Body Fluids; Capillary Permeability; Carbon Di | 1963 |
[CIRCULATORY DISEASES AND ELECTROLYTES].
Topics: Aldosterone; Digitalis; Digitalis Glycosides; Diuretics; Edema; Electrolytes; Heart Failure; Hypokal | 1964 |
[THE WATER-ELECTROLYTE STATE IN EDEMA CAUSED BY CONGESTIVE CARDIO-CIRCULATORY INSUFFICIENCY. PHYSIOPATHOGENETIC CONSIDERATIONS AND THERAPEUTIC TRENDS].
Topics: Adrenal Cortex Hormones; Aldosterone; Chlorothiazide; Diet; Diet Therapy; Diuretics; Edema; Electrol | 1964 |
ALDOSTERONE AND ANGIOTENSIN. INTERRELATIONSHIPS IN NORMAL AND DISEASED STATES.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensins; Desoxycorticosterone; Digoxin; Dogs; Heart F | 1964 |
Aldosterone blockade in patients with systolic left ventricular dysfunction.
Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Mal | 2003 |
Toward a broader understanding of aldosterone in congestive heart failure.
Topics: Aldosterone; Animals; Heart Failure; Humans; Renin-Angiotensin System | 2003 |
Aldosterone receptor antagonists: biology and novel therapeutical applications.
Topics: Aldosterone; Heart Failure; Hirsutism; Humans; Hyperaldosteronism; Hypertension; Liver Cirrhosis; Mi | 2003 |
A neuroendocrine-immune interface. The immunostimulatory state of aldosteronism.
Topics: Aldosterone; Antioxidants; Cytokines; Endomyocardial Fibrosis; Heart Failure; Humans; Hyperaldostero | 2003 |
Neurohormone activation.
Topics: Aldosterone; Disease Progression; Heart Failure; Humans; Natriuretic Peptides; Neurotransmitter Agen | 2003 |
[Aldosterone].
Topics: Aldosterone; Animals; Heart Failure; Humans; Receptors, Mineralocorticoid | 2004 |
[Significance of aldosterone antagonist therapy].
Topics: Aldosterone; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dr | 2004 |
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; | 2004 |
A quick glance at rapid aldosterone action.
Topics: Aldosterone; Cardiovascular System; Gene Expression Regulation; Heart Failure; Humans; Receptors, Mi | 2004 |
Regulation of epithelial ion transport by aldosterone through changes in gene expression.
Topics: Aldosterone; Anti-Inflammatory Agents; Biological Transport, Active; Cortisone; Epithelial Cells; Ex | 2004 |
Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects.
Topics: Aldosterone; Animals; Coronary Disease; Cytochrome P-450 CYP11B2; Female; Gene Expression Regulation | 2004 |
Aldosterone target organ protection by eplerenone.
Topics: Aldosterone; Blood Vessels; Brain; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hype | 2004 |
Aldosterone-induced vasculopathy.
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Fibrosis; Heart Arrest; Heart Failure; Humans; | 2004 |
Eplerenone in the treatment of chronic heart failure.
Topics: Aldosterone; Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineraloc | 2004 |
The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Topics: Aldosterone; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; My | 2004 |
Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Endopeptidases; Heart Failure; Humans; Natriuretic | 2004 |
Role of aldosterone blockade in the management of hypertension and cardiovascular disease.
Topics: Aldosterone; Animals; Heart Failure; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Recept | 2004 |
The clinical implications of aldosterone escape in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Endothelium, Vascular | 2004 |
Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; R | 2004 |
Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Ischemia; Myo | 2004 |
Pharmacogenomics of heart failure -- focus on drug disposition and action.
Topics: Aldosterone; Cardiovascular Agents; Cytochrome P-450 Enzyme System; Heart Failure; Humans; Myocardiu | 2004 |
[Therapeutic application of ANP: past and future].
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Cardiopulmonary Bypass; Chronic Disease; Cyclic GMP | 2004 |
[Renin-angiotensin-aldosterone system and natriuretic peptide system--reference to cardiovascular diseases].
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiovascular Diseases; Drug Design; Heart Fa | 2004 |
[Heart failure and renin-angiotensin-aldosterone system: studies on aldosterone].
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Dehydroepiandrosterone; Gene Expression Regulation, | 2005 |
[Aldosterone antagonist therapy for chronic heart failure].
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure | 2005 |
[Aldosterone and heart failure].
Topics: Aldosterone; Heart Failure; Humans | 2005 |
[Left ventricular remodeling post myocardial infarction].
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Proco | 2005 |
Pathophysiology of heart failure following myocardial infarction.
Topics: Aldosterone; Angiotensins; Fibrosis; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardia | 2005 |
Cardiovascular effects of aldosterone.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2005 |
Aldosterone receptor antagonists: biology and novel therapeutic applications.
Topics: Aldosterone; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Ant | 2005 |
Autonomic effects of spironolactone and MR blockers in heart failure.
Topics: Aldosterone; Autonomic Nervous System; Diuretics; Heart Failure; Heart Rate; Humans; Mineralocortico | 2005 |
Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Collagen; E | 2005 |
The new biology of aldosterone.
Topics: Aldosterone; Biomarkers; Blood Pressure; Central Nervous System; Epithelial Cells; Gene Expression; | 2005 |
Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Vessels; Calcium; Diuretics; Heart Fail | 2004 |
Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Hypertension; Ligands; Mineralocorticoid Receptor A | 2005 |
Aldosterone receptor antagonism in heart failure.
Topics: Aldosterone; Clinical Trials as Topic; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists | 2005 |
The role of aldosterone blockers in the management of chronic heart failure.
Topics: Aldosterone; Animals; Chronic Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Kidney; | 2005 |
Natriuretic peptides: novel therapeutic targets in heart failure.
Topics: Aldosterone; Animals; Fibrosis; Heart; Heart Failure; Humans; Natriuresis; Natriuretic Peptides | 2005 |
[Aldosterone in heart failure].
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Animals; Apoptosis; Cytochrome P-450 CYP11 | 2005 |
The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascu | 2006 |
[Cardiac aldosterone].
Topics: Aldosterone; Dehydroepiandrosterone; Heart Failure; Humans | 2006 |
[The role of aldosterone in cardiovascular alterations in patients with chronic kidney disease].
Topics: Aldosterone; Coronary Artery Disease; Heart Failure; Humans; Kidney Failure, Chronic | 2006 |
Water and sodium retention in edematous disorders: role of vasopressin and aldosterone.
Topics: Aldosterone; Body Water; Edema; Female; Heart Failure; Humans; Hyponatremia; Liver Cirrhosis; Pregna | 2006 |
Neurohormones and heart failure: the importance of aldosterone.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
Topics: Aldosterone; Animals; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineralocorticoid | 2006 |
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
Topics: Aldosterone; Algorithms; Disease Progression; Disease Susceptibility; Drug Labeling; Eplerenone; Fib | 2006 |
Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2006 |
Pathophysiology of volume overload in acute heart failure syndromes.
Topics: Acute Disease; Aldosterone; Angiotensins; Blood Volume; Heart Failure; Humans; Pulmonary Wedge Press | 2006 |
Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?
Topics: Adrenal Cortex; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Topics: Administration, Oral; Aldosterone; Amides; Angiotensin II; Animals; Antihypertensive Agents; Enzyme | 2007 |
Role of aldosterone blockade in heart failure.
Topics: Aldosterone; Drug Evaluation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Recepto | 2005 |
Natriuretic peptides and remodeling in heart failure.
Topics: Aldosterone; Animals; Cardiotonic Agents; Disease Progression; Dose-Response Relationship, Drug; End | 2005 |
A primer on aldosterone for gynecologists/obstetricians.
Topics: Aldosterone; Female; Gynecology; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Ant | 2007 |
[Aldosterone].
Topics: Aldosterone; Cardiomegaly; Heart Failure; Humans; Myocardium | 2007 |
[Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Aldosterone; Chronic Disease; Contraindications; Eplerenone; Heart Failure; Humans; Mineralocorticoi | 2007 |
Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Topics: Aldosterone; Contraindications; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypert | 2007 |
The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
Topics: Aldosterone; Animals; Atherosclerosis; Cardiovascular Diseases; Heart Failure; Humans; Hyperaldoster | 2007 |
The importance of lost minerals in heart failure.
Topics: Aldosterone; Calcium; Heart Failure; Humans; Hyperaldosteronism; Magnesium; Parathyroid Hormone; Ren | 2007 |
Aldosterone antagonism in heart failure.
Topics: Aldosterone; Angiotensins; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists | 2007 |
Macro- and micronutrients in patients with congestive heart failure, particularly African-Americans.
Topics: Aldosterone; Black or African American; Heart Failure; Humans; Nutritional Status; Oxidative Stress | 2007 |
Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure.
Topics: Aldosterone; Arachidonic Acid; Cytochrome P-450 Enzyme System; Cytokines; Estradiol; Heart Failure; | 2008 |
Aldosterone blockade in patients with chronic heart failure.
Topics: Aldosterone; Heart Failure; Humans | 2008 |
The salt-avid state of congestive heart failure revisited.
Topics: Aldosterone; Heart Failure; Humans; Models, Biological; Renin-Angiotensin System; Sodium; Water | 2008 |
ACE Inhibitors in heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Circulation | 1984 |
An overview of the clinical pharmacology of enalapril.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Di | 1984 |
Angiotensin converting enzyme (ACE) inhibitors.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Capt | 1982 |
Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Dipeptides; Diuretics; Dose-Respon | 1984 |
[Congestive heart failure].
Topics: Aldosterone; Heart Failure; Homeostasis; Humans; Kinetics; Renin-Angiotensin System | 1982 |
Biology of cardiac failure.
Topics: Aldosterone; Arginine Vasopressin; Blood Circulation; Cardiac Output; Heart Failure; Humans; Kidney; | 1982 |
Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.
Topics: Aldosterone; Angiotensin II; Captopril; Drug Interactions; Heart Failure; Hemodynamics; Humans; Hype | 1980 |
Body fluid homeostasis in congestive heart failure and cirrhosis with ascites.
Topics: Aldosterone; Angiotensin II; Blood Volume; Body Fluids; Body Water; Cardiac Volume; Heart Failure; H | 1982 |
Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke).
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disorders; Electrolyt | 1995 |
'Til death do us part: a case of failed affection.
Topics: Adrenal Glands; Aldosterone; Atrial Natriuretic Factor; Heart Failure; Humans; Hyperplasia; Hypothyr | 1995 |
"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Drug Evaluation; Heart Failure; Humans; Hyper | 1995 |
Renal adaptation to the failing heart. Understanding the cascade of responses.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Fac | 1994 |
Aldosterone and antialdosterone therapy in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Heart Failure; Humans; Mi | 1993 |
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart; | 1993 |
Role of aldosterone in congestive heart failure.
Topics: Aldosterone; Atrial Natriuretic Factor; Heart Failure; Humans; Renin-Angiotensin System; Spironolact | 1993 |
Two new culprits in cardiovascular disease: QT dispersion and aldosterone.
Topics: Aldosterone; Animals; Death, Sudden; Electrocardiography; Heart Failure; Humans; Prognosis; Survival | 1995 |
[Neurohormonal factors in heart failure. I].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Autonomic | 1996 |
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Chronic Disease; Drug T | 1995 |
Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides.
Topics: Aldosterone; Angiotensin II; Cardiac Volume; Catecholamines; Diastole; Endocardium; Endomyocardial F | 1995 |
Aldosterone and heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Endomyocardial Fibrosi | 1995 |
The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure.
Topics: Adult; Aldosterone; Cardiomyopathy, Hypertrophic; Cell Division; Collagen; Connective Tissue; Corona | 1995 |
[Chronic cardiac insufficiency: current treatment and future outlook].
Topics: Adrenergic Antagonists; Aldosterone; Angiotensin II; Cardiotonic Agents; Cardiovascular Agents; Clin | 1996 |
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic Disease; Heart Failure; Huma | 1996 |
[Improvement of patients' condition by using a mechanical heart-assist device].
Topics: Activities of Daily Living; Adult; Aldosterone; Catecholamines; Exercise Tolerance; Follow-Up Studie | 1996 |
[Ace inhibitors: treatment of congestive heart failure].
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Depression, Chemica | 1994 |
[Hypertrophy due to left cardiac insufficiency: role of the neurohumoral system].
Topics: Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Heart Failure; Humans; | 1997 |
Aldosterone and artery compliance in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Compliance; Heart Failure; | 1998 |
Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Heart Failure; Humans; Miner | 1999 |
[Role of aldosterone block in combined therapy of heart failure].
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Hum | 1999 |
Aldosterone antagonists in hypertension and heart failure.
Topics: Aldosterone; Animals; Female; Heart Failure; Humans; Hypertension; Male; Mineralocorticoid Receptor | 2000 |
Aldosterone and myocardial fibrosis in heart failure.
Topics: Adult; Aldosterone; Animals; Cardiomyopathies; Dose-Response Relationship, Drug; Fibrosis; Heart Fai | 2000 |
Aldosterone and vascular damage.
Topics: Adrenal Cortex; Aldosterone; Arteries; Autonomic Nervous System; Baroreflex; Body Water; Compliance; | 2000 |
The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Topics: Aldosterone; Animals; Antihypertensive Agents; Eplerenone; Heart Failure; Humans; Hypertension; Mine | 2000 |
Spironolactone in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Mineralocorti | 2000 |
Aldosterone, a new appreciation of its role in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Mineralocorticoid Rece | 2000 |
Neurohormonal factors in heart failure.
Topics: Aldosterone; Cardiotonic Agents; Cytokines; Heart Failure; Humans; Renin-Angiotensin System; Sympath | 2000 |
Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Blood Vessels; Cardiovasc | 2000 |
[Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combi | 2001 |
K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion.
Topics: Aldosterone; Animals; Antihypertensive Agents; Benzothiadiazines; Clinical Trials as Topic; Disease | 2001 |
The spironolactone renaissance.
Topics: Aldosterone; Androgen Antagonists; Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Colla | 2001 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Cardiovascular System; Clinical Trials as Topic; Endothelium, Vascular; Eplere | 2001 |
Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Bi | 2001 |
Aldosterone in congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Mineralocorti | 2001 |
Aldosterone antagonists - revisited.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Humans; Male; Mineralo | 2001 |
Rationale for the use of aldosterone antagonists in congestive heart failure.
Topics: Aldosterone; Animals; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Cont | 2002 |
Neurohumoral blockade in CHF management.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2000 |
Aldosterone receptor blockade in the management of heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Heart Failure; Humans; Miner | 2002 |
Converting enzyme inhibition and blood pressure regulation.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Dogs | 1976 |
The kidney in heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Cardiac Output; Dogs; Edema; Edema, Cardiac; Glomerular Filtra | 1977 |
Congestive heart failure in dogs: therapeutic concepts.
Topics: Aldosterone; Animals; Blood Volume; Cardiac Output; Diet, Sodium-Restricted; Digitalis Glycosides; D | 1977 |
[Pathophysiological aspects of the renin-angiotensin-aldosterone system].
Topics: Adrenal Insufficiency; Aldosterone; Angiotensin II; Bartter Syndrome; Contraceptives, Oral; Half-Lif | 1977 |
Angiotensin II blockade and the functions of the renin-angiotensin system.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Dogs; Heart Failure; Hypertension, Renal; Kidn | 1976 |
Renal consequences of valvular heart disease.
Topics: Aldosterone; Angiocardiography; Contrast Media; Diuresis; Diuretics; Drug Hypersensitivity; Edema; E | 1975 |
Mechanisms regulating renin release.
Topics: Aldosterone; Angiotensin II; Animals; Aortic Diseases; Blood Pressure; Brain; Calcium; Catecholamine | 1976 |
[Renin, aldosterone and prostaglandins in heart failure].
Topics: Aldosterone; Animals; Aspirin; Double-Blind Method; Heart Failure; Hemodynamics; Humans; Kidney Func | 1991 |
ANF and the renin-angiotensin system in the regulation of sodium balance: longitudinal studies in experimental heart failure.
Topics: Aldosterone; Angiotensins; Animals; Atrial Natriuretic Factor; Diet, Sodium-Restricted; Dogs; Heart | 1991 |
Role of neuroendocrine mechanisms in the pathogenesis of heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Disease Models, Animal; Dogs; Heart | 1991 |
Corticosteroids, kidneys, sweet roots and dirty drugs.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adrenal Cortex Hormones; Aldosterone; Animals; Carbenoxolone; | 1991 |
Interaction between atrial natriuretic peptide, renin system and vasopressin in heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Dogs; Heart Failure; Humans; Renal Circulation; Ren | 1990 |
Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.
Topics: Aldosterone; Animals; Enalapril; Enalaprilat; Heart Failure; Hemodynamics; Humans; Kidney; Myocardiu | 1990 |
Angiotensin-converting enzyme inhibitors in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Electrolytes; Heart Failure; Hemodynamics; Hu | 1989 |
Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone.
Topics: Aldosterone; Atrial Natriuretic Factor; Endocrine Glands; Heart Failure; Humans; Renin | 1986 |
Clinical applications of antimineralocorticoids.
Topics: Aldosterone; Angiotensin II; Ascites; Glucose; Heart Failure; Humans; Hypertension; Liver Cirrhosis; | 1988 |
[Clinical steroid analysis, using H3 and C14 (determination of their secretion, plasma concentration, secretion rate, as well as metabolism and renal clearance rate)].
Topics: 17-alpha-Hydroxypregnenolone; Adrenal Cortex Hormones; Aldosterone; Carbon Isotopes; Chemistry, Clin | 1965 |
Aldosterone in clinical medicine.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Heart Failure; Humans; Hyperaldosteronism; | 1968 |
Endocrine factors in congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Animals; Blood Pressure; Body Weight; Diet, Sodium-Restricted; Do | 1968 |
[Changes in renal hemodynamics and function in cardiac insufficiency].
Topics: Aldosterone; Angiotensin II; Animals; Arteriovenous Anastomosis; Cardiac Volume; Catecholamines; Diu | 1969 |
[Congestive heart failure and aldosterone].
Topics: Adolescent; Aldosterone; Angiotensin II; Heart Failure; Humans; Male; Renin | 1971 |
Circulation: overall regulation.
Topics: Aldosterone; Angiotensin II; Blood Circulation; Blood Pressure; Body Fluids; Cardiac Output; Heart F | 1972 |
[Congestive heart failure].
Topics: Acetazolamide; Aldosterone; Angiotensin II; Benzothiadiazines; Catecholamines; Diuretics; Ethacrynic | 1974 |
Renal regulation of sodium excretion. Function in health and in edema-forming states.
Topics: Aldosterone; Colloids; Edema; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Kidney Dise | 1973 |
Shock following acute myocardial infarction. Current understanding of hemodynamic mechanisms.
Topics: Acidosis; Aldosterone; Animals; Arrhythmias, Cardiac; Arteries; Blood Flow Velocity; Blood Pressure; | 1968 |
[Role of aldosterone in the pathogenesis of cardiac insufficiency (review of the literature)].
Topics: Aldosterone; Animals; Cats; Chlorine; Depression, Chemical; Dogs; Edema; Heart Failure; Humans; Hype | 1967 |
Pathogenesis of ascites in cirrhosis of liver. II.
Topics: Aldosterone; Animals; Ascites; Ascitic Fluid; Ethanol; Heart Failure; Hemodynamics; Humans; Hyperald | 1969 |
Edema.
Topics: Aldosterone; Animals; Disease Models, Animal; Dogs; Edema; Heart Failure; Humans; Hyponatremia; Kidn | 1970 |
[Recent knowledge of diseases with abnormal aldosterone secretion].
Topics: Addison Disease; Adolescent; Adrenal Cortex Hormones; Adrenal Gland Neoplasms; Adult; Aldosterone; A | 1971 |
[Renal regulation of the sodium balance].
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Capillaries; Dogs; Glomerular Filtration Rate; He | 1971 |
[Aldosterone deficiency].
Topics: Adult; Aldosterone; Autonomic Nervous System; Endocrine System Diseases; Heart Failure; Heparin; Hum | 1971 |
[The iduretic effect of cardiac glycosides].
Topics: Absorption; Aldosterone; Animals; Cardiac Glycosides; Digitalis Glycosides; Digoxin; Diuresis; Diure | 1971 |
[Physiopathology of the kidney in heart failure].
Topics: Aldosterone; Heart Failure; Hemodynamics; Humans; Kidney; Regional Blood Flow; Sodium; Sympathetic N | 1971 |
[Role of aldosterone in congestive heart failure].
Topics: Aldosterone; Animals; Dogs; Heart Failure; Humans | 1966 |
Plasma renin concentration in human hypertension.
Topics: Aldosterone; Female; Heart Failure; Humans; Hypertension; Hypertension, Malignant; Kidney Failure, C | 1967 |
120 trials available for aldosterone and Cardiac Failure
| Article | Year |
|---|---|
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.
Topics: Adult; Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors | 2022 |
Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.
Topics: Aldosterone; COVID-19; Heart Failure; Humans; Pandemics; Potassium; Stroke Volume | 2023 |
Serum aldosterone in right ventricular failure versus left ventricular failure before and after mineralocorticoid receptor antagonists: case-control clinical trial.
Topics: Aldosterone; Case-Control Studies; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Pr | 2023 |
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
Topics: Administration, Oral; Adolescent; Adult; Aldosterone; Area Under Curve; Benzoates; Dose-Response Rel | 2020 |
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Chol | 2018 |
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Chol | 2018 |
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Chol | 2018 |
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Chol | 2018 |
Heart failure with preserved ejection fraction in children: hormonal imbalance between aldosterone and brain natriuretic peptide.
Topics: Adolescent; Adult; Age Factors; Aldosterone; Cardiomegaly; Child; Child, Preschool; Disease-Free Sur | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.
Topics: Adult; Aldosterone; Cardiac Imaging Techniques; Collagen; Double-Blind Method; Eplerenone; Female; F | 2013 |
Renal and hormonal effects of systemic nitric oxide inhibition in patients with congestive heart failure and in healthy control subjects.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Blood Flow Velocity; Enzyme Inhibitors; Female; Glomer | 2013 |
The effect of vitamin d on aldosterone and health status in patients with heart failure.
Topics: Aged; Aldosterone; Biomarkers; Double-Blind Method; Female; Health Status; Heart Failure; Humans; Ma | 2014 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.
Topics: Aged; Aldosterone; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Diuretics; Dose-Response Relatio | 2015 |
Prognostic value of aldosterone and cortisol in patients hospitalized for acutely decompensated chronic heart failure with and without mineralocorticoid receptor antagonism.
Topics: Aged; Aldosterone; Biomarkers; Chronic Disease; Cohort Studies; Female; Follow-Up Studies; Heart Fai | 2015 |
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biomarkers; B | 2016 |
Transtubular Potassium Concentration Gradient as a Surrogate Measure of Arterial Underfilling in Acute Decompensated Heart Failure.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Heart Failure; Humans; Male; | 2016 |
Neurohumoral Modulation During Waon Therapy in Chronic Heart Failure - Subanalysis of Waon-CHF Study.
Topics: Aldosterone; Case-Control Studies; Chronic Disease; Complementary Therapies; Heart Failure; Humans; | 2017 |
Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure.
Topics: Aged; Aldosterone; Diet, Sodium-Restricted; Diuretics; Dose-Response Relationship, Drug; Echocardiog | 2009 |
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2009 |
Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide.
Topics: Administration, Oral; Aldosterone; Cross-Over Studies; Delayed-Action Preparations; Drug Administrat | 2009 |
Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study.
Topics: Aged; Aldosterone; Diabetes Mellitus; Fasting; Female; Heart Failure; Homeostasis; Humans; Insulin; | 2009 |
Endurance exercise training in older patients with heart failure: results from a randomized, controlled, single-blind trial.
Topics: Aged; Aldosterone; Anaerobic Threshold; Angiotensin II; Cardiac Output, Low; Cardiac Volume; Echocar | 2009 |
Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction.
Topics: Adult; Aged; Aldosterone; Biomarkers; Cross-Over Studies; Drug Resistance; Drug Therapy, Combination | 2010 |
Enalapril in infants with single ventricle: results of a multicenter randomized trial.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; | 2010 |
Relationship between plasma aldosterone concentration and soluble cellular adhesion molecules in patients referred to coronary angiography.
Topics: Aged; Aldosterone; Atherosclerosis; Cohort Studies; Coronary Angiography; E-Selectin; Europe; Female | 2011 |
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
Topics: Aldosterone; Confidence Intervals; Double-Blind Method; Eplerenone; Female; Health Status Indicators | 2012 |
Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
Topics: Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cystatin C; Diuretics; Double-Blin | 2012 |
Do high doses of AT(1)-receptor blockers attenuate central sympathetic outflow in humans with chronic heart failure?
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Female; Heart Failure; Humans; Losartan; Male; | 2013 |
Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure | 2002 |
Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diureti | 2002 |
A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Ascites; Azepines; Benzamides; Edema; Female | 2003 |
Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Blood Pressu | 2003 |
[Level of angiotensin II and aldosterone in plasma is often elevated in patients with heart failure treated with converting enzyme inhibitors--preliminary results].
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diastole; Heart Failure; Huma | 2002 |
Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Atrial Natri | 2003 |
Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Cross-Over Studies; Diuretics; Double | 2003 |
Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Echocardiograp | 2003 |
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuret | 2003 |
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).
Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz | 2003 |
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).
Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz | 2003 |
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).
Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz | 2003 |
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).
Topics: Aged; Aldosterone; Cause of Death; Disease Progression; Diuretics; Female; Heart Failure; Hospitaliz | 2003 |
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Co | 2003 |
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.
Topics: Aldosterone; Biomarkers; Endothelins; Heart Failure; Humans; Multivariate Analysis; Neurotransmitter | 2004 |
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme | 2004 |
The effect of dietary sodium restriction on neurohumoral activity and renal dopaminergic response in patients with heart failure.
Topics: Aged; Aldosterone; Creatinine; Diet, Sodium-Restricted; Dopamine; Female; Heart Failure; Humans; Kid | 2004 |
Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Cardiovascular Agents; Endothelin-1 | 2004 |
Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, D | 2004 |
Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure.
Topics: Aldosterone; Diuretics; Female; Furosemide; Heart; Heart Failure; Humans; Male; Middle Aged; Mineral | 2004 |
RALES, EPHESUS and redox.
Topics: Aldosterone; Animals; Heart Failure; Humans; Inflammation; Mineralocorticoid Receptor Antagonists; M | 2005 |
Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure.
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cardiomyopathy, Dilated; Chronic Disease; Cy | 2005 |
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
[Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Carbazoles; Carvedilol; Femal | 2005 |
Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure.
Topics: Aldosterone; Echocardiography; Exercise Test; Exercise Therapy; Exercise Tolerance; Female; Heart Fa | 2006 |
Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?
Topics: Aged; Aged, 80 and over; Aldosterone; Combined Modality Therapy; Diet, Sodium-Restricted; Diuretics; | 2008 |
Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
Topics: Aged; Aldosterone; Biomarkers; Canrenone; Disease Progression; Double-Blind Method; Echocardiography | 2007 |
Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.
Topics: Aged; Aldosterone; Amides; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhib | 2007 |
Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Heart Failure; Humans; Indoles; Ma | 2007 |
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Chromatography, High Pressure Liquid; | 2008 |
Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure.
Topics: Acute Disease; Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardia | 1981 |
Hemodynamic effects of captropril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Hemodynamics; Human | 1982 |
Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects.
Topics: Aged; Aldosterone; Blood Pressure; Captopril; Chronic Disease; Clinical Trials as Topic; Coronary Di | 1982 |
Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Double-Blind | 1995 |
Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group.
Topics: Aldosterone; Cardiotonic Agents; Deoxyepinephrine; Digoxin; Diuretics; Dopamine Agonists; Double-Bli | 1995 |
Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine.
Topics: Administration, Oral; Aged; Aldosterone; Analysis of Variance; Blood Pressure; Deoxyepinephrine; Dih | 1995 |
Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Cardiotonic Agents | 1995 |
Renal response to candoxatrilat in patients with heart failure.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Cross-Over Studies; Cyclic GMP; Cyclohexanecarboxylic | 1995 |
The renin angiotensin aldosterone system and frusemide response in congestive heart failure.
Topics: Administration, Oral; Aged; Aldosterone; Captopril; Cross-Over Studies; Drug Therapy, Combination; F | 1995 |
Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure.
Topics: Aged; Aldosterone; Deoxyepinephrine; Female; Heart Failure; Hemodynamics; Humans; Kidney Function Te | 1995 |
Combined therapy of captopril and spironolactone for refractory congestive heart failure.
Topics: Adult; Aged; Aldosterone; Captopril; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; | 1994 |
Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Double-Blind Method; Exercise T | 1994 |
Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
Topics: Aldosterone; Echocardiography; Enalapril; Heart Failure; Heart Ventricles; Humans; Neurosecretory Sy | 1994 |
Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure.
Topics: Aged; Aldosterone; Arginine Vasopressin; Atrial Natriuretic Factor; Cyclic GMP; Diuresis; Diuretics; | 1995 |
Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT).
Topics: Adolescent; Adult; Aged; Aldosterone; Cardiotonic Agents; Deoxyepinephrine; Digoxin; Dopamine Agents | 1993 |
Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Double-Blind Method; Exercise Test; Fe | 1994 |
Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Captopril; Coronary Di | 1994 |
Renal effects of xamoterol in patients with moderate heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Diuresis; Double-Blind Method; Female; Heart Failure; Hemodynamic | 1993 |
Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Carbazoles; Carvedilol; Double-Blind Method; Endothelins; | 1996 |
Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Di | 1996 |
Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Digoxin; Dihy | 1996 |
Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Re | 1996 |
ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Therap | 1995 |
Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Blood Pressure; Cr | 1996 |
Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Blood Gas Ana | 1996 |
Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
Topics: Aldosterone; Atrial Natriuretic Factor; Cyclic AMP; Double-Blind Method; Heart Failure; Hemodynamics | 1996 |
[Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure].
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuret | 1996 |
Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; | 1997 |
Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Cardiotonic Agents; Deslanoside; Femal | 1997 |
[Does captopril decrease endothelial production of endothelin?].
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Echocardiography; Endothelin | 1997 |
Infusions with molsidomine and isosorbide-5-mononitrate in congestive heart failure: mechanisms underlying attenuation of effects.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Double-Blind Method; Drug Tolerance; Female; Fluid Shifts; | 1998 |
Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.
Topics: Adult; Aged; Aldosterone; Analysis of Variance; Double-Blind Method; Edema, Cardiac; Female; Heart F | 1998 |
Within-patient variability of hormone and cytokine concentrations in heart failure.
Topics: Aldosterone; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Case-Co | 1998 |
Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Aorta, Thoracic; Chronic Disease; Compliance; | 1998 |
Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Captopril; Ca | 1998 |
Neuroendocrine activation in heart failure is modified by endurance exercise training.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Coronary Disease; Exercise; Female; He | 1999 |
Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Antihypertensive Agents; Chronic Disease; Diuretics; Double-Bl | 1999 |
Impeded alveolar-capillary gas transfer with saline infusion in heart failure.
Topics: Aldosterone; Blood Pressure; Blood Proteins; Blood-Air Barrier; Capillaries; Carbon Monoxide; Glucos | 1999 |
Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Doub | 2000 |
Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins.
Topics: Aldosterone; Angiotensin II; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Rece | 2000 |
Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Cardiac Output; Cardiotonic Agents; Catecholamines; Ch | 2000 |
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Topics: Aged; Aldosterone; Cardiac Volume; Endomyocardial Fibrosis; Female; Follow-Up Studies; Heart Failure | 2001 |
Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Body Mass Index; Cachexia; | 2001 |
Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relation | 2002 |
Role of endothelin in modulation of heart rate variability in patients with decompensated heart failure.
Topics: Aged; Aldosterone; Clinical Trials as Topic; Electrocardiography, Ambulatory; Endothelin-1; Female; | 2001 |
Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibi | 2002 |
Effects of perindopril on aldosterone production in the failing human heart.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Catheterization; Female; Heart Failur | 2002 |
Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure.
Topics: Aged; Aldosterone; Analysis of Variance; Atrial Fibrillation; Atrial Natriuretic Factor; Female; Hea | 2002 |
Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin II and aldosterone in patients with chronic congestive heart failure.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Female; Heart Failu | 1992 |
Renal, haemodynamic and hormonal interactions between atrial natriuretic factor and arginine vasopressin in patients with congestive heart failure.
Topics: Aged; Aldosterone; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Pressure; Female; Heart Fa | 1992 |
Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Double-Blind Method; Female; Heart Failure; Hem | 1992 |
Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Digoxin; Drug Th | 1990 |
[Renin, aldosterone and prostaglandins in heart failure].
Topics: Aldosterone; Animals; Aspirin; Double-Blind Method; Heart Failure; Hemodynamics; Humans; Kidney Func | 1991 |
Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study.
Topics: Adult; Aged; Aldosterone; Captopril; Catecholamines; Child; Double-Blind Method; Female; Heart Failu | 1990 |
[Effects of dopamine infusion on the release of atrial natriuretic factor].
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Diuresis; Dopamine; Female; Glomerular Filtration Rate | 1990 |
Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study.
Topics: Adult; Aged; Aldosterone; Captopril; Clinical Trials as Topic; Digoxin; Epinephrine; Heart Failure; | 1987 |
Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Femal | 1987 |
Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure.
Topics: Aged; Aldosterone; Deoxyepinephrine; Depression, Chemical; Dihydroergotoxine; Dopamine; Dopamine Age | 1989 |
Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Aldosterone; Anthraquinones; Anti-Inflammator | 1989 |
A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Captopril; Chronic | 1989 |
Renal and adrenal resistance against atrial natriuretic peptide in congestive heart failure: effect of angiotensin I-converting-enzyme inhibition.
Topics: Adrenal Glands; Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuret | 1989 |
Low-dose enalapril in severe chronic heart failure.
Topics: Aged; Aldosterone; Chronic Disease; Electrocardiography; Enalapril; Heart Failure; Heart Function Te | 1989 |
Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure.
Topics: Adult; Aged; Aldosterone; Catecholamines; Drug Therapy, Combination; Epinephrine; Female; Heart Fail | 1986 |
[The atrial natriuretic factor in severe congestive heart failure. Plasma level, hemodynamic, hormonal and renal effects].
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Central Venous Pressure; Cli | 1985 |
Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture.
Topics: Adult; Aged; Aldosterone; Bumetanide; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; | 1986 |
Aldosterone and prolactin responsiveness after prolonged treatment of congestive heart failure with captopril.
Topics: Adult; Aged; Aldosterone; Captopril; Dexamethasone; Electrolytes; Epinephrine; Female; Heart Failure | 1985 |
Influence of digitalis on intracellular electrolytes in patients with congestive heart failure. Investigations on erythrocytes.
Topics: Adult; Aldosterone; Blood Pressure; Clinical Trials as Topic; Digitalis Glycosides; Diuresis; Erythr | 1966 |
641 other studies available for aldosterone and Cardiac Failure
| Article | Year |
|---|---|
Renal Hemodynamics and Renin-Angiotensin-Aldosterone System Profiles in Patients With Heart Failure.
Topics: Aldosterone; Biomarkers; Dobutamine; Heart Failure; Hemodynamics; Humans; Nitroprusside; Renin; Reni | 2022 |
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2021 |
Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure.
Topics: Aldosterone; Heart Failure; Humans; Kidney; Prognosis; Renin | 2021 |
Use of plasma renin and aldosterone profiles for prognostication in acute heart failure: A step forward but not ready for prime time.
Topics: Aldosterone; Heart Failure; Humans; Renin | 2022 |
Non-steroidal aldosterone receptor antagonism: a 'fine' treatment for heart failure patients?
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorti | 2022 |
Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study.
Topics: Aldosterone; Atherosclerosis; Atrial Fibrillation; Heart Atria; Heart Failure; Humans; Hyperaldoster | 2022 |
Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?
Topics: Aldosterone; Aminobutyrates; Anti-Inflammatory Agents; Atrial Natriuretic Factor; Biphenyl Compounds | 2022 |
Renin-angiotensin-aldosterone inhibition in chronic heart failure: From theory into practice.
Topics: Aldosterone; Angiotensins; Heart Failure; Humans; Renin; Renin-Angiotensin System | 2022 |
[Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.]
Topics: Aldosterone; Female; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; | 2022 |
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
Topics: Aldosterone; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphen | 2022 |
Already low drug dose antagonism of the renin-angiotensin aldosterone system decreases 1-year mortality and rehospitalization in old heart failure patients.
Topics: Aged, 80 and over; Aldosterone; Angiotensins; Female; Heart Failure; Hospitalization; Humans; Male; | 2022 |
Transient gene therapy using cell cycle factors reverses renin-angiotensin-aldosterone system activation in heart failure rat model.
Topics: Aldosterone; Animals; Cell Cycle; Heart Failure; Kidney; Myocardial Infarction; Rats; Renin; Renin-A | 2023 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Animals; Diabetes Mellitus, Type 2; Heart Failure; Humans; Mice; Sodium-Glucose Transpo | 2022 |
Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronary Arte | 2023 |
Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enzyme Inhibitors; H | 2023 |
Accelerated ageing and coronary microvascular dysfunction in chronic heart failure in Tgαq*44 mice.
Topics: Aging; Aldosterone; Angiotensins; Animals; Chronic Disease; Fibrosis; Heart Failure; Mice; Mice, Inb | 2023 |
Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Cardiovascular Agents; D | 2023 |
Prognosis after discontinuing renin angiotensin aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction.
Topics: Aldosterone; Antihypertensive Agents; Enzyme Inhibitors; Heart Failure; Humans; Myocardial Infarctio | 2023 |
A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Effectiveness A | 2023 |
Relationship Between Urinary Angiotensinogen and Mortality in Patients with Heart Failure with Reduced Ejection Fraction.
Topics: Aldosterone; Angiotensinogen; Creatinine; Heart Failure; Humans; Prognosis; Renin-Angiotensin System | 2023 |
The effect of taurine supplementation on the renin-angiotensin-aldosterone system of dogs with congestive heart failure.
Topics: Aldosterone; Animals; Dietary Supplements; Dogs; Furosemide; Heart Failure; Renin-Angiotensin System | 2023 |
Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study.
Topics: Aldosterone; Heart Failure; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Strok | 2023 |
Association and progression of multi-morbidity with Chronic Kidney Disease stage 3a secondary to Type 2 Diabetes Mellitus, grouped by albuminuria status in the multi-ethnic population of Northwest London: A real-world study.
Topics: Albuminuria; Aldosterone; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypertension; London; Mi | 2023 |
REMIniscence of aldosterone's role in myocardial remodelling.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium | 2023 |
Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mell | 2023 |
Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Antihypertensive Agents; Bisoprolol; Eplerenone; Heart F | 2023 |
Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental Heart Failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine Monophosphate; Aldosterone; Animals; Atrial Natriuret | 2019 |
Successful Depressor Effect Concomitant with Complete Normalization of High Renin and Aldosterone Profile by Percutaneous Transluminal Renal Angioplasty in a Patient with Acute Exacerbated Heart Failure with Preserved Ejection Fraction.
Topics: Aldosterone; Angioplasty; Dyspnea; Heart Failure; Humans; Hypertension, Renovascular; Male; Middle A | 2019 |
Incidental Congestive Heart Failure in Patients With Aldosterone-Producing Adenomas.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Aldosterone; Cohort Studies; Female; H | 2019 |
Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Melli | 2021 |
Adrenal cortex hypoxia modulates aldosterone production in heart failure.
Topics: Adrenal Cortex; Aldosterone; Animals; Cardio-Renal Syndrome; Catecholamines; Cell Hypoxia; Cell Line | 2020 |
Natriuretic peptide analogues with distinct vasodilatory or renal activity: integrated effects in health and experimental heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic GMP; Disease Models, Animal; Diuresis; Diure | 2021 |
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 2020 |
MiRNA-181a is a novel regulator of aldosterone-mineralocorticoid receptor-mediated cardiac remodelling.
Topics: Aldosterone; Animals; Heart Failure; Mice; MicroRNAs; Mineralocorticoids; Receptors, Mineralocortico | 2020 |
The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction.
Topics: Aldosterone; Heart Failure; Humans; Pharmaceutical Preparations; Registries; Renin-Angiotensin Syste | 2020 |
ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
Topics: Aldosterone; Angiotensins; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Heart Failure; | 2020 |
Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asia; | 2020 |
Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensins; Female; Heart Failure; Humans; Kidney Di | 2020 |
Association Between Neurohormone Levels and Exercise Testing Measures in Patients with Mechanical Circulatory Supports.
Topics: Adult; Aldosterone; Exercise; Exercise Test; Female; Heart Failure; Heart-Assist Devices; Hemodynami | 2020 |
Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEF.
Topics: Aldosterone; Atrial Fibrillation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spi | 2020 |
Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; H | 2021 |
Aldosterone: Behind the Scenes of Depression and Heart Failure?
Topics: Aldosterone; Depression; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolacto | 2020 |
Letter regarding the article 'Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study'.
Topics: Aldosterone; Heart Failure; Humans; Hyperkalemia; Italy; Renin-Angiotensin System | 2021 |
Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensins; COVID-19; Heart Failure; Hospitalizatio | 2021 |
Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cohor | 2020 |
Reply to the letter regarding the article 'Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study'.
Topics: Aldosterone; Heart Failure; Humans; Hyperkalemia; Italy; Renin-Angiotensin System | 2021 |
Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
Topics: Aldosterone; Biomarkers; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Heart Failure; Humans; Re | 2021 |
Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction.
Topics: Aged; Aldosterone; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Pe | 2022 |
Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction: Insights Into the Cardiorenal Syndrome.
Topics: Aldosterone; Biomarkers; Cardio-Renal Syndrome; Endothelial Cells; Heart Failure; Humans; Myocardium | 2021 |
Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin | 2022 |
Renin-Angiotensin-Aldosterone System and Natriuretic Peptides as Possible Targets of Waon Therapy in Heart Failure.
Topics: Aldosterone; Heart Failure; Humans; Natriuretic Peptides; Renin-Angiotensin System; Steam Bath | 2017 |
Monitoring renal safety in mineralocorticoid receptor antagonist trials.
Topics: Aldosterone; Heart Failure; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Spironolactone | 2017 |
The Influence of Exercise Therapy on the Heart Failure Disease Pathway.
Topics: Aldosterone; Exercise Therapy; Exercise Tolerance; Heart Failure; Humans; Stroke Volume | 2017 |
Reply: The Influence of Exercise Therapy on the Heart Failure Disease Pathway.
Topics: Aldosterone; Exercise Therapy; Exercise Tolerance; Heart Failure; Humans; Stroke Volume | 2017 |
Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Exercise Tolerance; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Stro | 2017 |
Reply: Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
Topics: Aldosterone; Exercise Tolerance; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Stro | 2017 |
Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Creatinine; Dog Diseases; Dogs; Fema | 2017 |
Association Between C1q/TNF-Related Protein-1 Levels in Human Plasma and Epicardial Adipose Tissues and Congestive Heart Failure.
Topics: Adipose Tissue; Aged; Aldosterone; Case-Control Studies; Cell Line; Cross-Sectional Studies; Cytochr | 2017 |
PECULIARITIES OF REMODELING OF HEART AND NEUROHUMORAL STATUS IN PATIENTS WITH CHRONIC HEART FAILURE AND CONCOMITANT RENAL DISEASE DEPENDING ON THE VALUE OF THE EJECTION FRACTION OF THE LEFT VENTRICLE.
Topics: Aldosterone; Chronic Disease; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocar | 2017 |
Evaluation of a Pharmacist-Driven Aldosterone Antagonist Stewardship Program in Patients With Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Cohort Studies; Female; Heart Failure; Humans; Male; Mi | 2019 |
Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hyperkalemia; Potassiu | 2018 |
Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.
Topics: Aldosterone; Heart Failure; Humans; Hyperkalemia; Incidence; Mineralocorticoid Receptor Antagonists; | 2018 |
Neurohormone levels remain elevated in continuous flow left ventricular assist device recipients.
Topics: Aldosterone; Aortic Valve; Case-Control Studies; Echocardiography; Female; Healthy Volunteers; Heart | 2018 |
Medicinals with properties of warming Yang and tonifying Qi in terms of Traditional Chinese Medicine: their effects on left ventricular\
ejection fraction and aldosterone in rats with induced failure heart.
Topics: Aldosterone; Animals; Drug Therapy, Combination; Drugs, Chinese Herbal; Heart Failure; Humans; Male; | 2016 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?
Topics: Aldosterone; Biomarkers; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Heart Failure; Huma | 2019 |
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Topics: Aldosterone; Aminobutyrates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animal | 2019 |
Mineralocorticoid Receptor Antagonists.
Topics: Aldosterone; Animals; Antihypertensive Agents; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2019 |
Aldosterone, the Mineralocorticoid Receptor and Mechanisms of Cardiovascular Disease.
Topics: Aldosterone; Cardiovascular Diseases; Gene Expression Regulation; Heart Failure; Humans; Receptors, | 2019 |
Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
Topics: Aldosterone; Animals; Cross-Over Studies; Dog Diseases; Dogs; Furosemide; Heart Failure; Heart Valve | 2019 |
Cardioprotective effect of the secretome of Sca-1+ and Sca-1- cells in heart failure: not equal, but equally important?
Topics: Aldosterone; Animals; Ataxin-1; Cells, Cultured; Disease Models, Animal; Female; Fibrosis; Galectin | 2020 |
No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril.
Topics: Aldosterone; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Fail | 2019 |
Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2 in the genomic pathway.
Topics: Aldosterone; Animals; Atorvastatin; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultur | 2013 |
[Effect of aldosterone on mesenteric resistance vessels in normal or heart failure rats and its mechanism].
Topics: Aldosterone; Animals; Heart Failure; Male; Mesenteric Arteries; Phenylephrine; Rats; Rats, Sprague-D | 2013 |
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
Topics: Acute Disease; Aged; Aldosterone; Cohort Studies; Female; Heart Failure; Hospitalization; Humans; Lo | 2013 |
Clinical characteristics of heart failure with preserved ejection fraction in children.
Topics: Aldosterone; Female; Heart Defects, Congenital; Heart Failure; Humans; Male; Natriuretic Peptide, Br | 2013 |
Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aldosterone; Arrhythmias, Cardiac; Biomarkers; Chi | 2014 |
Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure.
Topics: Adult; Aged; Aldosterone; Alleles; Atrial Fibrillation; Black or African American; Cytochrome P-450 | 2013 |
Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms.
Topics: Adrenal Glands; Aldosterone; Animals; Apoptosis; Arrestins; beta-Arrestin 1; beta-Arrestin 2; beta-A | 2014 |
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
Topics: Aldosterone; Angiotensin II; Animals; Arterial Pressure; Atrial Natriuretic Factor; Cardiac Pacing, | 2014 |
Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
Topics: Aged; Aldosterone; Arginase; Cell Survival; Drug Interactions; Eplerenone; Female; Gene Expression R | 2014 |
Evaluation of cardiac sympathetic nerve activity and aldosterone suppression in patients with acute decompensated heart failure on treatment containing intravenous atrial natriuretic peptide.
Topics: 3-Iodobenzylguanidine; Administration, Intravenous; Aged; Aldosterone; Atrial Natriuretic Factor; Fe | 2014 |
Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in L-NAME-induced hypertension.
Topics: Adiponectin; Aldosterone; Animals; Antioxidants; Arginine; Atrial Natriuretic Factor; Biomarkers; Bl | 2014 |
A comparison of the efficacy of surgical renal denervation and pharmacologic therapies in post-myocardial infarction heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angioten | 2014 |
Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease.
Topics: Aged; Aldosterone; Case-Control Studies; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meie | 2014 |
Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide.
Topics: Aldosterone; Animals; Cardiotonic Agents; Chronic Disease; Collagen; Cytochrome P-450 CYP11B2; Disea | 2014 |
Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model.
Topics: Aldosterone; Angiotensin II; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Catheter Abl | 2014 |
Aldosterone augments Na+-induced reduction of cardiac norepinephrine reuptake.
Topics: Aldosterone; Animals; Biological Transport; Heart Failure; Male; Myocardium; Norepinephrine; Norepin | 2014 |
Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction.
Topics: Adiponectin; Aldosterone; Animals; Calcium; Calcium-Binding Proteins; Calmodulin; Cyclic AMP-Depende | 2014 |
Mineralcorticoid antagonists in heart failure.
Topics: Aldosterone; Canrenone; Clinical Trials as Topic; Heart Failure; Humans; Mineralocorticoid Receptor | 2014 |
Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease.
Topics: Adult; Aged; Aldosterone; Biomarkers; Cross-Sectional Studies; Female; Fibroblast Growth Factor-23; | 2014 |
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
Topics: Acute Kidney Injury; Aldosterone; Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay | 2015 |
Renin-Angiotensin-aldosterone system activation during decongestion in acute heart failure: friend or foe?
Topics: Aldosterone; Female; Heart Failure; Humans; Male; Renin; Renin-Angiotensin System | 2015 |
Aldosterone promotes cardiac endothelial cell proliferation in vivo.
Topics: Aldosterone; Analysis of Variance; Animals; Blood Pressure; Cell Proliferation; Cells, Cultured; Dis | 2015 |
Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aldosterone; Angiotensin II Type 1 Receptor Blocke | 2015 |
Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure.
Topics: Aldosterone; Animals; Disease Models, Animal; Dogs; Echocardiography; Glomerular Filtration Rate; He | 2015 |
The secretion patterns and roles of cardiac and circulating arginine vasopressin during the development of heart failure.
Topics: Aldosterone; Animals; Arginine Vasopressin; Disease Models, Animal; Heart Failure; Male; Myocardium; | 2015 |
The Other Side of the RAAS: Aldosterone Improves Migration of Cardiac Progenitor Cells.
Topics: Aldosterone; Animals; Cell Movement; Cell- and Tissue-Based Therapy; Gene Expression Regulation; Hea | 2015 |
The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Aldosterone; Area Under Curve; Biomarkers; Female; Heart Fai | 2016 |
[Renal sympathetic denervation suppresses ventricular substrate remodeling in a canine high-rate pacing model].
Topics: Aldosterone; Angiotensin II; Animals; Cardiac Pacing, Artificial; Dogs; Enzyme-Linked Immunosorbent | 2015 |
Device therapy and aldosterone antagonists in the prognosis of heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Mineralocorticoid Rece | 2016 |
Aldosterone and right ventricular dysfunction: more data to be collected with prospective cohort studies.
Topics: Aldosterone; Cohort Studies; Heart Failure; Humans; Prospective Studies; Ventricular Dysfunction, Le | 2016 |
Inducible Knock-Down of the Mineralocorticoid Receptor in Mice Disturbs Regulation of the Renin-Angiotensin-Aldosterone System and Attenuates Heart Failure Induced by Pressure Overload.
Topics: Aldosterone; Animals; Collagen; Disease Models, Animal; Echocardiography; Electrolytes; Fibrosis; Ge | 2015 |
Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up.
Topics: Aged; Aldosterone; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Echocardiography; | 2015 |
Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue.
Topics: Adipocytes, Brown; Adipocytes, White; Adipose Tissue, Brown; Adipose Tissue, White; Aldosterone; Ani | 2016 |
Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases.
Topics: Aldosterone; Animals; Arrestins; beta-Arrestins; Cell Culture Techniques; Cell Movement; G-Protein-C | 2016 |
Rapid effects of aldosterone in primary cultures of cardiomyocytes - do they suggest the existence of a membrane-bound receptor?
Topics: A Kinase Anchor Proteins; Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic AMP; Egtazic Acid; | 2016 |
Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Heart Failure; Humans; Neprilysin; Re | 2016 |
Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community.
Topics: Adult; Aged; Aldosterone; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus; Female; He | 2016 |
Predictors for Tolvaptan Treatment and Future Perspectives.
Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Arginine; Benzazepines; Biomarkers; Diuresis | 2016 |
Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization.
Topics: Acute Disease; Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzym | 2017 |
Subclinical volume overload in stable outpatients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Asymptomatic Disease | 2016 |
Variability of biomarkers in patients with chronic heart failure and healthy controls.
Topics: Adult; Aged; Aldosterone; Biomarkers; Case-Control Studies; Chronic Disease; Creatinine; Female; Gal | 2017 |
Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Cytochrome P-450 CYP11B2; Disease | 2016 |
A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure.
Topics: Aldosterone; Animals; Cardiomegaly; Cytochrome P-450 CYP11B2; Cytochrome P-450 Enzyme Inhibitors; He | 2017 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2017 |
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.
Topics: Acute Coronary Syndrome; Aged; Aldosterone; Amides; Angina, Unstable; Anticholesteremic Agents; Card | 2017 |
Outcome Measures in HFpEF Trials: Should We Refocus?
Topics: Aldosterone; Exercise Tolerance; Heart Failure; Humans; Outcome Assessment, Health Care; Stroke Volu | 2017 |
Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Ca | 2008 |
Serum concentrations of BNP and ANP in patients with thyrotoxicosis.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Case-Control Studies; Female; Graves Disease; Heart F | 2009 |
Conventional therapy with an ACE inhibitor diminishes left ventricular dyssynchrony during the progression of heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Comorbidity; Disease | 2010 |
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Catecholamines; Chronic Disease; Dependovirus; Di | 2009 |
The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
Topics: Adolescent; Adult; Aged; Aldosterone; Blood Pressure; Female; Heart Failure; Heart Transplantation; | 2009 |
Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins.
Topics: Aldosterone; Animals; Arrhythmias, Cardiac; Calcium Signaling; Cells, Cultured; Down-Regulation; Hea | 2009 |
Letter by Reeder and Anderson regarding article, "Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16 294 patients".
Topics: Aged; Aged, 80 and over; Aldosterone; Calcium; Fractures, Bone; Heart Failure; Humans; Hyponatremia; | 2009 |
Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cytokines; Diastole; Drug Therapy, | 2009 |
Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism.
Topics: Aldosterone; Angiotensin II; Animals; Calcium; Cell Size; Heart Failure; Hyperaldosteronism; In Vitr | 2010 |
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, So | 2009 |
Effect of carperitide on plasma adiponectin levels in acute decompensated heart failure patients with diabetes mellitus.
Topics: Acute Disease; Adiponectin; Aged; Aldosterone; Atrial Natriuretic Factor; Biomarkers; Cardiovascular | 2009 |
Hemodynamic, hormonal, and renal actions of adrenomedullin 2 in experimental heart failure.
Topics: Aldosterone; Animals; Creatinine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; | 2008 |
Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Topics: Aldosterone; Animals; Biomarkers; Cardiac Pacing, Artificial; Cardiovascular Agents; Corticotropin-R | 2009 |
Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress.
Topics: Adrenocorticotropic Hormone; Aldosterone; Biomarkers; Chronic Disease; Diuretics; Follow-Up Studies; | 2009 |
Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensinogen; Black or African American; Cohort Studies; Diuretics; Fem | 2010 |
Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis.
Topics: Aged; Aged, 80 and over; Aldosterone; Diuretics; Female; Furosemide; Heart Failure; Hemofiltration; | 2010 |
Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
Topics: Aldosterone; Animals; Benzazepines; Blood Pressure; Disease Models, Animal; Dogs; Drug Therapy, Comb | 2010 |
Lack of adherence in heart failure therapy.
Topics: Aldosterone; Guideline Adherence; Heart Failure; Hospitals; Humans | 2010 |
Circulating biomarkers of collagen metabolism in cardiac diseases.
Topics: Aldosterone; Biomarkers; Carrier Proteins; Collagen; Connective Tissue Growth Factor; Heart Diseases | 2010 |
Congestive heart failure: where homeostasis begets dyshomeostasis.
Topics: Aldosterone; Calcium; Dietary Supplements; Heart Failure; Homeostasis; Humans; Hyperaldosteronism; M | 2010 |
Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Capillaries; Collagen; Cytochrome b Group; Desoxyco | 2010 |
Effect of sodium houttuyfonate on inhibiting ventricular remodeling induced by abdominal aortic banding in rats.
Topics: Aldosterone; Alkanes; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Collagen; Constrict | 2010 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
Multimarker approach for the prediction of heart failure incidence in the community.
Topics: Aged; Albuminuria; Aldosterone; Biomarkers; C-Reactive Protein; Creatinine; Female; Follow-Up Studie | 2010 |
Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study.
Topics: Aldosterone; Atrial Natriuretic Factor; Biomarkers; Chronic Disease; Erythropoietin; Female; Follow- | 2010 |
The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hyperte
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Drug Discovery; Drug Evaluation, Preclinical; Fibrosis; Heart | 2011 |
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.
Topics: Adrenal Glands; Aldosterone; Animals; Arrestins; beta-Arrestin 1; beta-Arrestins; Cell Line; Disease | 2011 |
Eplerenone in mild heart failure.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor | 2011 |
Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects.
Topics: Aldosterone; Animals; Blood Pressure; Cardiac Output; Creatinine; Endocrine System; Endothelin-1; Fe | 2011 |
Prognostic value of plasma renin activity in heart failure.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bioma | 2011 |
[The EMPHASIS-HF study].
Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinic | 2011 |
Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure.
Topics: Age Factors; Aged; Aldosterone; Angioplasty, Balloon, Coronary; Body Mass Index; Brain Ischemia; C-R | 2012 |
Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-Agonists; Aldosterone; Anemia, Iron-Deficiency | 2011 |
Heart failure not enough pump iron?
Topics: Adrenergic beta-Agonists; Aldosterone; Anemia, Iron-Deficiency; Animals; Antigens, CD; Cells, Cultur | 2011 |
Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.
Topics: Aged; Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Female; Fumarates; Heart Failur | 2011 |
The influence of cardiac resynchronization therapy on selected inflammatory markers and aldosterone levels in patients with chronic heart failure.
Topics: Aged; Aldosterone; Biomarkers; C-Reactive Protein; Cardiac Resynchronization Therapy; Chronic Diseas | 2011 |
Haemodynamic, endocrine and renal actions of adrenomedullin 5 in an ovine model of heart failure.
Topics: Adrenomedullin; Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic AMP; Disease Models, Animal; | 2012 |
Mineralocorticoid receptor antagonists for heart failure.
Topics: Aldosterone; Animals; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spi | 2011 |
Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial.
Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Randomi | 2011 |
Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure.
Topics: Aldosterone; Animals; Cell Proliferation; Echocardiography; Heart Failure; Hypertension, Pulmonary; | 2011 |
In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Collagen; D | 2012 |
Congestive heart failure as an initial manifestation of reninoma.
Topics: Adolescent; Aldosterone; Cardiomyopathy, Dilated; Female; Heart Failure; Humans; Hyperaldosteronism; | 2011 |
Impact of low-dose B-type natriuretic peptide infusion on urine output after total artificial heart implantation.
Topics: Aldosterone; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Heart Failure; Heart Vent | 2012 |
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Ho | 2012 |
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2012 |
[Hypertension-induced fibrosis: a balance story].
Topics: Aldosterone; Angiotensin II; Animals; Bone Morphogenetic Proteins; Cardiomegaly; Disease Models, Ani | 2012 |
Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Cardiovascular Agents; | 2012 |
Circulating aldosterone and mortality in female nursing home residents.
Topics: Aged; Aged, 80 and over; Aldosterone; Austria; Biomarkers; Female; Follow-Up Studies; Glomerular Fil | 2013 |
Renin-angiotensin-aldosterone activation in heart failure, aldosterone escape.
Topics: Aldosterone; Heart Failure; Humans; Renin-Angiotensin System | 2002 |
Chronic effects of an endothelin-converting enzyme inhibitor on cardiorenal and hormonal function in heart failure.
Topics: Aldosterone; Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Cardiac Output; Cardi | 2002 |
Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure?
Topics: Aged; Aldosterone; Creatinine; Female; Heart Failure; Humans; Leukocyte Count; Male; Middle Aged; Pr | 2002 |
Changes in concentrations of neuroendocrine hormones and catecholamines in dogs with myocardial failure induced by rapid ventricular pacing.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Cardiac Pacing, Artificial; Catecholamines; Dogs; D | 2002 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; | 2002 |
Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure.
Topics: Administration, Oral; Aldosterone; Animals; Canrenone; Collagen; Cyclodextrins; Disease Models, Anim | 2002 |
Long-term adrenomedullin administration in experimental heart failure.
Topics: Adrenomedullin; Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Car | 2002 |
New insights into the role of aldosterone in cardiorenal disease and the clinical implications. Introduction.
Topics: Aldosterone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Randomized | 2002 |
[Selective aldosterone blocker for hypertension and heart failure. Better tolerance than previous drugs].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hypertension; Spironolacto | 2002 |
Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats.
Topics: Aldosterone; Animals; Coronary Vessels; Heart Failure; Ligation; Male; Mineralocorticoid Receptor An | 2003 |
Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Aldosterone; Angiotensin Receptor Antagonists; Angio | 2002 |
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Cardiac Output; Cardiac Pacing, Artificial; Disease Models, An | 2003 |
Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load.
Topics: Adult; Aldosterone; Angiotensin II; Aquaporin 2; Aquaporin 6; Aquaporins; Arginine Vasopressin; Atri | 2003 |
Aldosterone blockade and heart failure.
Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial I | 2003 |
Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Age | 2003 |
A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension.
Topics: Adult; Aged; Aldosterone; Amino Acid Sequence; Biomarkers; Black People; Female; Genetic Predisposit | 2003 |
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
Topics: Administration, Oral; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriur | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis | 2003 |
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arteries; Asp | 2003 |
Sequential big endothelin plasma levels in heart transplant recipients during bridging therapy and after successful heart transplantation.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Austria; Biomarkers; Blood Urea Nitrogen; Creatinine; | 2003 |
[Cytokines and remodeling of the heart in patients with congestive heart failure].
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Biomarkers; Cardiomyopathy, Dilated; Catecholam | 2003 |
Isolation of crystalline aldosterone from the urine of patients with congestive heart failure.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Aldosterone; Body Fluids; Heart Failure; Urine | 1956 |
[Study of aldosteronuria in normal subjects and edematous cardiacs. I. Effect of varying intakes of sodium chloride].
Topics: Aldosterone; Body Fluids; Edema, Cardiac; Heart Failure; Humans; Sodium Chloride | 1956 |
[Study of aldosteronuria in normal subjects and edematous cardiacs. I. Effect of varying intakes of sodium chloride].
Topics: Aldosterone; Body Fluids; Edema, Cardiac; Heart Failure; Humans; Sodium Chloride | 1956 |
[Study of aldosteronuria in normal subjects and edematous cardiacs. I. Effect of varying intakes of sodium chloride].
Topics: Aldosterone; Body Fluids; Edema, Cardiac; Heart Failure; Humans; Sodium Chloride | 1956 |
[Study of aldosteronuria in normal subjects and edematous cardiacs. I. Effect of varying intakes of sodium chloride].
Topics: Aldosterone; Body Fluids; Edema, Cardiac; Heart Failure; Humans; Sodium Chloride | 1956 |
[Study of aldosteronuria in normal subjects and edematous cardiacs. II. Effect of prednisone in cardiac subjects].
Topics: Aldosterone; Body Fluids; Edema, Cardiac; Heart; Heart Failure; Humans; Prednisone | 1956 |
[Study of aldosteronuria in normal subjects and edematous cardiacs. II. Effect of prednisone in cardiac subjects].
Topics: Aldosterone; Body Fluids; Edema, Cardiac; Heart; Heart Failure; Humans; Prednisone | 1956 |
[Study of aldosteronuria in normal subjects and edematous cardiacs. II. Effect of prednisone in cardiac subjects].
Topics: Aldosterone; Body Fluids; Edema, Cardiac; Heart; Heart Failure; Humans; Prednisone | 1956 |
[Study of aldosteronuria in normal subjects and edematous cardiacs. II. Effect of prednisone in cardiac subjects].
Topics: Aldosterone; Body Fluids; Edema, Cardiac; Heart; Heart Failure; Humans; Prednisone | 1956 |
Increased aldosterone secretion in dogs with right-sided congestive heart failure and in dogs with thoracic inferior vena cava constriction.
Topics: Aldosterone; Animals; Constriction; Constriction, Pathologic; Dogs; Heart Failure; Vascular Diseases | 1957 |
The role of aldosterone in the pathogenesis of cardiac edema.
Topics: Aldosterone; Edema, Cardiac; Heart Failure; Humans | 1957 |
Hyperaldosteronism in heart disease.
Topics: Aldosterone; Heart Diseases; Heart Failure; Humans; Hyperaldosteronism | 1957 |
Aldosterone secretion in experimental congestive heart failure.
Topics: Aldosterone; Heart Failure; Humans | 1957 |
[Current concepts interpretative of some physiopathological aspects of congestive cardiac insufficiency].
Topics: Aldosterone; Body Fluids; Heart Failure; Water-Electrolyte Balance | 1957 |
ALDOSTERONE, antidiuretic hormone and congestive heart failure.
Topics: Aldosterone; Arginine Vasopressin; Heart Failure; Humans; Vasopressins | 1958 |
Effects of central venous congestion on sodium, potassium and water metabolism in the rat; response to desoxycorticosterone.
Topics: Aldosterone; Animals; Body Fluids; Desoxycorticosterone; Heart Failure; Hyperemia; Liver; Portal Sys | 1958 |
Impairment of the enzymatic inactivation of adrenal cortical hormones following passive venous congestion of the liver.
Topics: Adrenal Cortex Hormones; Aldosterone; Heart Failure; Histamine; Histamine Agents; Humans; Hyperemia; | 1958 |
[The role of the adrenal cortex in pathogenesis of congestive heart failure].
Topics: Adrenal Cortex; Aldosterone; Heart Failure; Humans | 1958 |
[Behavior of aldosterone in patients with chronic circulatory failure].
Topics: Aldosterone; Heart Failure; Humans | 1958 |
[Relation of aldosterone to blood circulation with reference to cardiac failure].
Topics: Aldosterone; Blood Circulation; Heart Failure; Humans | 1958 |
[Notes on supposed relations between some steroids and aldosterone in edematigenous syndromes].
Topics: Adrenal Cortex Hormones; Aldosterone; Heart Failure; Humans; Kidney Neoplasms; Liver Cirrhosis; Neop | 1958 |
[Aldosterone, glomerular filtration and sodium retention].
Topics: Aldosterone; Heart Failure; Humans; Kidney; Liver Diseases; Sodium; Sodium, Dietary | 1959 |
Aldosterone in congestive heart failure.
Topics: Aldosterone; Body Fluids; Heart Failure; Humans | 1959 |
[Hyperaldosteronism of congestive heart failure; clinical contribution].
Topics: Aldosterone; Heart Failure; Humans; Hyperaldosteronism | 1958 |
In patients with severe systolic dysfunction, only brain natriuretic peptide is related to diastolic restrictive pattern.
Topics: Adult; Aged; Aldosterone; Area Under Curve; Biomarkers; Blood Pressure; Cardiomyopathies; Diastole; | 2003 |
[The new diuretics and their cardio-renal indications].
Topics: Aldosterone; Carbonic Anhydrase Inhibitors; Diuretics; Heart; Heart Failure; Kidney; Mineralocortico | 1960 |
Idiopathic edema. Report of a case with orthostatic edema and hyperaldosteronism.
Topics: Aldosterone; Edema; Heart Failure; Humans; Hyperaldosteronism; Medical Records | 1960 |
Mechanisms of salt and water retention in congestive heart failure. The importance of aldosterone.
Topics: Aldosterone; Heart Failure; Sodium Chloride; Sodium Chloride, Dietary | 1960 |
Spironolactone used with mercaptomerin in the treatment of congestive cardiac failure.
Topics: Aldosterone; Diuretics; Heart Failure; Mineralocorticoid Receptor Antagonists; Organomercury Compoun | 1961 |
A comparison of the properties of chlorothiazide, spironolactone and a combination of both as diuretic agents.
Topics: Aldosterone; Chlorothiazide; Diuretics; Heart Failure; Liver Cirrhosis; Mineralocorticoid Receptor A | 1961 |
[Cortisone-like drugs in the therapy of water and salt retention in cirrhotic and cardiac patients in the decompensation phase. Relation to the urinary elimination of aldosterone. antidiuretic substances and electrolytes].
Topics: Adrenal Cortex Hormones; Aldosterone; Cortisone; Electrolytes; Heart Failure; Humans; Liver Cirrhosi | 1960 |
[On changes in the blood circulation time during the treatment of hemodynamic cardiac insufficiency with diuretics and cardiac glycosides].
Topics: Aldosterone; Blood Circulation; Blood Circulation Time; Cardanolides; Cardiac Glycosides; Cardiotoni | 1960 |
Relation between diuretic agents and aldosterone in cardiac and cirrhotic patients with sodium retention.
Topics: Aldosterone; Diuretics; Heart Failure; Humans; Liver Cirrhosis; Sodium | 1961 |
[Apparently irreducible cardiac edema. Remarkable effect of a spirolactone].
Topics: Aldosterone; Diuretics; Edema, Cardiac; Heart Failure; Mineralocorticoid Receptor Antagonists; Spiro | 1961 |
[Spirolactone. Its use in the treatment of cardiac and cirrhotic edema. Apropos of 6 case reports].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Spironolactone | 1961 |
[Spirolactones. Their use in the treatment of cardiac and cirrhotic edemas (apropos of 6 case reports)].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Mineralocorticoid Receptor Antagonist | 1960 |
Effect of an aldosterone antagonist on the fluid retention of aminonucleoside nephrosis.
Topics: Aldosterone; Antihypertensive Agents; Heart Failure; Hormone Antagonists; Mineralocorticoid Receptor | 1959 |
Acute effects of cardiac glycosides on aldosterone secretion in dogs with hyperaldosteronism secondary to chronic right heart failure.
Topics: Aldosterone; Animals; Cardiac Glycosides; Dogs; Glycosides; Heart Failure; Hyperaldosteronism | 1962 |
[Observations on the use of an aldosterone antagonist (aldactone) in the therapy of water retention].
Topics: Aldosterone; Diuretics; Edema; Edetic Acid; Heart Failure; Humans; Mineralocorticoid Receptor Antago | 1962 |
[Diuretic and saluretic action of an aldosterone antagonist (spirolactone, SC-9420) associated with an iso-indoline derivative (Hygroton) in refractory cardiac edema].
Topics: Aldosterone; Antihypertensive Agents; Chlorthalidone; Diuretics; Edema, Cardiac; Heart Failure; Indo | 1962 |
[Spontaneous and induced variations of aldosteronuria and electrolyte balance in subjects with initial and chronic edemigenic cardiac failure].
Topics: Aldosterone; Chronic Disease; Heart Failure; Humans; Water-Electrolyte Balance | 1962 |
[Cardiac insufficiency and aldosterone].
Topics: Aldosterone; Heart Failure; Humans | 1962 |
Aldosterone and the circulation.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium; Sodium, Dietary | 1962 |
[Aldosterone and edema of cardiac patients. (Apropos of a case)].
Topics: Aldosterone; Edema; Edetic Acid; Heart Failure; Humans | 1962 |
[Treatment of 12 cases of so-called irreversible cardiac edemas by the antagonistic aldosterone medication].
Topics: Aldosterone; Edema, Cardiac; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironol | 1963 |
[Triamterene, a supposed aldosterone inhibitor. Diuretic activity in edematous subjects].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Mineralocorticoid Receptor Antagonist | 1963 |
[Pressure of the tissues in various post-infarct complications and under the influence of aldosterone, spirolactone and saline administration].
Topics: Aldosterone; Heart Failure; Humans; Myocardial Infarction; Sodium Chloride; Spironolactone | 1962 |
[The hormonal factors involved in water and salt retention in the cardiac patient].
Topics: Aldosterone; Heart Failure; Humans; Natriuresis; Vasopressins; Water; Water-Electrolyte Balance | 1962 |
The role of the adrenal cortex and the kidney in the pathogenesis of cardiac edema.
Topics: Adrenal Cortex; Aldosterone; Edema, Cardiac; Heart Failure; Humans; Kidney; Potassium; Sodium | 1963 |
[Studies on the urinary excretion of aldosterone. II. On the role of aldosterone in the pathogenesis of some clinical syndromes].
Topics: Aldosterone; Diabetes Insipidus; Edema; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Liv | 1962 |
[Preliminary observation on the clinical use of aldosterone antagonistic drugs (spironolactone) in edemigenic syndromes].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Mineralocorticoid Receptor An | 1962 |
OBSERVATIONS ON METABOLISM OF ALDOSTERONE IN MAN.
Topics: Aldosterone; Blood Circulation; Heart Failure; Humans; Liver Cirrhosis; Male; Metabolism; Tritium | 1963 |
[PATHOGENETIC ASPECTS AND THERAPEUTIC PROBLEMS IN CONGESTIVE INSUFFICIENCY OF THE GREATER CIRCULATION].
Topics: Aldosterone; Animals; Blood Pressure; Blood Pressure Determination; Blood Proteins; Capillary Permea | 1963 |
[HORMONAL CONTROL OF WATER-ELECTROLYTE BALANCE].
Topics: Aldosterone; Diuretics; Edema; Estrogens; Heart Failure; Humans; Ketones; Liver Diseases; Metyrapone | 1963 |
[ON USE OF THE BLOCKING AGENT ALDOSTERONE].
Topics: Aldosterone; Aortic Valve; Diuretics; Heart Failure; Humans; Hyperaldosteronism; Mitral Valve Insuff | 1963 |
[URINARY ALDOSTERONE EXCRETION IN PATIENTS WITH CARDIAC INSUFFICIENCY].
Topics: Aldosterone; Heart Failure; Humans; Urine | 1963 |
EFFECT OF AN ALDOSTERONE ANTAGONIST (SPIRONOLACTONE) ON PATIENTS WITH SEVERE CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Antihypertensive Agents; Body Fluids; Diuresis; Diuretics; Female; Geriatrics; Heart Fa | 1963 |
[STUDIES ON THE BEHAVIOR OF ADRENAL CORTEX HORMONES IN HYDROPIC HEART INSUFFICIENCY].
Topics: Adrenal Cortex Hormones; Aldosterone; Blood Chemical Analysis; Heart Failure; Hydrocortisone; Urine | 1963 |
[A FUNCTION TEST FOR INDIRECT APPRAISAL OF MINERALOCORTICOID RESERVE OF HUMAN ADRENAL CORTEX].
Topics: Addison Disease; Adrenal Cortex; Adrenal Insufficiency; Aldosterone; Angiotensins; Heart Failure; Hu | 1963 |
[ON THE MECHANISM OF ACTION OF THE DIURETIC ACTIVITY OF 2,4,7-TRIAMINO-6-PHENYL-PTERIDINE (TRIAMTERENE)].
Topics: Aldosterone; Ascites; Blood Chemical Analysis; Body Weight; Diuretics; Heart Failure; Humans; Hypera | 1963 |
ALDOSTERONE AND THE EDEMA OF CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Chromatography; Diuretics; Edema; Geriatrics; Heart Diseases; Heart Failure; Hypertensi | 1964 |
[HORMONAL FACTORS IN CARDIAC INSUFFICIENCY].
Topics: Aldosterone; Angiotensins; Catecholamines; Heart Failure; Humans; Hypertension; Hyperthyroidism; Met | 1963 |
RENIN, ANGIOTENSIN AND ALDOSTERONE IN EXPERIMENTAL SECONDARY HYPERALDOSTERONISM.
Topics: Adrenal Glands; Aldosterone; Angiotensins; Arteriovenous Fistula; Blood Chemical Analysis; Desoxycor | 1964 |
SODIUM CONTENT AND URINARY ALDOSTERONE EXCRETION IN PATIENTS WITH CONGESTIVE HEART FAILURE BEFORE AND AFTER TREATMENT AND COMPARISON WITH NORMAL SUBJECTS UNDERGOING SALT RESTRICTION.
Topics: Aldosterone; Blood Chemical Analysis; Body Fluids; Diet, Sodium-Restricted; Heart Failure; Humans; S | 1964 |
[DIURESIS, ELECTROLYTES AND ALDOSTERONE AFTER TRIAMTERENE: FINDINGS IN THE SO-CALLED "REFRACTORY EDEMAS" OF PATIENTS WITH HEART DISEASE AND LIVER CIRRHOSIS].
Topics: Aldosterone; Ascites; Diuresis; Diuretics; Edema; Electrolytes; Heart Failure; Liver Cirrhosis; Pter | 1963 |
[USE OF AN INHIBITOR OF ALDOSTERONE SYNTHESIS (SU-4885, METOPIRONE) IN SOME REFRACTORY EDEMATOUS STATES].
Topics: Aldosterone; Ascites; Edema; Heart Failure; Hepatitis; Ketones; Liver Cirrhosis; Metyrapone; Mineral | 1963 |
[CIRCULATORY DISORDERS AND THE KIDNEY].
Topics: Aldosterone; Blood Circulation; Blood Volume; Cardiovascular Diseases; Heart Failure; Humans; Kidney | 1964 |
[NATRIURETIC DRUGS].
Topics: Acetazolamide; Aldosterone; Ascites; Chlorothiazide; Dexamethasone; Diabetes Insipidus; Diuresis; Di | 1963 |
CARDIAC FAILURE AND HORMONAL CONTROL OF FLUID AND ELECTROLYTE BALANCE.
Topics: Aldosterone; Angiotensins; Catecholamines; Corticosterone; Cortisone; Edema; Guanethidine; Heart Fai | 1964 |
[PLACE OF ALDACTONE IN THE THERAPY OF EDEMA].
Topics: Aldosterone; Edema; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Spironolactone | 1964 |
[STUDY ON ALDOSTERONE AND ELECTROLYTE METABOLISM IN CARDIAC INSUFFICIENCY].
Topics: Adrenal Cortex Hormones; Aldosterone; Anura; Blood Chemical Analysis; Body Weight; Desoxycorticoster | 1964 |
[ALTERATIONS IN THE EXCRETION OF ALDOSTERONE AND ELECTROLYTES IN HEPATIC CIRRHOSIS, CONGESTIVE HEART FAILURE AND IDIOPATHIC EDEMAS].
Topics: 17-Ketosteroids; Aldosterone; Ascites; Edema; Electrolytes; Heart Failure; Humans; Liver Cirrhosis; | 1964 |
HYPERSECRETION OF ALDOSTERONE IN DOGS WITH A CHRONIC AORTIC-CAVAL FISTULA AND HIGH OUTPUT HEART FAILURE.
Topics: Adrenocorticotropic Hormone; Aldosterone; Animals; Aorta; Arteriovenous Fistula; Blood Pressure; Cor | 1964 |
CARDIAC EDEMA.
Topics: Aldosterone; Diuretics; Drug Therapy; Edema; Edema, Cardiac; Heart Failure; Humans; Hyponatremia; Me | 1964 |
NEW VIEWPOINTS IN THE USE OF PROGESTERONE IN THE TREATMENT OF CARDIAC OEDEMAS ASSOCIATED WITH SECONDARY HYPERALDOSTERONISM.
Topics: Aldosterone; Dexamethasone; Diuresis; Drug Therapy; Edema; Edema, Cardiac; Heart Failure; Humans; Hy | 1964 |
[ALDOSTERONE INHIBITORS IN THE TREATMENT OF EDEMAS].
Topics: Aldosterone; Ascites; Drug Therapy; Edema; Geriatrics; Heart Failure; Humans; Liver Cirrhosis; Miner | 1964 |
DISTRIBUTION OF BODY SODIUM, POTASSIUM, AND WATER AND THE EXCRETION OF ALDOSTERONE IN DOGS WITH SPONTANEOUS HEART FAILURE.
Topics: Aldosterone; Animals; Ascites; Dog Diseases; Dogs; Edema; Heart Failure; Humans; Mitral Valve Insuff | 1965 |
ALDOSTERONE AND THE EDEMA OF CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Drug Therapy; Edema; Heart Failure; Humans; Metabolism; Spironolactone | 1965 |
SPLANCHNIC EXTRACTION AND CLEARANCE OF ALDOSTERONE IN SUBJECTS WITH MINIMAL AND MARKED CARDIAC DYSFUNCTION.
Topics: Aldosterone; Blood; Heart Failure; Iodine Isotopes; Physiology; Radiometry; Rose Bengal; Spleen | 1965 |
STEROIDS PRODUCED IN VITRO BY ADRENAL GLANDS OF NORMAL AND ARTERIOSCLEROTIC RATS DURING AND AFTER DRUG-INDUCED MYOCARDIAL NECROSIS.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Aldosterone; Arteriosclerosis; Heart Failure; In Vitro Tech | 1965 |
DECREASED PLASMA CLEARANCE AND HEPATIC EXTRACTION OF ALDOSTERONE IN PATIENTS WITH HEART FAILURE.
Topics: Aldosterone; Blood; Cardiac Catheterization; Heart Failure; Heart Septal Defects; Humans; Liver; Phy | 1965 |
OBSERVATIONS OF ALDOSTERONE METABOLISM IN CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Blood; Body Fluids; Heart Failure; Kidney Function Tests; Liver; Liver Circulation; Met | 1964 |
[ALDOSTERONE IN EDEMA SYNDROME. HYPERALDOSTERONISM IN CONGESTIVE CARDIAC INSUFFICIENCY].
Topics: Aldosterone; Edema; Heart Failure; Humans; Hyperaldosteronism; Syndrome | 1964 |
[INVESTIGATION OF PLASMA ALDOSTERONE AND ALDOSTERONE METABOLISM IN HEALTHY SUBJECTS AND PATIENTS WITH HEART, LIVER AND KIDNEY DISEASE].
Topics: Aldosterone; Blood; Healthy Volunteers; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Hyp | 1965 |
CONJUGATION OF 1,2-3H-ALDOSTERONE IN HUMAN LIVER AND KIDNEYS AND RENAL EXTRACTION OF ALDOSTERONE AND LABELED CONJUGATES FROM BLOOD PLASMA.
Topics: Aldosterone; Blood; Chromatography; Fluids and Secretions; Glucuronates; Heart Failure; Hepatic Vein | 1965 |
METABOLISM OF ALDOSTERONE IN SEVERAL EXPERIMENTAL SITUATIONS WITH ALTERED ALDOSTERONE SECRETION.
Topics: Aldosterone; Animals; Blood; Dogs; Heart Failure; Hemorrhage; Hypophysectomy; Kinetics; Liver Circul | 1965 |
[Aldosterone excretion in patients with chronic circulatory insufficiency].
Topics: Aldosterone; Biological Transport; Body Fluids; Heart Failure; Humans | 1959 |
Electrolyte imbalance and aldosterone secretion in congestive heart failure.
Topics: Acid-Base Imbalance; Aldosterone; Biochemical Phenomena; Electrolytes; Heart Failure; Humans; Water- | 1959 |
[Urine aldosterone in cardiac patients resistant to mercurial diuretics].
Topics: Aldosterone; Body Fluids; Diuretics; Heart Failure; Organomercury Compounds | 1960 |
[Aldosterone and edema. Physiopathology of hyperaldosteronuria in lipoid nephrosis and cardiac insufficiency].
Topics: Aldosterone; Body Fluids; Edema; Heart Failure; Humans; Nephrosis, Lipoid; Nephrotic Syndrome | 1959 |
[The secondary hyperaldosteronism of cardiac insufficiency. Pathogenic study and physiopathological implications].
Topics: Aldosterone; Heart Failure; Humans; Hyperaldosteronism | 1960 |
[Clinical use of spirolactone SC-9420 "Aldactone"].
Topics: Aldosterone; Diuretics; Heart Failure; Mineralocorticoid Receptor Antagonists; Spironolactone | 1962 |
Hormones and the pathogenesis of congestive heart failure: vasopressin, aldosterone, and angiotensin II. Further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis.
Topics: Aldosterone; Angiotensin Amide; Angiotensin II; Heart Defects, Congenital; Heart Failure; Humans; Hy | 1962 |
[Aldostegone-antagonistic steroids as diuretics. Spironolactone in the treatment of hepatic and cardiac edemas].
Topics: Aldosterone; Diuretics; Edema, Cardiac; Edetic Acid; Heart Failure; Liver Cirrhosis; Mineralocortico | 1961 |
[Overloading of NaCI and aldosterone in cardiac insufficiency].
Topics: Aldosterone; Heart Failure; Humans; Ions; Sodium; Sodium Chloride; Sodium, Dietary | 1961 |
The use of an aldosterone antagonist in refractory congestive heart failure.
Topics: Aldosterone; Antihypertensive Agents; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor A | 1961 |
[A comparison of two spirolatone preparations in the long-term treatment of edematous heart insufficiency].
Topics: Aldosterone; Edema; Heart Failure; Humans; Long-Term Care; Mineralocorticoid Receptor Antagonists | 1962 |
[Hypokalemis, hypochloremia and alkalosis in the long-term treatment of edematous heart insufficiency with benzothiadiazine diuretics. III. Effects of spirolactone].
Topics: Aldosterone; Alkalosis; Chlorothiazide; Diuretics; Edema; Heart Failure; Mineralocorticoid Receptor | 1962 |
[Aldactone (aldosterone antagonist SC-9, 420) in the treatment of the edemas of heart patients and cirrhotic patients. Bioclinical study].
Topics: Aldosterone; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Mineralocorticoid Receptor An | 1962 |
Effect of nolomirole on monocrotaline-induced heart failure.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Aldosterone; Animals; Ascitic Fluid; Atrial Natriur | 2004 |
[Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Germany; Heart Failure; Humans; Mineralocorticoid | 2003 |
Is the female heart more sensitive to aldosterone for early remodeling?
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Estr | 2004 |
Aldosterone levels after angiotensin receptor blocker treatment.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Te | 2004 |
Diuretic use, progressive heart failure, and death in patients in SOLVD.
Topics: Aldosterone; Cause of Death; Diuretics; Heart Failure; Humans; Potassium; Stroke Volume; Ventricular | 2004 |
Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Caspase 2; Caspase 3; Caspase 8; Ca | 2004 |
Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction.
Topics: Aldosterone; Animals; C-Reactive Protein; Electrocardiography; Guanidines; Heart Failure; Inflammati | 2004 |
Aldosterone. An important factor in heart failure treatment.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists | 2004 |
Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats.
Topics: Adrenomedullin; Aldosterone; Animals; Body Weight; Dinoprost; Disease Progression; Drug Evaluation, | 2004 |
Treatment of heart failure with spironolactone--trial and tribulations.
Topics: Adrenergic beta-Antagonists; Aging; Aldosterone; Drug Therapy, Combination; Glomerular Filtration Ra | 2004 |
Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol.
Topics: Acute Disease; Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Dogs; Dose-Response | 2004 |
Furosemide and the progression of left ventricular dysfunction in experimental heart failure.
Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Biomarkers; Disease Models, Animal; Disease Progress | 2004 |
Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain.
Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Diuretics; Electrolytes; Furosemide; Heart Failure; | 2004 |
Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart.
Topics: Adult; Aged; Aldosterone; Animals; Blotting, Southern; Cardiac Catheterization; Cell Size; Cells, Cu | 2004 |
[Secondary hyperaldosteronism with cyclic edema as a sequel to the chronic use of laxatives in a case of anorexia nervosa].
Topics: Aldosterone; Anorexia Nervosa; Catecholamines; Edema; Heart Failure; Humans; Hyperaldosteronism; Lax | 1960 |
Aldosterone: from integrative physiology to cellular biology and back.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists | 2004 |
The neuroendocrine-immune interface gone awry in aldosteronism.
Topics: Aldosterone; Animals; Central Nervous System; Heart Failure; Humans; Hyperaldosteronism; Kidney; Min | 2004 |
[Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2004 |
Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
Topics: Adrenergic beta-Agonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anim | 2005 |
ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hypertension; Mineralo | 2005 |
Effects of aldosterone on forearm vasculature in treated chronic heart failure.
Topics: Aged; Aldosterone; Analysis of Variance; Blood Flow Velocity; Dose-Response Relationship, Drug; Fema | 2005 |
Calcium, magnesium, and oxidative stress in hyperaldosteronism.
Topics: Aldosterone; Animals; Calcium; Heart Failure; Humans; Hyperaldosteronism; Magnesium; Oxidative Stres | 2005 |
Increased susceptibility to heart failure in response to volume overload in mice lacking natriuretic peptide receptor-A gene.
Topics: Aldosterone; Angiotensin I; Animals; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Disease Su | 2005 |
Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Bradykinin B2 Receptor A | 2004 |
Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
Topics: Administration, Oral; Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic GMP; Disease Models, A | 2005 |
Aldosterone and heart failure: the rest of the story.
Topics: Aldosterone; Animals; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotens | 2005 |
Aldosterone in heart failure: pathophysiology and treatment.
Topics: Aldosterone; Death, Sudden, Cardiac; Endothelium, Vascular; Heart Failure; Humans; Hypertension; Min | 2004 |
Angiotensin II, but not aldosterone and renin, correlates positively with increased concentrations of N-terminal pro-brain natriuretic peptide in patients with chronic heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Biomarkers; Female; Heart Failure; Humans; Male; Natriuretic Pept | 2005 |
Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure.
Topics: Aldosterone; Biomarkers; Disease Progression; Epinephrine; Exercise Test; Exercise Tolerance; Female | 2006 |
Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Eplerenone; H | 2005 |
Ischemic etiology of heart failure identifies patients with more severely impaired exercise capacity.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Blood Flow Velocity; Blood Pressure; Echocardiography; | 2005 |
High prevalence of microalbuminuria in chronic heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Angiotensin-Converti | 2005 |
The proinflammatory heart failure phenotype: a case of integrative physiology.
Topics: Aldosterone; Animals; Calcium; Coronary Circulation; Cytokines; Disease Models, Animal; Heart Failur | 2005 |
The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure.
Topics: Aldosterone; Biomarkers; C-Reactive Protein; Dinoprost; Female; Heart Failure; Humans; Intercellular | 2006 |
The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Topics: Actins; Aldosterone; Animals; Blotting, Western; Cytochrome P-450 CYP11B2; Drug Therapy, Combination | 2006 |
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients.
Topics: Aged; Aldosterone; AMP Deaminase; Angiotensin II; Atrial Natriuretic Factor; Endothelin-1; Epinephri | 2006 |
Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements.
Topics: Aldosterone; Animals; Calcitriol; Calcium; Cytoplasm; Dietary Supplements; Heart Failure; Humans; Hy | 2006 |
Mineralocorticoid-receptor blockade, hypertension and heart failure.
Topics: Aldosterone; Clinical Trials as Topic; Eplerenone; Heart Failure; Hormone Antagonists; Humans; Hyper | 2005 |
Carvedilol reduces aldosterone release in systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Biomarkers; Carbazoles; Carvedilol; Female; Follow-Up Stud | 2006 |
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Topics: Aldosterone; Angiotensin II; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Cytoc | 2007 |
[Changes of parameters of hemodynamics and systems of neurohumoral regulation in patients with implanted cardiac pacemakers after switching from DDD to VVI pacing mode].
Topics: Aldosterone; Biomarkers; Equipment Design; Female; Follow-Up Studies; Heart Failure; Humans; Male; M | 2006 |
A case of ACTH-independent bilateral macronodular adrenal hyperplasia and severe congestive heart failure.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Heart Failure; Humans; Hydrocortisone; Hyperplasia; Mal | 2006 |
Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.
Topics: Aged; Aged, 80 and over; Aldosterone; C-Reactive Protein; Cause of Death; Cohort Studies; Comorbidit | 2007 |
Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2007 |
Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Cells, Cultured; Cytokines; Cytoprotection; Endothe | 2007 |
Curriculum in cardiology: Integrated diagnosis and management of diastolic heart failure (Am Heart J 2007;153:189-200).
Topics: Adult; Aldosterone; Diastole; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spirono | 2007 |
Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure.
Topics: Aldosterone; Alleles; Black or African American; Chronic Disease; Cytochrome P-450 CYP11B2; Echocard | 2007 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang | 2007 |
Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; | 2007 |
Safety and efficacy of nesiritide in pediatric heart failure.
Topics: Adolescent; Adult; Aldosterone; Biomarkers; Cardiac Output, Low; Cardiomyopathies; Child; Child, Pre | 2007 |
Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone.
Topics: Aldosterone; Animals; Canrenoic Acid; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type | 2008 |
Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine Vasopressin; Atrial Natriur | 2008 |
Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; | 2008 |
New twist to the role of the renin-angiotensin system in heart failure: aldosterone upregulates renin-angiotensin system components in the brain.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Brain; Disease Models, Animal; Heart Failure; | 2008 |
Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure?
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Brain; Disease Models, Animal; Heart Failure; | 2008 |
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Topics: Aldosterone; Animals; Clodronic Acid; Collagen; Cytokines; Eplerenone; Factor XIIIa; Heart Failure; | 2008 |
Translational research goes both ways: lessons from clinical studies.
Topics: Aldosterone; Amino Acid Sequence; Antihypertensive Agents; Biomedical Research; Clinical Trials as T | 2008 |
Heart failure in the elderly.
Topics: Aged; Aldosterone; Aminophylline; Digitalis; Diuretics; Heart Failure; Humans; Hypertension; Organom | 1967 |
Exchange of aldosterone between plasma and thoracic duct lymph.
Topics: Aldosterone; Animals; Arthritis, Rheumatoid; Ascites; Carbon Isotopes; Dogs; Edema; Esophageal and G | 1967 |
Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; D | 1984 |
Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Blood Pressure; Chronic Disease; Electrolytes; Enalapril; Female; | 1983 |
Variable clinical response to long-term angiotensin inhibition in severe heart failure: demonstration of additive benefits of alpha-receptor blockade.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cap | 1982 |
Angiotensin-converting enzyme inhibitors.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Hum | 1980 |
Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure.
Topics: Adult; Aged; Aldosterone; Aprotinin; Blood Pressure; Body Weight; Captopril; Drug Interactions; Fema | 1984 |
Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Urea Nitro | 1980 |
Role of the renin-angiotensin-aldosterone system in the regulation of blood pressure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diet | 1980 |
Clinical improvement and hormonal changes in severe cardiac failure after captopril treatment.
Topics: Administration, Oral; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibi | 1981 |
Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure.
Topics: Aldosterone; Captopril; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Physical Exe | 1982 |
The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Dipeptides; Enalap | 1983 |
Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dipeptides; Dose-Respon | 1983 |
Hypokalemia in cardiac decompensation.
Topics: Aldosterone; Heart Failure; Humans; Hydrogen-Ion Concentration; Hypokalemia; Potassium; Sodium-Potas | 1984 |
Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone.
Topics: Aged; Aldosterone; Captopril; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Mi | 1983 |
The renin-angiotensin system in congestive cardiac failure: a selective review.
Topics: Aldosterone; Angiotensin II; Animals; Captopril; Heart Failure; Hemodynamics; Humans; Renin; Renin-A | 1983 |
The renin-angiotensin--aldosterone system and the clinical course of acute myocardial infarction.
Topics: Adult; Aged; Aldosterone; Arrhythmias, Cardiac; Epinephrine; Female; Heart Failure; Humans; Male; Mi | 1983 |
Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure.
Topics: Adult; Aged; Aldosterone; Digoxin; Female; Heart Failure; Humans; Injections, Intravenous; Male; Mid | 1983 |
Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure.
Topics: Administration, Oral; Aged; Aldosterone; Chronic Disease; Epinephrine; Female; Heart Failure; Hemody | 1983 |
Captopril in congestive heart failure resistant to other vasodilators.
Topics: Aldosterone; Captopril; Catecholamines; Drug Resistance; Follow-Up Studies; Heart Failure; Hemodynam | 1984 |
Hyponatremia in congestive heart failure treated with diuretics.
Topics: Aldosterone; Diuretics; Heart Failure; Humans; Hyponatremia; Renin; Sodium | 1984 |
Renin and angiotensin responses to posture and exercise in elderly patients with heart failure.
Topics: Aged; Aging; Aldosterone; Epinephrine; Female; Heart Failure; Humans; Male; Middle Aged; Norepinephr | 1984 |
Single-dose i.v. Aldactone for congestive heart failure: a preliminary observation.
Topics: Aged; Aldosterone; Canrenoic Acid; Diuresis; Female; Heart Failure; Humans; Injections, Intravenous; | 1983 |
A clinical study on the role of the renin-angiotensin-aldosterone system and catecholamines in chronic congestive heart failure.
Topics: Aldosterone; Blood Pressure; Captopril; Catecholamines; Chronic Disease; Heart Failure; Hemodynamics | 1982 |
Acute and chronic effects of captopril therapy in patients with refractory heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Captopril; Follow-Up Studies; Heart Failure; Hemodynamics; Humans | 1982 |
Short and long-term effects of treatment with low dose captopril in patients with severe congestive heart failure.
Topics: Aged; Aldosterone; Captopril; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prolin | 1982 |
Long-term treatment of congestive heart failure with captopril.
Topics: Adult; Aged; Aldosterone; Captopril; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; | 1982 |
Long-term control of congestive heart failure with captopril.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Volume; Captopril; Cardiac Output; Creatinine; Drug | 1982 |
Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies.
Topics: Aged; Aldosterone; Angiotensin II; Captopril; Dose-Response Relationship, Drug; Female; Heart Failur | 1982 |
Mechanisms governing the postural response and baroreceptor abnormalities in chronic congestive heart failure: effects of acute and long-term converting-enzyme inhibition.
Topics: Adult; Aged; Aldosterone; Captopril; Female; Heart Failure; Hemodynamics; Humans; Long-Term Care; Ma | 1982 |
Aldosteronism in pregnancy: association with virilization of female offspring.
Topics: Adrenalectomy; Adult; Aldosterone; Clitoris; Female; Heart Failure; Humans; Hyperaldosteronism; Infa | 1983 |
The effect of diuretics on lymphocyte magnesium and potassium.
Topics: Aged; Aldosterone; Amiloride; Diuretics; Female; Heart Failure; Humans; Lymphocytes; Magnesium; Male | 1981 |
[Treatment of acute left cardiac insufficiency: a labyrinth without the thread of Ariane?].
Topics: Aldosterone; Angiotensin II; Blood Pressure; Cardiac Output; Heart Failure; Heart Ventricles; Hemody | 1981 |
The occurrence of hyperaldosteronism in infants with congestive heart failure.
Topics: Aldosterone; Body Weight; Epidemiologic Methods; Furosemide; Heart Failure; Humans; Hyperaldosteroni | 1980 |
The pathogenesis of peripheral cardiac edema.
Topics: Aldosterone; Animals; Dogs; Edema, Cardiac; Heart Failure; Hemodynamics; Humans; Kidney; Liver Circu | 1980 |
The renin-angiotensin-aldosterone system and catecholamines in chronic congestive heart failure. Effect of angiotensin I converting enzyme inhibitor SQ 14225 (Captopril).
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Captopril; Catecholamines; Chr | 1980 |
Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Female; Furosemide; Heart Failure; Hemodynamics; Humans; H | 1980 |
Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Blood Urea Nitrogen; Creatinine; Female; H | 1981 |
Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy.
Topics: Administration, Oral; Adult; Aged; Aldosterone; Angiotensin II; Captopril; Cardiac Output; Female; H | 1981 |
Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy.
Topics: Aged; Aldosterone; Angiotensin II; Captopril; Heart Failure; Humans; Kinetics; Male; Middle Aged; Po | 1981 |
Effect of dexamethasone on the diurnal rhythm of plasma aldosterone in patients with congestive heart failure.
Topics: Adolescent; Adult; Aldosterone; Circadian Rhythm; Dexamethasone; Female; Heart Failure; Humans; Hydr | 1981 |
Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Urea Nitrogen; Captopril; Chronic Disease; Creatinin | 1982 |
Renin, the heart and hypertension.
Topics: Aldosterone; Captopril; Heart Failure; Humans; Hypertension; Renin | 1982 |
Prostacyclin therapy in patients with congestive heart failure.
Topics: Aged; Aldosterone; Cardiac Output; Epinephrine; Epoprostenol; Female; Heart Failure; Heart Rate; Hum | 1982 |
Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone.
Topics: Aged; Aldosterone; Body Weight; Chlorides; Circadian Rhythm; Electrolytes; Heart Failure; Humans; Hy | 1981 |
[Mineralocorticoid function of the adrenal cortex in chronic circulatory insufficiency].
Topics: Adolescent; Adrenal Cortex; Adult; Aged; Aldosterone; Chronic Disease; Female; Heart Failure; Humans | 1980 |
The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure.
Topics: Adult; Aged; Aldosterone; Deoxyepinephrine; Dopamine Agonists; Dose-Response Relationship, Drug; Dru | 1995 |
Increased plasma levels of adrenomedullin in patients with heart failure.
Topics: Adrenomedullin; Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Atrial Natriur | 1995 |
Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure.
Topics: Aldosterone; Animals; Aspirin; Atrial Natriuretic Factor; Disease Models, Animal; Dogs; Drug Adminis | 1995 |
Morphometric analysis of atrial natriuretic peptide-containing granules in atriocytes of rats with experimental congestive heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Disease Models, Animal; Evaluation Studies as Topic | 1995 |
Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention.
Topics: Aged; Aldosterone; Body Fluids; Body Water; Feedback; Female; Follow-Up Studies; Heart Failure; Hema | 1994 |
Pharmacologic management of heart failure: neurohormonal agents.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; H | 1993 |
Carotid arterial compliance in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Aldosterone; Cardiomyopathy, Dilated; Carotid Artery, Common; Compliance; Female; Heart | 1994 |
Low-dose enoximone therapy in pre-transplant patients: hemodynamic, echocardiographic, and neurohumoral findings.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Combined Modality Therapy; Dose-Response Relationship | 1994 |
Atrial natriuretic peptide response is blunted in patients with acute myocardial infarction and mild left ventricular dysfunction.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output, Low; Female; He | 1994 |
Short- and long-term neurohormonal activation following acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Case-Control | 1993 |
Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aldosterone; Atrial Natriuretic Factor; Cardia | 1993 |
Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration.
Topics: Adult; Aged; Aldosterone; Diuresis; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; | 1993 |
Captopril and spironolactone therapy for refractory congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Captopril; Drug Therapy, Combination; Female; Heart Fai | 1993 |
Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages.
Topics: Aldosterone; Atrial Natriuretic Factor; Captopril; Female; Follow-Up Studies; Heart Failure; Hemodyn | 1993 |
Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Case-Control Studies; Endothelins; Female; Foll | 1993 |
Invasive pharmacodynamics of fosinopril in patients with congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Chromatography, High Pressure | 1995 |
[Effect of cilazapril on exercise tolerance and neurohumoral factors in patients with asymptomatic chronic heart failure after myocardial infarction].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Fact | 1995 |
Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy.
Topics: Aldosterone; Animals; Cardiomyopathy, Dilated; Dog Diseases; Dogs; Female; Heart Failure; Male; Refe | 1995 |
[Inhibition of the neurohumoral axis after intravascular fluid depletion in congestive heart failure with water retention: mechanisms of the perpetuation of the syndrome].
Topics: Adult; Aldosterone; Blood Pressure; Cardiac Output, Low; Diuresis; Feedback; Female; Heart Failure; | 1995 |
Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure.
Topics: Aged; Aged, 80 and over; Aging; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Diuretics; F | 1995 |
Plasma levels of endothelin-1 at rest and after exercise in patients with moderate congestive heart failure.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Cardiomyopathy, Dilated; Disease Progression; Endothe | 1995 |
Neuroendocrine response to standing and mild exercise in patients with untreated severe congestive heart failure and chronic constrictive pericarditis.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Exercise; Growth Hormone; Heart Failure; Heart Rate; | 1996 |
Responses of plasma norepinephrine and renin-angiotensin-aldosterone system to dynamic exercise in patients with congestive heart failure.
Topics: Aldosterone; Angiotensin II; Exercise; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Age | 1996 |
Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Dog Dis | 1996 |
Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Chagas Cardiomyopathy; Di | 1996 |
Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Creatinine; Dog Dis | 1997 |
Comparative bioactivity of atrial and brain natriuretic peptides in an ovine model of heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Biological Availability; Blood Pressure; Female; Ha | 1997 |
Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atr | 1997 |
Plasma renin activity in heart failure-prone SHHF/Mcc-facp rats.
Topics: Aging; Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Blood Volume; Disease Suscep | 1997 |
Indomethacin attenuates the renal actions of atrial natriuretic factor in dogs with chronic heart failure.
Topics: Aldosterone; Animals; Arteriovenous Fistula; Atrial Natriuretic Factor; Chronic Disease; Creatinine; | 1997 |
Influence of hemodynamic changes on neuroendocrine response in acute heart failure.
Topics: Acute Disease; Aged; Aldosterone; Cardiac Catheterization; Diuretics; Epinephrine; Female; Heart Fai | 1997 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 1997 |
Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.
Topics: Aldosterone; Animals; Atrial Function, Left; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; | 1997 |
The activated immune system and the renin-angiotensin-aldosterone system in congestive heart failure.
Topics: Adult; Aldosterone; Angiotensin II; Antigens, CD; Female; Heart Failure; Humans; Male; Middle Aged; | 1998 |
Correlation between aortic pulse wave velocity and norepinephrine, epinephrine, aldosterone and plasma renin activity in very elderly subjects and in patients with congestive heart failure.
Topics: Aged; Aging; Aldosterone; Aorta; Catecholamines; Epinephrine; Female; Heart Failure; Humans; Norepin | 1998 |
Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm.
Topics: Aged; Aldosterone; Atrial Fibrillation; Atrial Natriuretic Factor; Catecholamines; Endothelins; Fema | 1998 |
[Case of primary aldosteronism associated with heart and kidney failure].
Topics: Aldosterone; Biomarkers; Female; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Kidney Dis | 1998 |
Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 1998 |
How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines.
Topics: Acute Disease; Aged; Aged, 80 and over; Aldosterone; Atrial Natriuretic Factor; Biomarkers; Diuretic | 1998 |
Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure.
Topics: Aldosterone; Analysis of Variance; Animals; Atrial Natriuretic Factor; Azepines; Cardiac Pacing, Art | 1998 |
The level of plasma neuroendocrine activity and the concentration of digoxin in the serum of patients with mild chronic heart failure.
Topics: Aged; Aged, 80 and over; Aldosterone; Atrial Natriuretic Factor; Catecholamines; Chronic Disease; Di | 1998 |
An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Biomarkers; Endothelin-1; Epinephri | 1998 |
Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese.
Topics: Aldosterone; Angiotensinogen; Asian People; Atrial Natriuretic Factor; Cohort Studies; Female; Gene | 1999 |
How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Captopril; | 1999 |
Aldosterone and spironolactone in heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Hum | 1999 |
Aldosterone antagonism in heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Hear | 1999 |
Correlation between atrial natriuretic peptide and baroreflex sensitivity in patients with congestive heart failure.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Baroreflex; Catecholamines; Echocardiography; Female; | 1999 |
Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Analysis of Variance; Angiotensin-Converting Enzyme | 2000 |
Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Extremities; Furosemide; Heart Fai | 2000 |
[Decrease in mortality on spironolactone being added to the conventional treatment of heart failure].
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diuretics; Dr | 2000 |
Differential responses of circulating and tissue adrenomedullin and gene expression to volume overload.
Topics: Adrenomedullin; Aldosterone; Animals; Aorta, Thoracic; Arteriovenous Shunt, Surgical; Atrial Natriur | 2000 |
Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Hear | 1999 |
Epidemiology and pathophysiology of heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Disease Progression | 2000 |
Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Aorta; Coronary Vessels; Female; Heart Failure; Hemodynamics; | 2000 |
Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Car | 2000 |
Activity of the renin-angiotensin-aldosterone and sympathetic nervous system and their relation to hemodynamic and clinical abnormalities in infants with left-to-right shunts.
Topics: Aldosterone; Cardiac Output, Low; Heart Defects, Congenital; Heart Failure; Hemodynamics; Humans; In | 2001 |
Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Female; Gene De | 2001 |
Cardiac and renal dysfunction in chronic heart failure: relation to neurohumoral activation and prognosis.
Topics: Adult; Aged; Aldosterone; Creatinine; Female; Heart; Heart Failure; Hemodynamics; Humans; Kidney; Ma | 2001 |
Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure.
Topics: Aged; Aldosterone; Autonomic Nervous System; Electrocardiography, Ambulatory; Female; Heart Failure; | 2001 |
New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Eplerenone; Heart F | 2001 |
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Anta | 2001 |
[Activity of the renin-angiotensin-aldosterone system and its impact on the effectiveness of treatment of chronic heart failure in patients with pulmonary tuberculosis].
Topics: Aldosterone; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Capto | 2001 |
Usefulness of carperitide for the treatment of refractory heart failure due to severe acute myocardial infarction.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Bronchodilator Agents; Female; Heart F | 2001 |
Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction.
Topics: Acute Disease; Aged; Aldosterone; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhi | 2001 |
Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations.
Topics: Aged; Aldosterone; Arginine Vasopressin; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Endo | 2001 |
Neurohormonal blockade in chronic heart failure. How much is enough? Can there be too much?.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Re | 2002 |
The endothelin-aldosterone axis and cardiovascular diseases.
Topics: Adrenal Cortex; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clin | 2001 |
Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Topics: Adrenomedullin; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic F | 2002 |
Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Chronic Diseas | 2002 |
The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldosterone; Atrial Natriuretic Factor; Case-Control Studies; | 2002 |
[Aldosterone blockade in heart failure. So much for so little].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
Aldosterone in myxoedema.
Topics: Aldosterone; Dose-Response Relationship, Drug; Heart Failure; Humans; Hyperaldosteronism; Myxedema; | 1978 |
Thyroxine-replacement therapy, aldosterone, and cardiac failure.
Topics: Aldosterone; Heart Failure; Hormones; Humans; Hypothyroidism; Thyroxine | 1979 |
Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure.
Topics: Adult; Aged; Aldosterone; Captopril; Coronary Circulation; Digitalis Glycosides; Diuretics; Dose-Res | 1979 |
The renin-angiotensin-aldosterone system in congestive failure in conscious dogs.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cons | 1976 |
Aldosterone and renin-angiotensin responses to stimuli in patients with treated congestive heart failure.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Angiotensin II; Circadian Rhythm; Dose-Response Rela | 1976 |
[State of the neurohumoral regulatory system in circulatory insufficiency].
Topics: 17-Ketosteroids; Adult; Aged; Aldosterone; Angiotensinogen; Coronary Disease; Cortisone; Endopeptida | 1976 |
Effects of the oral converting enzyme inhibitor SQ 14225 in experimental high output failure.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 1979 |
Effects of the oral converting enzyme inhibitor, SQ 14225, in a model of low cardiac output in dogs.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 1979 |
RAA in CHF.
Topics: Aldosterone; Angiotensin II; Edema; Heart Failure; Humans; Renin | 1979 |
Time-related changes in urinary aldosterone and electrolyte excretion during amiloride administration to congestive heart failure patients [proceedings].
Topics: Aldosterone; Amiloride; Electrolytes; Heart Failure; Humans; Pyrazines; Time Factors | 1979 |
Relation of plasma aldosterone concentration to diuretic treatment in patients with severe heart disease.
Topics: Adult; Aged; Aldosterone; Body Water; Body Weight; Diuretics; Extracellular Space; Female; Heart Fai | 1979 |
The diurnal rhythm of plasma aldosterone and plasma renin activity in patients with congestive heart failure.
Topics: Adult; Aldosterone; Circadian Rhythm; Female; Heart Failure; Humans; Male; Middle Aged; Renin | 1977 |
Syndrome of hyporeninemic hypoaldosteronism. Study of two cases and review of the literature.
Topics: Aldosterone; Cryoglobulins; Heart Failure; Humans; Hyperkalemia; Immunoglobulin G; Immunoglobulin M; | 1977 |
Sodium metabolism.
Topics: Aldosterone; Edema; Extracellular Space; Female; Glomerular Filtration Rate; Heart Failure; Humans; | 1977 |
The role of renin and aldosterone in the salt retention of edema.
Topics: Aldosterone; Blood Pressure; Edema; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Cortex | 1977 |
[Hyperkalemia caused by hyporeninism: role of the hydrochlorothiazide-amiloride combination].
Topics: Aged; Aldosterone; Amiloride; Diabetes Complications; Female; Heart Failure; Humans; Hydrochlorothia | 1977 |
Regulation of sodium balance in normal and edematous states.
Topics: Aldosterone; Capillaries; Desoxycorticosterone; Edema; Extracellular Space; Glomerular Filtration Ra | 1978 |
The pathophysiology of sodium balance.
Topics: Aldosterone; Glomerular Filtration Rate; Heart Failure; Humans; Hypernatremia; Hyponatremia; Kidney; | 1978 |
The renin-angiotensin-aldosterone system in rabbits with congestive heart failure produced by aortic constriction.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Constriction, Pathologic; De | 1977 |
Renin and aldosterone in the cardiomyopathic hamster in congestive heart failure.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Body Weight; Cricetinae; Heart; Heart Failure; | 1977 |
Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure.
Topics: Adult; Aged; Aldosterone; Amiloride; Angiotensin II; Digoxin; Female; Furosemide; Heart Failure; Hum | 1976 |
[Hormonal disturbances and the treatment of refractory forms of congestive circulatory insufficiency].
Topics: Aldosterone; Body Water; Circadian Rhythm; Diuresis; Drug Therapy, Combination; Furosemide; Glucocor | 1976 |
Changes of blood pressure, plasma renin activity and plasma aldosterone concentration following the infusion of Sar1-Ile8-angiotensin II in hypertensive, fluid and electrolyte disorders.
Topics: Acidosis, Renal Tubular; Aldosterone; Angiotensin II; Bartter Syndrome; Blood Pressure; Cushing Synd | 1976 |
[Use of aldactone-saltucine in patients with heart failure].
Topics: Adult; Aged; Aldosterone; Body Weight; Butanes; Chlorides; Diuretics; Drug Combinations; Drug Evalua | 1975 |
Hemodynamics, compartments and the renin-aldosterone system in chronic heart failure.
Topics: Aged; Aldosterone; Body Weight; Extracellular Space; Female; Heart; Heart Failure; Hemodynamics; Hum | 1975 |
The kidney in congestive heart failure.
Topics: Aldosterone; Angiotensin II; Heart Failure; Hematuria; Humans; Kidney; Kidney Failure, Chronic; Natr | 1975 |
[Activity of renin and diurnal excretion of aldosterone in patients with heart defects with circulatory insufficiency].
Topics: Aldosterone; Blood Circulation; Circadian Rhythm; Heart Failure; Humans; Renin; Rheumatic Heart Dise | 1975 |
Proceedings: Plasma aldosterone levels in patients with severe, treated heart failure.
Topics: Aldosterone; Heart Failure; Humans | 1976 |
[The circadian rhythm of plasma vasoactive intestinal peptide, atrial natriuretic peptide, renin activity, aldosterone and cortisol in heart transplantation. The effects of immunosuppressive therapy].
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Cardiomyopathy, Dilated; Circadian Rhythm; Female; He | 1992 |
[Interrelation of plasma volume, fluid metabolism and neurohormonal activation after ultrafiltration in congestive heart failure].
Topics: Adult; Aged; Aldosterone; Body Water; Female; Heart Failure; Humans; Male; Middle Aged; Neurotransmi | 1992 |
Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic F | 1992 |
Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; Electrocardiography; Hear | 1992 |
Regulatory peptides in the plasma of patients with chronic cardiac failure at rest and during exercise.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Chronic Disease; Exercise; Exercise Test; Femal | 1992 |
Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition.
Topics: Adult; Aged; Albuminuria; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; beta 2-Microglobul | 1992 |
[Effects of treatment of arrhythmias requiring therapy in dilated cardiomyopathy with amiodarone on alpha human atrial natriuretic peptide].
Topics: Aged; Aldosterone; Amiodarone; Arginine Vasopressin; Arrhythmias, Cardiac; Atrial Natriuretic Factor | 1992 |
[The renin-angiotensin-aldosterone system and antidiuretic hormone in chronic circulatory failure in elderly subjects].
Topics: Aged; Aldosterone; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Renin; Renin-A | 1992 |
Aldosterone reduces baroreceptor discharge in the dog.
Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Dogs; Endothelium, Vascular; Female; H | 1992 |
Clinical studies of enalapril treatment for patients with severe congestive heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Digoxin; Drug Evaluation; Drug Therapy, Com | 1992 |
The relationship between diuretic dose, and the haemodynamic response to captopril in patients with cardiac failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Captopril; Cardiac Output; Dose-Response R | 1992 |
[Plasma endothelin is increased in heart failure--no effect of a short infusion of atrial natriuretic factor].
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cardiomyopathy, Dilated; Cyclic GMP; Endothe | 1991 |
CAPD: a successful treatment in patients suffering from therapy-resistant congestive heart failure.
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Electrocardiography; Heart Failure; Humans; | 1991 |
[Continuous enoximone infusion in patients with severe heart failure in dilated cardiomyopathy, hemodynamic, neurohumoral, chemical laboratory and clinical results].
Topics: Aldosterone; Atrial Natriuretic Factor; Cardiomyopathy, Dilated; Cardiotonic Agents; Enoximone; Epin | 1991 |
Atrial natriuretic peptide, aldosterone, and plasma renin activity in peripartum heart failure.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Hyperthermia, Induced; | 1991 |
Neuroendocrine activity in untreated heart failure.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Epinephrine; Female; Heart Failure; Humans; Male; Midd | 1991 |
Atrial natriuretic peptide in patients with acute myocardial infarction without functional heart failure.
Topics: Aldosterone; Analysis of Variance; Atrial Natriuretic Factor; Catecholamines; Female; Heart Failure; | 1991 |
[Endothelin in arterial hypertension].
Topics: Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Endothelins; Heart Failure; Humans; Hyperten | 1991 |
Atrial natriuretic factor after dopamine infusion in healthy subjects and in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Diuresis; Dopamine; Female; Glo | 1991 |
[Symptoms complex of traditional Chinese medicine in patients with congestive heart failure].
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Female; Hear | 1991 |
Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Cardiomyopathy, Dilated; Female; Heart Failure; Hemat | 1991 |
[The early hemodynamic and hormonal changes in patients with left ventricular dysfunction].
Topics: Aldosterone; Atrial Natriuretic Factor; Cardiomyopathy, Dilated; Heart Failure; Hemodynamics; Humans | 1991 |
The influence of right heart catheterisation on pulmonary arterial pressure in chronic heart failure: relationship to neuroendocrinal changes.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Cardiac Catheterization; Chronic Disease; Elect | 1991 |
Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.
Topics: Aldosterone; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Aged; Natriuresi | 1991 |
Acute administration of captopril lowers the natriuretic and diuretic response to a loop diuretic in patients with chronic cardiac failure.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Blood Pressure; Captopril; Creatinine; Diuresi | 1991 |
Long-term treatment of congestive heart failure with oral ibopamine. Effects of rhythm disorders and neurohormonal alterations.
Topics: Administration, Oral; Aged; Aldosterone; Angiotensin II; Arrhythmias, Cardiac; Cardiotonic Agents; D | 1990 |
[Effects of captopril on plasma renin activity angiotensin II and aldosterone level in cardiac failure patients].
Topics: Adult; Aged; Aldosterone; Angiotensin II; Captopril; Female; Heart Failure; Humans; Male; Middle Age | 1991 |
Effect of captopril on congestive heart failure.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Captopril; Epinephrine; Female; Half-Life; Heart Failure | 1990 |
Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease.
Topics: Adult; Aged; Aldosterone; Captopril; Coronary Disease; Drug Tolerance; Female; Heart Failure; Hemody | 1990 |
Plasma atrial natriuretic factor in low output heart failure syndromes.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Blood Volume; Bradycardia; Cardiac Output, Low; Femal | 1990 |
[Captopril and hypertensive cardiopathy : therapeutic effects and hormonal changes].
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Captopril; Female; Heart Failure; Humans; Hypertension | 1990 |
[The role of the renin-angiotensin-aldosterone system and vasopressin in the development of heart failure during continuous electric stimulation of the heart].
Topics: Aldosterone; Angiotensin II; Blood Volume; Heart Failure; Hemodynamics; Humans; Pacemaker, Artificia | 1990 |
Short- and long-term mechanisms of sudden cardiac death in congestive heart failure.
Topics: Aldosterone; Arrhythmias, Cardiac; Death, Sudden; Diuretics; Heart Failure; Humans; Magnesium; Potas | 1990 |
[The effect of hemosorption on the aldosterone and vasopressin content of the blood in patients with decompensated chronic cor pulmonale].
Topics: Adult; Aldosterone; Chronic Disease; Drug Interactions; Female; Heart Failure; Hemoperfusion; Hepari | 1990 |
Role of renal nerves in control of sodium excretion in chronic congestive heart failure.
Topics: Aldosterone; Animals; Aorta; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Chlorides; D | 1989 |
DOCA administration and atrial natriuretic factor in dogs with chronic heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Chronic Disease; Desoxycorticostero | 1989 |
Atrial natriuretic peptide, renin and aldosterone in obstructive lung disease and heart failure.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Heart Failure; Hemodynamics; Homeostasis; Humans; Lung | 1989 |
Role of endogenous atrial natriuretic factor in acute congestive heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Constriction; Disea | 1989 |
[Choice for the treatment of congestive heart failure].
Topics: Administration, Oral; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; B | 1989 |
Neuroendocrine response in acute heart failure and the influence of treatment.
Topics: Acute Disease; Aged; Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; C | 1989 |
[The effect of bunazosin vs captopril on hemodynamic and neurohumoral parameters in patients with congestive heart failure].
Topics: Adrenergic alpha-Antagonists; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; | 1989 |
Renal and hormonal effects of phosphodiesterase III inhibition in congestive heart failure.
Topics: Aldosterone; Arginine Vasopressin; Forearm; Glomerular Filtration Rate; Heart Failure; Hormones; Hum | 1989 |
Plasma aldosterone and renin activity.
Topics: Aldosterone; Captopril; Heart Failure; Humans; Infant; Infant, Newborn; Renin; Renin-Angiotensin Sys | 1989 |
Cardiovascular circulatory adjustments and renal function in acute heart failure.
Topics: Acute Disease; Aged; Aldosterone; Epinephrine; Heart Failure; Hemodynamics; Humans; Kidney; Leg; Mid | 1989 |
Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones.
Topics: Adult; Aged; Aldosterone; Body Fluids; Diuretics; Female; Heart Failure; Humans; Kidney Function Tes | 1989 |
[The use of digoxin, lasix and finoptin in treating circulatory failure in hypertension].
Topics: Aged; Aldosterone; Digoxin; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hy | 1989 |
[Effect of isolated ultrafiltration on plasma hormone levels in patients with heart failure resistant to drug therapy].
Topics: Adult; Aged; Aldosterone; Drug Resistance; Female; Heart Failure; Hemofiltration; Humans; Hyperaldos | 1989 |
Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes.
Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Catecholamines; E | 1987 |
Spontaneous neurohormonal fluctuation in chronic congestive heart failure.
Topics: Adult; Aged; Aldosterone; Arginine Vasopressin; Chronic Disease; Circadian Rhythm; Electrolytes; Fem | 1988 |
Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure.
Topics: Administration, Oral; Aldosterone; Arginine Vasopressin; Benzazepines; Fenoldopam; Heart Failure; He | 1988 |
Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Diet, Sodium-Restricted; Edema; Heart Failure; Humans | 1985 |
Studies on the secretion, metabolism and action of atrial natriuretic peptide in man.
Topics: Aldosterone; Arrhythmias, Cardiac; Atrial Natriuretic Factor; Cardiac Pacing, Artificial; Chromatogr | 1986 |
Antidiuretic hormone and atrial natriuretic peptide in congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Captopril; Female; Heart Failure; Huma | 1986 |
Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Electrocardiography; Electrolytes; He | 1986 |
Atrial natriuretic factor secretion in dogs with experimental high-output heart failure.
Topics: Aldosterone; Animals; Arteriovenous Fistula; Atrial Natriuretic Factor; Blood Pressure; Cardiac Outp | 1987 |
[Human atrial natriuretic peptide: a secretory product of the heart and its significance for physiology and clinical practice].
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Diuresis; Heart Failure; Humans; Hypertensio | 1987 |
High plasma concentration of the atrial natriuretic peptide (ANP) with suppressed aldosterone secretion in congestive heart failure.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Heart Failure; Humans; Middle Aged | 1988 |
Hormonal determinants of sodium excretion in rats with experimental high-output heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriovenous Fistula; Atrial Natriu | 1988 |
Plasma atrial natriuretic peptide in cardiac transplant recipients. A prospective study.
Topics: Adolescent; Adult; Aldosterone; Atrial Natriuretic Factor; Female; Follow-Up Studies; Heart Failure; | 1988 |
Neurohumoral and hemodynamic changes in congestive heart failure: lack of correlation and evidence of compensatory mechanisms.
Topics: Adaptation, Physiological; Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Captopril; Epinephri | 1988 |
[Atrial natriuretic factor, catecholamines and the renin-angiotensin system in cardiac insufficiency. Relation to hemodynamic parameters].
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Catecholamines; | 1988 |
Radioimmunoassay of atrial natriuretic peptide in human plasma: application to studies of volume and blood pressure homeostasis.
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Electrolytes; Extracellular Space; Heart Fai | 1988 |
Changes in the levels of plasma atrial natriuretic peptide, hemodynamic measurements, and the levels of vasoactive hormones during the clinical course of congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Atrial Natriuretic Factor; Epinephrine; Heart Failure; | 1988 |
[Hemodynamic and renal effects of synthetic atrial natriuretic factor (alpha-h-ANF) in patients with congestive heart failure].
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Diuresis; Female; Glomerular Filtratio | 1988 |
Clinical and hemodynamic experience with enalapril in congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Aldosterone; Blood Pressure; Dipeptides; Enalapril; Enzyme Inhibi | 1985 |
Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Rel | 1986 |
Intracellular electrolytes in cardiac failure.
Topics: Aged; Aldosterone; Body Fluids; Catecholamines; Diuretics; Female; Heart Failure; Humans; Intracellu | 1986 |
Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Enalapril; Heart Failure; Hemodyna | 1986 |
Plasma concentrations of angiotensin II and aldosterone during acute left ventricular failure in the dog. Effect of converting enzyme inhibition.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Enalapril; Ena | 1986 |
Role of diuretics, hormonal derangements, and clinical setting of hyponatremia in medical patients.
Topics: Aldosterone; Arginine Vasopressin; Diuretics; Electrolytes; Epinephrine; Furosemide; Heart Failure; | 1988 |
Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Arginine Vasopressin; Drinking; Female; Heart Failure; Humans; Ki | 1986 |
[Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure].
Topics: Aged; Aged, 80 and over; Aldosterone; Carbon Dioxide; Cardiotonic Agents; Catecholamines; Deoxyepine | 1987 |
Discrepancy between first-dose converting enzyme inhibition at rest and subsequent inhibition during exercise in chronic heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; | 1988 |
[Blood levels of activated renin, aldosterone, catecholamine in congestive heart failure. I. Role of the adrenergic and dopaminergic systems].
Topics: Adult; Aldosterone; Catecholamines; Dopamine; Epinephrine; Female; Heart Failure; Hemodynamics; Huma | 1987 |
[Blood levels of activated renin, aldosterone, catecholamine in congestive heart failure. II. Effects of dopaminergic stimulation with a dopamine agonist: ibopamine].
Topics: Adult; Aldosterone; Blood Volume; Catecholamines; Deoxyepinephrine; Dopamine; Female; Heart Failure; | 1987 |
Sodium and water balance in chronic congestive heart failure.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Body Water; Captopril; Chronic Disease; Female; Heart Fail | 1986 |
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
Topics: Adult; Aged; Aldosterone; Amiloride; Diuretics; Female; Furosemide; Heart Failure; Heart Function Te | 1987 |
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
Topics: Adult; Aged; Aldosterone; Amiloride; Diuretics; Female; Furosemide; Heart Failure; Heart Function Te | 1987 |
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
Topics: Adult; Aged; Aldosterone; Amiloride; Diuretics; Female; Furosemide; Heart Failure; Heart Function Te | 1987 |
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
Topics: Adult; Aged; Aldosterone; Amiloride; Diuretics; Female; Furosemide; Heart Failure; Heart Function Te | 1987 |
[Plasma renin activity and aldosterone concentration of patients with congestive cardiomyopathy].
Topics: Adult; Aldosterone; Cardiomyopathy, Dilated; Heart Failure; Humans; Renin | 1986 |
Acute changes in plasma renin activity, plasma aldosterone concentration and plasma electrolyte concentrations following furosemide administration in patients with congestive heart failure--interrelationships and diuretic response.
Topics: Aged; Aged, 80 and over; Aldosterone; Diuresis; Electrolytes; Female; Furosemide; Heart Failure; Hum | 1987 |
Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure.
Topics: Aged; Aldosterone; Blood Gas Analysis; Cardiotonic Agents; Catecholamines; Deoxyepinephrine; Dopamin | 1986 |
[Hemofiltration and the neurohumoral system in patients with severe heart failure].
Topics: Adult; Aldosterone; Angiotensin II; Blood; Catecholamines; Female; Heart Failure; Humans; Male; Midd | 1985 |
Bed rest and increased diuretic treatment in chronic congestive heart failure.
Topics: Adult; Aged; Aldosterone; Bed Rest; Body Weight; Chronic Disease; Combined Modality Therapy; Diureti | 1985 |
Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies.
Topics: Administration, Oral; Aldosterone; Animals; Anura; Biological Transport; Blood Urea Nitrogen; Body W | 1985 |
Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine.
Topics: Adult; Aldosterone; Deoxyepinephrine; Dopamine; Female; Growth Hormone; Heart Failure; Humans; Hydro | 1986 |
[Role of aldosterone in the development of edema].
Topics: Aldosterone; Edema; Female; Heart Failure; Humans; Liver Cirrhosis; Middle Aged; Nephrotic Syndrome | 1985 |
[Neurohumoral aspects of myocardial infarct and its complications].
Topics: 17-Ketosteroids; Adrenal Glands; Adult; Aged; Aldosterone; Epinephrine; Female; Heart Failure; Hemod | 1974 |
[Observations on the excretion and secretion of aldosterone and other adrenal cortex steroids during administration of heparin and heparinoids and in patients with cardiac decompensation].
Topics: Adrenal Cortex Hormones; Aldosterone; Heart Failure; Heparin; Heparinoids; Humans | 1969 |
Aldosterone in cardiac and hepatic failure.
Topics: Aldosterone; Heart Failure; Humans; Liver Diseases; Water-Electrolyte Balance | 1967 |
[Excretion of steroid metabolites by women with cardiac thyrotoxicosis].
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aldosterone; Androsterone; Et | 1964 |
[Angiotensin intradermoreaction in patients with liver cirrhosis in the ascitic phase. Results and interpretation in relation to the pathogenesis of the altered hydrosaline metabolism in cirrhogenic liver diseases].
Topics: Aldosterone; Angiotensin II; Ascites; Diabetes Insipidus; Heart Failure; Humans; Hypertension; Jaund | 1966 |
Role of aldosterone in edema formation.
Topics: Aldosterone; Angiotensin II; Edema; Heart Failure; Humans; Hyperaldosteronism; Kidney; Liver; Liver | 1966 |
[Adrenal and extra-adrenal effects of a synthetic polypeptide (Ba 30920) stimulating the adrenal cortex].
Topics: Addison Disease; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Asthma; Fema | 1963 |
[Hormonal interference with water and electrolyte metabolism in congestive heart failure].
Topics: Aldosterone; Angiotensin II; Estrogens; Glucocorticoids; Heart Failure; Humans; Kidney; Progesterone | 1966 |
Deoxycorticosterone secretion in chronic experimental heart failure and during infusion of angiotensin II.
Topics: Aldosterone; Angiotensin II; Animals; Carbon Isotopes; Chromatography, Paper; Corticosterone; Desoxy | 1968 |
[The physiological relationship between the renin-angiotensin system and aldosterone].
Topics: Adult; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; Heart Failure; Humans; Hyperald | 1965 |
[Secondary hyperaldosteronisms].
Topics: Aldosterone; Angiotensin II; Heart Failure; Hyperaldosteronism; Hyperkalemia; Hypertension, Malignan | 1969 |
Plasma renin in congestive heart failure in man.
Topics: Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Digoxin; Female; Furosemide; Heart Failu | 1970 |
[Physiopathology of the kidney in congestive heart insufficiency].
Topics: Aldosterone; Angiotensin II; Heart Failure; Hemodynamics; Humans; Kidney; Sodium | 1970 |
Effect of furosemide and hydrochlorothiazide on plasma renin activity in man.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Furosemide; Heart Failure; Humans; Hydrochlorothi | 1970 |
[The kidney and adrenal glands in experimental heart failure].
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Cricetinae; Heart Failure; Kidney; Renin; Wate | 1971 |
A steady-state control analysis of the renin-angiotensin-aldosterone system.
Topics: Absorption; Aldosterone; Angiotensin II; Animals; Blood Pressure; Constriction; Diet; Feedback; Hear | 1972 |
[Adrenal glycoative function in congestive heart failure. I. Changes in blood and urinary cortisol and the ACTH loading test].
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Blood Glucose; Female; Heart | 1972 |
Response of plasma aldosterone to postural change, diuretica, angiotensin II, sodium restriction or loading and prostaglandin.
Topics: Adrenocortical Hyperfunction; Aldosterone; Angiotensin II; Ascites; Cushing Syndrome; Diet; Diet, So | 1973 |
[Symposium on pathophysiology of congestive heart failure. 1. Relationship of renin-angiotensin-aldosterone system to cardio-renal hemodynamics on chronic congestive heart failure (author's transl)].
Topics: Aldosterone; Angiotensin II; Chronic Disease; Heart; Heart Failure; Hemodynamics; Humans; Kidney; Re | 1973 |
Aldosterone and its regulation during diuresis in patients with gross congestive heart failure.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Body Weight; Chromatography, Paper; Creatinine; Diet | 1974 |
Idiopathic edema.
Topics: Adult; Age Factors; Aldosterone; Edema; Female; Heart Failure; Humans; Hydrochlorothiazide; Hydrosta | 1974 |
[Physiopathology of water-electrolyte disorders in cardiac insufficiency].
Topics: Aldosterone; Catecholamines; Heart Failure; Hemodynamics; Humans; Hyperaldosteronism; Hypokalemia; H | 1973 |
[Changes in the activity of the renin-aldosterone system under the effect of diuretics in patients with circulatory insufficiency].
Topics: Adult; Aldosterone; Diuresis; Ethacrynic Acid; Female; Furosemide; Heart Failure; Humans; Male; Midd | 1972 |
[Iatrogenic heart failure in a case of congenital hypoaldosteronism treated by subcutaneous DOCA implant].
Topics: Acid-Base Equilibrium; Adrenal Insufficiency; Aldosterone; Anemia, Hypochromic; Child, Preschool; De | 1972 |
Pathophysiologic changes in arteriosclerotic and nonarteriosclerotic rats, following isoproterenol-induced myocardial infarction.
Topics: Adrenal Glands; Alanine Transaminase; Aldosterone; Animals; Arteriosclerosis; Aspartate Aminotransfe | 1972 |
Influence of volume expansion on proximal tubular sodium reabsorption in congestive heart failure.
Topics: Aged; Aldosterone; Aminohippuric Acids; Chlorides; Chlorothiazide; Chromium Isotopes; Diuresis; Eryt | 1973 |
[Edema in the patient with heart disease].
Topics: Aldosterone; Blood Pressure; Edema; Glomerular Filtration Rate; Heart Diseases; Heart Failure; Human | 1973 |
A possible form of acute cardiomyopathy as encountered in sugar cane field workers in Tongaat, Natal.
Topics: Acclimatization; Acute Disease; Adult; Agricultural Workers' Diseases; Aldosterone; Amiloride; Cardi | 1973 |
Prolactin and electrolyte balance.
Topics: Aldosterone; Animals; Heart Failure; Humans; Prolactin; Water-Electrolyte Balance | 1973 |
Salivary electrolytes in digitalis-treated patients with and without raised aldosterone excretion.
Topics: Adult; Aged; Aldosterone; Calcium; Digoxin; Female; Heart Failure; Humans; Male; Middle Aged; Potass | 1973 |
[Symposium on pathophysiology of congestive heart failure (discussion)].
Topics: Aldosterone; Heart Failure; Humans; Kidney; Renin; Sodium | 1973 |
[Symposium on pathophysiology of congestive heart failure. 2. A clinical study of the "water-electrolyte regulation mechanism" in chronic congestive heart failure with emphasis on renin and catecholamine].
Topics: Adult; Aldosterone; Catecholamines; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Age | 1973 |
[Distribution of fluid between the cells and the extracellular media and mineralocorticoid function of the adrenal glands in cardiac insufficiency].
Topics: Adrenal Glands; Adult; Aldosterone; Antipyrine; Body Fluids; Chromatography, Paper; Coronary Disease | 1969 |
Hyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis.
Topics: Acetazolamide; Adult; Aldosterone; Ascites; Female; Furosemide; Heart Failure; Heart Valve Diseases; | 1968 |
Physiologic aspects of edema.
Topics: Aldosterone; Animals; Blood Vessels; Body Water; Capillary Permeability; Dogs; Edema; Heart Failure; | 1972 |
[Electrocardiographic observations in secondary aldosteronism].
Topics: Aged; Aldosterone; Body Weight; Digitalis Glycosides; Diuresis; Electrocardiography; Female; Heart F | 1972 |
Magnesium deficiency in patients on long-term diuretic therapy for heart failure.
Topics: Adult; Aged; Aldosterone; Bone and Bones; Diet; Digoxin; Diuretics; Erythrocytes; Female; Heart Fail | 1972 |
[Electrolytes and aldosterine in patients with chronic circulatory insufficiency].
Topics: Adrenal Glands; Adult; Aged; Aldosterone; Female; Heart Failure; Humans; Male; Middle Aged; Potassiu | 1971 |
Metabolic and histopathological consequences of a fatty liver during the acute stages of myocardial infarction in rats.
Topics: Acute Disease; Adrenal Glands; Alanine Transaminase; Aldosterone; Animals; Aspartate Aminotransferas | 1971 |
[Hormonal activity of the adrenals in congestive circulatory insufficiency].
Topics: 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Adrenal Glands; Adult; Aged; Aldosterone; Cortis | 1971 |
Clinical studies on the role of aldosterone concerning the edema formation in chronic congestive heart failure.
Topics: 17-Hydroxycorticosteroids; Adolescent; Adult; Aged; Aldosterone; Ascites; Chromatography; Diuretics; | 1971 |
Aldosterone in congestive heart failure.
Topics: Adrenal Glands; Aldosterone; Heart Failure; Humans; Kidney; Secretory Rate | 1965 |
The role of aldosterone in the pathogenesis of congestive heart failure.
Topics: Aldosterone; Animals; Dogs; Edema; Female; Heart Diseases; Heart Failure; Humans; Mannitol; Potassiu | 1967 |
The effect of aldosterone on sodium and potassium metabolism in congestive cardiac failure.
Topics: Aldosterone; Furosemide; Heart Failure; Humans; Hypokalemia; Potassium; Sodium; Water-Electrolyte Ba | 1969 |
[Secretion and inactivation of aldosterone in hydropic heart insufficiency].
Topics: Aldosterone; Carbon Isotopes; Heart Failure; Humans; Tritium | 1969 |
[Induced aldosteronism in hydropic heart insufficiency].
Topics: Acid-Base Equilibrium; Adult; Aged; Aldosterone; Body Weight; Carbon Isotopes; Cardiac Glycosides; E | 1969 |
Further observations on biochemical alterations associated with congestive cardiac failure in infancy.
Topics: Aldosterone; Blood Volume; Electrolytes; Heart Failure; Humans; Infant; Infant, Newborn; Kidney Func | 1969 |
[Aldosterone and antidiuretic hormone in circulatory insufficiency].
Topics: Adolescent; Adult; Aged; Aldosterone; Coronary Disease; Female; Heart Failure; Humans; Male; Middle | 1969 |
[Pictures of hypovolemic, anedemic circulatory insufficiency associated with secondary hypoaldosteronism].
Topics: Adrenal Glands; Adrenal Insufficiency; Aged; Aldosterone; Electrocardiography; Female; Heart Failure | 1969 |
Desoxycorticosterone secretion rate studies in edematous patients.
Topics: Adult; Aged; Aldosterone; Desoxycorticosterone; Edema; Female; Heart Failure; Humans; Liver Cirrhosi | 1970 |
Renin, aldosterone, and hypertension. The hepatic metabolism of renin and aldosterone. A review with new observations on the hepatic clearance of renin.
Topics: Aldosterone; Animals; Blood; Disease Models, Animal; Dogs; Heart Failure; Hemorrhage; Hepatic Veins; | 1970 |
[Excretion of adrenal hormones in patients with congestive circulatory insufficiency].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adult; Aged; Aldosterone; Androgens; Electro | 1970 |
Studies on the mechanism of experimental congestive heart failure in dogs.
Topics: Aldosterone; Aminohippuric Acids; Animals; Aorta; Ascites; Blood Pressure; Dogs; Edema; Female; Glom | 1970 |
[Research on arterial hypertension. Significance of aldosterone, catecholamines, amino acids and some electrolytes in compensated and decompensated cardiac lesions].
Topics: Adult; Aged; Aldosterone; Amino Acids; Catecholamines; Coronary Disease; Electrolytes; Female; Heart | 1970 |
Pathophysiology of cardiac failure in the newborn.
Topics: Acidosis, Respiratory; Adaptation, Physiological; Aldosterone; Asphyxia Neonatorum; Bicarbonates; Bl | 1970 |
[Causes of fluid retention in cardiac insufficiency].
Topics: Aldosterone; Animals; Cats; Dogs; Edema; Heart Atria; Heart Failure; Humans; Kidney; Mechanoreceptor | 1971 |
[On the behavior of Na+, Cl- ad K+ in plasma and urine and of aldosteronuria in decompensated cardiopathies].
Topics: Aldosterone; Chlorides; Heart Failure; Humans; Potassium; Sodium | 1967 |
[Clinical experiences with the new potassium sparing diuretic amilorid (Moduretic, Colectril, MK-870)].
Topics: Aldosterone; Alkalosis; Diabetes Mellitus; Diuretics; Ethacrynic Acid; Heart Failure; Humans; Potass | 1967 |
[The significance of aldosterone in the pathogenesis of edema in cardiac insufficiency].
Topics: Adult; Aged; Aldosterone; Edema; Female; Heart Diseases; Heart Failure; Humans; Male; Middle Aged; P | 1967 |
Amiloride. A potassium-sparing natriuretic agent.
Topics: Acetazolamide; Aldosterone; Ammonia; Ascites; Bicarbonates; Blood Pressure; Chlorides; Chlorothiazid | 1968 |
Studies on cardiac output to blood volume, and renal circulation in chronic congestive heart failure.
Topics: Adult; Aged; Aldosterone; Arteriosclerosis; Blood Pressure; Blood Volume; Cardiac Output; Chronic Di | 1968 |
[Secretion, plasma concentration, distribution, metabolism and excretion of aldosterone in healthy and sick subjects].
Topics: Aldosterone; Edema; Glomerulonephritis; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Liv | 1968 |
[Hyperaldosteronism and the use of aldactone in cardiac insufficiency].
Topics: Adult; Aldosterone; Blood Flow Velocity; Blood Volume; Cardiac Output; Diuresis; Female; Heart Failu | 1968 |
Selective aldosterone deficiency.
Topics: 17-Ketosteroids; Adolescent; Adrenal Insufficiency; Aged; Aldosterone; Aminohippuric Acids; Carbon I | 1969 |
Secretion and turnover of aldosterone in various pathological states.
Topics: Adolescent; Adult; Aldosterone; Chronic Disease; Dehydration; Edema; Glomerulonephritis; Heart Failu | 1969 |
Clinical studies on the acid-base balance disturbance in congestive heart failure.
Topics: Acid-Base Equilibrium; Acidosis, Respiratory; Adult; Aldosterone; Alkalosis; Arteries; Benzothiadiaz | 1969 |
[Therapeutically induced aldosteronism in hydropic cardiac insufficiency].
Topics: Aldosterone; Carbon Isotopes; Cardiac Glycosides; Diuretics; Heart Failure; Humans; Hyperaldosteroni | 1969 |
[Aldosterone, electrolytes and cardiopulmonary insufficiency].
Topics: Adult; Aldosterone; Electrolytes; Erythrocytes; Female; Heart Failure; Humans; Lung Diseases; Male; | 1969 |
Why we have gone to the dogs.
Topics: Aldosterone; Animals; Cardiac Output; Dog Diseases; Dogs; Exercise Test; Guanethidine; Heart; Heart | 1966 |
Distribution, conjugation, and excretion of labeled aldosterone in congestive heart failure and in controls with normal circulation: development and testing of a model with an analog computer.
Topics: Adult; Aldosterone; Computers, Analog; Female; Heart Failure; Humans; Kidney; Liver; Male; Middle Ag | 1966 |
Clinical pharmacology of diuretic drugs.
Topics: Acetazolamide; Aldosterone; Ammonium Chloride; Chlorothiazide; Diuretics; Heart Failure; Humans; Org | 1966 |
[Pathogenetic problems of congestive failure. II. Effects of aldosterone on electrolytes (Na+ and K+) in the saliva and urine of normal subjects and decompensated heart patients].
Topics: Adult; Aged; Aldosterone; Heart Failure; Humans; In Vitro Techniques; Middle Aged; Potassium; Sodium | 1966 |
[Pathogenetic problems in congestive cardiac insufficiency. IV. The electrolytes (Na+, K+) in sweat induced by heat and in urine of normal subjects exposed to various stimuli (aldosterone, sodium chloride)].
Topics: Aldosterone; Electrolytes; Heart Failure; Humans; Potassium; Sodium; Sodium Chloride; Sweat | 1966 |
Aldosterone metabolism in cardiac failure.
Topics: Aldosterone; Chlorothiazide; Diet, Sodium-Restricted; Digitalis Glycosides; Heart Failure; Humans; H | 1966 |